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Prostate cancer is the most common form of cancer in males. In the UK, 1 in 8 males will develop 
prostate cancer in their lifetime, making research into this condition important. Current research 
is focused on the identification and development of new therapeutic targets and the repurposing 
of existing drugs for cancer therapy; to specifically exploit aggressive tumours associated with 
poor prognosis. 
Constitutive activation of the inflammatory transcription factor Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and reduced expression of the tumour suppressor maspin 
have both been implicated in prostate cancer progression. Poly (ADP-ribose) polymerase-1 
(PARP-1), a DNA strand break repair protein, is a known transcriptional co-regulator of NF-kB. 
Continuous activation of PARP-1 is implicated in increased inflammatory signalling, cellular 
dysfunction and consequently tumour progression. Previous studies have shown that inhibition of 
NF-kB using PARP inhibitors can sensitise tumour cells to chemotherapeutic agents. Histone 
deacetylases (HDAC) play a role in the modification and regulation of gene expression and 
HDAC-1 is highly expressed and activated in metastatic prostate cancer. It is also involved in the 
repair of DNA double strand breaks by Homologous recombination (HR). Maspin is an 
endogenous inhibitor of HDAC-1 and studies have shown that HDAC-1 inhibitors limit activation 
of NF-kB, stimulate re-expression of maspin and induce a “BRCAness phenotype”. To this end, 
combined inhibition of PARP-1 and HDAC-1 to target NF-kB and HDAC-1 may serve as a novel 
therapy in tumours which are deficient in maspin.  
The interactive effects between NF-kB, PARP-1 and maspin on the cellular behaviours of prostate 
cancer cells proficient (PC3) or depleted (DU145) for maspin were investigated in the presence 
or absence of specific inhibitors of PARP-1 (Rucaparib) and HDAC-1 (Trichostatin A), alone and 
in combination. A normal prostate cell line (PNT1A) proficient for maspin was also used. Mouse 
embryonic fibroblasts (MEF) proficient and deficient for NF-kB subunits were utilised to 
compare maspin expression levels and investigate sensitivity to treatments. siRNA was also used 
 III 
in mechanistic studies to explore the roles of maspin and PARP-1 in cell survival following 
treatment with Rucaparib and TSA, alone and in combination. 
Rucaparib as a single agent significantly reduced survival in DU145 prostate cancer cells depleted 
in maspin, compared to PNT1A and PC3 prostate cells proficient for maspin. DU145 cells 
expressed reduced levels of PARP-1 protein and increased levels of IKKα. MEF cells deficient 
for IKKα expressed maspin and were less sensitive to Rucaparib than MEF cells expressing IKKα. 
Maspin silencing by siRNA in cells proficient for maspin reduced PARP-1 expression levels and 
enhanced cell sensitivity to Rucaparib. PARP-1 silencing by siRNA in DU145 and PC3 cells 
expressing differential levels of maspin did not significantly affect sensitivity to Rucaparib. These 
data indicate that increased sensitivity to Rucaparib is likely independent to reduced PARP-1 
protein levels but may be in part due to increased levels of IKKα and consequently maspin. IKKα 
may therefore serve as a potential target for cancer therapy and maspin expression may represent 
a novel predictive biomarker for PARP inhibitor sensitivity in prostate cancers.   
Combination of TSA with Rucaparib reduced prostate cancer survival, supporting tumour specific 
sensitivity to co-treatment. At GI50 concentrations there was no significant difference in cell 
sensitivity, following co-treatment, between DU145 and PC3 cells, suggesting that sensitivity to 
co-treatment is independent of IKKα and maspin expression status. Despite a lack of variance in 
cell survival between DU145 and PC3 cells in the presence of co-treatments at GI50, there was a 
significant increase in DNA single and double strand break in DU145 cells, compared to PNT1A 
and PC3 cells. RAD51 expression was reduced in both DU145 and PC3 cells exposed to co-
treatment, indicating dysfunctional DNA DSB repair by HR in both of these cell lines. The 
increased DNA damage response to co-treatment at GI50 in DU145 cells could therefore be 
attributable to a known BRCA mutation or increased “PARP trapping” at DNA breaks. HDAC 
inhibitors are known to induce a “BRCAness” phenotype and sensitise cells to DNA repair 
inhibitors by reducing the capacity to repair DSBs via HR. Loss of HR capacity requires a reliance 
on the NHEJ pathway for DNA repair and this pathway is upregulated by PARP. Acetylation of 
PARP-1 in the presence of TSA may lead to the promotion of DNA repair by NHEJ. However, 
in the presence of Rucaparib, NHEJ is blocked via “PARP trapping” at the site of DNA breaks, 
 IV 
resulting in synthetic lethality. Combination of PARP and HDAC inhibitors represent a promising 
therapeutic strategy for prostate cancer irrespective of BRCA status.   
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Chapter One Introduction 
1.1 Cancer 
Cancer is the most common cause of mortality in the UK after cardiovascular disease (Global 
Burden of Disease Cancer, 2015) and it will affect one in two at some point in life (Torjesen, 
2015). The development of cancer is a multistep process characterised by genetic changes that 
drive abnormal and uncontrolled cell division. Without treatment these abnormal cells invade and 
destroy surrounding tissues around the body via a process known as metastasis. There are over 
200 different types of cancer which are classified according to the tissue and cell type from which 
they arise. Cancers derived from epithelial cells are known as carcinomas and account for 90% 
of all cancers. Other cell types which give rise to cancer formation are those of the blood and 
lymphatic system (Leukaemia’s and Lymphoma’s), connective tissue (sarcoma) and central 
nervous system (Cancer Research UK).  
Ten biological capabilities that enable cancer development have been identified (Table 1.1) and 
have the potential for exploitation. Drug development is currently focused on targeting these 
hallmarks (Hanahan and Weinberg, 2011). 
Table 1.1: Hallmarks of Cancer. 
Cancer hallmarks and targeting agents which exploit such hallmarks have been developed or are in clinical 
trials (Hanahan and Weinberg, 2011). 
Cancer Hallmark Targeting agent 
Evade growth suppressors Cyclin-dependant kinase inhibitors 
Avoid immune destruction Immune activating anti-CTLA4 mAb 
Enabling replicative immortality Telomerase inhibitors 
Tumour promoting inflammation Selective anti-inflammatory drugs 
Activating invasion and metastasis Inhibitors of HGF/c-Met 
Inducing angiogenesis Inhibitors of VEGF signalling 
Genome instability and mutation PARP inhibitors 
Resisting cell death Pro-apoptotic BH3 mimetics 
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Deregulating cellular energetics Aerobic glycolysis inhibitors 
Sustaining proliferative signalling EGFR inhibitors 
 
1.1.1. Carcinogenesis 
The transformation of cells into invasive cancerous cells is a process known as carcinogenesis. It 
is a multistep process, characterised by a series of genetic and epigenetic alterations which drive 
tumour development. Carcinogenesis comprises three distinct stages: tumour initiation, tumour 
promotion and cancer progression (Pitot, 1993). 
The formation of a tumour is initiated in response to irreversible genetic mutation to cellular 
DNA, which causes cells to break free from the normal constrains of regulated growth. Genetic 
mutations may be spontaneous, or due to reactive oxygen species (ROS) and harmful carcinogens 
which modify the molecular structure of DNA; prompting permanent genetic change during DNA 
synthesis. For example, 8-Oxoguanine (8-oxoG) is a product of oxidative DNA damage which 
induces replication errors and hinders transcription. Pairing of 8-oxoG with adenine results in a 
DNA base mismatch and failure to repair such DNA lesion via break excision repair leads to 
further DNA damage and genetic mutation (Allgayer et al., 2013). Damage to the epigenome 
which regulates gene expression, or damage to chromosomes may lead to the initiation of 
carcinogenesis (Franco et al., 2008).  
As mutated cells expand and proliferate, tumour formation and further genetic change is promoted 
(Kufe et al., 2003). Alterations to genes which control the cell cycle, such as tumour suppressors 
and proto-oncogenes prompt uncontrolled cell growth and proliferation. These alterations are 
generally somatic; however, germ-line mutations of these genes may predispose an individual to 
heritable cancer.  
Tumour suppressor genes (TSG) such as p53, for example, are inactivated forms of cellular genes. 
They control inappropriate cell growth and differentiation by initiating cell death. When TSG 
become mutated or deactivated they are no longer able to regulate cell growth in a controlled 
manner, and so cell proliferation is enhanced (Chial, 2008). Mutations in p53 have been reported 
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in almost every type of cancer; ranging between 10% in haematopoietic malignancies and up to 
100% in high grade carcinomas of the ovaries (Rivlin et al., 2011). 
Proto-oncogenes are genes which encode growth factors, nuclear transcription factors and 
inhibitors of apoptosis. Conversion of a proto-oncogene into an oncogene generally occurs due to 
a "gain of function" mutation. Oncogene over-expression leads to increased cell proliferation and 
survival, as growth factors and inhibitors of apoptosis become up-regulated (Croce, 2008).  
A loss of function in TSG's and a gain of function in proto-oncogenes drives cells into 
malignancy; the final phase of carcinogenesis whereby phenotypical change occurs. Cells begin 
to acquire more aggressive characteristics, such as the ability to move beyond the primary tumour 
location via the bloodstream or lymphatic system by a process known as metastasis (Kufe et al., 
2003). Successful metastasis allows tumour cells to metastasise to secondary sites within the 
body. Metastatic tumours are accountable for ~90% of cancer-related mortalities (Spano et al., 
2012). 
1.2 Prostate cancer 
1.2.1 Incidence and aetiology 
Prostate cancer (PC) is the most common cancer in men in the UK. Over 47,000 new cases are 
diagnosed every year and it is estimated that will 1 in 8 males will be affected by the disease at 
some point in their lifetime (Prostate cancer UK). Diagnosis of PC has increased over the last 10 
years, which is likely due to wide-spread implementation of the prostate specific antigen (PSA) 
test, increased disease awareness and consequently increased incidence (Cancer Research UK). 
Whilst the exact aetiology of PC remains unclear, incidence is significantly correlated with 
increasing age, family history and ethnicity (Daniyal et al., 2014). According to Cancer Research 
UK, more than half of diagnosed cases between years 2012 and 2014 were in males aged 70 and 
over. Diagnosis is rare in males under the age of 50. Unlike other types of cancer, genetic markers 
that predispose PC have not yet been identified, despite a strong link between family history and 
disease development. Males with a first degree relative diagnosed with PC are 2-3 times more 
likely to be diagnosed than a male with no family history (Kommu et al., 2004). Black males are 
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twice as likely to be diagnosed with PC compared to white males of the same age in the UK 
(Lloyd et al., 2015). 
1.2.2 Diagnosis 
Early stage PC is asymptomatic. As the disease progresses symptoms begin to arise. These 
symptoms include bladder obstruction, dysuria, impotence, and in the later stages unexplained 
weight loss and bone pain in the lower back, hips and pelvis (Prostate cancer UK). 
When a patient presents with symptoms indicative of PC, serum PSA is measured and a digital 
rectum examination (DRE) is performed. PSA is a protein produced by the prostate gland that is 
elevated in the presence of PC. In 1994 PSA was approved as a diagnostic marker for early stage 
PC, and since the widespread implementation of PSA testing the incidence of PC metastasis and 
mortality has decreased (Lewis and Hornberger, 2016). Routine PSA testing as a diagnostic tool 
for PC has led to over-diagnosis as the test is specific to the prostate but not to PC. Other factors 
such as prostate enlargement, prostatitis and increasing age contribute to elevated PSA levels. 
When PSA levels are raised, a digital rectal examination (DRE) is performed to check if the 
surface of the prostate gland has changed. A hard and bumpy surface is indicative of PC; however, 
the cancer is not always detectable as changes to the gland are generally not apparent in the early 
stages. PSA and DRE results are used to assess the risk of having PC, but the presence of PC is 
confirmed only after a transrectal ultrasonography (TRUS) guided biopsy (Prostate cancer UK).   
1.2.2.1 Gleason grading and pathological staging 
Upon PC diagnosis, the cancer is graded and staged to establish prognosis and to ensure 
appropriate treatment.  
The Gleason grading system was devised in the 1960's by Dr Donald Gleason and it is the gold 
standard for grading PC to confirm tumour aggressiveness. The system is based on the histological 
examination of PC cells obtained from a biopsy, to determine how different they are in appearance 
from normal prostate cells (Humphrey, 2004). The morphological appearance of the cells is given 
a grade from 1-5, with scores 1-2 considered normal, and 3-5 cancerous. Multiple patient samples 
are taken, and an overall Gleason score is calculated by adding the most common sample grade 
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with the highest sample grade. Scores can range from 2-10 with increasing score correlating to 
disease progression and poor prognosis. PC is defined by an overall Gleason score between 6 and 
10 (Prostate cancer UK).  
The tumour, node and metastasis (TNM) staging system represented in Table 1.2 is used alongside 
the Gleason grading system throughout the UK. The system assesses how far a cancer has spread 
by identifying the size and localisation of the primary tumour (T), the extent of spread to lymph 
nodes (N) and/or metastasis (M) to distant sites. Once tumour grade and stage has been confirmed, 
patients are stratified into 3 pathologic categories; localised disease, locally advanced disease and 
advanced metastatic disease.  
Table 1.2: Tumour, node and metastasis (TNM) staging of Prostate cancer. 
The TNM staging system is used to describe the extent of spread of cancer. 
TNM stage Description 
T1 The cancer cannot be seen on a scan or felt during prostate examination. It is 
identifiable microscopically 
T2 The cancer can be identified on scans but is confined to the prostate gland 
T2a The cancer is only in half of one side of the prostate gland 
T2b The cancer is in more than half of one side of the prostate gland 
T2c The cancer is present in both sides of the prostate gland but is confined 
T3a The cancer extends beyond the outer layer of the prostate but has not spread 
to the seminal vesicles 
T3b The cancer has spread to the seminal vesicles 
T4 The cancer has spread to nearby organs 
NX Lymph nodes cannot be assessed 
N0 Nearby lymph nodes are free from cancer cells 
N1 Cancer cells are present in lymph nodes near to the prostate 
MX Cancer spread was not investigated 
M0 The cancer has not spread to other parts of the body 





PC treatment options are dependent on the pathological stage of the cancer upon diagnosis.  
Localised PC tumours are confined to the prostate and are classified into low and high-risk 
localised tumours dependent on their risk of disease progression at diagnosis. Low risk PC 
patients, with a PSA value lower than 10ng/ml, do not receive treatment but are placed under 
active surveillance; whereby the PC is monitored over time for any change indicative of disease 
progression. A cohort study conducted in 1298 monitored males with low risk PC’s for 60 months 
with frequent PSA tests and biopsies. At 60 months only 5 males had progressed to metastatic PC 
and 2 mortalities were reported (Tosoian et al., 2015). Other studies have also emphasised the 
effectiveness of active surveillance as an intervention for risk reclassification (Klotz et al., 2009, 
Welty et al., 2015). Around 30% of patients under surveillance will eventually be reclassified to 
high risk PC and offered treatment (Klotz and Emberton, 2014).  
When the disease has progressed but is still confined to the prostate, surgical removal of the entire 
prostate (radical prostatectomy) and/or radiotherapy is considered. Radiotherapy directly destroys 
DNA within the cancerous cells by targeting them with ionising radiation (IR). When the DNA 
is damaged beyond repair, the cancer cells stop proliferating and die. Patients can receive 
radiotherapy in either of two forms: external beam or internal irradiation (brachytherapy). 
External beam therapy utilises high-energy rays which directly target the tumour. Brachytherapy 
delivers radiation directly to the site of the tumour sealed in seeds or pellets. They are implanted 
in the body using a needle or catheter (Begg et al., 2011, Cancer Research UK). Some patients 
may be selected for neo-adjuvant endocrine therapy with radical prostatectomy and/or external 
beam radiation if they are at increased risk of disease progression (Kent and Hussain, 2003). Five 
year survival for patients with locally advanced PC is 93% (Cancer Research UK), however many 
of these patients will still go on to develop metastatic PC. 
Metastatic PC is not curable, but its progression can be controlled with endocrine therapies such 
as Bicalutamide and Flutamide which inhibit androgen-stimulated tumour growth. They stop 
testosterone and dihydrotestosterone from reaching the androgen receptor, preventing the 
activation of androgen regulated genes (Wirth et al., 2007, Osguthorpe and Hagler, 2011). Other 
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anti-androgen drugs include Cyproterone acetate, a luteinizing hormone-releasing hormone 
(LHRH) antagonist that reduces LH production in the pituitary gland; subsequently supressing 
testosterone secretion  (Hou, 2009, Reissmann et al., 2000). Response to these treatments is 
generally short lived and the cancerous cells eventually escape from a state of androgen 
dependence to androgen independence (castrate-resistant PC). It is at this stage when further 
treatment options are limited, and risk of mortality is increased. Chemotherapeutic agents 
Docetaxel and Cabazitaxel are employed as a last line therapy to slow tumour progression and 
provide symptomatic relief. Many side effects accompany these agents as they lack tumour 
specificity and damage all dividing cells. Healthy cells are highly proliferative in tissues where a 
demand for new cells is high, for example, bone marrow, hair and the lining of the digestive 
system. Damage to these healthy dividing cells induces side effects such as myelosuppression, 
hair loss and nausea (Cancer Research UK).  
Resistance and side effects to standard treatments at advanced stages of PC highlight a need for 
novel therapies. In the late 1980's, complex signalling networks that regulate cellular activities 
such as growth and survival were discovered. Many of these signalling networks were found to 
be altered in cancer cells and scientists have since attempted to overcome these alterations through 
the development of specific targeting therapies; otherwise known as "magic bullets" (Chabner 
and Roberts, 2005). Research into the molecular mechanisms that drive the progression of PC is 
required as a means to improve treatment and disease survival.  
1.3 DNA damage and repair 
DNA encodes genetic information in each living cell and its integrity and stability is essential to 
life (Clancy, 2008). When DNA becomes damaged it is important that it is repaired efficiently to 
maintain normal cellular functioning and genomic stability. Defective DNA repair can lead to 
genetic mutation and ultimately cancer (Hoeijmakers, 2001). The ways in which DNA becomes 
damaged is large since it is continuously exposed to a multitude of endogenous and exogenous 
genotoxic insults. Endogenous damage can result from products of normal cellular metabolism, 
for example, hydrolysis, alkylation or oxidation by production of intracellular reactive oxygen 
species (ROS) (Torgovnick and Schumacher, 2015). Exogenous DNA damaging agents include 
 8 
ultraviolet (UV) light, ionizing radiation (IR) and genotoxic chemicals such as those present in 
cigarette smoke and chemotherapeutic agents (Hoeijmakers, 2001).  
Cells possess a number of distinct and highly conserved DNA damage response (DDR) pathways 
which coordinate the repair of damaged DNA (Curtin, 2012). The main repair pathways are Base 
or nucleotide excision repair (BER/NER), Non-homologous end joining (NHEJ) and 
Homologous recombination (HR). Poly ADP-ribose polymerase-1 (PARP-1), an enzyme 
associated with DNA damage and repair, has been investigated in the studies presented in this 
thesis. The enzyme plays a role in single strand break (SSB) BER and double strand break (DSB) 
HR and NHEJ repair (Swindall et al., 2013).   
1.3.1 Single strand BER 
BER is the primary DNA repair pathway for single strand breaks (SSB). Its main function is to 
protect cells against mutations induced by endogenous DNA damaging agents. The pathway is 
initiated by specific DNA glycosylase enzymes, such as 8-Oxoguanine-DNA glycosylate 1 
(OGG1), which recognise and excise damaged DNA bases by directly binding and hydrolysing 
the N-glycosylic bond to generate an abasic (AP) site. Several DNA repair proteins, including 
PARP-1, bind to the site of excision and recruit AP-endonuclease repair enzymes (Curtin, 2012). 
AP-endonuclease hydrolyses the AP site, enabling repair of the DNA break by one of two sub-
pathways; short-patch BER or long-patch BER.  
Short-patch BER is the predominant mode of BER. AP-endonuclease generates a 3’ terminus at 
the site of DNA damage which allows DNA polymerase β to replace the missing nucleotide using 
the complimentary strand as a template. DNA ligase completes repair in partnership with PARP-
1 and XRCC1 which acts as a scaffold protein. Long patch BER is more complex. Up to 13 
nucleotides are replaced by DNA polymerase β/δ/ε and proliferating cell nuclear antigen (PCNA). 
Flap endonuclease 1 (FEN1) excises the DNA flap-like structure and DNA ligase reseals the DNA 
strand (Krokan and Bjørås, 2013, Curtin, 2012). 
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Figure 1.1: Model of base excision repair (BER). 
BER is comprised of two pathways: short and long patch DNA break repair. The first steps in BER are 
break recognition, base removal and incision. The nick in the DNA is repaired by short patch BER (the 
predominant pathway) or long patch BER. The BER repair pathway in which a break is repaired is 
dependent on the state of the 5’ and 3’ ends. Ligation completes the repair process (adapted from Curtin, 
2012).  
 
1.3.2 Double strand break repair 
The most dangerous form of DNA lesion is a DSB. If left unrepaired DSBs pose a major threat 
to genomic integrity, and may lead to genetic mutation, carcinogenesis and ultimately cell death 
(Hoeijmakers, 2001). They arise from IR, ROS, chemotherapeutic agents and during replication 
of a SSB or other type of DNA lesion. IR directly affects the structure of DNA and induces a DSB 
by directly colliding with it and breaking the phosphodiester backbone. It is also indirectly 
involved in DNA damage by splitting water molecules near DNA which generates ROS. ROS 
induces further damage by reacting with nearby DNA to generate abasic sites, SSBs and sugar 
moiety modifications which may spontaneously convert into DSBs. Together, these structural 
Repaired DNA 
Damaged bases are removed by glycosylases 
Short patch 
repair 

















changes to DNA result in cell cycle arrest and consequently cell death (Borrego-Soto et al., 2015, 
Cannan and Pederson, 2016). 
To overcome the threats posed by DSBs, cells detect and repair the damaged DNA through highly 
conserved DSB repair pathways. The two main DSB repair pathways are NHEJ and HR (Figure 
1.2). The origin and stage in the cell cycle when the DSB occurs determines which pathway is 




Figure 1.2: The principle DNA double strand break repair pathways. 
(A) Non-homologous end-joining and (B) Homologous recombination.  
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1.3.2.1 Non-homologous end joining (NHEJ) 
NHEJ occurs primarily in G0/G1 phase of the cell cycle and is the main pathway in which DSBs 
are repaired (Mao et al., 2008). The pathway mediates direct relegation of the damaged DNA in 
the absence of a homologous template. The initial step of the pathway is recognition and binding 
of the Ku heterodimer (Ku70 + Ku80) to the DSB, which leads to the recruitment and activation 
of DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) (Davis and Chen, 2013). Ku 
and DNA-PKcs form an active complex to bring together the ends of the DSB in readiness for 
processing and re-ligation. Various proteins, such as the MRE11-RAD50-NBS1 (MRN) complex, 
facilitate end processing of the DNA strands which are then synthesised by DNA polymerase. 
DNA ligase 4 and its associated protein XRCC4 complete repair (Christmann et al., 2003).  
1.3.2.2 Homologous recombination (HR) 
HR is an error free template-dependent repair pathway that occurs primarily in S and G2 phase 
of the cell cycle. It is the favoured mechanism for the repair of DSBs which arise due to replication 
fork stalling or collapse (Helleday et al., 2007). The pathway is initiated by the MRN complex 
which recognises and binds to a DSB, leading to the stimulation and activation of ATM; a protein 
kinase that phosphorylates downstream effector targets such as p53, H2AX and BRCA1. The 
damaged DNA is resected by the MRN complex to expose single-stranded overhangs of DNA at 
the 3’ ends on either side of the DSB. Replication protein A (RPA) then binds to the exposed 
single-stranded DNA ends and unwinds the DNA secondary structure, to enable RAD51 binding 
and formation of a helical nucleoprotein filament. RAD51 recognises and invades a homologous 
sequence of intact DNA on the sister chromatid and uses it as a template to repair the broken DNA 
ends by DNA synthesis (Hoeijmakers, 2001, Kowalczykowski, 2015). 
1.4 Poly ADP-ribose polymerase-1 (PARP-1) 
1.4.1 PARP discovery 
The first PARP enzyme was discovered in the 1960’s when Chambon et al. (1963) discovered 
enhanced synthesis of an acid insoluble material when adding nicotinamide mononucleotide 
(NMN) to chicken liver nuclear extracts incubated with α32P-ATP. The acid insoluble product 
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was later identified as a polymer of adenosine diphosphoribose (ADP-ribose), a molecule 
created from ATP and NMN with NAD+ (Nicotinamide adenine dinucleotide) as the immediate 
substrate (Chambon et al., 1966). Nishizuka et al. (1967) evidenced that NAD+ contained an 
ADP-ribose moiety which was integrated into the ADP-ribose polymer with the concomitant 
release of nicotinamide. The enzyme responsible for such reaction was initially named ADP-
ribose transferase (ADPRT) but is now known as poly (ADP-ribose) polymerase-1 (PARP-1).  
Since the discovery of PARP-1, many other genes containing the PARP signature have been 
identified and there are now 18 members of the PARP super-family (Héberlé et al., 2015, 
Citarelli et al., 2010). PARP’s are nuclear enzymes that catalyse the transfer of ADP-ribose onto 
glutamic acid residues of themselves and histone proteins via the hydrolysis of NAD+ (Figure 
1.3). Subsequently, Poly (ADP-ribose) (PAR) chains are formed; a process known as 
PARylation (Smith, 2001, de Murcia and de Murcia, 1994). PARP-1 is the most abundant 
isoform of the PARP super-family and will be the main focus of this thesis.  
 
Figure 1.3: Schematic representation to show the process of PARylation in response to DNA damage 
induced PARP-1 activation. 
 
1.4.2 Structure of PARP-1 
The PARP-1 gene is located on chromosome 1q41-42 and encodes the 1014 amino acid, 116KDa, 
PARP-1 protein. It is a nuclear enzyme that plays a role in many cellular processes including 
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transcriptional regulation, recombination, chromatin structure formation, gene expression, DNA 
repair and cellular dysfunction (Gibson and Kraus, 2012). The PARP-1 protein, shown in Figure 
1.4, is comprised of three functional domains: an N-terminal DNA binding domain (DBD) , a 
central auto modification domain (AD) and a highly conserved C-terminal catalytic domain 
(CAT) (Kim et al., 2005).  
 
Figure 1.4: Schematic representation of the PARP-1 protein and its three domains.  
The PARP signature sequence is located within the catalytic domain and comprises the sequence most 
conserved among PARPs (yellow box). Zn= zinc fingers, NLS= nuclear localisation zone, BRCT= BRCA1 
carboxyl terminal. 
 
The N-terminal DBD of the PARP-1 protein contains two zinc fingers (Zn1 and Zn2) which act 
as nick sensors to allow PARP-1 to recognise and bind to DNA breaks. The two zinc fingers play 
different roles in the recognition of DNA breaks. Zn1 recognises both DNA single and double 
strand breaks,  however Zn2 detects only single strand breaks (de Murcia et al., 1994). A third 
zinc finger (Zn3) has more recently been identified and has been shown to play a role in the 
coordination of DNA-dependent enzyme activation (Langelier et al., 2011, Langelier et al., 2008). 
A nuclear localisation signal (NLS) that targets PARP-1 to the nucleus is also present within the 
N-terminal DBD. 
The AD domain of PARP-1 is located in the centre of the PARP-1 enzyme. It comprises 15 highly 
conserved amino acid residues which allow the enzyme to poly (ADP-ribosyl)ate itself. The 
domain also comprises a BRCA1 C-terminal phosphopeptide-binding motif which is found in a 
number of proteins involved in the DNA damage response (Luo and Kraus, 2012a).  
The CAT domain is the most conserved region of the PARP-1 protein. It contains the “PARP 
signature” sequence that is required for PAR synthesis (de Murcia et al., 1994). 
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1.4.3  PARP-1 and DNA repair 
PARP-1 is a well-recognised DNA strand break-activated enzyme. It is best known for its role in 
the recognition and repair of DNA single strand breaks (SSB’s) via the BER pathway, although 
it also plays a role in repair of double strand breaks (DSB’s) by Homologous recombination (HR) 
and Non-homologous end joining (NHEJ) (Swindall et al., 2013, Veuger et al., 2004).  
1.4.3.1 PARP-1 in single strand break repair 
PARP-1 is catalytically activated following recognition and binding to a DNA SSB. Once active, 
PARP-1 transfers ADP-ribose units from nicotinamide adenine dinucleotide (NAD+) to itself and 
other substrates to produce poly ADP-ribose (PAR). This “PARylation” process creates a 
negatively charged target at the site of the SSB which attracts other DNA damage repair proteins 
to the breakage site to form the BER multi-protein complex. This complex is comprised of the 
scaffold protein XRCC1 (x-ray repair cross-complementing 1), DNA ligase III and DNA 
polymerase pol β (Javle and Curtin, 2011), as described in 1.3.1. Following PARylation, PARP-
1 is released from the site of the DNA break to enable repair. 
DNA damaging agents have been used to investigate the role of PARP-1 in BER. Potent activators 
of PARP-1 include DNA damaging agents that induce DNA lesions repaired by the BER pathway, 
such as monofunctional alkylating agents and ionising radiation (IR). UV irradiation on the other 
hand is not a potent activator of PARP-1 and predominantly causes lesions that are repaired by 
the NER pathway (de Murcia and de Murcia, 1994). Further studies by De Murcia et al. (1997) 
showed that PARP-1-/- mice were more sensitive to IR and oxidative damage, and cells from these 
mice were increasingly sensitive to the alkylating agent N-methyl-N-nitrosourea (MNU). A more 
recent study by Fisher et al. (2007) assessed the importance of PARP-1 in SSB repair. PARP-1-/- 
and wild-type DT40 chicken cells were exposed to the DNA damaging agent H2O2 and levels of 
DNA strand breaks were measured. H2O2 was found to induce similar levels of DNA damage in 
both cell types, however PARP-/- cells took longer to repair DNA strand breaks following removal 
of the DNA damaging agent. To confirm whether the delay in strand break repair rate was due to 
defects in SSB repair, the experiments where repeated in Ku70-/- and XRCC3-/- DT40 cells which 
lack functional DNA DSB repair. PARP-1-/- cells were still the only cells which took longer to 
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repair DNA strand breaks and it was therefore concluded that such observation was indeed due 
to defective SSB repair.  
1.4.3.2 PARP-1 in double strand break repair 
For decades the focus has been on the role of PARP-1 in SSB repair, however in more recent 
years PARP-1 has emerged as a key player in DSB repair by HR and NHEJ (De Vos et al., 2012). 
DSB's are cytotoxic lesions that drive genetic instability and activate cell death if unrepaired 
(Pfeiffer et al., 2000). Studies have revealed that PARP-1 becomes activated upon recognition 
and binding to a DSB (Benjamin and Gill, 1980). Its exact roles in DSB repair are still under 
investigation.   
The interaction of PARP-1 with DSB repair proteins such as ATM, MRE11 and NBS1 highlight 
a role for PARP-1 in the HR repair pathway (Haince et al., 2008). PARP-1 binds to stalled 
replication forks arising from unrepaired SSBs and becomes activated. Once activated, PARP-1 
interacts with MRE11 to “jumpstart” the stalled fork and to enable HR repair of the DNA (Bryant 
et al., 2009). A Biochemical study uncovered an interaction between PARP-1 and DNA-PK; a 
protein associated with the NHEJ DSB repair pathway (Ruscetti et al., 1998), as previously 
described in 1.3.2.1. PARP-1 was shown to stimulate and ADP-ribosylate DNA-PK in the 
presence of NAD+; enabling phosphorylation of PARP-1 by DNA-PK. Chemical inhibition of 
PARP blocked DNA-PK stimulation; suggesting that such enzymes may function together in 
response to DNA damage. Veuger et al. (2004) further supported the role of PARP in NHEJ DSB 
repair. Inhibition of PARP-1 and DNA-PK was shown to inhibit DSB repair following IR 
exposure, and inactive PARP-1 supressed DNA-PK activity and vice versa. Other studies have 
proposed that PARP-1 is involved in an alternative NHEJ pathway which operates when the 
classical NHEJ pathway is genetically or chemically compromised. Wang et al. (2006) revealed 
that PARP-1 competes with Ku for binding to a DNA DSB and with the help of DNA ligase III 
is able to repair the damage.  
While specific mechanisms have not yet been identified, these studies suggest that PARP is a key 
player in DSB repair. Cells deficient in proteins involved in both the HR or NHEJ DNA repair 
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pathways have shown sensitivity to PARP inhibitors and exploitation of PARP-1 as a therapeutic 
target in disease is a current area of investigation (Yi et al., 2019).   
1.4.4 PARP-1 as a mediator of tumour promoting inflammation  
Despite its anti-mutagenic role in DNA repair, PARP-1 activation is also implicated in 
inflammatory signalling and disease. Continuous activation of PARP-1 in response to ROS-
mediated DNA damage and chronic inflammation promotes stress signalling, leading to increased 
inflammatory signalling, cellular dysfunction and DNA damage (Swindall et al., 2013).  
One of the first mediators of inflammation identified as a target for PARP-1 was NF-kB; a well-
known inflammatory transcription factor (described in section 1.5). Briefly, hyperactivated 
PARP-1 upregulates NF-kB in response to DNA damage, leading to inflammation and 
upregulation of pro-inflammatory cytokines such as tumour necrosis factor a and interleukin 6 
(Wang et al., 2017). PARP-1 deficient cells have been found to be defective in NF-kB dependent 
transcription activation, but not in its nuclear translocation, in response to TNF-alpha (Oliver et 
al., 1999). The group also discovered that macrophages from PARP+/+ mice exposed to 
lipopolysaccharide treatment presented rapid NF-kB activation, but macrophages from PARP-1-
/- mice did not. The findings demonstrated a functional association between PARP-1 and NF-kB; 
leading to the synthesis of inflammatory mediators.  
Despite its role as a co-factor for NF-kB, PARP-1 has also been implicated in the switch of cell 
death pathways from highly regulated apoptosis, to inflammatory necrosis in response to high 




Figure 1.5: The two sides to PARP-1 activation.  
PARP-1 acts as a pro-survival factor (white segment) to maintain cell survival and genomic stability. 
Prolonged activation of PARP-1 promotes tumorigenesis due to over production of NAD and ATP 
consumption which drives genetic instability and cell necrosis (black segment) (Giansanti et al., 2010).  
 
1.4.5 PARP-1 activity  
PARP-1 activation is largely driven by DNA damage (as discussed in section 1.4.3 ) and it is 
therefore not surprising that PARP-1 enzyme activity is upregulated in cancer. Increased PARP-
1 activity and formation of PAR has been reported in several tumour types including 
hepatocellular, breast, melanoma and prostate; highlighting the potential of PARP-1 activity as a 
biomarker to determine which patients will be benefit from PARP inhibitor therapy (Nomura et 
al., 2000, Schiewer and Knudsen, 2014). 
1.4.6 PARP-1 activity and expression 
PARP-1 protein is overexpressed in a number of different tumour types compared to non-
malignant tissues (reviewed in Wang et al. (2017)). Ossovskaya et al. (2010) assessed PARP-1 
expression in over 8000 primary malignant and normal human tissues. PARP-1 expression was 
low in majority of normal specimens but was significantly increased in several malignancies 
including those derived from the breast, ovaries, uterus, skin and lung. Other studies have also 
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demonstrated overexpression of PARP-1 in prostate, colorectal and glioblastoma (Schiewer et al., 
2012, Dziaman et al., 2014, Murnyak et al., 2017).  
1.4.7 PARP-1 Inhibitor development  
The first PARP inhibitor, 3-aminobezamide (3-AB), was identified almost forty years ago during 
a pivotal study where a defect in the BER pathway was identified in the presence of 3-AB, 
resulting in defective DNA repair and increased cytotoxicity to DNA methylating agents in 
leukaemia cells. It was these findings that demonstrated the potential of 3-AB as a therapeutic 
strategy for the treatment of leukaemia and other cancers (Durkacz et al., 1980). Since then, many 
more potent and more specific small molecule inhibitors of PARP-1 have been developed and in 
2003 the first PARP-1 inhibitor (PARPi), AG014699/Rucaparib entered clinical trials (Plummer 
et al., 2008). There are now four PARP inhibitors (Rucaparib, Olaparib, Niraparib and 
Talazoparib) licensed for therapeutic use by the FDA and a number of others are in clinical 
development (reviewed in Yi et al. (2019).  
1.4.7.1 Rucaparib development 
The studies carried out for submission of this thesis utilised the PARP inhibitor Rucaparib 
(AG014699). As previously mentioned, Rucaparib was the first PARP inhibitor to enter anti-
cancer clinical trials and its development from bench to bedside will be described in further detail 
below.  
Rucaparib was developed by the laboratories of Roger Griffin and Bernard Golding at Newcastle 
University in collaboration with Cancer Research UK and Agouron Pharmaceuticals (part of 
Pfizer GRB). In the early 1990s, the group aimed to make and test novel PARP inhibitors, which 
included the quinazolinones and the benzimidazole carboxamides, for use as both chemo- and 
radio-sensitizers. The compounds were tested in a range of cell culture models including human 
cancer cells. Despite poor aqueous solubility in all compounds tested, the benzimidazole 
carboxamides were most potent (Curtin et al., 2004, Smith et al., 2005). The amine substitution 
of 2-aryl ring at the para position of the core structure enhanced compound potency and PARP-1 
inhibitory activity, however issues with aqueous solubility remained (White et al., 2004). To 
overcome this issue, the groups at Agouron and Newcastle developed tricyclic lactam indoles 
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which lead to the discovery of the lead PARP-1 inhibitor AG014361 (Reviewed in Curtin and 
Szabo (2013)). Further development led to the identification of AG014447 and it was the 
phosphate salt of this compound, AG014699 (Rucaparib), that was selected for clinical trial due 
to its improved aqueous solubility and high potency as a PARP-1 inhibitor in combination with 
temozolomide in xenograft models (Thomas et al., 2007, Plummer et al., 2008). In October 2019 
Rucaparib, known commercially as Rubraca®, was approved for use on the NHS in female 
patients with relapsed ovarian, fallopian tube and peritoneal cancers (NICE, 2019). The 
therapeutic potential of PARP inhibitors is discussed in further detail below. 
1.4.7.2 PARP inhibitors for cancer therapy 
PARP inhibitors have shown potential in clinical medicine as potentiators of chemotherapy and 
radiotherapy; and as stand-alone agents which selectively kill cells with defective DNA repair 
(Drew and Plummer, 2009). They may be the first deliberate examples of cancer therapy targeted 
at a specific gene product. 
1.4.7.2.1 PARP inhibitors in combination therapy 
PARP inhibitors have been utilised in combination with chemo- or radiotherapy to inhibit the 
repair of genotoxic lesions caused by these DNA damaging therapies. Combined therapy aims to 
overcome single therapy resistance and improve therapeutic response.  
Various studies have demonstrated the effectiveness of PARP inhibitors in combination with the 
alkylating agent temozolomide, a known activator of PARP-1 and inducer of SSBs in tumour cell 
and xenograft models (Delaney et al., 2000, Curtin et al., 2004, Calabrese et al., 2004). As 
previously mentioned, the first human trial using a clinical PARPi established a tolerable dose 
when combined with temozolomide in advanced melanoma patients (Plummer et al., 2008). The 
group also reported improved response rate in metastatic melanoma patients exposed to Rucaparib 
and temozolomide in combination, compared with temozolomide alone (Plummer et al., 2013). 
PARPis have also been shown to enhance the cytotoxicity of topoisomerase 1 poisons, inducers 
of DNA strand breaks, such as topotecan, camptothecin and irinotecan in in vitro and in vivo 
models. Studies have demonstrated the efficacy of the PARPi AG14361 in sensitising leukaemia 
cells to camptothecin by increasing the persistence of DNA strand breaks (Smith et al., 2005). In 
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vivo mouse studies demonstrated enhancement of topotecan-induced tumour growth delay 
following Rucaparib induced PARP-1 inhibition in neuroblastoma (Daniel et al., 2009). PARP 
inhibitors also enhance radiotherapy cytotoxicity in tumours (reviewed in Zaremba and Curtin 
(2007)). The work of Veuger et al. (2003) showed inhibition of IR-induced DNA DSB repair in 
mouse embryonic fibroblasts exposed to the novel PARPi AG14361; highlighting the potential 
of PARP inhibitors as tumour radiosensitizers. More recent studies have supported these findings, 
demonstrating radio-sensitization by PARP inhibition in colon, glioma and ovarian cancers 
(Calabrese et al., 2004, Dungey et al., 2008, Bi et al., 2018). These results support a role for 
combining radiotherapy and PARP inhibitors for cancer therapy in patients who fail to respond 
to traditional treatments. Clinical trials are currently underway (www.clinicaltrials.gov).   
1.4.7.2.2 PARP inhibitors as a monotherapy 
In 2005, two pivotal studies reported the efficacy of PARP inhibitors as stand-alone therapies in 
in BRCA1 and BRCA2 defective tumours (Bryant et al., 2005, Farmer et al., 2005). Bryant et al. 
(2005) implanted BRCA2 deficient and complimented cells into nude mice and monitored tumour 
growth following a five-day exposure to the PARP inhibitors NU1025 and AG14361, precursors 
to Rucaparib. Three out of the five mice subject to BRCA2 deficient tumours were sensitive to 
PARP inhibition, with one mouse presenting complete remission. Farmer et al. (2005) also 
reported increased sensitivity of BRCA1 and 2 deficient cell lines to the PARP inhibitors 
KU0058684 and KU0058948. These studies demonstrated the effectiveness of PARP inhibitors 
as single agents in the selective killing of tumour cells deficient in BRCA. They concluded that 
increased sensitivity to PARP inhibition in these cell lines was due to synthetic lethality; when 
loss of two genes is lethal and results in cell death. In this case, synthetic lethality following PARP 
inhibition occurred due to the accumulation of DNA SSBs resulting in un-repaired stalled 
replication forks and consequently DSBs. BRCA deficient cells are unable to repair these breaks 
due to defective HR and therefore are subject to death (Figure 1.6). PARP inhibitors as 
monotherapies are now approved for use in the clinic in patients with BRCA defective breast and 
ovarian tumours (Deeks, 2015, Moore et al., 2018, McCann and Hurvitz, 2018, Jiang et al., 2019). 
Evidence also supports a role for PARP inhibitors in sporadic cancers harbouring defects in other 
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components of the HR DNA repair pathway. These defects induce a BRCA-like phenotype and 
this concept is known as “BRCAness” (Reviewed in Lim and Ngeow (2016)). 
 
 
Figure 1.6: Schematic representation of synthetic lethality. 
DNA damage induces SSBs which are repaired by BER. Inhibition of BER by PARP inhibition results in 
SSB persistence. Unrepaired SSBs lead to DSB formation which are normally repaired by HR. In the 
absence of BRCA, DNA cannot be repaired, or are repaired by error prone NHEJ, leading to genomic 
instability and cell death. Figure adapted from (Banerjee et al., 2010).  
 
1.4.7.3 PARP inhibition in prostate cancer 
Advanced prostate tumours often harbour mutations in DDR genes such as BRCA1, BRCA2, ATM 
and RAD51. Tumours with mutations in these genes are at increased risk of metastatic progression 
and poor prognosis, which makes them suitable candidates for PARPi therapy (Pritchard et al., 
2016). A phase 2 clinical trial (TOPORP-A, Trial of PARP inhibition in Prostate cancer) reported 
a high response to the PARP inhibitor Olaparib in metastatic, castration-resistant prostate cancer 
patients with defective DNA-repair genes. Next generation sequencing of DNA obtained from 
patient biopsies identified homozygous deletions and/or deleterious mutations in DNA repair 
genes and 88% of tumours harbouring these defects were sensitive to Olaparib treatment (Mateo 
et al., 2015). These results have now received therapy designation by the FDA for treatment of 
BRCA1/2 or ATM-mutation metastatic PC. Trials assessing potential “BRCAness” in PCs are 
ongoing to identify other potential biomarkers that may predict tumour response to PARPi 
(Ramakrishnan Geethakumari et al., 2017).  
PARP-1
DNA damage (SSB)
Inhibition of BER by PARPi
Normal cell with functional HR HR deficient cancer cell (eg: BRCA deficient)
Selective cell death (synthetic lethality)
DNA replication (DNA DSB or 
replication fork collapse)
DNA repair via HR Impaired DNA repair via HRCELL SURVIVAL CELL DEATH
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1.5 Nuclear factor kappa B (NF-κB) 
Transcription factors such as Nuclear factor kappa B (NF-kB) regulate and respond to changes in 
the environment by influencing gene expression (Hayden and Ghosh, 2012). As part of a 
molecular signalling cascade, NF-kB proteins are able to induce and repress the expression of 
genes which are involved in the regulation of important biological processes such as immune 
response, apoptosis, inflammation, cell stress and proliferation (Oeckinghaus and Ghosh, 2009).  
Dysregulation of NF-kB activity has been implicated in the pathology of diseases such as cancer, 
as mentioned in section 1.4.4 and below in section 1.5.3, and recently the NF-kB signalling 
pathway has shown potential for exploitation in cancer therapy (Reviewed in Pires et al. (2018).  
1.5.1 The NF-kB superfamily and associated proteins. 
NF-κB is an entire family of transcription factors which each share a N-terminal Rel homology 
domain (RHD) comprised of approximately 300 amino acids (Figure 1.7). The RHD is 
responsible for DNA binding, dimerization and nuclear translocation following interaction with 
inhibitors of NF-kB (IκB) proteins (Xiao and Fu, 2011).  
There are five genes which encode the family of NF-kB transcription factors: NFKB1, NFKB2, 
RELA, RELB and c-REL. The protein products of these genes are p50, p52, p65/RelA, RelB and 
c-Rel, respectively (Pires et al., 2018). RelA, RelB and c-Rel proteins contain transactivation 
domains (TAD) which are responsible for the transcriptional activity of these proteins at target 
gene promotors. The p50 and p52 proteins do not contain TADs and mediate their transcriptional 






Figure 1.7: NF-κB subunits which comprise the NF-κB family.  
Each subunit has a DNA binding and dimerization domain known as the REL homology domain. RelA, 
RelB and c-Rel also comprise other dimers which determine context-specific gene regulation by NF-κB 
(Perkins, 2012). LZ: leucine zipper. TAD: Transactivation domain. 
 
1.5.2 NF-kB activation pathways. 
There are two fundamental NF-kB activation pathways (Figure 1.8), referred to as the canonical 
(classical) and non-canonical (alternative) pathways. In both pathways, NF-κB activation within 
the cell is tightly controlled by an IκB kinase (IKK) complex which is comprised of: IKKα, IKKβ 
and NEMO (Gilmore, 2006).  
1.5.2.1 Canonical activation of NF-kB 
The canonical NF-kB pathway is activated in response to inflammatory stimuli in the cellular 
environment such as tumour necrosis factor receptor (TNFR), IL-1 receptor (IL-1R), growth 
factors or exposure to bacterial products such as lipopolysaccharides (LPS). These receptors 
activate the IκB kinase (IKK) complex, which phosphorylates and degrades IκB. NF-kB proteins 
are then free to translocate to the nucleus where they bind to promoter elements and activate 
expression of various genes (Sun and Ley, 2008, Oeckinghaus and Ghosh, 2009, Huang and 
Hung, 2013). For example, NF-kB induces the expression of various pro-inflammatory genes, 
including those encoding TNF-a or IL-1; inflammatory cytokines that are implicated in the 
inflammatory response to infections and disease (Tak and Firestein, 2001). The canonical 
pathway can also be activated by genotoxic stimuli, as discussed in section 1.5.3. 
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1.5.2.2 Non canonical activation of NF-kB 
The non-canoncial signalling pathway for activation of NF-kB is primarily for the activation of 
RelB complexes during B and T cell organ development. As such the pathway proceeds through 
an IKK complex excluding NEMO and becomes activated only by a small selection of specific 
stimuli such as: B-cell activating factor (BAFF), Lymphotoxin β (LTβ), CD40 ligand and receptor 
activator of NF-κB ligand (RANKL). Receptor binding leads to the synthesis of NF-κB-inducing 
kinase (NIK); which causes the formation of p52 from p100 after IKKα complex activation. IKKα 
activation sequentially leads to phosphorylation of two serine residues adjacent to the p100 
complex domain, which in turn liberates the RelB complex; allowing translocation into the 
nucleus and NF-kB activated gene expression (Xiao and Fu, 2011). 
 
 
Figure 1.8: Schematic representation of the canonical and non-canonical NF-κB signalling pathways. 
The canonical pathway (left) is activated by stimuli such as TNF-a and IL-1, leading to phosphorylation 
and degradation of IkB. The p65-p50 heterodimer is release enabling translocation into the nucleus. The 
pathway may also be activated in response to genotoxic stress. The non-canonical pathway (right) results 
in NIK phosphorylation and activation of IKKa which phosphorylates p100. Phosphorylation of p100 





1.5.3 DNA damage-induced NF-kB activation as a driver of cancer.  
A critical connection between NF-κB, inflammation and cancer has been established in various 
human cancers including those derived from the breast, prostate, lymphoma, ovaries and lungs 
(Karin, 2009, Chen et al., 2011, Jin et al., 2014b, Wang et al., 2015a). NF-kB signalling in tumour 
progression is complex, but may be in part due to mutational activation of upstream components 
in the IKK-NF-κB signalling pathways; or exposure to pro-inflammatory stimuli in the tumour 
micro-environment (Karin et al., 2002). In normal cells NF-κB activation supports the immune 
defence system by targeting unstable cells and eliminating them via the release of cytokines. In 
cancers, enhanced NF-κB signalling exerts a pro-tumorigenic effect by excessive cytokine release 
and growth factor production (Hoesel and Schmid, 2013). The immune response caused by 
prolonged inflammation promotes DNA damage, leading to oncogenic mutation, cell migration 
and tumour initiation (Xiao and Fu, 2011). 
DNA damage-induced NF-kB activation has been widely documented and is thought to 
coordinate cell survival, alongside DNA repair, by upregulating anti-apoptotic genes; an enabling 
characteristic of cancer development (Coussens and Werb, 2002). NF-kB activation in response 
to DNA damage drives carcinogenesis by enhancing cellular stress, recruiting inflammatory 
factors and accumulating further DNA damage; leading to malignant progression, resistance to 
chemotherapy and IR. To this end, chemical inhibition of NF-kB is an attractive therapeutic target 
(Janssens and Tschopp, 2006). Interactions between PARP-1 and NF-kB have been well 
documented. Hassa et al. (2001) showed that PARP-1 directly interacts with NF-kB to 
synergistically activate transcriptional factors independent of enzymatic activity and DNA-
binding activity. DNA repair inhibitors such as PARP inhibitors can limit NF-kB activation and 
sensitive tumour cells to chemotherapy and IR. For example, breast cancer cell models expressing 
varied levels of activated NF-kB were exposed to the PARP-1 inhibitor AG14361 following 
exposure to lethal doses of IR; a known inducer of NF-kB activity. AG14361 was shown to inhibit 
NF-kB binding to DNA following IR, highlighting a role for PARP-1 in the activation of NF-kB 
(Veuger et al., 2009). More recent studies from the same group demonstrated that radio-
sensitisation by PARP-1 inhibition is exclusively due to NF-kB inhibition, and not due to the 
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inhibition of DNA repair. Using the PARP inhibitor AG014699 (Rucaparib) and siRNA targeting 
PARP-1, they showed a significant increase in apoptosis and a reduction in cell survival following 
exposure to IR in mouse embryonic fibroblasts (MEF) proficient in NF-kB p65, but not MEFs 
deficient in NF-kB p65 (Hunter et al., 2012).  The group proposed that IR activates PARP-1 
leading to the formation of negatively charged PAR polymer and activation of NF-kB. PAR 
attracts p65 binding, resulting in protection against apoptosis and radio-resistance. In the presence 
of Rucaparib, PARP is unable to form PAR and hence there is a reduction in DNA binding and 
transcriptional activation of NF-kB following IR, with radio-sensitization and increased 
apoptosis. Other studies have also supported the efficacy of PARP inhibitors as inhibitors of 
tumour proliferation and invasion by attenuating NF-kB signalling (Martin-Oliva et al., 2004, 
Wang et al., 2013). 
1.5.3.1 NF-kB activation in prostate cancer  
NF-kB signalling has been implicated in prostate cancer progression and poor prognosis. 
Constitutive activation and nuclear expression of NF-kB and IKKa has been observed in 
aggressive AR deficient prostate cancer cell lines and patient samples, but not in AR proficient 
cells; suggesting that activation of NF-kB may contribute to the malignant properties of AR 
deficient tumour cells (Lindholm et al., 2000). Other studies have also demonstrated that NF-kB 
activation maintains androgen independent growth of prostate tumours cells (Jin et al., 2008a). 
The group also investigated the role of NF-kB signalling in PC initiation and progression using a 
NF-kB-activated prostate cancer mouse model. They reported activation of NF-kB following 
deletion of one IkBa allele did not induce tumorigenesis, but continuous NF-kB activation 
enhanced earlier onset of PC in a Hi-Myc PC mouse model. To further explore the mechanism by 
which NF-kB signalling contributes to tumour progression, an NF-kB gene expression signature 
was generated from a non-malignant NF-kB-activated androgen-depleted mouse prostate. The 
signature successfully distinguished between different subsets of PC and predicted clinical 
outcome (Jin et al., 2014b). Nuclear accumulation of IKKa is also associated with AR 
independent PC development and studies have found that it is necessary for metastasis in 
transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. The exact mechanisms are 
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unknown but nuclear IKKa has been shown to induce a metastatic phenotype by repressing 
transcription of the tumour suppressor maspin (Luo et al., 2007).  
Other studies have correlated constitutive activation of the NF-kB p65 subunit and its binding to 
DNA with increased Gleason grade and prostate tumour aggressiveness and metastasis. 
Metastatic PC-3M cells transfected with mutated IKBa to block NF-kB activity were injected 
into the prostate gland of nude mice. Mice exposed to control PC-3M cells produced fast growing, 
aggressive tumours, whereas PC-3M cells with IKBa mutation produced slow growing tumours 
with limited metastatic potential. These data show the significance of NF-kB activity as a driver 
of tumour progression and metastasis (Huang et al., 2001). Immunohistochemical analysis of 
prostate samples revealed increased nuclear staining for NF-kB p65 in high grade 
adenocarcinoma samples compared to benign tumour tissues (Shukla et al., 2004). A further 
indication for the role of NF-kB signalling in PC proliferation and progression is the inhibitory 
effect of the NF-kB inhibiting drug Aspirin on prostate cancer cell proliferation, migration and 
invasion (Lloyd et al., 2003, Bilani et al., 2017).   
Together these findings support pro-inflammatory signalling and constitutive activation of NF-
kB as drivers of tumour progression and malignancy in PC; making inhibition of NF-kB signalling 
an attractive therapeutic target.  
1.5.3.2 NF-kB in other cancers  
Aberrant NF-kB signalling has also been implicated in other cancers and examples are presented 
below in Table 1.3. 









Breast cancer  
 
Breast cancer cell 
lines 
Hormone-independent breast cancer cells 
presented high constitutive NF-kB activation, 
and this was associated with proliferation. 
Inhibition of NF-kB activation by repression of 
IkBa super-repressor reduced proliferation. 
(Yamaguchi et al., 
2009) 
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Breast cancer cell 
lines and tumour 
specimens 
NF-kB p65 was constitutively active in ER- 
cell lines and tumour samples. All of these 
tumours were poorly differentiated with 
metastasis and poor prognosis. 
(Nakshatri et al., 1997) 
Breast cancer 
specimens 
NF-kB p65 was activated predominantly in 
ER- breast cancers. NF-kB disabled cell death 
pathways and permitted cell proliferation; 
contributing to tumour progression.  
(Biswas et al., 2004) 
 
Lung cancer  
 
Lung specimens IkBa phosphorylation and NF-kB p65 nuclear 
staining was significantly increased in non-
small cell lung cancer cells compared to 
normal epithelial cells. IkBa expression and 
nuclear p65 correlated with poor survival rates. 
(Jin et al., 2008b) 
Non-small cell lung 
cancer meta-analysis 
on published articles 
Higher NF-kB expression was associated with 
short survival and was closely associated with 
tumour stage, metastasis and survival. They 
concluded that NF-kB expression may be an 
unfavourable prognostic marker.  
(Gu et al., 2018) 
Lung cancer 
specimens  
NF-kB expression was higher in de-
differentiated lung cancer specimen compared 
to normal specimens. Expression correlated 
with reduced apoptosis indicating 
unfavourable prognosis for overall survival.  
(Zhang et al., 2006) 
 




Constitutive NF-kB activation is a common 
characteristic in ALL and is plays a role in 
leukaemia cell survival.  
(Kordes et al., 2000) 
Acute myeloid 
leukaemia (AML) 
Pharmacological inhibition of NF-kB in 
primary AML blasts induced apoptosis. This 
was not the Normal hematopoietic stem cells 
were not affected by such inhibition suggesting 
that inhibition of the NF-kB pathway as a 
potential therapeutic approach for AML. 
(Frelin et al., 2005) 
 




NF-kB p65 expression was increased in 
epithelial ovarian tumours compared to normal 
ovarian tissue and expression was correlated to 
poor histological differentiation and late clinical 
stage.  
(Guo et al., 2008) 
Ovarian cancer 
specimens 
NF-kB p65 and RelB were co-expressed with 
IKKa in newly diagnosed advanced ovarian 
cancers. NF-kB p50 expression was associated 
with poorer prognosis. They proposed that the 
p50 gene is a direct target for the p65 gene and 
becomes upregulated to attenuate the cascade. 
p50 homodimer accumulation in the cytoplasm 
fails to down-regulate NF-kB target pro-
survival factors in the ovarian cells. 
 








NF-kB is constitutively active in melanoma 
cells compared to normal melanocytes and is 
further increased under oxidative stress.  
(Meyskens et al., 1999) 
Tissue biopsies NF-kB p65 proteins are overexpressed in the 
nuclei of dysplastic nevi and melanoma cells 
compared to normal nevi and melanocytes.  
IKBa expression is decreased in melanomas 
relative to normal skin.  
(McNulty et al., 2004) 
 
1.6 Maspin 
Maspin is a 42kDa protein encoded by the class II tumour suppressor gene SERPINB5. It was first 
identified as a tumour suppressor in 1994 by subtractive hybridisation to identify candidate 
tumour suppressor genes in human breast carcinoma cells (Zou et al., 1994). Class II tumour 
suppressor genes function in the negative regulation of cell growth. These genes are not altered 
at the DNA level, but changes to their regulation, and consequently expression, effect their 
phenotype (Sager, 1997). 
1.6.1 Structure and function 
Maspin belongs to the serine protease inhibitor (serpin) superfamily. The distinctive structural 
characteristics of serpin members are 3 b-pleated sheets (A-C), 8-9 a-helices (A-H) and a reactive 
centre loop (RCL) which enables optimal configuration for protease binding and inhibition (Law 
et al., 2006). Figure 1.9 illustrates the crystal structure of maspin. It is a unique member of the 
serpin family and is characterised as a non-inhibitory serpin due to its short, hydrophobic RCL 
which makes it incapable of protease inhibition.  
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Figure 1.9: X-ray crystal structure of maspin. 
Maspin is comprised of 3 b-pleated sheets, a-helices and a short RCL. Figure from (Law et al., 2005) 
 
Despite its non-inhibitory activity, the RCL of maspin has been shown to be required for many of 
maspin’s functional abilities such as its effects on cell adhesion, invasion and apoptosis (Sheng 
et al., 1996, Ngamkitidechakul et al., 2003, Khanaree et al., 2013). Other studies have refuted the 
role of the RCL of maspin as an inhibitor of cell migration and invasion (Cella et al., 2006, 
Ravenhill et al., 2010). Such contentions in the literature highlight a need to conduct further 
research to ascertain the effect of the RCL on cell behaviours.  
Another unique aspect of the maspin protein structure is its G α-helix (G-helix) which is capable 
of an “open and closed” conformational change which results in a rearrangement of charged 
residues within the molecule (Law et al., 2005). A fully functioning G-helix is essential for maspin 
functioning and effects of cell migration and adhesion. Mutations in the G-helix have been found 
to attenuate the inhibition of cell migration and adhesion by maspin in breast and prostate tumour 
cells; highlighting a requirement for a functional G-helix to enable the tumour suppressive action 
of maspin (Ravenhill et al., 2010). More recent reports have also confirmed a role for the G-helix 
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of maspin on the migration and adhesion of endothelial cells and potential application as anti-
angiogenic therapy (Zha et al., 2015).  
1.6.2 Maspin regulation 
Maspin expression in epithelial cells is regulated by various transcription factors within the 
maspin promoter such as Ets and Ap1. The Ets site is able to activate transcription alone whereas 
the Ap1 site requires assistance from Ets to achieve activation and subsequent expression of 
maspin. Reduced Ets and Ap1 site function has been reported in primary breast and prostate 
tumour cells expressing reduced levels of maspin. Function was abolished in invasive breast and 
prostate tumour cells (Zhang et al., 1997a, Zhang et al., 1997b). To this end, loss of maspin 
expression during tumour progression may be in part due to the absence of transactivation through 
Ets and Ap1 binding sites within the maspin promotor region. 
The tumour suppressor gene p53 has also been implicated in the regulation of maspin. Maspin 
expression was increased in maspin deficient breast and prostate cancer cells following adenoviral 
mediated expression of wild type p53. DNA-damaging agents and cytotoxic drugs induced the 
expression of maspin in cells containing wild type p53 (Zou et al., 2000). An inverse correlation 
between mutant p53 and maspin expression has been identified in other cancers including  gastric, 
colon and ovarian (Zhang and Zhang, 2002, Song et al., 2002, Lee et al., 2008, Alvarez Secord et 
al., 2011). 
Maspin expression can be epigenetically regulated and changes in expression are associated with 
DNA methylation, histone deacetylation and chromatic accessibility (Khalkhali-Ellis, 2006). 
Aberrant epigenetic regulation has been associated with maspin gene silencing; an oncogenic 
process in various cancers including those of the breast, prostate, thyroid and colon (Zou et al., 
1994, Boltze et al., 2003, Bettstetter et al., 2005, Wu et al., 2010). Both methylation and histone 
deacetylation are reversible biological modifications and treatment of maspin deficient cancer 
cells with demethylating agents and histone deacetylase (HDAC) inhibitors has been shown to 
induce the re-expression of maspin; making them attractive therapeutic targets (Domann et al., 
2000, Murakami et al., 2004, Abbas and Gupta, 2008). Interestingly, maspin specifically interacts 
and endogenously inhibits histone deacetylase 1 (HDAC-1) and therefore the inhibitory 
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maspin/HDAC-1 interaction may be the molecular basis for the tumour suppressor effects of 
maspin (Kaplun et al., 2012).  
1.6.3 The role of Maspin in normal biology. 
To fully elucidate the roles of Maspin in cancer progression it is important to understand its 
biological function in normal organ development. 
1.6.3.1 Mammary gland 
Maspin was originally identified in human mammary epithelial cells and has since been found to 
play an important role in mammary gland development. Transgenic mice were shown to 
overexpress maspin in the mammary gland under the control of the whey acidic protein (WAP); 
a gene promotor which is expressed mid-pregnancy and throughout lactation (Pittius et al., 1988). 
Over expression of maspin by the WAP promotor during these stages inhibited alveolar 
development and differentiation during pregnancy, indicating that the regulation of maspin 
expression is vital to proper development of the mammary gland during pregnancy (Zhang et al., 
1999).  
1.6.3.2 Development 
To explore the role of Maspin in normal embryonic development, maspin knockout and 
heterozygous mice were developed. Maspin knockout resulted in embryonic lethality at the peri-
implantation stage due to disruption of the endodermal layer, however this was not reported in 
heterozygous maspin models (Gao et al., 2004). Heterozygous knockout models appeared 
morphologically normal after birth but later presented a defect in mammary gland and ovarian 
development at puberty; supporting the crucial role of maspin in early embryonic development. 
Male heterozygous maspin knockout mice models displayed aberrant prostate development and 
hyperplastic lesions; implicating maspin in the epithelial development of the prostate (Shao et al., 
2008). Maspin is not strictly an embryonic gene as it is expressed in adult cell types such as 
myoepithelial cells of the breast (Bodenstine et al., 2012). To this end, maspin functioning is 
diverse and further investigation is required to explore the roles maspin plays in regulating 
development.  
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1.6.3.3 Cell behaviour and tumour suppression 
Maspin was first recognised as a tumour suppressor gene over 25 years ago when Zou et al. (1994) 
utilised subtractive hybridisation to identify candidate tumour suppressor genes that were 
defective in breast carcinomas. Decreased expression of maspin was identified in mammary 
tumour cells. Structural alterations to the maspin gene were not found in the tumour cells 
indicating that decreased expression in these tumours was due to changes in regulation. Following 
this discovery, various studies have explored the role of maspin in cell behaviours which are 
altered during cancer development and progression. These behaviours include proliferation, 
angiogenesis, apoptosis, cell migration and invasion.  
1.6.3.3.1 Angiogenesis 
Maspin is a known inhibitor of angiogenesis; the process in which new blood and lymphatic 
vessels are formed to enable growth and development. Angiogenesis is also a fundamental step 
in cancer and the transition of tumours from benign to malignant (reviewed in Nishida et al. 
(2006)). Formation of new vessels provide tumour cells with the vital nutrients and oxygen 
required for growth. Cells are able to metastasize to other sites in the body by penetrating the 
vessels and circulating through the intravascular system. In vitro studies have demonstrated 
reduced angiogenesis in cultured endothelial cells exposed to recombinant maspin produced in 
Escherichia coli as a recombinant glutathione S-transferase (GST) fusion protein. Recombinant 
maspin inhibited cell migration induced by basic fibroblast growth factor and vascular endothelial 
growth factor. In vivo, angiogenesis was blocked in rats implanted with rat corneas and non-
inflammatory pellets containing Maspin. Maspin derivatives with mutant RCL were unable to 
inhibit migration but were still able to block angiogenesis in vitro and in vivo; implying that the 
RCL of maspin does not affect angiogenesis (Zhang et al., 2000a). The same group utilized an 
athymic mouse xenograft model to determine if the ability of maspin to inhibit angiogenesis plays 
a role in its anti-tumour activity. They implanted LNCaP cells into the mice and monitored tumour 
growth and angiogenesis following treatment with exogenous maspin. Maspin-treated tumours 
presented reduced microvessel density compared to control tumours. (Zhang, 2004). Injection of 
maspin-transfected DU145 cells into the human bone microenvironment has also been shown to 
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limit angiogenesis; suggesting that maspins effect on angiogenesis is not limited to primary 
tumours (Cher et al., 2003).   
1.6.3.3.2 Apoptosis  
Maspin also plays a role in apoptosis. It is the only pro-apoptotic member of the serpin family 
and its effects are specific to pathological or pharmacological apoptotic stimuli (Liu et al., 2004). 
Jiang et al. (2002) provided the first evidence that maspin re-expression in breast cancer cells is 
not sufficient to induce apoptosis in vitro. Endogenous expression of maspin sensitises cells to 
staurosporine (STS)-induced apoptosis and is characterised by increased DNA fragmentation, 
PARP and caspase-8 and 3. It was reported in breast and prostate cancer cells that the apoptosis-
sensitising effect of maspin occurs in response to increased expression of bax; a pro-apoptotic 
member of the Bcl-2 family. Following exposure to bax siRNA, maspin-transfected cells became 
resistant to drug-induced apoptosis. The link between maspin and bax up-regulation in these 
tumours may explain why maspin is often deficient in invasive tumour cells (Liu et al., 2004). 
Intracellular maspin as an active inducer of apoptosis and bax up-regulation has also been 
identified in endothelial cells. The pro-apoptotic effect of maspin was also found to be dependent 
on an intact RCL (Li et al., 2005). A further study found that maspin limits tumour progression 
via the mitochondrial apoptosis pathway (Latha et al., 2005). These findings demonstrate a role 
for maspin in the regulation of cell death and suggest that maspin may be used as a target for 
apoptosis-based therapies.  
1.6.3.3.3 Migration and invasion 
Maspin as an inhibitor of cell migration and invasion was first reported in breast and prostate 
cancer cells exposed to recombinant maspin (rMaspin). Time-lapse microscopy demonstrated that 
rMaspin blocks cell motility leading to reduced cell invasion and metastasis (Sheng et al., 1996). 
A later study demonstrated that maspin exerts its inhibitory effects on both tumour and vascular 
smooth muscle cell (VSMC) migration in the absence of protease inhibition. Despite this, maspin 
may also indirectly influence the cell-surface plasminogen system which may contribute to its 
tumour supressing capabilities (Bass et al., 2002). The group also reported that the inhibitory 
effects of maspin on cell migration in VSMC’s was mediated by binding to b1 integrins on the 
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cell surface (Bass et al., 2009). Other studies have explored the anti-invasion functions of maspin 
in vivo. Implantation of TM40D mammary tumour cells into mice mammary glands were found 
to be highly invasive. A significant reduction of cell invasion and metastasis was reported in 
TM40D cells which were transfected with maspin (Shi et al., 2001). The same group delivered 
maspin/SERPINB5 DNA to female mice bearing mammary tumours. Primary tumour growth and 
metastasis was significantly inhibited, and this was correlated with increased apoptosis (Shi et al., 
2002). Maspin has also been found to supress tumour growth, invasion and metastasis via 
inhibition of histone deacetylases (Bernardo et al., 2011, Dzinic et al., 2014).  
1.6.4 Maspin in cancer 
The role of maspin in cancer progression is conflicting as its expression is down-regulated in 
cancers of the breast, prostate, stomach and skin but up-regulated in cancers of the pancreas, 
colon, gallbladder and thyroid. Different expression patterns between tumours may be explained 
by the subcellular location of maspin in cancer cells and epigenetic modifications (reviewed in 
Berardi et al. (2013)).  
1.6.4.1 Subcellular localisation of maspin 
Maspin is primarily a cytoplasmic protein but may also localise in the nucleus and is secreted. 
Nuclear expression of maspin is required for its tumour suppressor function and is associated with 
improved cancer survival in various tumours including those of the breast, ovaries, head and neck. 
Cytoplasmic expression is associated with aggressive behaviour and poor prognosis (Solomon et 
al., 2006, Goulet et al., 2011). Nuclear expression of maspin is associated with aggressive 
behaviour and poorer prognosis in cancers of the stomach, rectum and colon (Bettstetter et al., 
2005, Berardi et al., 2013, Gurzu et al., 2016). The tumour suppressive function of maspin is 
dependent on subcellular localisation and the organ in which it is expressed. More studies are 
required to understand how maspin is regulated by microenvironment of different tumours. 
1.6.4.2 Epigenetic effects of maspin 
Maspin is epigenetically regulated in a tissue-specific manner and changes to gene expression are 
implicated in cancer progression.  
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Studies have reported aberrant cytosine methylation and chromatin configuration at the maspin 
promoter in several progressive tumours deficient in maspin. Treatment of aberrantly methylated, 
maspin null breast cancer cell lines with the DNA demethylating agent, 5‐aza‐2′‐deoxycytidine 
(5‐aza‐dC) was shown to reactivate maspin gene expression in a dose dependent manner (Domann 
et al., 2000). Immunohistochemistry studies have also demonstrated that aberrant methylation of 
the maspin promotor occurs in vivo during breast carcinogenesis and is associated with loss of 
maspin expression (Futscher et al., 2004). These results support that aberrant methylation of the 
maspin promotor is implicated in maspin gene silencing and cancer progression.  
Maspin has also been shown to regulate the acetylation state of various transcription factors and 
proteins by interacting and inhibiting histone deacetylase 1 (HDAC-1). HDAC-1 hydrolyses N-
acetyl lysine residues in histone and other proteins, leading to chromatin condensation, reduced 
binding of transcription factors to DNA and consequently suppression of gene expression. A yeast 
two-hybrid screen study confirmed the role of maspin as a negative regulator of HDAC-1 activity 
in prostate tissues. The study reported a downregulation of maspin and upregulation of HDAC-1 
in prostate tumour cells, leading to epigenetic changes in favour of dedifferentiation and 
resistance to cell death. These findings support the role of maspin in tumour suppression, cell 
cycle arrest and improved prognosis in cancers (Li et al., 2006). 
1.6.4.3 Maspin in prostate cancer  
Maspin is expressed in normal prostate cells but is often downregulated during tumour 
development and progression. Studies that have explored the role of maspin in prostate cancer are 
detailed below in Table 1.4. Re-activation of maspin expression in prostate tumours is an 
attractive therapeutic target to reduce primary risk of metastasis. 
Table 1.4: Maspin expression in prostate cancer 
Cancer 
sample 





Cells treated with 
recombinant maspin 
exhibited inhibitory effects 
on cell invasion and 
migration  






Maspin downregulation Maspin expression was 
inversely correlated with 
gleason score and 
positively correlated with 
lower tumour stage. 





Maspin downregulation  Maspin expression in 
benign tissues, slightly in 
grade 3 tumours and absent 
in grade 4/5 tumours.  




Maspin downregulation Maspin transfection 
decreased tumour growth, 
reduced osteolysis and 
decreased angiogenesis. 




Maspin downregulation Loss of maspin expression 
correlated to higher tumour 
stage, increasing histologic 
dedifferentiation and 
increased p53 mutation. 






in primary prostate 
cancers 
Loss of maspin expression 
in prostate tumours. 
Upregulation of maspin in 
response to androgen 
ablation suggesting a role 
for maspin in growth 
inhibition and/or apoptosis 
of prostate cancer cells 
during androgen ablation.  
(Zou et al., 2002) 
 
1.6.4.4 Maspin in other cancers 
The expression patterns of maspin in other cancers are presented in Table 1.5. As mentioned 
above in section 1.6.4 and 1.6.4.1, maspin expression is variable between tumour types and this 
is in part due its subcellular location.  
Table 1.5: Maspin expression in other cancers. 
Cancer sample Maspin 
expression 
Key study findings Reference 
 








Loss of maspin occurred most 
frequently in advanced 
cancers. Transfection of 
mammary carcinoma cells 
with maspin reduced cells 
ability to induce tumours and 
metastasise. 







Decreased maspin levels 
correlated with tumour 
progression. Maspin 
downregulation associated 
with increased risk of distant 
metastasis.  






Nuclear maspin = good 
prognosis, Cytoplasmic 
maspin = poor prognosis 
(Mohsin et al., 
2003) 
 











expression = Poorer prognosis 







Loss of maspin contributed to 
invasion and metastasis. 






Enhanced maspin expression 
was associated with favourable 
prognosis 
(Takanami et al., 
2008) 
 






Systematic meta and bio-
informatic analysis of 
databases revealed down-
regulated maspin in gastric 
cancers compared to normal 
mucosa and dysplasia. Higher 
levels associated with 
increased survival.  







Cancer samples expressed 
reduced levels of maspin 
compared to normal mucosa 
and dysplasia. Maspin 
expression was negatively 
associated with invasive depth 
and metastasis but correlated 
with expression of Caspase-3 








Patients with both nuclear and 
cytoplasmic maspin expression 
survived longer than 
cytoplasmic expression alone. 
Expression is inversely 





(Lee et al., 2008) 
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Maspin expression was absent 
in most tumour samples (87.5 
%). Aberrant expression of 
maspin in some cells occurs 
due to epigenetic modification. 





expression lost in 
the transition 
from radial 
growth to vertical 
growth phase 
Maspin correlated with 
decreased angiogenesis and 
tumour thickness; supporting 
its role as a tumour suppressor.  
(Chua et al., 2009) 
 







Maspin was absent in normal 
pancreatic ducts and low-grade 
precancerous lesions. 90% of 
ductal carcinoma samples and 
high-grade precancerous 
lesions expressed maspin. 









Pancreatic carcinoma cells 
acquire maspin expression 
through epigenetic de-
repression of the maspin locus.  
(Fitzgerald et al., 
2003) 
 








IBD and invasive colorectal 
cancers expressed increased 
maspin compared to inactive 
IBD and normal colonic 
mucosa 





Maspin correlated with depth 
of invasion and high-grade 
tumour budding.  
(Umekita et al., 
2006) 
 









Maspin was not expression in 
normal mucosa or adenoma. 
Maspin was expressed in 60% 
of gallbladder tumour and this 
increased from dysplasia to 
carcinoma suggesting that 
maspin may play a role in 
early steps of carcinogenesis 








Maspin expression was 
increased in patients with 
cholelithiasis compared to 
those without. Expression also 
correlated with metaplasia and 
expression may increase 
susceptibility to gallbladder 
carcinoma development.  




1.7 Histone deacetylase  
Histone deacetylases (HDACs) are a family of enzymes that have a crucial role in biological 
processes, largely transcriptional gene repression. There are 18 mammalian HDAC enzymes 
which are categorised into two groups; The class III HDACs which comprise the NAD+ dependent 
sirtuins 1-7 and the classical HDAC enzymes. Classical HDACs fall into two phylogenetic 
classes, class 1 and 2 (de Ruijter et al., 2003). HDAC-1, a member of the class 1 classical HDAC 
family, was the first protein shown to have histone deacetylase activity (Taunton et al., 1996). It 
is a ubiquitous protein located in the cell nucleus and it plays a role in the regulation of cell 
proliferation and survival. HDAC-1 has also been implicated in the regulation of cancer cell 
proliferation and survival (Senese et al., 2007). 
1.7.1 HDAC-1 structure and function 
HDAC-1 is a homolog of the yeast protein Rpd3. It is an enzyme that catalyses the removal of 
acetyl residues from core histones and non-histone proteins, leading to chromatin structure 
condensation and transcriptional repression (Seto and Yoshida, 2014). It shares an almost 
identical catalytic core domain and conserved C-terminal tail with HDAC2. The HDAC catalytic 
domain is formed by a stretch of more than 300 amino acids and it partially overlaps an N-terminal 
HDAC association domain (HAD) which is essential for homo- and heterodimerisation. The C-
terminus of HDAC-1 contains a lysine-rich sequence that is crucial for nuclear localisation of the 
enzyme (Taplick et al., 2001).  
Mice studies have demonstrated a crucial role for HDAC-1 in normal mammalian development 
and proliferation. HDAC-1 gene knockout in mice results in embryonic lethality at day 10 due to 
proliferation and developmental retardation. HDAC-1 deficient embryonic stem cells have also 
presented aberrant cell proliferation and reduced viability. Upregulation of cyclin-dependent 
kinase p21 and p27 expression in these deficient models highlighted an essential role of HDAC-
1 in the regulation of cell proliferation via the repression of cell cycle inhibitors (Lagger et al., 
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2002). Other studies have also reported decreased cell viability in HDAC deficient cells 
(Yamaguchi et al., 2010, Jamaladdin et al., 2014).   
1.7.2 HDAC-1 in cancer initiation 
HDAC-1 has been implicated in cancer initiation and progression due to its role in the negative 
regulation of genes such as cell cycle inhibitors, tumour suppressor genes, apoptotic and 
differentiation factors. This brings about changes to cell proliferation, adhesion, migration and 
invasion; enabling characteristics of cancer development (Parbin et al., 2014).  
HDAC inhibitors have emerged as anti-cancer therapies that induce cell cycle arrest, apoptosis 
and differentiation, and inhibit cell proliferation and angiogenesis (Min et al., 2015). These 
therapies have also been shown to down-regulate DNA repair pathways and enhance cell 
sensitivity to DNA damaging agents. For example, HDAC inhibition downregulates the 
expression of genes associated with HR repair including BRCA1/2 and RAD51; leading to 
sustained DNA damage signalling and defective DNA repair (Kachhap et al., 2010). The potential 
of HDAC inhibitors will be discussed further in section 1.7.3. 
1.7.2.1 HDAC-1 in prostate cancer 
HDAC-1 is frequently upregulated in prostate cancers and is associated with an aggressive 
phenotype that contributes to tumour progression. Immunohistochemical analysis of HDAC-1 in 
prostate carcinoma specimens reported high expression of class 1 HDAC proteins and this 
correlated with tumour dedifferentiation and higher proliferative fractions (Weichert et al., 
2008b). These findings were in line with in vitro studies that utilised a panel of PC cell lines and 
prostate tissues to investigate the expression profile of HDAC-1 and its role in tumour 
development. They reported increased HDAC-1 protein expression in pre-malignant and 
malignant lesions; particularly in hormone refractory prostate tumours. To support the human 
tissue data the group examined the correlation between androgen manipulation and HDAC-1 
expression in mouse models. Castration resulted in HDAC-1 upregulation compared to untreated 
control; highlighting a potential dependence of HDAC-1 on the hormone environment (Halkidou 
et al., 2004).  
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The tumour suppressor maspin influences the acetylation of transcription factors and other 
proteins by interacting and endogenously inhibiting HDAC-1 in tumour cells and tissues; 
including those derived from the prostate (Kaplun et al., 2012). To this end, reduced maspin and 
increased HDAC-1 expression during prostate cancer progression (discussed in 1.6.4.2) may be 
due to a maspin/HDAC-1 interaction in which HDAC-mediated protein deacetylation is regulated 
by maspin. Chemical HDAC inhibitors as inducers of maspin re-expression are an attractive 
potential target for cancer patients with aggressive tumours deficient in maspin. 
1.7.2.2 HDAC-1 in other human cancers 
Aberrant expression of HDAC-1 has been implicated in various human cancer types (Table 1.6) 
and the overexpression of HDACs, particularly HDAC-1, is associated with poor prognosis due 
to repression of important growth suppressive genes.  
Table 1.6: Expression of HDAC-1 in human cancers. 
Cancer type HDAC-1 expression Reference 
Lung HDAC-1 is overexpressed in lung cancer and 
correlates with poor prognosis. Overall 
survival was better in lung cancer patients 
with low HDAC-1 expression. 
(Minamiya et al., 2011, 
Cao et al., 2017) 
Colon HDAC-1 expression is enhanced in highly 
proliferating and dedifferentiated colorectal 
tumours. High expression significantly 
reduced survival. 
(Weichert et al., 2008c, 
Stypula-Cyrus et al., 
2013) 
Breast  HDAC-1 expression is increased in breast 
cancer cells compared to normal epithelial 
breast cells. HDAC-1 knockdown supressed 
proliferation and migration of breast cancer 
cells.  
(Tang et al., 2017) 
Ovarian  High expression of HDAC-1 is associated 
with poor prognosis in ovarian carcinomas. 
HDAC-1 overexpression is associated with 
chemotherapeutic resistance. HDAC-1 
silencing enhances response to therapy.  
(Weichert et al., 2008a, 
Liu et al., 2018) 
Liver HDAC-1 is upregulated in human 
hepatocarcinoma and liver cancer cell lines. 
Inactivation of HDAC-1 results in reduced 
cell proliferation and increased apoptosis.  
(Xie et al., 2012, 
Buurman et al., 2012) 
 
1.7.3  HDAC inhibitors for cancer therapy 
The role of HDAC in cancer progression has led to the development of HDAC inhibitors (HDACi) 
as potential anti-cancer therapies. HDACis can counteract the abnormal acetylation status of 
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proteins in cancer cells, leading to the reactivation of tumour suppressors and consequently 
induction of apoptosis, cell differentiation and inhibition of tumour cell migration and invasion 
(Li and Seto, 2016). HDAC inhibitors also exacerbate DNA damage by inducing the accumulation 
of ROS and downregulating DNA repair proteins involved in DSB repair (reviewed in Marks 
(2010). ROS accumulation following HDAC inhibition may occur via the inhibition of ROS 
scavengers. For example, the HDAC inhibitor SAHA has been shown to upregulate TBP2, an 
inhibitor of the ROS scavenger thioredoxin (Xu et al., 2006).  
The HDAC inhibitory activity of the naturally occurring compounds Butyrate and Trichostatin A 
(TSA) was discovered in the late 1970s and early 1990s, respectively (Riggs et al., 1977, Yoshida 
et al., 1990). These studies demonstrated the efficacy of these compounds as inducers of cell 
differentiation, cell cycle arrest, and inhibitors of cell growth and survival in transformed cells; 
attributable to the inhibition of the HDAC enzymes. There are now a range of natural and 
synthetic chemical compounds that target HDAC and they are comprised of four main structural 
classes: Hydroxamic acids, short-chain fatty acids, cyclic peptides and benzamides. These 
molecules possess varied specificity, pharmacokinetic properties and toxicological characteristics 
(Walkinshaw and Yang, 2008). Vorinostat (sub-eroylanilide hyroxamic acid/SAHA) is 
structurally similar to TSA and was the first FDA-approved HDAC inhibitor for the treatment of 
lymphoma. Over 15 class I HDAC inhibitors have been tested or are under pre-clinical and 
clinical studies to date (Reviewed by Li and Seto (2016)).  
The studies carried out for submission of this thesis utilised the pan HDAC inhibitor Trichostatin 
A (TSA). For this reason, this drug will be discussed in further detail below.  
1.7.3.1 Trichostatin A 
The organic anti-fungal antibiotic TSA is produced by Streptomyces hygroscopicus and is a 
derivative of a primary hydroxamic acid (Tsuji et al., 1976). It is a potent and specific inhibitor 
of HDAC that alters gene expression by reversibly interacting with the HDAC catalytic site to 
inhibit substrate binding; leading to increased histone acetylation and accumulation of acetylated 
histones in the cell (Yoshida et al., 1990). TSA exerts its anti-cancer effects at nanomolar 
concentrations in tumours cells by enhancing the expression of apoptosis-related genes to induce 
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cell differentiation and growth arrest. Various in vitro and in vivo studies have demonstrated the 
efficacy of TSA as a potent inhibitor of proliferation and inducer of apoptosis in tumours 
including those from the breast, bone, lung and prostate (Vigushin et al., 2001, Roh et al., 2004, 
Kim et al., 2006a, Zhang et al., 2015). Increasing concentrations of TSA were shown to suppress 
the proliferation of metastatic prostate cell line PC3 in a time dependent manner. Further 
evaluation revealed increased cell cycle arrest at G1 phase, upregulation of the apoptotic proteins 
caspase-3, caspase-9 and downregulation of bcl-1 (Zhang et al., 2015). TSA has also been shown 
to induce the reversal process of epithelial-mesenchymal transition in PC3 cells; leading to 
attenuated cell invasion and migration capabilities (Wang et al., 2015b). TSA is currently only 
used in laboratory experiments due to its high potency and toxicity. However, it is a cheap and 
effective HDAC inhibitor for preliminary proof of principle experiments (reviewed in 
Eckschlager et al. (2017)). 
1.8 Combined PARP and HDAC inhibition as a potential cancer therapy 
Combination therapy is gaining prominence in cancer therapeutics as multiple defective cellular 
components are often involved in tumorigenesis. Many reports have shown that HDAC inhibitors 
sensitise tumour cells to PARP inhibitors for cancer therapy. For example, prostate cells exposed 
to the HDACi SAHA in combination with the PARPi Olaparib have shown a synergistic decrease 
in cell viability. This coincided with increased apoptosis and DNA damage which concomitantly 
downregulated DNA repair proteins associated with HR (Chao and Goodman, 2014). 
Glioblastoma studies have also reported down-regulation of the DNA response following 
inhibition of HDAC and sensitisation to PARP inhibition (Rasmussen et al., 2016). The efficacy 
of PARP and HDAC inhibitor co-targeting has also been explored in triple negative breast 
cancers. Co-treatment inhibited cell proliferation, particularly in BRCA mutated cell lines 
(Marijon et al., 2018). These results demonstrate a rationale to combine a HDACi with a PARPi 
to limit DNA repair and sensitise aggressive tumours to PARP inhibition.  
1.9 Rationale and hypothesis 
Studies have explored the potential of HDAC and PARP inhibitors as co-targeting agents for 
cancer therapy, but they have not yet explored the effects of NF-kB and maspin on cell sensitivity 
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to HDACi and PARPi co-treatment. Downregulation of Maspin has been associated with 
constitutive activation of NF-kB activation in PC. Constitutive activation of NF-kB is common 
in many cancers and correlates with increased metastatic potential and therapeutic resistance (Xia 
et al., 2014). 
IKKa, an activator of NF-kB signalling, exerts its pro-metastatic effects in tumours by repressing 
transcription of the maspin gene; leading to gene silencing and tumour exacerbation (Luo et al., 
2007). Inhibition of IKKa has been shown to enhance maspin expression in prostate tumours, 
resulting in reduced tumour invasiveness (Mahato et al., 2011, Leopizzi et al., 2017). Thus, 
inhibition of NF-kB with a PARPi represents an attractive target for therapeutic exploitation.  
One of the most interesting concepts of combining PARP inhibitors is  to induce synthetic lethality 
by combining them with agents that hinder DNA repair by HR, such as HDAC inhibitors which 
have been shown to mimic a HR-deficient phenotype by downregulating the expression of major 
DNA repair signalling HR proteins (reviewed in Groselj et al. (2013). Studies have linked NF-kB 
to HDAC, showing that the transactivation function of NF-kB is in part regulated through its 
association with HDAC 1 and 2 corepressor proteins (Ashburner et al., 2001). Maspin interacts 
and endogenously inhibits HDAC-1 (Kaplun et al., 2012) and chemical inhibition of HDAC-1 
has been found to prevent activation of NF-kB (Place et al., 2005). Studies using PC cells and 
clinical specimens have demonstrated the re-expression of maspin following inhibition of HDAC-
1 (Abbas and Gupta, 2008). 
These studies, along with experimental interactions and text mining on the STRING database 
(Figure 1.10), show a link between PARP-1, NF-kB, maspin and HDAC. The STRING database 
aims to collect and integrate data of all functional interactions between expressed proteins in a 
large number of organisms (Szklarczyk et al., 2017). Despite known interactions between these 





Figure 1.10: STRING network visualisation of PARP-1, HDAC-1, SERPINB5/Maspin and NF-kB 
protein-protein interactions.  
The interaction network highlights the predicted associations with proteins of interest. The network nodes 
are proteins and the edges connecting each protein together signify the predicted functional associations. 
Each coloured line represented different types of evidence which supports the protein-protein interaction 
(Pink: experimental determined interactions, Green: text mining, Black: co-expression, Light blue: database 
evidence and Purple: protein homology).  
 
It is hypothesised that constitutively activated NF-kB down regulates maspin leading to a more 
aggressive phenotype and resistance to cancer therapy. Inhibition of constitutively active NF-kB 
with the PARP inhibitor Rucaparib will enhance maspin expression and sensitise PC cancer cells 
to therapy. This sensitisation will be increased following combination treatment of Rucaparib 
with the HDAC inhibitor Trichostatin A (TSA). The interplay between these molecules and the 
potential effects of PARP-1 and HDAC-1 inhibition is depicted in the schematic presented below 
in Figure 1.11.  
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Figure 1.11: Potential interplay between PARP-1, NF-kB, IKKa, HDAC-1 and maspin molecules and 
the hypothetical effects of PARP and HDAC inhibitors on the expression and regulation of these 
molecules.  
PARP-1 is a known co-activator of NF-kB. Constitutive activation of NF-kB is an unfavourable phenotype 
in cancer and is associated with increased metastatic potential and tumour progression. Downregulation of 
the tumour suppressor maspin is also an unfavourable phenotype in cancer and such downregulation is 
associated with increased expression of IKKa; an activator of NF-kB. Inhibition of NF-kB with a PARP-1 
inhibitor may enhance expression of maspin leading to a more favourable phenotype. Maspin is an 
endogenous inhibitor of HDAC-1 and inhibition of HDAC-1 limits activation of NF-kB. Thus, combined 
inhibition of PARP-1 and HDAC-1 limit NF-kB and upregulate maspin to sensitise tumours to cancer 
therapies. Green arrows represent upregulation, red arrows represent downregulation and flat arrowheads 
represent inhibition. 
 
1.10 Aims  
The general aim of this thesis is to investigate the effect of PARP-1 and HDAC-1 on cell 
behaviours in prostate cell models of varied maspin expression. More specifically, the studies 
presented in this thesis aim to: 
1. Confirm a relationship between NF-kB and maspin in prostate cells. 
2. Investigate cell viability, growth, survival and DNA damage in response to PARP and HDAC 
inhibitors in prostate cells of varied maspin status. 
3. Investigate the combined effects of PARP and HDAC inhibitors on cell viability, growth, 









Downregulation induces an aggressive 
phenotype in prostate tumours
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4. Investigate the combined effects of PARP and HDAC inhibitors on cell migration in prostate 
cells of varied maspin status. 
5. Investigate the role of maspin and NF-kB in cell survival with use of maspin and PARP-1 
siRNA, alone and in combination with PARP and HDAC inhibitors; with a view to show 
mechanism between maspin and NF-kB in tumour progression. 
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Chapter Two  
Materials and methods 
2.1 Materials and reagents 
Essential experimental chemicals were obtained from Sigma Aldrich (Poole, Dorset, UK) unless 
otherwise stated in the text. Sterile plasticware for cell culture experiments was supplied by 
CellStar (Greiner Bio-One, Gloucester). Cell culture media and components were supplied by 
Life Technologies (Paisley, UK). All other lab equipment was from Eppendorf (Stevenage, UK) 
or Sigma Aldrich, unless otherwise stated. Primary antibodies used for Western blotting and 
Immunofluorescence were obtained from various sources (Table 2.3). Secondary antibodies for 
Western blotting (Table 2.4) were supplied from Dako (Cambridgeshire, UK), and those used for 
Immunofluorescence were from Thermo Fisher Scientific (Waltham, MA USA). 
Table 2.1: Buffers and solutions 
Buffer/solution Preparation 
1% Acetic acid 10ml Acetic acid in 1 litre distilled water. 
1% BSA /PBS blocking agent (BSA/PBS block)  100mg Bovine Serum Albumin (w/v) in 
10ml 1x PBS. 
10 X PBS 80g NaCl, 2g KCl, 6.1g Na2HPO4 and 2g 
KH2PO4 in 1 litre distilled water. 
SDS-PAGE running buffer 2.4g Tris, 14.4g Glycine and 10% SDS 
(w/v) in 1 litre distilled water. 
Carnoys fixative 30% Acetic acid (v/v) in 70% Methanol 
(v/v). 
PBS/0.5% Tween 20 (PBS-T) 500µl Tween 20 in 1 litre 1x PBS 
PBS/0.05% Tween 20/5 % milk powder (PBS-
MT) 
5% milk powder in 100ml 1X PBS-T. 
Total protein extraction buffer (RIPA)  300µl 5M NaCl, 100µl 0.5M EDTA, 500µl 
1M Tris, 100µl Triton-X, 100µl 10% 
Sodium Deoxycholate, 100µl 10% SDS 
and one complete EDTA free PIC tablet in 
8.4ml distilled water.  
SDS-PAGE 10% resolving gel 3.3ml Acrylamide (30%, 37.5:1 
Acrylamide: Bis-Acrylamide), 2.5ml 
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1.5M Tris-HCl pH 8.8, 100µl SDS (10%), 
100µl 
APS (10%) and 5µl TEMED in 4ml 
distilled water. 
SDS-PAGE stacking gel 1ml Acrylamide (30%, 37.5:1 Acrylamide: 
Bis-Acrylamide), 2.5ml 0.6M Tris-HCl 
pH6.8, 100µl SDS (10%), 100 µl APS 
(10%), 5µl TEMED in 3.2ml distilled 
water. 
SRB solution 4% SRB (w/v) in 1% Acetic acid in 500ml 
distilled water 
Transfer buffer 2.9g Glycine, 5.8g Tris, 0.37g SDS and 
200ml Methanol to 1 litre in distilled 
water. 
Lysis solution  2.5M NaCl (146.1g), 0.1M EDTA (37.2g), 
10mM Tris (1.21g) in 1 litre distilled 
water. pH 10 with concentrated 10M 
NaOH. 
Alkaline electrophoresis solution 0.3M NaOH (12g) and 1 mM EDTA 
(0.37g) in 1 litre distilled water.  
Neutralising buffer 0.4M Tris (12g) in 1 litre distilled water. 
pH 7.5 with concentrated HCL. 
APS, ammonium persulfate; BSA, bovine serum albumin; PBS, phosphate buffered saline; SDS, 
sodium dodecyl sulphate; SDS-PAGE, polyacrylamide gel electrophoresis; SRB,Sulforhodamine 
B;TEMED, N,N,N’,N’-Tetramethylethylenediamine; Tris, Tris(hydroxymethyl)aminomethane; 
EDTA, Ethylenediaminetetraacetic acid; PIC, protease inhibitor cocktail . 
 
The cell lines utilised in the in vitro experiments described in this thesis are presented in Table 
2.2. 
DU145 cells harbour two mutations in the tumour suppressor p53 gene; one on either allele.  PC3 
cells do not express p53 due to a base pair deletion of one allele and a frame shift mutation in the 
other. PNT1A cells are wildtype for p53 (Chappell et al., 2012). The PTEN tumour suppressor 
gene is also mutated in DU145 cells. PC3 cells do not express PTEN due to a loss of function in 
both gene alleles. PTEN (phosphatase and tensin homolog) is involved in the regulation of cell 
behaviours such as growth, survival and migration. Function is frequently lost in cancer 
development; leading to increased cell proliferation and reduced cell death (Song et al., 2012).  
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2.1.1 PARP Inhibitor AG014699 
The PARP inhibitor used throughout this thesis was AG014699, otherwise known as Rucaparib. 
It was the first PARP inhibitor entered into clinical trials as a chemo-potentiator. It was obtained 
from Stratech Scientific Ltd (Suffolk, UK) and stored at -20˚c as a 10mM stock solution in 
Dimethyl Sulfoxide (DMSO). The drug was diluted in DMSO to make stock concentrations, and 
further diluted in appropriate media so that the DMSO concentration was 0.5% (v/v) when added 
to cells. The chemical structure of Rucaparib is presented in Figure 2.1. 
 
Figure 2.1: Chemical structure of the potent PARP inhibitor Rucaparib. 
Obtained from: http://www.selleckchem.com/ 
 
2.1.2 Histone deacetylase inhibitor Trichostatin A 
The histone deacaetylase (HDAC) inhibitor selected for use was Trichostatin A (TSA). It was 
obtained from Sigma Aldrich (Poole, Dorset, UK) and stored at -20˚c as a 1mM stock solution in 
DMSO.  The chemical structure of TSA is presented in Figure 2.2. 
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Figure 2.2: The chemical structure of HDAC inhibitor Trichostatin A. 
Obtained from: http://www.sigmaaldrich.com/ 
 
2.2 General methods 
2.2.1 Mammalian cell culture 
Immortalised prostate and mouse embryonic fibroblast (MEF) cell lines were selected for in vitro 
experiments. Prostate cells were kindly provided by Dr Luke Gaughan, Newcastle UK. Cell lines 
are summarised below and in Table 2.2 to assist with interpretation of results. 
§ PNT1A: Normal prostate epithelial cells established by transfection with a plasmid 
containing SV40 genome with a defective replication origin (Sigma Aldrich) . Primary 
culture was obtained from a 35-year old male.  
§ DU145: Epithelial prostate cancer cells isolated from brain metastasis (Stone et al., 
1978b). They are AR- and express negligible amounts of endogenous maspin (Ma et al., 
2012).  
§ PC3: Grade 4 prostatic adenocarcinoma cells isolated from bone metastasis. Highly 
aggressive cells that express maspin. They are androgen receptor (AR) - and prostate 
specific antigen (PSA) - (Tai et al., 2011). 
§ MEF p65+/+: Immortalised MEF cells derived from primary cells. 
§ MEF p65-/-: Immortalised MEF cells. Knockout for NFkB p65. 
§ MEF IKKa-/-: Immortalised MEF cells. Knockout for IKKa. 
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2.2.1.1 Resurrection of cryopreserved cell lines from frozen storage 
Cell lines were resurrected from long-term storage at -150˚c by warming at 37˚c to thaw the cell 
suspension which was diluted in freezing media (80% v/v complete medium, 10% (v/v) FCS and 
10% (v/v) DMSO). Traces of DMSO were removed from the cell suspension via centrifugation 
at 1200rpm, and cell pellets were re-suspended in fully supplemented growth media (Table 2.2) 
in sterile tissue culture flasks.  
2.2.1.2 Routine culture of cell lines 
Mammalian cell lines were cultured as monolayers in plastic tissue culture flasks and maintained 
in exponential growth at 37°C in a humidified incubator (5% CO2 and 95% O2). Cells were 
assigned their own growth reagents (Table 2.2) under sterile conditions in class II tissue culture 
hoods.  
During routine sub-culture, and in experiments, media was removed from the flasks and the cells 
were briefly washed in sterile 1X PBS. A 2ml volume of 1X 0.5% (v/v) Trypsin/PBS was added, 
and the cells were incubated in the trypsin solution for 5 minutes. When cells were detached from 
the flask surface, trypsin was inactivated by the addition of an equal volume of fully supplemented 
media. Cells were seeded into new flasks at their optimum growing densities, as identified by cell 
proliferation assays. Seeding densities were calculated by counting the cells in the original cell 
suspension using a haemocytometer, as later described. 
2.2.1.3 Cell counting using a haemocytometer 
In the cell studies described in this thesis, a haemocytometer was used to count cells. 
2.2.1.3.1 Principle 
A haemocytometer is a thick glass microscope slide containing two flat chambers of known depth 
with a grid of perpendicular lines etched onto the surface.  The slide is prepared by breathing over 
it and sliding a glass cover slip over the chambers. Each chamber is comprised of 9 large 1mm2  
squares of 0.1mm depth, which are further divided into 16 smaller squares (see figure). The 
volume of each large square is 0.1mm3. It is known that 1mm3 is equal to 1µl, and the conversion 
factor for 1ml is x 104.  
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Figure 2.3: Chamber layout of a haemocytometer 
 
2.2.1.3.2 Method 
The cell suspension was mixed thoroughly and 10µl was pipetted on to the edge of the 
haemocytometer chamber where it was drawn under the coverslip by capillary action. Using a 
40X objective under the microscope, cells lying within the four 1mm2 corner squares were 
counted; including those lying on the top and left-hand lines. The following formula was applied 





2.2.1.4 Preparing cell stocks for long term freezer storage  
Exponentially growing cells were removed from culture flasks with 1X 0.5% (v/v) Trypsin/PBS 
as previously described in 2.2.1.2. The cell pellet was re-suspended in freezing media (80% v/v 
complete medium, 10% (v/v) FCS and 10% (v/v) DMSO) to a concentration of 1 x 106 cells/ml 
and transferred to cryovials. Cell suspensions were stored overnight at -80oc and then transferred 
to a -120oc freezer for long term storage.  
2.2.1.5 Mycoplasma testing 
2.2.1.5.1 Principle 
A major problem in cell culture laboratories is mycoplasma contamination. Mycoplasmas are not 
detectable by morphological changes to the cell or visual presence in the cell culture medium. 
1mm
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They induce changes to the cell such as: altered protein and nucleic acid synthesis, altered cell 
metabolism, viability and growth (Drexler and Uphoff, 2002). A quick and cost-effective way to 
check for mycoplasma contamination is to stain cells with 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI). DAPI is an indirect nucleic acid stain which binds to DNA and forms 
strong fluorescent DNA-DAPI complexes which fluoresce blue under a fluorescent microscope. 
Uncontaminated cultures stained with DAPI will highlight the cell nuclei, however cultures which 
are contaminated with mycoplasma will also show discreet fluorescent filaments over the 
cytoplasm and occasionally in intercellular spaces (Nikfarjam and Farzaneh, 2012b). The DAPI 
staining technique can produce false positive or false negative results, and therefore the gold 
standard is to confirm findings with a rapid and sensitive detection method such as polymerase 
chain reaction (PCR).  Cell cultures were tested for mycoplasma contamination by routine testing 
using the PCR based Venor™GeM Mycoplasma detection kit (Cambio, Cambridge, UK) 
alongside DAPI staining, on a three-monthly basis. 
2.2.1.5.2 Method 
Cells were grown on to sterile circular glass coverslips (22 mm diameter, 1mm thickness) in wells 
of a sterile 24 well plate. After a 72-hour incubation period, cells were fixed with Carnoys fixative 
(Table 2.1), briefly washed with PBS and then mounted onto microscope slides with Vectorshield 
hard set mounting medium with DAPI (Vector laboratories; Peterborough, UK). Images of cells 
in a fixed state were captured at a 40X magnification using a confocal microscope (Leica 
Microsystems Ltd, UK). For PCR based mycoplasma screening, 100µl of cell culture supernatant 
was taken from a 90% confluent flask of cells, heated for 5 minutes at 95oc and centrifuged at 
13000 rpm for 2 minutes. PCR reaction tubes were set up containing 2µl of centrifuged 
supernatant and 23µl of PCR mastermix. For positive control, 2µl of positive control DNA was 
added to the positive control reaction tube. PCR was set up and carried out for 1 cycle at 94oc for 
2 minutes, 39 cycles of 94oc for 30 seconds, 55oc for 1 minute and 72oc for 30 seconds. Products 
were then ran on a 1.5% agarose gel for 20 minutes at 100v alongside positive and negative 
controls, and bands were visualised on the G: Box chemo xx6 imaging system (Syngene, 
Cambridge, UK). Positive samples will have a band at 270 base pairs (BP).  
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2.2.2 Assessment of cell and nuclear morphology 
2.2.2.1.1 Principle 
Examining the morphological characteristics of cells in culture such as their shape, structure and 
form, is essential for successful cell culture experiments. Regular assessment of cell morphology 
by microscopy enables detection of contamination, but also cell deterioration, detachment and 
death. Assessment of cell morphology is often carried out alongside cytotoxicity experiments to 
evaluate the effects of cytotoxic drugs on cell health. It is also important to assess nuclear 
morphology in response to cytotoxic agents, as this can give a good indication to the mode of cell 
death. For example, cells undergoing apoptosis display characteristic nuclear alterations such as: 
chromatin condensation, nuclear fragmentation and formation of apoptotic bodies.  
2.2.2.1.2 Method 
To assess cell morphology, cells were seeded onto 6 well plates at 2.5x104/ml and then incubated 
for 24 hours to enable cell adherence. The morphology of the cells was then visualised by eye and 
images were captured on a Leica optical microscope at a 10X magnification. For detection of 
nuclear morphology, cells were seeded on to circular coverslips (22 diameter, 1mm thickness) in 
wells of a sterile 24 well plate at the same density. Following the incubation period cells were 
washed twice with PBS and fixed with 100% methanol at -20oc for 10 minutes. Cells were then 
washed with PBS and mounted onto microscope slides with Vectorshield hard set mounting 
medium with DAPI (Vector laboratories; Peterborough, UK). Fluorescent images were captured 
using a Leica DMi8 inverted confocal microscope (Leica Microsystems Ltd, UK) at a 40X 
magnification. For cytotoxicity experiments, cells were exposed to appropriate drugs alone, and 
in combination for 72 hours prior to any fixing and imaging steps.  
2.2.3 Proliferation and cytotoxicity assays 
2.2.3.1 WST-1 assay  
2.2.3.1.1 Principle 
WST-1 reagent is a tetrazolium salt that measures metabolic activity of the cell and therefore 
cellular proliferation and viability in culture. The assay is based on the ability of viable cells to 
 60 
cleave the tetrazolium salt and produce an orange formazan dye (Figure 2.4). The formazan dye 
is soluble and can be quantified by spectrophotometry at an absorbance of 450nm. The amount 
of formazan dye formed is proportional to the number of metabolically active cells within the 
sample, which directly correlates with cell viability. 
 
Figure 2.4: WST-1 is metabolised to a soluble formazan product which is indicative of cell viability. 
 
2.2.3.1.2 Method 
Cells in exponential growth were harvested, centrifuged (1200 rpm for 6 minutes) and re-
suspended in appropriate growth medium (Table 2.2). To assess cell proliferation, a series of cell 
suspensions at various concentrations (1x105, 5x104, 2.5x104, 1.2x104, and 0.5x104 cells/ml) were 
prepared and 100µl was then pipetted into the wells of a 96 well plate in triplicate. Media was 
added to outer wells of the plate to account for a phenomenon known as the “edge effect” 
(Lundholt et al., 2003). This phenomenon is when the media around the perimeter of the plate 
evaporates, leading to discrepancies with results. Three plates were set up for each cell line and 
one plate was incubated in 10µl/well WST-1 reagent for two hours daily, at 24-hour intervals for 
a total of 72 hours. Absorbance was measured at 450nm using a FLUOstar OMEGA microplate 
reader (BMG LABTECH Ltd, Buckinghamshire, UK). 
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The WST-1 method was also employed to assess the effects of drugs on cell viability.  Cells were 
seeded at their optimum density for proliferation and then returned to incubation (37oc, 5% CO2) 
for 24 hours to allow cells to adhere. Media was aspirated and replaced with fresh media 
containing increasing concentrations of drugs. As drugs were dissolved in DMSO, each well 
contained 0.5% DMSO, including untreated controls. Cells were returned to incubation for 72 
hours before WST-1 was applied. 
2.2.3.1.3 Analysis 
Mean absorbance data was plotted against time graphically on an x-y plot. When drugs were 
added to cells the concentration required to inhibit cell growth by 50% (GI50) was calculated for 
each cell line in each independent experiment. Each assay contained three replicates and results 
presented represent data from three independent experiments. GraphPad PRISM software was 
used to produce point to point graphs, calculate cell doubling time and perform appropriate 
statistical analysis. 
2.2.3.2 Sulforhodamine B (SRB) colorimetric assay for cell growth inhibition 
2.2.3.2.1 Principle 
Cell growth inhibition in response to drug treatment was investigated using the Sulforhodamine 
B (SRB) protein dye assay. This assay is a rapid, sensitive and cost-effective technique to 
determine cell density by measuring cellular protein content. Colour intensity at an absorbance of 
570nm is directly proportional to the amount of protein and subsequently cell mass. 
2.2.3.2.2 Method 
Cells were seeded onto 96 well plates at their optimum growing densities. Medium was added to 
the outer wells of the plates to compensate for the “edge effect”, as previously described in section 
2.2.3.1.2. After a 24-hour incubation period to allow cells to adhere, media was aspirated and 
replaced with 100µl of media containing relevant concentrations of drug in 0.5% (v/v) DMSO. 
Once drug was added to the cells, an additional plate of control cells was fixed with 25µl of 
Carnoys fixative (Table 2.1) to measure the cell density at time 0. Cells were exposed to the drug 
for 72 hours at 37oc, fixed in Carnoys fixative and briefly washed in distilled water. When dry, 
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cells were stained with 0.4% SRB solution (diluted in 1% acetic acid) for 30 minutes, washed in 
1% acetic acid to remove unbound dye and solubilised in 10mM Tris (pH 10.5) for 20 minutes. 
Absorbance of SRB was measured at 570nm using the Spark™ 10M multimode microplate reader 
(Tecan group Ltd, Switzerland) to determine cell density. 
2.2.3.2.3  Analysis 
Mean absorbance data was plotted graphically, and the drug concentration required to inhibit cell 
growth by 50% (GI50) was calculated for each cell line in each independent experiment. Each 
assay contained ten replicates for each drug concentration and results presented represent data 
from three independent experiments. GraphPad PRISM software was used as described in 
2.2.3.1.3. 
2.2.3.3 Cell counting assay 
Cells were seeded into 6 well plates at 2.5x104/ml and returned to incubation for 24 hours. Media 
was replaced with fresh media containing appropriate concentrations of cytotoxic drugs, 
alongside an untreated control with equivalent 0.5% DMSO (1% DMSO for drug combination 
experiments). After 72 hours cells were washed with PBS, trypsin was applied and then cells were 
counted as described in section 2.2.1.3. 
2.2.3.4 Resazurin (Alamar blue) cell viability assay  
2.2.3.4.1 Principle  
Resazurin is a cell permeable redox indicator used to assess cell viability and mitochondrial 
metabolic activity. The assay is based on the ability of viable and metabolically active cells to 
reduce resazurin into a pink, fluorescent, Resorufin product Figure 2.5. The Resorufin product 
can be quantified by spectrophotometry at an absorbance of 560nm. The amount of resorufin 
formed is proportional to the number of metabolically active cells within the sample, which 
directly correlates with cell viability. 
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Figure 2.5: Resazurin is reduced to a resorufin product by metabolically active cells. 
Obtained from: https://www.creative-bioarray.com/support/resazurin-cell-viability-assay.html 
. 
2.2.3.4.2 Method 
Cells were harvested and seeded into 96 well plates as described in section 2.2.3.2, dosed with 
appropriate drugs and cultured for 72 hours. 10µl of resazurin sodium salt solution (1mg/ml in 
PBS) was then added to each well and the plates were placed into incubation for a further 2 hours 
at 37oC. Absorbance was measured at 570nm using a FLUOstar OMEGA microplate reader 
(BMG LABTECH Ltd, Buckinghamshire, UK). 
2.2.3.4.3 Analysis 
Data was analysed as described in 2.2.3.1.3. 
2.2.4 Protein expression analysis 
2.2.4.1 Preparation of whole cell extracts  
Whole cell lysates were prepared by re-suspending harvested cell pellets in an appropriate volume 
of ice cold RIPA lysis buffer (Table 2.1) and EDTA-free complete protease inhibitors (Roche 
Applied Science, Burgess Hill, UK) at 1X concentration. Samples were then vortexed and placed 
on ice for 30 minutes to achieve lysis. Lysate samples were centrifuged at 1200 rpm for 5 minutes 
to remove cell debris and the supernatant was transferred to clean 1.5ml eppendorf’s for 
quantification. 
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2.2.4.2 Protein quantification by BCA assay 
2.2.4.2.1 Principle 
The Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific Inc, IL, USA) 
measures the total protein concentration of a lysate sample against a known protein standard. The 
assay is a colorimetric technique based on the reduction of Cu+2 to Cu+1 by protein in an alkaline 
medium. BCA chelates to CU+1 in a ratio of 2:1 to form a purple-coloured reaction product. 
Absorbance of this product is measured at 570nm using a FLUOstar OMEGA microplate reader 
(BMG LABTECH Ltd, Buckinghamshire, UK). 
2.2.4.2.2 Method 
Bovine serum albumin (BSA) standards of various concentrations were prepared as shown in 
Table 2.5. Lysate samples, diluted 1:10 in RIPA lysis buffer, were loaded in quadruplicate onto a 
96 well plate in 10µl volumes. Standards were loaded alongside each lysate sample. 190µl of 
BCA working reagent was prepared as per the manufacturer’s instructions and added to each well. 
After a 30-minute incubation period at 37oc, absorbance was measured at 570nm on the Spark™ 
10M multimode microplate reader (Tecan group Ltd, Switzerland). Known concentrations of each 
BSA standard were plotted against mean absorbance, and linear regression analysis was carried 
out using GraphPad PRISM to calculate unknown protein concentrations. Results were then 
multiplied by 10 to account for initial sample dilutions.  
 
Table 2.5: Preparation of diluted BSA standards 
BSA standard 
(mg/ml) 
Vial Volume of RIPA lysis 
buffer (µl) 
Volume and source of 
BSA (µl) 
2 A 0 300 of BSA stock 
1.5 B 125 375 of BSA stock 
1 C 325 325 of BSA stock 
0.75 D 175 175 of vial B dilution 
0.5 E 325 325 of vial C dilution 
0.25 F 325 325 of vial E dilution 
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0.125 G 325 325 of vial F dilution 
0.025 H 400 100 of vial G dilution 
0 I 400 0 
 
2.2.4.3 Preparation of protein samples for gel electrophoresis 
Cell lysate samples were diluted to 20µg protein, unless otherwise stated, as per BCA assay 
calculations, in 2X laemelli sample buffer at a 1:1 ratio. Diluted samples were centrifuged (1400 
RPM for one minute) and placed onto a heat block for 5 minutes at 100oc to enable protein 
denaturation and epitope exposure.  
2.2.4.4 Separation of proteins by SDS- polyacrylamide (PAGE) gel electrophoresis 
2.2.4.4.1 Principle 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a method used to 
separate proteins under denaturing conditions according to their molecular weight. PAGE is based 
upon the principle that a charged molecule will migrate in a negative to positive direction through 
a gel towards an electrode when an electric field is applied. SDS, a detergent, denatures the 
proteins and reduces them to linear molecules with uniform charge. This allows the proteins to 
migrate through the gel according to their molecular weight. 
2.2.4.4.2 Method 
SDS PAGE gels were made using 10% resolving and stacking gels (Table 2.1). A 10% gel was 
selected due to the weight of the proteins of interest. Combs were added to the stacking gel to 
form wells for protein loading. Gels were placed into a Bio-Rad mini-PROTEAN® tetra cell tank 
(Bio-Rad; Hertfordshire, UK) and the inner and outer reservoirs were filled with SDS running 
buffer (Table 2.1) according to the manufacturer’s instructions. Protein samples were loaded into 
the wells of the stacking gel alongside a protein molecular weight marker (Bio-Rad; 
Hertfordshire, UK). Proteins were separated by electrophoresis at 100V for two hours.  
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2.2.4.5 Western Blotting 
2.2.4.5.1 Principle 
Separated proteins are transferred from SDS-PAGE gels onto nitrocellulose membranes by 
application of an electrical current. Protein transfer to nitrocellulose membrane is followed by 
immunodetection by specific antibodies.  
2.2.4.5.2 Method 
Two mini-PROTEAN® transfer pads (Bio-Rad; Hertfordshire, UK), two filter paper sheets (Bio-
Rad; Hertfordshire, UK) and one Protran premium 0.45 nitrocellulose membrane (Amersham 
Biosciences; Buckinghamshire, UK) cut to 8cm x 6cm, were soaked in transfer buffer for 30 
minutes (Table 2.1). The apparatus was set up and the blotting cassette was put together as shown 
in Figure 2.6. Proteins were transferred from the gel to the membrane (Table 2.1) for 1 hour at 
100V on ice. When transfer was complete the membranes were removed from the transfer cassette 
and prepared for immuno-detection. 
 




The membrane was blocked in 10ml of PBS-MT (Table 2.1) at room temperature for 1 hour to 
prevent non-specific antibody binding. After blocking, the membrane was incubated overnight at 
4oc in appropriate primary antibody, specific to the protein of interest, diluted in PBS-MT (Table 
2.3). The next day the membrane was washed in PBS-T three times for 5 minutes, and then 
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incubated in appropriate secondary antibody (Table 2.4) diluted in PBS-MT for one hour at room 
temperature. Following incubation of the secondary antibody, four 20-minute washes in PBS-T 
were carried out before detection of protein by enhanced chemiluminescence (ECL).  
2.2.4.7 Enhanced chemiluminescence (ECL) protein detection 
2.2.4.7.1 Principle 
ECL is a light emitting system that requires the oxidation of luminol in the presence of an 
enhancer under alkaline conditions by horseradish peroxidase (HRP). Chemical enhancers 
increase the light intensity and prolong the duration of light emission so that peak emission occurs 
between 2- and 30-minutes following incubation with chemiluminescent reagents. Light emission 
is proportional to protein quantity and can be measured using a G:Box chemi XX6 imaging system 
and Genesys  capturing software (Syngene, Cambridge, UK). 
2.2.4.7.2 Method 
ECL prime detection fluid was used as described in the manufacturer’s instructions (GE 
Healthcare; Buckinghamshire, UK). Luminol enhancer and peroxide reagents were applied to the 
nitrocellulose membrane at a 1:1 ratio and left for 1 minute. Excess ECL reagent was removed 
and the membrane was placed protein side up in the G:Box chemi XX6 imaging system. Images 
were captured with an exposure of the appropriate time.  
2.2.4.7.3 Analysis 
Protein levels were assessed visually by comparing between expression bands. On some 
occasions differences between expression bands were difficult to detect by eye, and so the bands 
were also quantified using Image J software and then standardised to a loading control. 
Quantitative data was plotted graphically in GraphPad PRISM.   
2.2.5 Immunofluorescence 
2.2.5.1.1 Principle 
Immunofluorescence is a technique used to visually assess the presence and subcellular 
localisation of target molecules in a cell sample. The technique involves the use of a primary 
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antibody which specifically binds to a molecule of interest, and a secondary antibody which is 
chemically conjugated to a fluorescent dye. When the secondary antibody is bound to the primary 
antibody, the molecule of interest can be located and visually assessed by fluorescent confocal 
microscopy. The nucleus of each cell can also be visualised by combing a DAPI DNA 
counterstain. 
2.2.5.1.2 Method 
Cells were seeded at a density of 1x104/ml on to sterile circular glass coverslips (22 mm diameter, 
1mm thickness) in wells of a sterile 24 well plate. Following a 48-hour incubation at 37oc, cells 
were washed in ice cold PBS and fixed with 100% methanol at -20oc for 10 minutes. Excess fixing 
agent was washed away with PBS and wells were blocked for 30 minutes in 500µl bovine serum 
albumin (BSA) blocking buffer (1% BSA in 1X PBS). Cells were then incubated at 4oc overnight 
in 100µl of appropriate primary antibodies diluted in BSA blocking buffer (Table 2.1). Following 
incubation with primary antibodies, cells were washed in 500µl PBS/0.1% Tween and then 
incubated in the dark for 1 hour at room temperature in secondary fluorescent antibody diluted in 
BSA blocking buffer. Cells were washed with distilled water and mounted onto microscope slides 
with Vectorshield hard set mounting medium with DAPI (Vector laboratories; Peterborough, 
UK). 
2.2.5.1.3 Analysis 
Images of cells in a fixed state were captured at 40X magnification using a Leica DMi8 inverted 
confocal microscope (Leica Microsystems Ltd, UK). Images were merged together, with LAS X 
software (Leica Microsystems Ltd, UK), so that the expression location of the proteins of interest 
could be visualised alongside the cell nucleus. 
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2.2.6 Quantifying single DNA breaks 
2.2.6.1 Quantifying DNA single strand breaks by Alkaline single cell gel electrophoresis 
assay (comet assay) 
2.2.6.1.1 Principle 
The alkaline comet assay is a technique used to assess DNA damage caused by SSBs. Cells are 
encapsulated in low melting point agarose and pipetted onto pre-coated slides. Cells are then lysed 
under alkaline conditions to unwind the DNA, allowing it to migrate out of the cell in structures 
resembling comets during electrophoresis. To determine the extent of DNA damage the DNA is 
visualised using Vectorshield hard set mounting medium with DAPI (Vector laboratories; 
Peterborough, UK). Cells that have accumulated DNA breaks appear as fluorescent comets with 
tails of fragmented DNA. The intensity of the comet tail relative to the head is a reflection of the 
number of DNA breaks, as described by (Collins et al., 1995) and presented in Figure 2.7 . 
 
Figure 2.7: Comet visual classification (0-4) following staining with DAPI.  
 
2.2.6.1.2 Method 
Glass microscope slides were pre-coated in 1% agarose and left to dry. Meanwhile, cells which 
were exposed to drugs for 72 hours were harvested at a density of 5x104, centrifuged (1500 rpm 
for 3 minutes) and re-suspended in ice cold PBS. Cells were then mixed with 70µl of 1% low 
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melting point (LMP) agarose at 37oc, pipetted onto the dry pre-coated glass slides and refrigerated 
at 4oc for 10 minutes. Once set, the slides were incubated in comet lysis solution (Table 2.1) at 
4oc for one hour in the dark, to prevent DNA repair and protect from further DNA damage. Slides 
were then placed into a wide electrophoresis tank and immersed in cool alkaline electrophoresis 
solution for 40 minutes to unwind the DNA, before electrophoresis at 21V in the dark for 40 
minutes.  The slides were then washed in neutralising buffer, at 5 minutes intervals for 15 minutes 
at 4oc. A drop of Vectorshield hard set mounting medium with DAPI (Vector laboratories; 
Peterborough, UK) was added to the slides to stain the comets and then a coverslip was applied 
in readiness for visualisation and quantification.  
2.2.6.1.3 Analysis  
A Leica DMi8 inverted confocal microscope and associated LAS X software (Leica 
Microsystems Ltd, UK) was used to visualise comets and capture images at 40X magnification. 
Fifty comets were scored visually based upon the 5 recognisable classes of comet, with 0 being 
undamaged, and 4 being maximally damaged (Figure 2.7). 
2.2.7 Quantifying DNA double strand breaks 
2.2.7.1 gH2AX immunofluorescence assay 
2.2.7.1.1 Principle 
H2AX is a histone H2A variant that is ubiquitously expressed throughout the genome and plays 
a key role in the cellular response to DNA damage. DNA double strand breaks (DSBs) prompt 
rapid phosphorylation of H2AX at serine 139 to form gH2AX foci. The number of gH2AX foci 
has been shown to correspond with the number of DSBs within the cell nucleus. Increased levels 
of gH2AX foci have been observed in a number of human cancer cell models including cervical, 
breast, ovarian and melanoma (reviewed in Palla et al. (2017)) and are associated with tumour 
progression and poor prognosis. gH2AX foci are also a useful biomarker for monitoring the 
efficacy of DNA damaging agents in tumour cells (Ivashkevich et al., 2012).  
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This assay detects gH2AX foci in cell nuclei by binding a specific gH2AX primary antibody with 
a fluorescently tagged secondary antibody to enable visual identification of foci by microscopy.  
2.2.7.1.2 Method 
PNT1A, DU145 and PC3 cells were seeded onto sterile circular glass coverslips in wells of a 
sterile 24 well plate, as described in section 2.2.5. Following a 24-hour incubation period to allow 
cell adherence, culture medium was removed and replaced with medium containing GI50 
concentrations of Rucaparib and TSA, alone and in combination. GI50 drug concentrations 
required for each cell line are presented in Chapter Four, section 4.3.7, Table 4.3. Following a 72-
hour incubation period at 37oc, cells were washed in ice cold PBS and fixed with 100% methanol 
at -20oc for 10 minutes. Excess fixing agent was washed away with PBS and wells were blocked 
for 30 minutes in 500µl bovine serum albumin (BSA) blocking buffer (1% BSA in 1X PBS). 
Cells were then incubated at 4oc overnight in 100µl of primary mouse monoclonal gH2AX 
antibody diluted in BSA blocking buffer (Table 2.1). Following incubation with the primary 
antibody, cells were washed in 500µl PBS/0.1% Tween and then incubated in the dark for 1 hour 
at room temperature in secondary fluorescent antibody Alexa Fluor goat anti-mouse (Dako) 
diluted in BSA blocking buffer. Cells were washed with distilled water and mounted onto 
microscope slides with Vectorshield mounting medium with DAPI to counterstain the DNA.  
2.2.7.1.3 Analysis 
Images of cells were captured at 63X magnification using a Leica DMi8 inverted confocal 
microscope (Leica Microsystems Ltd, UK). gH2AX foci were manually quantified in 20 nuclei 
from each treatment slide. Graphs were produced and data was statistically analysed using 
GraphPad prism software. 
2.2.8 Scratch assay  
2.2.8.1.1 Principle 
The in vitro scratch assay, otherwise known as wound healing assay, is a simple and inexpensive 
method used to measure cell migration. An artificial “wound” is created by scratching down the 
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centre of a culture dish containing a confluent cell monolayer. Microscopic images of the scratch 
are captured over time, at regular intervals, to monitor closure of the gap as cells migrate.  
2.2.8.1.2 Method 
Cells were seeded into six well plates at a density of 1x105/ml and incubated for 24 hours to allow 
formation of a confluent monolayer. A p200 pipette tip was then used to gently scratch across the 
centre of the cell monolayer to create a cell free “wound”. Cells were washed with PBS to remove 
cell debris and then appropriate drugs, diluted in fresh fully supplemented media, were added to 
the wells. Cells were visualised at 10X magnification and images of the scratch wound were taken 
following the addition of drugs, and every 24 hours thereafter for a total of 72 hours. 
2.2.8.1.3 Analysis 
Wound closure over time was assessed visually and quantitatively. Image J software was used to 
assess wound closure by tracing the wound parameter to generate a numerical value (pixels) of 
the wound area. Percentage wound closure was calculated from the raw data to produce graphs in 
GraphPad prism.  
2.2.9 xCELLigence real-time cell analyser (RTCA) 
The xCELLigence RTCA system uses micro electric biosensor technology to analyse and 
quantify cellular events in a non-invasive label free, real time manner. The system measures 
electrical impedance across micro-electrodes which are integrated across the bottom of specially 
designed microtiter plates. The impedance measurement is presented as cell index (CI) and is 
used to quantify cell status. CI is a dimensionless parameter and cell status may be viability, 
migration or invasion depending on the type of assay used. The xCELLigence system was used 
to investigate cell migration in the studies described in this thesis.   
2.2.9.1 Cell migration CIM-Plate assays 
2.2.9.1.1 Principle 
The CIM-plate 16 is an electronically integrated Boyden chamber which is used to assess cell 
migration. It is comprised of an upper and lower chamber which snap together. The lower 
chamber has 16 wells whereby appropriate chemoattractant is added as a reservoir for cells in the 
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corresponding upper chamber. The upper chamber has 16 wells which are sealed with a 
polyethylene terephthalate (PET) microporous membrane. Cells are seeded into the upper 
chamber of the plate and pass through the microporous membrane onto gold impendence 
electrodes towards chemoattractant in the lower chamber. The impedance signal produced by cell 
movement from the upper chamber to the lower chamber enables a quantitative kinetic 
measurement representative of cell migration.  
2.2.9.1.2 Method 
Transwell CIM-plates (ACEA Biosciences, Inc, USA) were assembled for migration assays as 
per manufacturer’s instructions. Initially, 160µl (10% FCS, 1% pen/strep) and 50µl (serum 
starved) of media was added to the lower and upper chambers of the plate which were then locked 
together and placed into the xCELLigence RTCA DP device for 30 minutes (37oc, 5% CO2 and 
95% O2) to allow plates to reach equilibrium. Following incubation, a baseline measurement was 
taken, and cells were seeded at their optimum seeding densities into wells of the upper chamber. 
Plates were incubated for a further 15 minutes to allow cells to settle onto the membrane. Cell 
migration through the 8µM pore membrane was measured by a microelectrode on the underside 
of the membrane, giving a cell index value based on impedance. Cell migration was measured 
every 5 minutes for 72 hours in the xCELLigence DP system according to the manufacturer’s 
instructions.  
2.2.9.1.3 Analysis 
Raw data was acquired and analysed with the RTCA software (version 1.2.1, ACEA Biosciences 
Inc). GraphPad PRISM software was then utilised to produce graphical representations.  
2.2.10 Transient small interfering ribonucleic acid (siRNA) transfection 
2.2.10.1.1 Principle 
Ribonucleic acid (RNA) interference (RNAi) is a common tool used to silence any gene by 
inactivation of the corresponding mRNA. The most common way to knockdown gene expression 
by RNAi technology is with use of small interfering RNA (siRNA). siRNA is double stranded 
RNA (dsRNA) that is cleaved by the RNase III enzyme DICER to produce 2 nucleotide overhangs 
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at the 3’ end of the dsRNA. The cleaved siRNA, along with dicer and argonaute-2 (Ago-2) 
proteins, forms a complex known as the RNA-induced silencing complex (RISC); which uses the 
siRNA as a guide to target and cleave mRNA. The cleaved mRNA becomes degraded, leading to 
a loss of RNA transcript and therefore gene silencing. The mechanism of gene silencing is 
presented below in Figure 2.8.  
 
Figure 2.8: siRNA gene silencing mechanism. 
siRNA is transfected into the cell and enters the cytoplasm where it becomes cleaved by the RNase III 
enzyme dicer to produce a 2-nucleotide overhang at the 3’ end of the dsRNA. Cleaved siRNA forms a RISC 
complex with dicer and Ago-2. One of the siRNA strands is cleaved by dicer and removed from the 
complex. The remaining strand in the RISC can bind to the complementary target mRNA sequence. Ago-
2 binds both the siRNA and target mRNA, resulting in mRNA cleavage and consequently gene silencing.  
 
 
This technique relies on siRNA being imported into the cell by transfection. Lipid transfection is 
the most common method of transfection and is the method employed in this thesis. Lipid 
transfection reagents couple a nucleic acid to a cationic lipid to produce a liposome that interacts 
with the cell membrane and enables transportation of the nucleic acid into the cell. 
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Five siRNA molecules were used in this thesis; two were used to knockdown the expression of 
human Maspin, one to knockdown human PARP-1 and two were used as control/non-specific 
siRNAs. Maspin and PARP-1 siRNA target sequences were obtained from the theses of group 
members Dr Louise Brown and Dr Jill Hunter, respectively. The siRNA target sequences are 
presented below in Table 2.6.  



































Maspin siRNA was obtained from Qiagen and reconstituted in 100µl sterile, RNase-free water to 
make a stock concentration of 10µM. Corresponding control siRNA was reconstituted to a 20µM 
concentration. PARP-1 and control siRNA was purchased from Dharmacon and reconstituted in 
1x siRNA buffer to make 20µM stock concentrations. All siRNA oligos were stored at -20°C in 
aliquots until required for transfection. 
Cells were seeded into 6 well plates and incubated at 37°C/5% CO2 for 24 hours prior to 
transfection to enable cell adherence. Cells were then transfected with either 10nM Maspin or 
control siRNA, or 50nM PARP-1 or control siRNA. In sterile conditions, siRNAs were incubated 
in serum free RPMI media for 5 minutes and then mixed with Hiperfect siRNA transfection 
reagent (Qiagen, UK). Transfection mixes were briefly vortexed and incubated at room 
temperature for 30 minutes, to allow the siRNA molecules to form complexes with the Hiperfect, 
and then added directly to the cell culture plate containing cells in a dropwise manner. Cells were 
returned to incubation for 6 hours, before aspirating the media and replacing with fully 
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supplemented media for a desired time period at 37°C/5% CO2. Samples were harvested, lysed 
and then protein knockdown was assessed by Western blotting, as described in 2.2.4. 
2.2.11 Statistical Analysis 
All statistical tests presented were carried out using GraphPad Prism software. The statistical tests 
used throughout this thesis are described below and are specified, as appropriate, in each chapter. 
2.2.11.1 One-way	analysis	of	variance	(ANOVA)	
The one-way ANOVA is a hypothesis-based test that determines whether there are any 
statistically significant differences between the means of three or more independent groups whilst 
considering only one independent variable.  If at least two group means are statistically different 
from each other the test returns a statistically significant result. In this instance, a post hoc test is 
carried out to determine which specific groups differ from each other. Tukey’s with multiple 
comparisons is a common post hoc test and was the post hoc test selected for use in this thesis. It 
compares the means of all treatments to the mean of every other treatment to allow identification 
of groups that significantly differ.  
2.2.11.2 Two-way	ANOVA	
The two-way ANOVA test is an extension of one-way ANOVA. It compares the mean differences 
between the means of three or more independent groups of data that have been split in to two 
independent variables. Like one-way ANOVA, a post hoc test such as Tukey’s with multiple 
comparisons may be carried out if a significant difference is identified between groups.  
2.2.11.3 Independent	T-test	
The independent t-test (unpaired t-test) compares the means of two independent groups, assuming 




Chapter Three  
In vitro studies to characterise a panel of immortalised cell lines.  
3.1  Introduction 
This chapter presents the characterisation of prostate and Mouse Embryonic Fibroblasts (MEF) 
cell lines used throughout this thesis. Additionally, it explores the effect of maspin protein 
expression on the levels and localisation of PARP-1 and NF-kB subunits.  
3.1.1 Cell lines  
Immortalised cell lines are used in medical research to study biological processes at the cellular 
and molecular level. They are cost effective, provide an unlimited supply of cells and bypass 
ethical issues associated with the use of animal and human tissue (Kaur and Dufour, 2012).  
The cell lines selected for study throughout this thesis are summarised in 2.2.1 and Table 2.2. 
DU145 and PC3 human prostate cancer cells are two of the most commonly used androgen-
independent cell lines used in prostate cancer research (Sampson et al., 2013). The PNT1A cell 
line was selected for use as a non-cancerous control. The MEF cells used throughout this thesis 
are isogenic immortalised mouse embryonic fibroblasts engineered from primary cells through 
the introduction of a targeted gene mutation. MEF p65+/+ and p65-/- cells are proficient and 
deficient in the NF-kB p65/RelA gene, respectively. MEF IKKa-/- cells are deficient in the IKKa 
gene. These cell models provide a system for the study of NF-kB genes and their role in cellular 
processes and drug response. Any differences between the isogenic MEF cells in the studies 
presented in thesis provide functional validation attributed to the presence or absence of the NF-
kB p65 and IKKa genes.  
3.1.2 Cell line authentication 
Cell line authentication is important to confirm that you are working with cells that are not cross 
contaminated or misidentified and to add stringency in research results. Despite a rise in cell line 
authentication to meet the demands of high impact journals, many cell lines remain unidentified; 
and there are still an unknown number of publications reporting on misidentified cell lines. 
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Misidentified cell lines impact study reproducibility and validity in research data (Almeida et al., 
2016). To this end, many published articles have been retracted (Clement-Schatlo et al., 2012, He 
et al., 2015, Zhang et al., 2013). HeLa cells are a cervical cancer cell line that have been widely 
documented as a contaminant of tissue culture. The immortalised cell line was derived from the 
cervical cancer cells of Henrietta Lacks, a patient who died of cancer in 1951 (Masters, 2002). 
HeLa were the first immortalised human cancer cell line and are still the most commonly used 
human cell line in biomedical research. Hela cell contamination is a common problem in tissue 
culture research due to rapid proliferation and lack of contact inhibition. The controversy 
surrounding HeLa cell contamination began in the 1960’s when Gartler (1967) demonstrated that 
the epidermoid carcinoma KB cell line identified by Harry Eagle in 1955 was misidentified and 
was in fact HeLa. Strikingly, the original stocks of KB given to the ATCC by Harry Eagle, after 
50 years of testing, still show no authentic material. Vaughan et al. (2017) explored the impact of 
HeLa cell misidentification on scientific literature to highlight the need for journals to require cell 
line authentication testing as a condition of publication. Using the PubMed database, they 
identified 631 journal articles between the years 2000-2014 that stated the use of KB. Only 57 of 
these articles correctly acknowledged that KB were in fact HeLa.  
Short tandem repeat (STR) profiling is the gold standard technique for human cell line 
authentication to the individual gene level. It adheres to a strict standard (ASN-0002) for human 
cell line authentication set out by the American National Standards Institute (ANSI) and the 
American Type Culture Collection (ATCC) (Almeida et al., 2016). STR profiling is an analytical 
DNA technique that utilises primers to identify repeated sequences of DNA (STR loci) that are 
typically 2 to 6 base pairs long. The STR profile generated from a given test sample is compared 
to a parental cell line on the ATCC database to confirm authenticity (Nims et al., 2010). 
Authentication of non-human cell lines is less clear and is burdened by the lack of development 
in testing, databases and accepted STR standards. 
3.1.3 Mycoplasma 
Mycoplasma is a prokaryotic organism that is a frequent contaminant of cell cultures. The 
presence of mycoplasma compromises host cell line physiology by altering gene expression, 
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inducing chromosomal abnormalities and changing cell growth characteristics; consequently 
hindering the results and conclusions of any experiment (Nikfarjam and Farzaneh, 2012a). For 
example, Zhang et al. (2000b) investigated the effects of mycoplasma on gene expression in 
immortalised cervical and prostate cell lines. They measured the transcripts of 38 cytokine genes 
before and after mycoplasma contamination; finding that 55-74% of the cytokine genes expressed 
in the two cell lines were altered. Other studies have also reported changes to gene expression and 
cell growth following Mycoplasma contamination (Miller et al., 2003, Liu and Shou, 2011).  
The main sources of mycoplasma contamination vary from personnel to materials and equipment 
used in the tissue culture laboratories. It is important that laboratories adhere to strict rules for 
aseptic technique to limit contamination, and test cell stocks for potential contamination on a 
regular basis. DNA staining and PCR based methods are the most common techniques used to 
detect mycoplasma contamination.  
3.1.4 Cell proliferation 
Cell proliferation is defined as an increase in cell number secondary to cell growth and division 
(Romar et al., 2016). Assessment of cell proliferation is crucial to cell studies as it provides 
information about general cell health and maintenance. The traditional way to assess cell 
proliferation in cultured cells is by cell counting with a haemocytometer. It is low cost and a direct 
measure of cell number; it is also time consuming and relies on thorough training to minimise 
human error (Morten et al., 2016). Various multiwell-plate assays have been developed to 
measure cell proliferation; each of which monitor different parameters such as protein content, 
DNA synthesis and metabolic activity (Reviewed in Riss et al. (2004) and Orellana and Kasinski 
(2016)). The type of multiwell-plate assay used is dependent on personal preference, the nature 
of the study, cost and the equipment available. The assays are easy to use and are able to assess 
cell proliferation on a large scale, in less time and with increased sensitivity. There are some 
disadvantages to the use of multiwell plate assays for the assessment of cell proliferation. 
Spectrophotometers are only accurate in a linear range and do not discriminate between the 
sample of interest and contaminants that absorb at the same wavelength. Spectrophotometer 
results may also be influenced by temperature, pH and impurities (Geisler, 2015).  
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3.1.5 Cell morphology 
Regular assessment of cell morphology is important when carrying out cell culture work to ensure 
that cells are healthy and free from contamination. Cell deterioration and change to normal 
morphology may occur for a variety of reasons, such as contamination of the culture, cellular 
stress and cytotoxicity. Changes to cell morphology include change in cell shape, size and 
viability.  
3.1.6 Protein expression and localisation 
Proteins are versatile macromolecules and they are involved in virtually every cellular process. 
The expression of proteins within a cell provides insight into complex biological processes.  
Investigating the expression levels of specific proteins is important for cell characterisation but 
also for their roles in disease and progression (Ponten et al., 2009). Many proteins play a role in 
disease and its progression; making them suitable targets for therapeutic exploitation. For 
example, PARP-1 is overexpressed in many different tumours and is associated with disease 
deterioration, metastasis and therapeutic resistance (as discussed in Chapter one, section 1.4). To 
this end, PARP inhibitors have been developed to selectively target PARP-1 with an aim to 
overcome drug resistance and improve disease outcome (Wang et al., 2017).   
Identifying the sub-cellular localisation of a protein within a cell is also an essential step towards 
understanding its function, interaction partners and potential roles in functional biological 
networks. Changes to protein subcellular localisation alters normal cell functioning, behaviour 
and regulation which contributes to the development and progression of human disease, including 
cancer (Hung and Link, 2011). 
3.2 Chapter aims 
The aim of this chapter was to characterise the cell lines used throughout this thesis, to validate 
cell lines, identify optimal conditions for exponential cell growth and seeding, and to assess 
differences in protein expression and localisation for subsequent investigations. The following 
parameters were explored:  
• Cell line authentication 
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• Mycoplasma 
• Cell proliferation rates  
• Cellular morphology 
• Expression and localisation of PARP-1, NF-kB p50, NF-kB p65, IKKα, IKBα, RelB, 
Maspin and HDAC-1 proteins in prostate cell line models by Western Blotting and 
Immunofluorescence. 
3.3 Results 
3.3.1 Authentication of cell lines by DNA STR analysis 
Human cell lines were authenticated by Northgene (Newcastle, UK) to confirm the identity of the 
cell lines and to ensure the validity of research findings. Cell samples were collected using an 
FTA card sample collection kit provided by NorthGene. 
Briefly, cells were harvested, centrifuged and resuspended in fresh fully supplemented media to 
create a cell suspension of 5x105/ml. 50µl of the cell suspension was pipetted on to the centre of 
an FTA card; chemically treated filter paper that that is designed for the collection and 
preservation of biological samples for subsequent DNA analysis. Cell samples were then sent to 
NorthGene in plastic bags with a desiccant for testing and analysis. 
The DNA STR profiles of each cell line were authenticated using markers provided by the ASN-
0002 standard. The STR profile for each cell line was compared against the STR profiles of the 
parental cell lines on the ATCC DNA STR database and a matching percentage was calculated. 
DU145 and PC3 cells were successfully authenticated with a 95% and 94% match, respectively. 
PNT1A was not successfully authenticated as a full allelic reference profile could not be obtained 
on the ATCC database in accordance with the ASN-0002 standards. The STR profile for PNT1A 
was unique and did not match with any samples on the database. A reference STR profile for the 
PNT1A cell line was found online on the ExPASy Bioinformatics resource portal and two STR 
loci that fit the ASN-0002 standard criteria, vWA and Amelogenin, matched with the PNT1A cell 
line. The other Locus identified were not comparable against the criteria. Mouse embryonic 
fibroblasts were not authenticated as these cell lines are not derived from a human source. 
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Table 3.1: PNT1A cell allelic data.  
Genotypes were identified by STR analysis and could not be matched to a profile on the ATTC database. 
Two comparable STR locus were matched online.  








D5 12 | 12 - - 
D13 11 | 11 - - 
D7 10 | 10  - - 
D16 10 | 11 - - 
vWA 17 | 19  17 | 19  Match 
Amelogenin X | Y X | Y Match 
TPOX 8 | 8 - - 
CSF1PO 12 | 12 - - 
THO1 6 | 6 - - 
 
Table 3.2: DU145 cell allelic data.   









D5 10 | 1 10 | 1 Match 
D13 12 | 14 12 | 13 | 14 Mis-Match 
D7 7 | 10 | 11 7 | 10 | 11 Match 
D16 11 | 13 11 | 13 Match 
vWA 17 | 18 | 19 17 | 18 | 19 Match 
Amelogenin X | Y X | Y Match 
TPOX 11 | 11 11 | 11 Match 
CSF1PO 10 | 11 10 | 11 Match 
THO1 7 | 7 7 | 7 Match 
 
Table 3.3: PC3 cell allelic data.  
STR Locus Genotypes: PC3 (cell 
sample) 
 
Genotypes: PC3 Prostate 
Adenocarcinoma Human 




D5 13 | 13 13 | 13 Match 
D13 11 | 11 11 | 11 Match 
D7 8 | 8  8 | 11  Mis-Match 
D16 11 | 11 11 | 11 Match 
vWA 17 | 17  17 | 17  Match 
Amelogenin X | X X | X Match 
TPOX 8 | 9 8 | 9 Match 
CSF1PO 11 | 11 11 | 11 Match 
THO1 6 | 7 6 | 7 Match 
 
3.3.2 Mycoplasma screening 
All of the cell lines used throughout this thesis were screened for mycoplasma using the PCR 
based Venor GeM Mycoplasma Detection Kit, as described in section 2.2.1.5. All prostate and 




Figure 3.1: Mycoplasma testing of (A) Prostate and (B) Mouse embryonic fibroblast (MEF) cell lines 
by PCR using the Venor®GeM OneStep detection kit.  
DNA products were visualised by gel electrophoresis through a 1.5% agarose gel containing SYBR™safe 
(ThermoFisher Scientific, Cramlington, UK). A positive result for mycoplasma gives rise to a band ~270bp. 
All samples tested were negative for mycoplasma contamination (191bp).  
 
Prostate cells were also fixed and stained with DAPI for identification of mycoplasma. Briefly, 
cells were seeded onto glass coverslips in 6-well plates and then fixed with ice cold methanol 
when in exponential growth. Fixed cells were washed in PBS and then mounted onto microscope 
slides with Vectorshield mounting medium containing DAPI. Cell nuclei were visualised by 
confocal microscopy to confirm the presence or absence of mycoplasma contamination. Presence 












































































presented below in Figure 3.2 is representative of mycoplasma contaminated cells stained with 
DAPI. 
 
Figure 3.2: DAPI staining of cells contaminated with mycoplasma.  
The DAPI image demonstrates fluorescence of the eukaryotic cell nuclei and the extra nuclear prokaryotic 
DNA (green arrows). 
 
In line with the PCR data presented in Figure 3.1, the representative DAPI images presented 
below in Figure 3.3 confirm the absence of mycoplasma contamination in all prostate cell lines.  
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Figure 3.3: DAPI staining of prostate cells to confirm the absence of Mycoplasma contamination. 
(A) PNT1A, (B) DU145 and (C) PC3 cell nuclei were stained with DAPI and visualised by confocal 





3.3.3 Proliferation rates of cell lines 
The cell proliferation rate and optimal cell density required for exponential growth was identified 
by WST-1 assay for each cell line, as described in section 2.2.3.1. Prostate cell lines cells 
proliferated exponentially at a cell density of 2.5x104/ml for 72 hours (Figure 3.4 and Figure 3.5). 
MEF p65+/+, MEF p65-/- and MEF IKKα-/- cells proliferated exponentially at a cell density of 
0.5x104/ml for 72 hours. A mean doubling time of 34 +/-1hr was observed for all prostate cell 
lines when seeded at their optimum densities. A mean doubling time of 21 +2hr was observed 




Figure 3.4: Representative growth curves to show cell proliferation of prostate cells.  
(A) PNT1A, (B) DU145 and (C) PC3 cells were seeded at various densities ranging from 1x105/ml to 
0.5x104/ml. Proliferation was measured via cleavage of the WST-1 tetrazolium salt at 24-hour intervals, for 







Figure 3.5: PNT1A, DU145 and PC3 cells proliferate exponentially at a density of 2.5x104/ml. 
(A) A cell seeding density of 2.5x104/ml was selected as the optimum seeding density for all experiments, 
unless otherwise stated, to ensure at least 1-2 cell doublings within the exponential growth phase. Error 
bars represent standard error of the mean (SEM). (B) Normalised graph to show the percentage increase in 
cell proliferation over 72 hours at a density of 2.5 x104/ml. There was no significant difference in cell 
proliferation between DU145, PC3 and PNT1A cells (One-way ANOVA, p=1.0000). Data are the average 
of at least three independent experiments and error bars represent standard error of the mean (SEM). 
 
Table 3.4: Optimum cell densities and doubling times. 
Cell proliferation rates were measured by WST-1 assay and doubling times were calculated by non-linear 
regression of the curve of log absorbance against time in GraphPad PRISM. Data represents the mean of at 
least three independent experiments +/- SD. 









/ml 34 1.23 
DU145 2.5x10
4
/ml 35 2.81 
PC3 2.5x10
4



















3.3.4 Cell morphology 
Cell morphology was assessed during routine subculture and during experiments by light 
microscopy. Cells were seeded at their optimum growing densities and images were captured 
using a Leica optical microscope 24 hours later, when cells had adhered to the surface of culture 
flasks.  
Prostate cell lines presented epithelial-like morphology, appeared polygonal in shape and attached 
to the surface of the culture flasks in discrete patches (Figure 3.6). There were visible differences 
in morphology between the three different prostate cell lines. Normal PNT1A prostate cells are 
larger than the cancerous DU145 and PC3 prostate cells. PNT1A and PC3 appeared to be more 
elongated than DU145 cells. 
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Figure 3.6: Cell morphology of (A) PNT1A, (B) DU145 and (C) PC3 prostate cells in culture.  
Cells were seeded at 2.5x104/ml. Images were captured 24 hours after seeding by Brightfield microscopy, 
X10 magnification. 
 
MEF cells presented a fibroblast-like morphology, as shown in Figure 3.7. MEF IKKa-/- knockout 




Figure 3.7: Cell morphology of MEF cells (A) p65+/+, (B) p65-/- and (C) IKKa-/- in culture.  




3.3.5 Protein expression and subcellular localisation 
The expression levels of PARP-1, NF-kB p50, NF-kB p65, IKKα, IKBα, RelB, maspin and 
HDAC-1 proteins were visualised in PNT1A, DU145 and PC3 prostate cells by Western blotting 
(Figure 3.8). Briefly, exponentially growing cells were harvested, cell lysates were prepared and 
loaded onto 10% SDS-PAGE gels prior to protein separation by gel electrophoresis; as described 
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in section 2.2.4. Separated proteins were electro-transferred onto nitrocellulose membrane and 
probed for the proteins of interest using specific antibodies (Table 2.3 and Table 2.4). The house 
keeping protein, Anti-Actin, was used as a loading control. This loading control was chosen due 
to its general expression across all eukaryotic cells. It must be acknowledged that the protein 
expression data for PNT1A cells are from a different experiment and therefore the protein levels 
in these cells are subjective and the best estimates.  
PARP-1 protein levels were higher in PNT1A and PC3 cells than DU145 cells. Interestingly, 
DU145 cells expressed higher levels of NF-kB p50 protein but lower levels of NF-kB p65 and 
RelB when compared to PNT1A and PC3 prostate cells. IKKα protein expression levels were also 
higher in DU145 cells. Expression of IKBα appeared equal in all cells lines relative to loading 
control. As expected, maspin levels were less in DU145 cells than that observed in PNT1A and 





Figure 3.8: Representative Western blots of whole PNT1A, DU145 and PC3 prostate cell protein 
extracts. 
Blots were probed using antibodies against: PARP-1, NF-kB p50, NF-kB p65, IKKα, IKBα, RelB, maspin, 




Protein expression levels were normalised to Anti-Actin loading controls and quantified using 
ImageJ densitometry software. This produced semi-quantitative measurements of protein 
expression which enabled standardised comparison of proteins between each cell line. This data 
is presented in Figure 3.9. Significant differences in the expression levels of proteins were 
determined by one-way ANOVA analysis followed by Tukey’s multiple comparisons test. The 
mean semi-quantified expression data mirrored the visual expression results presented in Figure 
3.8, whereby the expression of IKKα was inversely proportional to maspin expression (Figure 3.9 
D and G). PARP-1 expression (A) correlated with NF-kB p65 (C) and maspin (G) expression. 




Figure 3.9: Semi-quantitative expression of proteins in prostate cell lines. 
(A) PARP -1, (B) NF-kB p50, (C) NFkB p65, (D) IKKα, (E) IKBα, (F) RelB, (G) Maspin and (H) HDAC-
1 protein expression in PNT1A, DU145 and PC3 cell lines was quantified with ImageJ densitometry 
software. Expression data were normalised to β-actin and expressed as mean + SEM (n = 3). Significant 
differences were determined by one-way ANOVA analysis followed by Tukey’s multiple comparison test. 
*P < 0.05, **P < 0.01 and ***P <0.001.  
 
The results presented below (Figure 3.10-Figure 3.12) display the expression levels of the proteins 
investigated in each cell line along with immunofluorescence results to show their subcellular 
localisation. For immunofluorescence experiments, cells were grown on to glass coverslips for 
48 hours, fixed in 100% ice cold methanol, incubated with appropriate primary and secondary 
antibodies (Table 2.3 and Table 2.4) and then visualised with confocal microscopy, as described 
in section 2.2.5.  
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The expression of PARP-1 protein was less than the expression of maspin (P<0.05) in PNT1A 
cells. This could indicate that the maspin antibody worked better than the PARP-1 antibody for 
the immunofluorescence technique. HDAC-1 and IKKα expression levels were both reduced in 
the presence of maspin (P<0.05). Interestingly, there were higher levels of NF-kB p65 than NF-
kB p50 (Figure 3.10a). PARP-1 and HDAC-1 expression was confined to the nucleus of PNT1A 
cells. Maspin, NF-kB p65 and NF-kB p50 was confined to the cytoplasm. Expression of NF-kB 
p50 was low in comparison to NF-kB p65, in line with Western blotting results. IKKa, IKBa and 
RelB was expressed in both the nucleus and cytoplasm (Figure 3.10b).
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Figure 3.10: Protein quantification and Immunofluoresence staining of PNT1A cells.  
(A) Protein quantification of PARP-1, NFkB p50, NFkB p65, IKKα, IKBα, RelB, Maspin and HDAC-1 normalised to β-actin. Data presented are the mean + SEM of at least three 
independent experiments. (B) Immunofluorescence staining to show protein expression and localisation in PNT1A cells. Proteins were detected using Alexa Fluor 488 (green) and 
Alexa Fluor 568 (red) conjugated antibodies. Nuclei were counterstained with DAPI (blue). Scale bar = 18um.  
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The expression of PARP-1 protein was low in DU145 cells; significantly less than the expression 
of NF-kB p50 (P<0.001), IKKa (P<0.01), IKBa and HDAC-1 (P<0.05). There was no significant 
difference in the expression of PARP-1 and maspin. Maspin expression was lower than the 
expression of IKKa (P<0.01) and HDAC-1 (P<0.05). The expression levels of NF-kB p50 were 
higher than NF-kB p65, RelB and maspin. IKKa expression levels were higher than those of NF-
kB p65 (P<0.05) (Figure 3.11a). PARP-1 and HDAC-1 expression was confined to the nucleus. 
Maspin subcellular localisation was not apparent. NF-kB p65 and NF-kB p50 was confined to the 





Figure 3.11: Protein quantification and Immunofluoresence staining of DU145 cells.  
(A) Protein quantification of PARP-1, NF-kB p50, NF-kB p65, IKKα, IKBα, RelB, Maspin and HDAC-1 normalised to β-actin. Data presented are the mean + SEM of at least three 
independent experiments. (B) Immunofluorescence staining to show protein expression and localisation in DU145 cells. Proteins were detected using Alexa Fluor 488 (green) and 
Alexa Fluor 568 (red) conjugated antibodies. Nuclei were counterstained with DAPI (blue). Scale bar = 18um. 
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There was no significant difference in the expression levels of PARP-1, NF-kB p65, RelB and 
maspin in PC3 cells. NF-kB p65 levels were higher than those of NF-kB p50. Maspin expression 
levels were higher than the expression levels of both IKKα and HDAC-1 (P<0.05) (Figure 3.12a). 
PARP-1, HDAC-1 and RelB expression was confined to the nucleus of PC3 cells, however, NF-
kB p65 and NF-kB p50 was confined to the cytoplasm. Maspin is expressed in both the nucleus 
and cytoplasm. IKKa and IKBa also localised to both subcellular locations. RelB expression was 
confined to the nucleus (Figure 3.12). 
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Figure 3.12: Protein quantification and Immunofluoresence staining of PC3 cells. 
 (A) Protein quantification of PARP-1, NF-kB p50, NF-kB p65, IKKα, IKBα, RelB, Maspin and HDAC-1 normalised to β-actin. Data presented are the mean + SEM of at least three 
independent experiments. (B) Immunofluorescence staining to show protein expression and localisation in PC3 cells. Proteins were detected using Alexa Fluor 488 (green) and Alexa 
Fluor 568 (red) conjugated antibodies. Nuclei were counterstained with DAPI (blue). Scale bar = 18um. 
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In summary, PARP-1 protein expression levels were inversely correlated to the expression of 
HDAC-1 (P<0.05) and IKKα (P<0.01) proteins in DU145 cells, and vice versa in PNT1A and 
PC3 cells. PARP-1 and NF-kB p65 protein levels were higher in cell lines expressing increased 
levels of maspin; when compared to the cells which expressed low levels of maspin. In PNT1A 
cells NF-kB p50 expression levels were lower than NF-kB p65 levels. This pattern was 
increasingly evident in PC3 cells, in DU145 cells NF-kB p65 protein expression was significantly 
higher than NF-kB p50 (P<0.001). An expression pattern between maspin, HDAC-1 and IKKα 
was observed. IKKα and HDAC-1 corelate each other, and their expression is inversely correlated 
to the expression of maspin (P<0.05). Maspin, PARP-1 and NF-kB p65 correlate one another.  
PARP-1 was expressed in the nucleus of all prostate cells but was most intense in PNT1A and 
PC3 cells, in line with the total protein expression data (Figure 3.8 and Figure 3.9). NF-kB p50 
was expressed at low levels in the cytoplasm of PNT1A and DU145 cells but not in PC3 cells. 
PC3 cells have the least whole NF-kB p50 protein expression and the lack of expression by 
immunofluorescence may be that the antibody doesn’t work as well in Immunofluorescence. NF-
kB p65 was expressed in the cytoplasm of all cell lines and was most intense in PNT1A and PC3 
cells. Maspin was expressed in the cytoplasm of PNT1A cells and, interestingly, in both the 
cytoplasm and nucleus of PC3 cells. DU145 cells were not found to express maspin. IKKa was 
expressed in the cytoplasm and nucleus of all cell lines, however expression was more apparent 
in the nucleus of DU145 cells. Immunostaining of the HDAC-1 protein was most intense in 
DU145 and, interestingly, PC3 cell lines. 
The protein expression levels of maspin, NF-kB p65 and IKKa proteins were also visualised in 
MEF cell lines (Figure 3.13). MEF p65+/+ cells did not express maspin, MEF p65-/- cells expressed 
negligible levels of maspin. Maspin expression levels were highest in MEF IKKα -/- cells. These 
results correlate with the prostate cell protein expression data in Figure 3.9; whereby NF-kB p65 
inversely correlated with IKKα protein expression. IKKα expression is also inversely correlated 
with the expression of maspin. PARP protein expression levels were not assessed but previous 
studies carried out by Hunter et al. (2012) have shown comparable levels of PARP-1 between the 
MEF cell lines.  
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Figure 3.13: Western Blots of whole MEF cell protein extracts.  




The aim of this chapter was to authenticate and characterise the cell lines for in vitro use 
throughout this thesis.  
3.4.1 Cell line authentication and mycoplasma screening 
To overcome any potential contamination often seen in research (Capes-Davis et al., 2010), it is 
common practise to authenticate cell lines and routinely test for mycoplasma contamination as 
the consequences of widespread contamination and misidentification are vast. All human cell 
lines used throughout this thesis were tested for authenticity by STR analysis in accordance with 
ASN-0002 standards set out by the ATCC. DU145 and PC3 cell line STR profiles had >93% 
matching with the parental cell lines from the ATCC database. A range of 80-100% for cell line 
authenticity is due to cell line instability; resulting from a loss of heterozygosity or issues relating 
to their ploidy. Stresses such as extensive passage, microbial contamination and exposure to drugs 
are all factors which contribute to “genetic drift” or a loss of heterozygosity in cell lines (Marx, 
2014). The effects of genetic drift were controlled as far as possible throughout the experiments 
presented in this thesis by ensuring that fresh cell stocks were raised, and cell culture incubators 
were cleaned at regular intervals. A match <80% requires further investigation and analysis to 
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confirm cell line authenticity. The STR profile for the PNT1A cell line was not matched to a DNA 
profile that fits the ASN-0002 standard criteria. Two STR locus that meet the ASN-0002 standard 
were found on the ExPASy Bioinformatics resource portal and matched to the PNT1A cell 
sample. The MEF cells used in this thesis were not authenticated as methods for non-human cell 
line authentication are not well established (Almeida et al., 2016).   
All samples tested negative for mycoplasma contamination. The positive control showed a band 
~270 base pairs and this band was not present in the negative control or any of the cell line 
samples. No speckled dots around the cell nuclei were apparent following DAPI staining of 
prostate cells which confirmed that cells were negative. Routine testing for mycoplasma 
contamination ensured that any cell behaviours identified throughout experiments were due to the 
experimental variables rather than the presence of mycoplasma.   
3.4.2 Cell proliferation rates and morphology 
Cell proliferation experiments enabled identification of cell doubling times and optimum seeding 
densities, to ensure exponential growth for at least two cell doublings over 72 hours in future 
experiments. Cell doubling times followed the same trend in each independent experiment despite 
inter-assay variability. Normal prostate cells might be expected to proliferate at a slower rate than 
those of malignant origin; which are characterised by cell cycle acceleration. Nevertheless, we 
found all prostate cell lines to proliferate at the same rate +1hr regardless of their malignant status. 
PNT1A, DU145 and PC3 cells used throughout this thesis had mean doubling times of 34, 35 and 
34 hours, respectively. Doubling times can vary between cell passage number and methods 
employed to assess proliferation. The doubling times identified were in line with those found in 
other studies (Berthon et al. (1995), Stone et al. (1978a) and Kaighn et al. (1979)). These studies 
used manual counting methods to assess cell proliferation, but results were comparable to the data 
obtained from the WST-1 assays.  
MEF NF-kB p65+/+ cells proliferated 1.7-fold faster than the p65-/- and IKKa-/- MEF cells. As these 
cell lines are isogeneic, it is evident that the presence of NF-kB affects cell proliferation rate. NF-
kB is well known to affect the hallmarks of cancer and inflammatory disease by regulating the 
genes that control cell proliferation, inflammatory signalling and cell survival (Park and Hong, 
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2016). This was supported by a reduction in HeLa cell proliferation and malignant transformation 
following repression of NF-kB p65; highlighting a role for NF-kB in cell proliferation and tumour 
development Kaltschmidt et al. (1999). The effect of NF-kB expression on normal mouse 
mammary epithelial cell proliferation has also been investigated (Brantley et al., 2001); cells 
deficient in the IKBa gene, an inhibitor of NF-kB, were found to proliferate faster than cells with 
the IKBa gene. These results, along with our findings, show that NF-kB can positively influence 
both normal and cancerous cell proliferation.  
The morphology of the prostate cell lines matched those presented on the ATCC database. The 
ATCC is a global biological materials resource and standards organisation that acquires, 
authenticates, preserves and distributes standard reference cell lines and other materials. Changes 
to cell morphology generally coincide with changes to cell proliferation rates. For example, cells 
that are seeded at a high-density reach confluence quickly and begin to lose their shape. Cell 
proliferation slows down, cells become round and detached and eventually die. Regular 
assessment of these parameters ensures that cells are behaving correctly; providing confidence in 
the results obtained from our experiments. Changes to cell morphology and growth are associated 
with senescence, contamination, cellular stress and death; which may consequently hinder 
experiments. Cells entering a state of senescence become larger, lose their original shape and their 
cytoplasm appears flattened (Ben-Porath and Weinberg, 2004). Additionally, cells which are 
stressed lose contact with neighbouring cells, appear shrunken or swollen, elongated and display 
“blebbing” before their eventual death via apoptosis or necrosis. For example, Ratushnyy (2017) 
treated mesenchymal stem cells with hydrogen peroxide to assess the functional state and 
morphology of cells following exposure to oxidative stress. In addition to reduced cell viability 
and growth, cells appeared enlarged with granular cytoplasm; both of which are morphological 
features of cellular stress which indicate a likelihood of cell death. All of these morphological 
features can of course be harnessed as markers of cell death and damage following treatment with 
specific compounds.  
MEF cells have a relatively uniform morphology, appearing elongated and spindle-shaped with 
clear edges (Mackley et al., 2006). MEF IKKa-/- cells appeared larger and more elongated 
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compared to MEF p65+/+ and MEF p65-/- cells in culture (Figure 3.7); demonstrating the effects of 
gene manipulation on cell morphology and function.   
3.4.3 Protein expression and localisation 
PARP-1 expression has been shown to be increased in a number of cancers and is associated with 
disease progression and poor prognosis. Studies have provided an extensive PARP-1 mRNA 
expression profile in human primary cancers and normal tissues; reporting increased PARP-1 
gene and protein expression in several malignant tissue types. PARP-1 expression levels were 
found to be 1.14-fold higher in prostate adenocarcinomas compared to normal prostate tissue 
(Ossovskaya et al., 2010). Other studies have demonstrated a significant correlation between 
increased PARP-1 expression and tumorigenesis. For example, Salemi et al. (2013) reported 
increased PARP-1 expression in prostate cancer tissues compared to normal prostate tissues. They 
concluded that PARP-1 overexpression in cancers correlates with increased PARP-1 activity in 
tumours in response to increased DNA damage. Increased expression in tumours may also relate 
to its close functional relationship with pro-apoptotic factors. In line with these findings, our data 
revealed high expression of PARP-1 protein in the highly metastatic PC3 cell line. Interestingly, 
“normal” prostate PNT1A cells expressed more PARP-1 than the moderately metastatic DU145 
prostate cancer cells. Albeit expression was significantly less than PC3 cells which are most 
aggressive. Increased expression of PARP-1 protein in PC3 cells compared to DU145 cells was 
also reported by Yin and Glass (2006). The low expression of PARP-1 in the DU145 cells may 
be due to less basal PARP activity compared to the other cell lines. Some studies have correlated 
PARP-1 activity with PARP-1 protein expression levels (Tentori et al., 2006) whereas others have 
reported no correlation between PARP-1 activity and PARP-1 protein levels (Zaremba et al., 
2009). These contentions highlight the complexity of PARP-1 regulation. Phenotypic and 
behavioural changes within the cell clearly implicate PARP-1 regulation more than genotype or 
protein expression. PARP-1 is a nuclear protein used for cell cycle regulation, DNA repair and 
metabolic regulation. It was therefore not surprising that PARP-1 expression was located in the 
nucleus of the prostate cell lines.  
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As PARP-1 is a known co-activator of NF-kB (Hassa and Hottiger (2002), Martín-Oliva et al. 
(2004)) we expected levels of NF-kB to correspond to the expression of PARP-1. We found this 
to be the case for the NF-kB p65 subunit but not p50. A study by Weichert et al. (2007) found 
that high expression of NF-kB p65 was associated with activation of NF-kB signalling and poor 
prognosis in pancreatic cancer. Other studies have also observed overexpression of cytoplasmic 
and/or nuclear NF-kB p65 in cancers of the liver (Tai et al., 2000), cervix (Tilborghs et al., 2017) 
and prostate (Shukla et al., 2004). NF-kB p65 expression levels were higher in PNT1A cells than 
DU145 cells and this may be in part due to the expression of maspin. There is a clear correlation 
between maspin and NF-kB that needs exploring. Lessard et al. (2003) investigated NF-kB 
subcellular localisation and its prognostic significance in prostate cancer. They utilised tissue 
specimens to compare nuclear localisation with Gleason score and patient outcome. Nuclear 
localisation of the p65 NF-kB subunit was specific to cancer tissue. These comparisons were used 
to generate risk categories and stratify patients into low and high-risk categories of cancer 
progression. We found expression of p65 to be cytoplasmic in all of the prostate cell lines, 
suggesting that NF-kB is not constitutively activated. This may be due to a heterodimer vs 
homodimer balance. Dimerisation is required for NF-kB binding to DNA and different dimers are 
held in the cell cytoplasm by interaction with specific inhibitors. The NF-kB p65/p50 is the most 
abundant dimeric complex. The NF-kB p50 subunit lacks a transcriptional activation domain and 
forms homodimers with no ability to activate transcription. It can form heterodimers with the NF-
kB p65 subunit to enable translocation to the nucleus where they function as potent activators of 
gene expression (Siebenlist et al., 1994).  
Cytoplasmic and nuclear expression of IKBa in the prostate cancer cell lines suggests that NF-
kB may be constitutively active. IKBa is located in the nucleus where it prevents NF-kB 
activation and nuclear translocation. It is only when IKBa is phosphorylated and degraded that 
NF-kB is able to translocate to the nucleus and become activated (Wan and Lenardo, 2010). 
Cytoplasmic and nuclear expression of IKBa in our cells (Figure 3.10-Figure 3.12) suggests 
partial degradation of IKBa; an enabling characteristic of NF-kB nuclear translocation and 
consequential activation. As the NF-kB p65 and p50 subunits associated with canonical activation 
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of NF-kB were not found to be constitutively active in our cell lines, the expression and 
localisation of RelB, an NF-kB subunit associated with the non-canonical NF-kB pathway, was 
investigated. 
RelB expression results were analysed and total protein levels were highest in PC3 cells. High 
expression levels of RelB in PNT1A cells, compared to DU145 cells, was not expected. High 
RelB expression is associated with oncogenic transcription and tumour progression. High 
expression of RelB in metastatic PC3 cells is in line with other studies that have correlated 
increased levels of RelB with tumour progression. For example, immunohistochemistry analysis 
of laryngeal cancer samples showed increased expression of RelB with increased tumour stage 
and grade; establishing RelB as a useful biomarker of prognosis (Giopanou et al., 2017). The 
immunofluorescence data (Figure 3.10-Figure 3.12) shows nuclear localisation of RelB in DU145 
and PC3 cells. These results indicate that RelB is active in the prostate cancer cell lines 
irrespective of their total protein expression. Expression is nuclear and cytoplasmic in PNT1A 
cells, and therefore high total protein expression in these cells is not indicative of increased 
activation. Xu et al. (2009) investigated the role of RelB and the non-canonical NFkB pathway in 
prostate cancer progression. They reported a reduction in tumour growth in PC3 cells following 
inhibition and silencing of RelB. Wang et al. (2016) also reported a significant reduction in 
DU145 cell migration and invasion following knockdown of RelB. RelB complexes were 
frequently detected in the nucleus of prostate cancer tissue and were directly correlated to Gleason 
score. These results highlight a tumour-supportive role of RelB following activation via the non-
canonical NF-kB pathway.  
IKKa, an IKK kinase complex, is a core molecule in both canonical and non-canonical NF-kB 
activation and signalling (Israel, 2010). All prostate cell lines expressed the IKKa protein but 
expression levels were highest in DU145 cells which express the least maspin; highlighting a 
potential link between IKKa and maspin. High IKKa expression levels correlated to low 
expression maspin, and low IKKa expression correlated to increased maspin expression. These 
results are in line with a study carried out by Luo et al. (2007). Using a transgenic mouse model, 
they showed that IKKa plays a role in inflammation and metastasis by repressing the transcription 
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of tumour suppressor gene maspin. Inactive IKKa in mice was found to slow down prostate 
cancer growth and this correlated with increased expression of maspin. Additionally, nuclear 
expression of IKKa correlated with metastatic progression and maspin repression. An inhibitory 
effect on cell invasion was observed in breast cancer cells following knockdown of IKKa; 
however the relationship with maspin was not explored (Merkhofer et al., 2010). IKKa shuttles 
between the cytoplasm and nucleus; and when localised to the nucleus, the maspin gene is 
repressed. We showed nuclear expression of IKKa in all of our prostate cell lines but expression 
was greatest in low maspin expressing DU145 cells. We demonstrated increased expression of 
maspin in mouse embryonic cells deficient in IKKa (Figure 3.13). Leopizzi et al. (2017) found 
that nuclear translocation of IKKa stimulated maspin production. Hepatocarcinoma studies also 
reported increased expression of maspin and suppression of tumour metastasis following the 
downregulation of IKKa (Jiang et al., 2010). As NF-kB signalling is controlled by IKKa, the 
group also examined the expression of other NF-kB regulators and target genes to determine 
whether NF-kB was activated. Increased nuclear expression of NF-kB p65, typical of constitutive 
NF-kB activation, was found in tumour tissues expressing high levels of IKKa compared to 
normal liver tissue. This suggests that overexpression of IKKa drives NF-kB signalling and 
consequently, inflammatory signalling and tumour progression. The increased nuclear expression 
of IKKa in our DU145 cells suggests that these cells are more active in terms of NF-kB; and 
therefore, we would expect this cell type to be more aggressive. The results show that NF-kB p65 
and NF-kB p50 resides in the cytoplasm and are therefore not constitutively activated. The non-
canonical NF-kB subunit RelB is active in both DU145 and PC3 cells. The literature suggests that 
PC3 cells are more aggressive than DU145 cells (Ravenna et al., 2014). Nevertheless, both cell 
lines are metastatic, and it is important to explore other molecular markers which may contribute 
to the difference in IKKa expression between cell lines; such as maspin and HDAC.  
As previously mentioned, inhibition of the tumour suppressor gene maspin has been associated 
with increased cell migration and metastatic progression. The DU145 cells express the lowest 
levels of maspin protein from the panel of cell lines, but interestingly PC3 cells express high 
levels; greater than those of the normal PNT1A prostate cells. These expression levels inversely 
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correlate to the expression levels of IKKa and NF-kB p65. The MEF cell expression studies have 
also evidenced negligible expression of maspin in MEF p65 knockout cells, and high expression 
of maspin in MEF IKKa knockout cells. These results further support the inverse correlation 
between maspin and IKKa, and NF-kB p65 and IKKa.  
The literature suggests that normal cells should express much higher levels of maspin in 
comparison to cancerous cells. For example, Zhang (2004) investigated the expression pattern of 
maspin in human breast cell lines. Maspin was highly expressed in normal mammary epithelial 
cells, down regulated in primary breast tumours and deficient in metastatic tumour cells. The 
group also studied maspin gene expression in several human normal and prostate tumour cell 
lines. Maspin was highly expressed in CF3, CF91 and MLC normal cell lines compared to 
LNCaP, PC3 and DU145 tumour cells. Other studies have also reported high expression of maspin 
in benign prostate tissue samples compared to well-differentiated prostate carcinoma samples 
(Zou et al., 2002). McKenzie et al. (2008) compared basal expression levels of maspin in DU145, 
PC3, LNCaP prostate cells and normal BPH-1 prostate epithelial cells. In line with the protein 
expression data presented in Figure 3.9, maspin gene expression levels were higher in PC3 cells 
than DU145 cells and normal BPH-1 cells.  
As expected, expression of the maspin protein is confined to the cytoplasm of PNT1A cells but 
interestingly, it is expressed in both the cytoplasm and nucleus of PC3 cells. Maspin is 
predominantly expressed in the cytoplasm (<95%) of normal tissues, it may also be expressed in 
the nucleus (Pemberton et al., 1997). There are contentions in the literature with regards to nuclear 
expression of maspin and disease prognosis. Nuclear expression of maspin in breast, prostate and 
ovarian cancers has been associated with well-differentiated phenotype and improved survival, in 
colorectal cancers nuclear expression it is associated with poor disease outcome (Berardi et al., 
2013). Increased expression of maspin in both the cytoplasm and nucleus of PC3 cells, compared 
to DU145 cells, may be a more favourable phenotype in these cells despite being more aggressive. 
Goulet et al. (2011) demonstrated that nuclear localisation of maspin is required for its tumour 
supressing function. They examined several potential maspin-regulated genes, showing that at 
least two genes crucial to breast cancer progression were negatively regulated by nuclear maspin. 
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To this end, the cytoplasmic and nuclear expression of maspin in PC3 cells may be due to an 
interaction with various genes. Another factor which may explain contentions in results of maspin 
localisation could be cell line identification. The PC3 cells used throughout this thesis have been 
thoroughly authenticated and therefore the results can be validated. The significance of nuclear 
maspin localisation remains unclear and warrants further investigation but is beyond the scope of 
this thesis.  
Protein expression and localisation results support previous studies which demonstrate that 
maspin interacts and endogenously inhibits histone deacetylate 1 (HDAC-1) (Li et al., 2006). 
HDACs regulate a range of proteins and processes and are key elements in the regulation of gene 
expression, differentiation and homeostasis (Ropero and Esteller, 2007). Increased levels of 
HDACs are associated with prostate cancer progression (Wang et al., 2009b) and class 1 HDACs 
have been implicated in DNA damage signalling and repair; enabling characteristics of cancer 
development (Munshi et al. (2005) and Kim et al. (2003)). Histone deacetylation influences the 
expression of genes involved in cancer initiation and progression such as those involved in cell 
cycle, apoptosis, angiogenesis and migration (Glozak and Seto, 2007). High expression of 
HDAC-1 in DU145 cells compared to PNT1A and PC3 cells suggests that these cells are more 
aggressive and prone to DNA damage. Wang et al. (2009b) examined the levels of HDAC-1 
mRNA and total protein in a panel of prostate cancer cell lines, including the DU145 and PC3 
cells used throughout this thesis. They found HDAC-1 mRNA and protein expression levels to 
be high in androgen-independent cell lines; particularly PC3 cells. Halkidou et al. (2004) also 
showed upregulation of HDAC-1 expression in androgen independent prostate cancers; 
contributing to aggressive phenotype and metastatic potential. The group reported similar 
expression levels of HDAC-1 in DU145 and PC-3M cells. PC-3M cells are a metastasis-derived 
variant of PC3 with enhanced distant organ metastasis, and therefore we would expect the PC3 
cells to express less HDAC-1 that the more metastatic PC-3M variant. Despite contentions in 
literature, we can be confident that the findings presented in Figure 3.8 are valid.  
Ashburner et al. (2001) evidenced that HDAC-1 interacts with the NF-kB p65 subunit and inhibits 
its expression. This is in line with the protein expression results obtained for DU145 cells; 
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showing increased expression of HDAC-1 and low expression of NF-kB p65 and maspin. 
Chemical inhibition of HDAC has been shown to increase the expression of various DNA repair 
proteins, transcription factors and NF-kB. Studies have shown that exposure of cells to HDAC 
inhibitors results in the acetylation of NF-kB p65 on lysine residues; leading to IKK activation, 
IkBa degradation and increased nuclear binding and transactivation of NF-kB p65 (Dai et al., 
2005, Kim et al., 2006b). Interestingly, expression of IKKa was greatest in the DU145 cells which 
expressed the highest levels of HDAC-1. The expression of HDAC-1 was localised to the nucleus 
of all cell lines, as would be expected for a nuclear protein (Kim et al., 2010b). Expression was 
less visible in the maspin expressing cell lines, which supports the protein expression results 
obtained from western blotting and the findings presented by Li et al. (2006).   
Figure 3.14 summarises the main findings from the protein expression data presented in this 
chapter; highlighting clear inverse correlations between the expression of PARP-1 and IKKa, 






Figure 3.14 Schematic to summarise the expression of proteins in DU145 and PC3 cells. 
A) Reduced expression of PARP-1 in DU145 cells is associated with reduced expression of NF-kB p65 but 
increased expression of NF-kB p50 and IKKa. Maspin protein expression is reduced when IKKa is 
expressed and this is associated with reduced levels of HDAC-1. B) Increased expression of PARP-1 in 
PC3 cells is associated with increased expression of NF-kB p65 but reduced expression of NF-kB p50 and 
IKKa. Maspin protein expression is increased when IKKa levels are low and this is associated with 
increased levels of HDAC-1. Red arrows represent reduced expression and green arrows represent 
increased expression. Flat arrowheads indicate inhibition.  
 
3.5 Summary 
The studies presented in this chapter have shown that: 
• Cell lines are of the correct genotype and phenotype. 
• Maspin expression does not affect prostate cell proliferation rate. 
• IKKa protein expression is inversely correlated with the expression of maspin in prostate 
and MEF IKKa-/- cell lines, and increased maspin expression is inversely correlated to 
the expression of HDAC1. 
• Knockout of NF-kB p65 and IKKa subunits in MEF cells reduces proliferation rate. 
3.6 Future work 
Future work could include expanding the panel of cell lines and include patient samples to identify 



















cancer cell lines proficient and deficient for maspin, IKKa and PARP-1 genes to further explore 
potential mechanisms between these molecules. It would be interesting to see whether knockout, 
inhibition or silencing of IKKa enhances maspin in the cancer cells; and if this would result in 
decreased cell survival following exposure to treatments. Future experiments, beyond the scope 
of this thesis, could be to assess PARP and NF-kB activity and investigate the effects of PARP 
inhibition on cells with varied expression of NF-kB and maspin. PARP activity could be 
determined by measuring the formation of PAR polymer chains which are synthesised by PARP-
1 using NAD+ as a substrate. This could be achieved by immunocytochemistry or Western blot. 
NF-kB activity could be measured by luciferase gene reporter assay followed by bioluminescence. 
A reporter gene is an exogenous coding region joined to a promotor sequence in an expression 
vector. Protein expression data could also be compared to patient sample and omics data from 
various sources such as the human protein atlas to verify our findings.  
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Chapter Four  
Investigating the effects of PARP-1 and HDAC-1 inhibitors on cell 
growth and survival in cell lines with varied maspin expression.  
4.1 Introduction 
This chapter investigates the sensitivity of prostate and mouse embryonic fibroblast cell lines 
(proficient and deficient for NF-kB p65 and IKKa) to the PARP-1 inhibitor Rucaparib 
(AG014699) and HDAC-1 inhibitor Trichostatin A (TSA). Combined effects of these drugs were 
assessed in terms of cell growth, proliferation, morphology and protein expression relative to the 
expression levels of maspin and NF-kB.  
4.1.1 Choice of inhibitors 
Olaparib is currently the best studied PARP inhibitor (Chen and Du, 2018). In 2014 it was the 
first PARP inhibitor to be approved by the European medicines agency and the US food and drug 
administration (FDA) for the treatment of ovarian cancer. Rucaparib is a potent PARP inhibitor 
that was developed by researchers at Newcastle University. It was the first PARP inhibitor to 
enter anticancer human clinical trials in 2003. The trial assessed the safety and efficacy of 
Rucaparib in combination with the cytotoxic agent temozolomide in patients with advanced solid 
tumours (Plummer et al., 2008). In 2015 it was granted FDA approval for clinical use as a 
monotherapy in ovarian cancer patients with somatic and/or germline BRCA mutations (Drew et 
al., 2016). It was approved for use on the NHS in 2019. Rucaparib is currently in clinical 
development for the treatment of metastatic AR independent prostate cancer (Cancer Research) 
and for this reason it was selected for in vitro use throughout this thesis. 
HDAC inhibitors are a class of anti-cancer agents that play a role in epigenetic modification, cell 
death, apoptosis and cell cycle arrest in cancer cells (Kim and Bae, 2011). These roles are in part 
due to the downregulation of DNA repair pathways, leading to the persistence of DNA damage 
and increased sensitivity to DNA damaging agents. For example, the HDAC inhibitor TSA was 
shown to impair radiation-induced repair of DNA damage in head and neck squamous carcinoma 
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and breast cancer cell lines (Zhang et al., 2007). HDAC inhibitors have also been shown to 
downregulate DNA repair proteins and induce phosphorylated histone γH2AX, a marker of DNA 
double strand breaks, in normal and transformed cells (Lee et al., 2010).  
Trichostatin A (TSA) is a potent and specific inhibitor of class I and II HDAC activity. Maspin 
interacts and inhibits HDAC-1, therefore TSA was selected for use in the studies presented in this 
thesis. TSA was the first natural hydroxamate found to inhibit HDAC’s which are overexpressed 
in various cancers. Since its discovery in 1990 (Yoshida et al., 1990) studies have demonstrated 
a link between the inhibition of HDAC-1 and 2, and the suppression of tumour cell growth and 
survival (Vigushin et al., 2001, Chang et al., 2012).  
Both PARP and HDAC inhibitors prevent homologous recombination DNA repair and studies 
have explored the efficacy of these drugs as single and combined agents for cancer therapy (Chao 
and Goodman, 2014, Rasmussen et al., 2016, Marijon et al., 2018). Studies have not explored the 
role of maspin in treatment response. A proposed working model of Rucaparib and TSA co-
treatment in prostate cells of varied maspin expression is presented below. 
 
Figure 4.1 Proposed working model of TSA and Rucaparib co-treatment. 
Co-treatment will enhance anticancer efficacy by two mechanisms: Impairing DNA repair and inducing 
DNA damage, leading to enhanced cell cytotoxicity.  Figure adapted from (Yin et al., 2018). 
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4.1.2 Sensitivity to inhibitors and selection of methodology 
In vitro cytotoxicity assays are essential for determining the sensitivity of normal and cancerous 
cells to therapeutic agents. The clonogenic survival assay is considered the gold standard, 
however, the assay disregards the impact of cell-to-cell communication as the cells are seeded at 
very low densities (Mirzayans et al., 2007). Alternative, and frequently used, cytotoxicity testing 
assays include cell counting, SRB, WST-1 and Resazurin. These assays are based on biochemical 
events specific to living cells, such as protein content and metabolic activity (Assay principles are 
outlined in Chapter 2).  
It has been well documented that cellular cytotoxicity results vary depending on the method used 
(O'Donovan, 2012). Assays measure different endpoints such as protein binding, metabolism and 
physical growth. Therefore, different assays produce different results based on the variables that 
they are measuring. Haibe-Kains et al. (2013) analysed data from two large-scale 
pharmacogenomic studies: The Cancer Genome Project (CGP) (Garnett et al., 2012) and the 
Cancer Cell Line Encyclopaedia (CCLE) (Yoshida et al., 1990). Both studies presented gene 
expression profiles and drug sensitivity assays for over 700 cell lines and 138 drugs, and over 
1000 cell lines and 24 drugs, respectively. Comparison of gene expression profiles highlighted 
good concordance between the two studies, however drug sensitivity results did not. This was 
likely due to use of different cytotoxicity assays between the two studies; CGP measured 
dehydrogenase activity whereas CCLE measured cellular ATP (Weinstein and Lorenzi, 2013). 
An earlier study demonstrated that measurement of ATP levels better reflected cell viability 
compared to dehydrogenase inhibition. ATP levels were extensively depleted in non-viable cells, 
but dehydrogenase activity remained at 24% of untreated control cells (Maehara et al., 1987).  
Assessment of several methods is vital to enable selection of a single methodology; particularly 
for drug combination cytotoxicity studies, to ensure that results obtained from sequential data are 
directly comparable.  
4.1.3 Assessment of cell morphology in the presence and absence of Rucaparib and TSA.  
Cells exposed to treatments are generally susceptible to nuclear and morphological changes which 
differ from their normal state; such as pseudopodial protrusions, nuclear condensation, 
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fragmentation, blebbing and swelling. Assessment of cell morphology following treatment 
enables identification of cell stress and cytotoxicity; but also assists in the identification of cell 
death pathway in which treatments induce.  
4.1.4 Protein expression levels in the presence of Rucaparib and TSA. 
Previous studies have explored changes to the expression levels of proteins following exposure 
to PARP and HDAC inhibitors, alone and in combination. For example, Chao and Goodman 
(2014) and Rasmussen et al. (2016) both reported decreased expression levels of key DNA repair 
proteins, BRCA1 and RAD51, in prostate and glioblastoma cells, respectively; following PARP 
and HDAC inhibition alone. Combination treatment led to a decrease in HDAC-1 and PARP-1 
protein levels. These findings provide a rationale for assessment of protein expression levels as 
biomarkers to predict clinical response, and for the use of combined PARP and HDAC inhibitors 
in the treatment of cancers. Increased PARP-1 and HDAC-1 is implicated in tumour progression 
and reduced expression of these molecules may enhance patient survival. PARP and HDAC 
inhibitors limit DNA repair and enhance cell death, therefore the combination of the two inhibitors 
enhances anticancer efficacy by decreasing metastatic progression and improving patient 
prognosis. Changes to protein expression levels following PARP and HDAC inhibition, relative 
to the presence of NF-kB and maspin proteins have not previously been investigated, this is an 
interesting area of study as NF-kB activation via IKKa has been implicated in tumour progression 
via the repression of maspin. As discussed in Chapter 1, maspin repression is thought to enhance 
cell proliferation, apoptosis, migration and invasion; enabling characteristics of cancer 
development.  
 
4.2 Chapter aims 
This chapter investigates the effects of Rucaparib and TSA, alone and in combination, on cell 
growth and survival; relative to the expression of NF-kB and maspin. It is hypothesised that TSA 
will enhance the effects of Rucaparib in DU145 and PC3 cell lines; particularly DU145 cells 
which are depleted in maspin and are therefore more susceptible to DNA damage and resistant to 
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apoptosis. It is expected that co-treatment will reduce protein expression levels of NF-kB and 
PARP-1; resulting in increased maspin expression. The aims of this chapter are detailed below:  
• To investigate the effect of Rucaparib and TSA, alone and in combination, on cell growth 
and survival with use of multiple cytotoxicity assays such as manual cell counting, WST-
1, SRB and Resazurin; to optimise methodology for co-treatment studies.  
• To investigate the combined effects of Rucaparib and TSA on cell survival, relative to 
maspin expression.  
• To assess the effects of Rucaparib and TSA, alone and in combination, on cell and nuclear 
morphology in prostate cells.  
• To examine the effects of Rucaparib and TSA treatment, alone and in combination, on 
the protein expression levels of PARP-1, maspin and NF-kB subunits in prostate cells.  
• To investigate the Rucaparib and TSA sensitivity in MEF cell models. 
4.3 Results 
4.3.1 The effects of Rucaparib on prostate cell growth and survival and selection of 
methodology for future experiments. 
To assess prostate cell growth and survival, following exposure to Rucaparib, a series of cell 
growth and proliferation assays were conducted. WST-1, Resazurin, SRB and counting methods 
(see section 2.2.3 for assay protocols) were selected for comparison of effect and outcome; to 
identify a single methodology for later experiments (Figure 4.2). Cells were exposed to Rucaparib 
for 72 hours up to 50µM. 
A low dose (3µM) hormetic response to Rucaparib was identified by WST-1 assay in DU145 and 
PC3 cell lines (Figure 4.2B and C, respectively) but not PNT1A cells (Figure 4.2A). Cell viability 
was reduced in a dose dependent manner at drug concentrations >3µM, however GI50 (the 
concentration of drug required for 50% inhibition of cell growth) was not reached at 50µM in 
PNT1A and PC3 cells indicating reduced sensitivity to Rucaparib compared to DU145 cells. 
Resazurin assay results also displayed a low dose hormetic response to Rucaparib in DU145 cells 
 120 
but not PC3 and PNT1A cells. Interestingly, Resazurin data showed that that PC3 cells were most 
sensitive to Rucaparib (GI50 8.8µM) and PNT1A cells were least sensitive (GI50 >50µM).  
Assessment of growth inhibition by SRB assay and cell counting in response to drug treatment 
did not show a low dose stimulation to Rucaparib in any of the cell lines; but rather a dose 
dependent inhibition of cell growth (Figure 4.2). DU145 cells with lower levels of basal maspin 
were most sensitive to Rucaparib (GI50 8.2µM) compared to PC3 and PNT1A cells (GI50 15.7µM 
and 27.5µM, respectively).  
Mean Rucaparib GI50 concentrations were calculated and compared between growth and survival 
assays (Table 4.1). It was not possible to obtain GI50 Rucaparib concentrations for PNT1A and 
PC3 cells by WST-1 assay, and PNT1A cells by Resazurin assay.  
 
Table 4.1: Comparison of Rucaparib GI50 concentrations between different growth and survival 
assays in prostate cell lines.  
Data are the mean values (SD) from at least three independent experiments. 
Cell line GI50 (µM) 
 SRB Counting WST-1 Resazurin 
Mean ± standard deviation 
PNT1A 27.45 ±5.11 17 ±1.85 >50 >50 
DU145 8.2 ±1.46 8.7 ±0.95 37.3 ±2.51 38.84 ±6.31 








Figure 4.2: Comparison of growth inhibition by Rucaparib using WST-1, SRB, Resazurin and 
counting in Prostate cell lines.  
(A) PNT1A, (B) DU145 and (C) PC3 cells were treated with Rucaparib at various concentrations for 72 
hours and cell number was determined. Data shown are the average of at least three independent 
experiments and error bars represent SEM. 
 
 
The graphs presented in Figure 4.3 compared the differences in prostate cell survival between the 
growth and survival assays carried out following treatment with 10µM Rucaparib. A 10µM 
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concentration was selected as it is an approximate dose that is equitoxic in all cell lines with ~50% 
cell death by cell counting after 72 hours. 
After 72 hours there was no significant difference in cell response to drug treatment between SRB 
and cell counting methods in all cell lines (Figure 4.3). WST-1 results were significantly different 
to SRB and counting results but not to Resazurin assay in PNT1A and DU145 cells (Figure 4.3A 
and B). WST-1 results were significantly different to all methods carried out in PC3 cells (Figure 





Figure 4.3: Effect of 10µM Rucaparib on survival and growth of prostate cells, as measured by WST-
1, SRB, Counting and Resazurin assays. 
(A) PNT1A, (B) DU145 and (C) PC3 cells were exposed to Rucaparib for 72 hours and cell growth or 
viability was assessed. One-way ANOVA analysis with multiple comparisons was carried out to provide 
statistical significance (*p<0.05, ***P<0.001 and ****p<0.0001). 
 
In summary, Maspin depleted DU145 cells were most sensitive to Rucaparib in all of the methods 
assessed other than the Resazurin cell viability assay. Comparative assessment of the four growth 
and survival assays demonstrate that a single methodology is essential to ensure that results 





due to its simplicity, reproducibility and concordance with cell counting. The GI50   concentrations 
obtained from SRB experiments which are presented in Table 4.1 were taken forward in drug 
combination experiments described later in this chapter.  
4.3.2 The effects of Rucaparib on prostate cell morphology. 
PNT1A, DU145 and PC3 cells were exposed to various concentrations of Rucaparib for 72 hours 
to investigate changes to cell morphology and growth. Morphology was assessed by light 
microscopy, as described in 2.2.2.  
All cell lines showed prominent morphological change and decrease of cell number in a 
concentration dependant manner in comparison to untreated controls (Table 4.4). PNT1A cells 
were less sensitive to Rucaparib treatment and their morphology was only affected by drug 
concentrations >30µM. Rucaparib concentrations >10µM induced fibroblast-like morphology 
and pseudopodial protrusions, indicative of cellular stress, in both DU145 and PC3 cell lines. A 
drug concentration >30µM was cytotoxic to the cancerous cell lines but not to the normal prostate 
cells. At the GI50 dose (identified by SRB as shown in Table 4.1) cell morphology indicated a 








Figure 4.4: The assessment of cell morphology in response to Rucaparib by brightfield microscopy. 
DU145, PC3 and PNT1A cells were exposed to various concentrations of Rucaparib for 72 hours. Images 
are representative of three independent replicates. Red arrowheads indicate changes to morphology and 
green arrowheads indicate cell death. Images captured at X10 magnification.  
 
4.3.3 The effects of Rucaparib on prostate cell nuclear morphology. 
Changes to nuclear morphology following exposure to Rucaparib for 72 hours was assessed, as 
described in section 2.2.2.  Briefly, cells were fixed to glass coverslips and then stained with DAPI 
to enable visualisation of the cell nucleus by confocal microscopy.  
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Changes to nuclear morphology in response to increasing concentrations of Rucaparib were 
apparent in all prostate cell lines; particularly the cancerous cell lines (Figure 4.5). DU145 and 
PC3 cells exposed to 3µM Rucaparib presented with nuclear blebbing and fragmentation. Nuclear 
condensation was also apparent in response to increasing concentrations of Rucaparib in these 
cell lines. Exposure to Rucaparib appeared to cause nuclear swelling in the PC3 cells but not in 
the DU145 cells. PNT1A cells presented changes to nuclear morphology such as nuclear 
condensation membrane blebbing in response to Rucaparib despite reduced sensitivity in 
cytotoxicity assays. Cell nuclei were not affected by treatment with 3µM Rucaparib but nuclear 







Figure 4.5: The assessment of nuclear morphology in response to Rucaparib using DAPI staining 
and fluorescence microscopy.  
DU145, PC3 and PNT1A cells were exposed to  various concentrations of Rucaparib for 72 hours. Images 
are representative  of three independent replicates. Arrowheads indicate: (I) Nuclear condensation, (II) 
membrane “blebbing” and (III) cell swelling; all of which are features of cell death. Images were captured 
at X40 magnification. Scale bar= 32µM.  
 
 
To quantify changes to nuclear morphology following Rucaparib exposure, twenty cells were 
scored for each sample based on their nuclear morphology (Nuclear condensation, Nuclear 
fragmentation/membrane blebbing and cell swelling). The scoring criteria used was normal 
nuclear morphology, and indicators of cell death: chromatin condensation, nuclear condensation, 
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nuclear fragmentation and cell swelling. Scores were expressed as a percentage of the twenty cells 
assessed in each sample, as shown in Figure 4.6.  
In line with the representative images displayed in Figure 4.5, a decline in normal nuclear 
morphology was apparent with increasing Rucaparib concentration. The normal nuclear 
morphology of PNT1A and PC3 cells was reduced 4 and 5-fold following exposure to 50µM 
Rucaparib compared to untreated controls, respectively. An 11-fold decrease in normal nuclear 
morphology of DU145 cells treated with 50µM Rucaparib highlighted an enhanced sensitivity of 
this cell line to a PARP inhibitor; in line with cytotoxicity data presented in section 4.3.1. 
Cell samples treated with Rucaparib presented increased nuclear condensation and fragmentation, 
representative of apoptosis, in a dose dependent manner. Treated DU145 cells had the highest 
percentage of cells with nuclear fragmentation compared to PNT1A and PC3 cell lines. At a 10µM 
concentration ~50% of the DU145 cells presented fragmented nuclei compared to PNT1A and 
PC3 cells, where only ~20% and ~10% of nuclei were fragmented, respectively. Approximately 
5% of DU145 cells exhibited cell swelling, a morphological feature of cell necrosis, following a 
10µM exposure to Rucaparib. Cells did not present swelling at Rucaparib concentrations below 
and in excess of 10µM. PNT1A and PC3 cells were subject to ~5% cell swelling following 
exposure to Rucaparib at 30µM. At a cytotoxic 50µM concentration, cell swelling was only 







Figure 4.6: Quantification of changes to nuclear morphology following a 72-hour exposure period to 
Rucaparib.  
Epifluorescence was used to assess the changes to nuclear morphology in (A) PNT1A, (B) DU145 and (C) 
PC3 cells treated with increasing doses of Rucaparib for 72 hours. Twenty cells were scored per dose and 
results are the mean of at least two independent experiments. CC= chromatin condensation, NC= Nuclear 
condensation, NF= Nuclear fragmentation and CS= cell swelling. 
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4.3.4 The effects of Trichostatin A on prostate cell growth and survival and selection of 
methodology. 
Prostate cell growth and survival was assessed following 72-hour exposure to the HDAC inhibitor 
Trichostatin A (TSA) using the methods outlined in 2.2.3.  
Assessment of cell viability by WST-1 assay, following exposure to increasing concentrations of 
TSA revealed a hormetic response up to 10nM in PC3 cells (Figure 4.7C). This response was not 
apparent in PNT1A and DU145 cells (Figure 4.7A and B). Cell viability was reduced in a dose 
dependent manner at drug concentrations >10nM in PNT1A and DU145 cells, and >40nM in PC3 
cells. The cell viability of PNT1A and PC3 cells was not inhibited by 50% at the highest 
concentrations of TSA used (100nM).  
Assessment of growth inhibition by SRB assay and cell counting in response to TSA did not show 
a hormetic response and cell growth declined in a dose dependent manner (Figure 4.7). Both SRB 
and counting methods found the prostate cancer cells to be more sensitive to TSA, in comparison 
to the normal PNT1A cells. Cell growth following exposure to TSA was variable between the 
SRB and counting methods in PNT1A cells. At a 100nM TSA concentration, cell viability was 
reduced 2.2-fold when measured by counting than SRB assay (Figure 4.7A).  
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Figure 4.7: Comparison of growth inhibition by Trichostatin A using WST-1, SRB and counting 
methods in Prostate cell lines.  
(A) PNT1A, (B) DU145 and (C) PC3 cells were treated with Trichstatin A at various concentrations (0-
100nm) for 72 hours and cell number was determined. Data shown are the mean of at least three independent 
experiments and error bars represent SEM. 
 
 
The graphs presented in Figure 4.8 highlight the differences in prostate cell survival between the 





60nM concentration was selected as this concentration inhibited DU145 and PC3 cell growth by 
>50% (SRB and cell counting data).  
There was a significant difference in percentage cell survival between WST-1 and SRB (p<0.001) 
methods, and WST-1 and cell counting (p<0.001 and p<0.01 in DU145 and PC3 cells, 
respectively); in DU145 and PC3 cells (Figure 4.8B and C). Percentage cell survival between 
WST-1 and cell counting data, and SRB and cell counting data differed in PNT1A cells (Figure 
4.8D). Interestingly, there was no significant difference in PNT1A cell survival between WST-1 






Figure 4.8: Comparison of percentage growth and survival inhibition using WST-1, SRB and 
Counting in prostate cells treated with 60nM Trichostatin A.   
(A) PNT1A, (B) DU145 and (C) PC3 cells were exposed to Trichostatin A for 72 hours and cell growth 
and viability was assessed. One-way ANOVA analysis with multiple comparisons was carried out to 
provide statistical significance (*p<0.05, **p<0.01 and ***P<0.001). 
 
 
Mean TSA GI50 concentrations were calculated and compared between growth and survival assays 
(Table 4.1). A GI50 concentration for TSA could not be obtained for PNT1A and PC3 cells at the 
highest dose (100nM) by WST-1 assay. Therefore, additional WST-1 assays were carried out in 
these cell lines using increased drug concentrations (200nM and 300nM), to establish a drug 






Table 4.2: Comparing cytotoxicity to Trichostatin A in prostate cell lines by proliferation assays.  
Data are the mean values (SD) from at least three independent experiments. 
Cell line GI50 (nM) 
 SRB Counting WST-1 
Mean ± standard deviation 
PNT1A 188 ± 21.5 70 ± 5.93 215 ± 2.94 
DU145 45 ± 5.17 52 ± 5.08 82 ± 11.29 
PC3 49 ± 5.39 50 ± 13.29 214 ± 6.13 
 
In summary, data from SRB and cell counting showed that PNT1A cells were 4.1-fold and 3.8-
fold less sensitive to TSA than DU145 and PC3 cells, respectively (Table 4.2). There was no 
significant difference in drug sensitivity between DU145 and PC3 cells. Cytotoxicity data from 
WST-1 assays was not consistent with the data obtained from SRB and counting methods. DU145 
cells were 2.6-fold more sensitive to TSA than PNT1A and PC3 cells. Despite a difference in 
drug sensitivity for PNT1A cells between SRB and cell counting methods, SRB was selected as 
the methodology of choice due to its reproducibility and simplicity. The TSA GI50 concentrations 
obtained from SRB experiments (Table 4.2) were be combined with Rucaparib GI50 
concentrations (Table 4.1) in order to assess the effects of the drugs in combination on cell growth 
and survival.   
4.3.5 Trichostatin A affects prostate cell morphology in a dose dependent manner 
Prostate cells were exposed to increasing concentrations of TSA for 72 hours to investigate 
changes in cell morphology and growth. Morphology was assessed by light microscopy, as 
described in 2.2.2. Images are presented in Figure 4.9. 
In line with the findings presented in 4.3.4, PNT1A cells were less sensitive to TSA treatment and 
consequently, cell morphology was unaffected by exposure to the drug at concentrations up to 
100nM. Cells exposed to 100nM TSA presented pseudopodial protrusions; indicating cellular 
stress. Cell detachment was also apparent with increasing drug concentration, indicating cell 
death. DU145 and PC3 cells showed increased sensitivity to TSA treatment and changes to normal 
morphology were apparent in cells that were exposed to TSA concentrations >40nM (Figure 4.9). 
A number of cells displayed an elongated fibroblast-like morphology when exposed to 40nM 
TSA. TSA concentrations >40nM induced cell detachment and death in a dose dependent manner. 
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100nM TSA was not completely cytotoxic to the prostate cancer cell lines but a significant 
deterioration in cell health was apparent.   
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Figure 4.9: The assessment of cell morphology in response to Trichostatin A by brightfield 
microscopy.   
DU145, PC3 and PNT1A cells were exposed to various concentrations of Trichostatin A for 72 hours. 
Images are representative of three independent replicates. Red arrowheads indicate changes to morphology 






















4.3.6 Trichostatin A affects prostate cell nuclear morphology in a dose dependent 
manner.  
Changes to nuclear morphology following exposure to TSA for 72 hours was assessed by 
epifluorescence, as described in section 2.2.2.   
Changes to nuclear morphology and a decline in cell number in response to increasing 
concentrations of TSA was apparent in all prostate cell lines; particularly the cancerous cell lines 
(Figure 4.10). Cells were less sensitive to TSA concentrations <40nM. Cells exposed to 40nM 
and 60nM TSA exhibited signs of nuclear condensation. An 80nM drug concentration induced 
features of apoptosis such as nuclear blebbing and fragmentation in PNT1A and DU145 cells. 
Interestingly, PC3 nuclei exposed to 80nM TSA exhibited signs of swelling; a morphological 
characteristic of the necrosis death pathway. A visible decline in cell number was apparent 
following exposure to 100nM TSA in DU145 and PC3 cells. PNT1A cells were least sensitive to 
morphological change following drug exposure, but a limited number of cells presented signs of 






Figure 4.10: The assessment of changes to nuclear morphology in response to Trichostatin A using 
DAPI staining and fluorescence microscopy.   
PNT1A, DU145 and PC3 cells were exposed to various concentrations of Trichostatin A for 72 hours. 
Images are representative of three independent replicates. Arrowheads indicate: (I) Nuclear condensation, 
(II) membrane “blebbing” and (III) cell swelling; all of which are features of cell death. Images captured at 
X40 magnification. Scale bar= 32µM. 
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To quantify changes to nuclear morphology following treatment with TSA, twenty cells were 
scored for each sample based on nuclear morphology and then split into a percentage, as 
previously described in section 4.3.3.  
In line with the representative images displayed in Figure 4.10, there was a dose dependent 
decrease in normal cell nuclear morphology; particularly in the prostate cancer cell lines, as 
depicted in Figure 4.11. From the DU145 and PC3 cells scored, there was a 2.5 and 4-fold 
reduction in normal nuclear morphology in DU145 and PC3 cells exposed to 60nM TSA (a drug 
concentration growth inhibitory by >50% in these cell lines), compared to untreated cells. Normal 
nuclear morphology was further reduced 3.3 and 5.5-fold in DU145 and PC3 cells exposed to the 
highest TSA concentration (100nM), respectively. There was a 2-fold decrease in normal nuclear 
morphology in PNT1A cells exposed to 100nM TSA, compared to untreated controls.   
All of the prostate cell lines treated with TSA presented increased nuclear condensation and 
fragmentation, representative of apoptosis, in a dose dependent manner. A reduction in nuclear 
fragmentation was apparent in PNT1A cells following treatment with 100nM TSA. In DU145 
cells, there was a reduction in nuclear condensation following treatment with 100nM TSA.  
However, increasing TSA concentration did not correlate with increased chromatin condensation 
in any of the prostate cell lines. At 60nM, a drug concentration that is growth inhibitory (>50%) 
in DU145 and PC3 cells, approximately 28% of DU145 and 40% of PC3 cells presented nuclear 
fragmentation; compared to PNT1A cells whereby ~17% of the cells scored presented fragmented 
nuclear morphology. Cell swelling was apparent at low levels in the DU145 and PC3 cell samples 
exposed to drugs, however there was no correlation between cell swelling and increasing TSA 
concentration. PNT1A cells exhibited cell swelling following exposure to TSA at a concentration 
of 100nM.  
These data highlight increased nuclear sensitivity to DU145 and PC3 cells exposed to TSA, 






Figure 4.11: Quantification of changes to nuclear morphology following a 72 hour exposure period 
to Trichostatin A.  
Epifluorescence was used to assess the changes to nuclear morphology in (A) PNT1A, (B) DU145 and (C) 
PC3 cells treated with increasing doses of Trichostatin A for 72 hours. Twenty cells were scored per dose 
and results are the mean of at least two independent experiments. CC= chromatin condensation, NC= 





4.3.7 Evaluation of the combined effects of Rucaparib and Trichostatin A on prostate cell 
survival by SRB assay. 
Having optimised the methodology for assessment of cell growth inhibition, the sensitivity of 
prostate cells to Rucaparib and TSA in combination was determined by SRB assay. The respective 
GI50 concentrations of Rucaparib and TSA identified by SRB assay in previous studies (detailed 
in sections 4.3.1 and 4.3.4) are presented in Table 4.3 below. A GI50 concentration is used to 
measure the effects of treatments on whole cell growth. The choice to use SRB, and therefore 
GI50, came from the Northern Institute for Cancer Research, who use this as their primary screen, 
and from my data which shows that results from the SRB method are consistent with manual cell 
counting. It is important to acknowledge that in a purified enzyme system use of IC50 (half 
maximal inhibitory concentration) would be much lower than the GI50 used in a whole cell system. 
We did not look at the effects of treatments on PARP-1 and HDAC-1 activity in these studies and 
therefore GI50 concentration was favoured. 
Table 4.3: GI50 concentrations of Rucaparib and Trichostatin A identified by SRB assay in 
prostate cell lines of varying maspin expression. 
Cell line Mean GI50 ± SD 
 Rucaparib (!M) Trichostatin A (nM) 
PNT1A 27.45 ± 5.11 188 ± 21.5 
DU145 8.2 ± 1.46 45 ± 5.17 
PC3 15.7 ± 3.29 49 ± 5.39 
 
These drug concentrations were used to evaluate the combined effects of Rucaparib and TSA on 
cell survival after 72 hours. They were also used in other drug combination studies which are 
discussed throughout this chapter. The level of growth inhibition was normalised to Rucaparib, 
TSA and 1% DMSO alone controls.   
The results presented in Figure 4.12 show that prostate cells exposed to combination treatment 
for 72 hours are significantly more sensitive than cells exposed to Rucaparib or TSA alone. 
DU145 and PC3 cells were 1.5-fold more sensitive to the combination treatment than PNT1A 
cells; demonstrating increased efficacy of the drug combination in cancer cell lines. The GI50 
concentration of TSA applied to both DU145 and PC3 cell lines did not significantly differ. The 
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GI50 Rucaparib concentration for PC3 cells was ~2-fold higher than the concentration required to 





Figure 4.12: Combined treatment of Rucaparib and Trichostatin A enhances growth inhibition in 
prostate cell lines.  
(A) PNT1A, (B) DU145 and (C) PC3 prostate cell lines were exposed to Rucaparib and TSA, alone and in 
combination at their GI50 concentrations for 72 hours. Combination treatment is significantly more effective 
than Rucaparib alone in all cell lines (two-way ANOVA followed by Tukey’s multiple comparison test, 
*p<0.05, **p<0.01, ***p<0.001). The data presented are percentage of untreated controls and are the mean 






4.3.8 Trichostatin A enhances the effects of Rucaparib on cellular and nuclear 
morphology in prostate cell lines. 
The effects of combined treatment on cell morphology relative to single agent treatment was 
assessed after 72 hours. Cells cultured in media containing 1% DMSO without the addition of 
drugs were used as control. The representative images presented in Figure 4.13 show changes to 
normal cell morphology and increased cell death following treatment with Rucaparib and TSA 
alone and in combination.  
Untreated cells were intact and had reached ~80-90% confluence following 72 hours in culture. 
Cells treated with TSA and Rucaparib at their respective GI50 concentrations, and cells treated 
with a combination began to lose adherence from the cell surface; a feature which is typical of 
cellular stress and death. Rucaparib induced the appearance of cell elongation and pseudopodia; 
particularly in the DU145 and PC3 cells, as previously described. Following combination 
treatment with Rucaparib and TSA, reduced cell density, death and changes to morphology were 
extensive (Figure 4.13-Figure 4.15). PNT1A and PC3 cells presented pseudopodia and a number 
of PC3 cell nuclei appeared fragmented. DU145 cells did not display pseudopodia or 
fragmentation, but rather cell elongation and cell death; which was characterised by cell 
detachment and debris. The results presented in Figure 4.13-Figure 4.15 demonstrate that 
Rucaparib and TSA co-treatment enhances cell cytotoxicity in these cell lines; particularly the 






Figure 4.13: The assessment of cell morphology in response to Rucaparib and Trichostatin A, alone 
and in combination, by brightfield microscopy.  
PNT1A, DU145 and PC3 cells were exposed to various concentrations of Rucaparib and Trichostatin A, 
alone and in combination at GI50 concentrations, for 72 hours. Images are representative of three 
independent replicates. Red arrowheads indicate changes to morphology and green arrowheads indicate 
cell death. Images captured at X10 magnification. 
 
The effects of combined Rucaparib and TSA treatment on nuclear morphology relative to single 
agent treatment, at their respective GI50 concentrations, was examined after 72 hours using 
fluorescence microscopy and DAPI staining. Cell nuclei were examined to identify changes to 
morphology and characteristic features of cell death by apoptosis and necrosis. Representative 
images are displayed in Figure 4.14. Nuclear fragmentation and membrane blebbing, features of 
apoptosis, were identified in all prostate cells following treatment with Rucaparib. A number of 
PNT1A and DU145 nuclei appeared smaller and condensed; another feature commonly identified 
in cell death by apoptosis. Interestingly, a number of PC3 cell nuclei appeared swollen following 
treatment with Rucaparib, suggesting that these cells may be subject to cell death by necrosis 
following PARP inhibition.  
PNT1A, DU145 and PC3 cells exposed to TSA presented nuclear condensation. DU145 cells also 
displayed nuclear fragmentation and membrane blebbing. The combined treatment of Rucaparib 
and TSA had an increased effect on the nuclear morphology of all cell lines; particularly DU145 
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and PC3 cells. These cells displayed increased amounts of nuclear fragmentation, membrane 
blebbing and apoptotic bodies compared to cells exposed to each treatment alone. A limited 
number of PC3 cells were also swollen in response to combined treatment. The effects of 
combined treatment on PNT1A cells did not enhance changes to nuclear morphology compared 
to Rucaparib and TSA as single treatments. 
 
Figure 4.14: The assessment of nuclear morphology changes in response to Rucaparib and 
Trichostatin A in combination using DAPI staining and fluorescence microscopy.   
PNT1A, DU145 and PC3 cells were exposed to Rucaparib and Trichostatin A, alone and in combination at 
GI50 concentrations, for 72 hours. Images are representative of three independent replicates. Arrowheads 
indicate: (I) Nuclear condensation, (II) membrane “blebbing” and (III) cell swelling; all of which are 
features of cell death. Images captured at X63 magnification. Scale bar= 50µM. 
 
As previously described in section 4.3.3, the changes to nuclear morphology following treatment 
with Rucaparib and TSA, alone and in combination, at their respective GI50 concentrations was 
quantified (Figure 4.15).  
Quantitative analysis of multiple PNT1A cell samples exposed to treatments highlighted a 
significant reduction in normal nuclear morphology compared to untreated controls (p<0.001), as 
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shown in Figure 4.15A. Rucaparib and TSA alone did not significantly affect the normal nuclear 
morphology of DU145 cells, however, a significant reduction in normal nuclear morphology was 
apparent following co-treatment (p=0.05). There was no significant reduction in the normal 
nuclear morphology of PC3 cells following exposure to treatments alone and in combination. 
However, there is a visible reduction in the normal nuclear morphology of DU145 and PC3 cells 
exposed to treatments (Figure 4.15). The lack of statistical significance is a result of variation 
between repeated experiments. 
The difference in percentage normal nuclear morphology between cells exposed to treatments as 
single agents and in combination was not significant in all prostate cell lines; suggesting that co-
treatment is no more effective than Rucaparib alone. Despite this, a 1.4-fold increase in nuclear 
condensation was identified in co-treated PNT1A and DU145 cells, compared to cells treated with 
Rucaparib. The effects of Rucaparib and co-treatment on DU145 cell nuclear fragmentation was 
not significant. A 1.4-fold decrease in PNT1A cell nuclear fragmentation was identified following 
co-treatment. In PC3 cells, nuclear condensation and fragmentation levels were not enhanced by 
Rucaparib and TSA co-treatment, compared to cells exposed to Rucaparib alone. An increase in 




Figure 4.15: Quantification of changes to nuclear morphology following a 72 hour exposure period 
to Rucaparib and Trichostatin A, alone and in combination.  
Epifluorescence was used to assess the changes to nuclear morphology in (A) PNT1A, (B) DU145 and (C) 
PC3 cells treated with Rucaparib and Trichostatin A, alone and in combination at their GI50 concentrations, 
for 72 hours. Twenty cells were scored per dose and results are mean of at least two independent 
experiments. CC= chromatin condensation, NC= Nuclear condensation, NF= Nuclear fragmentation and 





4.3.9 The effects of Rucaparib and TSA, alone and in combination on whole protein 
expression.  
The expression levels of PARP-1, Maspin, NF-kB p65, IKKα and IKBα proteins were visualised 
by Western blotting in PNT1A, DU145 and PC3 prostate cell samples which were exposed to 
Rucaparib and TSA, alone and in combination, for 72 hours. Briefly, cells were exposed to 
treatments at their respective GI50 concentrations. Cells were then harvested, lysates were 
prepared and loaded onto SDS-PAGE gels for protein separation; prior to electro-transfer, 
antibody probing and chemiluminescent detection (as described in section 2.2.4). Anti-Actin was 
used as a loading control alongside Ponseau-S staining. Ponseau-S staining was carried out to 
ensure that the drug treatments did not affect the expression of the Anti-actin loading control.   
The expression of proteins in PNT1A cells exposed to drug treatments are presented in Figure 
4.16. Anti-Actin protein bands were not clear and consistent in the PNT1A samples. 
Consequently, Ponseau-S staining was carried out and used as loading control. The stain 
highlighted a variance in protein loading between samples, particularly in the TSA treated sample. 
PARP-1 protein levels were reduced in PNT1A cells exposed to combination treatment, relative 
to untreated control and Ponseau-S staining. Expression was not affected by single agent 
treatment. Similarly, Maspin and NF-kB p65 expression levels were significantly lower in 
PNT1A cells exposed to combination treatment. Expression of IKKa was reduced following TSA 
exposure; however, it is not possible to determine whether this is a true result, or rather a fault 
with chemiluminescent detection. A repeat of this experiment was not completed due to time 
constraints. Rucaparib and TSA treatment reduced expression levels of IKBa and levels were 





Figure 4.16: PNT1A protein expression following exposure to treatments.  
Western blot of whole cell extracts of PNT1A cells at 72 hours after treatment with Rucaparib and TSA, 
alone and in combination. Blots were probed using antibodies against: PARP-1, Maspin, NF-kB p65, IKKα, 
IKBα, RelB and Anti-Actin. Blots were stained with Ponseau-S as additional load control. Results from a 
single experiement. 
 
Treated DU145 cell protein expression results (Figure 4.17) highlight a reduction in PARP-1 
expression following co-treatment, but not with single agents alone. Interestingly, TSA and c-
treatment reduced maspin expression at 72 hours. Rucaparib treatment has no effect on the 
expression of maspin and NF-kB p65, however expression is reduced in DU145 samples exposed 
to TSA. There is an increase in maspin and NF-kB p65 protein levels following co-treatment, 
compared to TSA alone, but not greater than the expression levels of untreated control and 
Rucaparib treated cell samples. Rucaparib reduces the expression of IKKa, however TSA has a 
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greater effect. IKKa protein expression was also reduced in the presence of co-treatment, relative 
to loading control. Rucaparib and TSA reduce IKBa expression and co-treatment enhances this 
effect. Anti-Actin loading control suggests that more protein is present in the co-treated sample, 
however Ponseau-S staining highlights equal loading between samples. To this end, expression 
results were compared to Ponseau-S loading control.  
 
Figure 4.17: DU145 protein expression following exposure to treatments.  
Western blot of whole cell extracts of DU145 cells at 72 hours after treatment with Rucaparib and TSA, 
alone and in combination. Blots were probed using antibodies against: PARP-1, Maspin, NF-kB p65, IKKα, 
IKBα, RelB and Anti-Actin. Blots were stained with Ponseau-S as additional load control. Results from a 
single experiement. 
 
Rucaparib and TSA treatment alone had no effect on the expression levels of PARP-1, maspin 
and NF-kB p65 proteins in PC3 cells, however, expression of these proteins was reduced 
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following co-treatment (Figure 4.18). The expression levels of IKKa were reduced by Rucaparib 
and TSA. An almost loss of IKKa expression was apparent following co-treatment. Rucaparib 
reduced IKBa expression levels. The levels of IKBa protein expression was further reduced 
following co-treatment; however, exposure to TSA alone had no effect on expression levels.  
Anti-Actin expression shows equal loading of PC3 samples. Ponseau-S staining of proteins 
ensures adequate quality control.   
 
Figure 4.18: PC3 protein expression following exposure to treatments.  
Western blot of whole cell extracts of PC3 cells at 72 hours after treatment with Rucaparib and TSA, alone 
and in combination. Blots were probed using antibodies against: PARP-1, Maspin, NFkB p65, IKKα, IKBα, 




In summary, the above protein expression results indicate that Rucaparib and TSA treatment, 
alone and in combination, do not enhance the expression of maspin. TSA treatment reduces 
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maspin expression in PNT1A and DU145 cells but not PC3 cells. Maspin expressed in all cell 
lines following co-treatment. Co-treatment also reduces the expression of PARP-1 and NF-kB 
p65 expression in all cell lines.   
4.3.10 NFkB affects Rucaparib sensitivity in MEF cells. 
In support of the findings presented in section 3.3.5 and 4.3.1, MEF cells were used to investigate 
sensitivity to Rucaparib relative to the presence, or absence, of NF-kB subunits. Growth inhibition 
assays were carried out with p65+/+, p65-/- and IKKa-/- MEF cells exposed to increasing 
concentrations of Rucaparib (Figure 4.19). As expected, MEF p65-/- cells were significantly more 
sensitive to Rucaparib than p65+/+ and IKKa-/- cells (one-way ANOVA with Tukey’s multiple 
comparisons test. p<0.001 and p<0.01, respectively). The growth of p65+/+ and IKKa-/- cells was 
not suppressed by >50% at the highest concentration of Rucaparib used; indicating reduced drug 
sensitivity in these cell lines.  
 
Figure 4.19: Cytotoxicity to Rucaparib in Mouse embryonic fibroblast cell lines by SRB assay.  
MEF cells were treated with Rucaparib at various concentrations for 72 hours and cell number was 




Mean Rucaparib GI50 concentrations for MEF cells were calculated (Table 4.4). Due to a lack of 
sensitivity, it was not possible to obtain GI50 Rucaparib concentrations for MEF p65+/+ and IKKa-
/- cells. 
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Table 4.4: MEF GI50 values following exposure to Rucaparib for 72 hours. 
Cell line Mean GI50 (µM) ± SD 
MEF p65 +/+ - 
MEF p65 -/- 11 ± 11.39 
MEF IKKa -/- - 
 
These findings in addition to the experiments carried out in prostate cells highlight a link between 
NFkB p65 and PARP inhibitor sensitivity. MEF p65-/- cells, which express low levels of maspin 
and high levels of IKKa, are most sensitive to Rucaparib treatment. These findings correlate to 
the protein expression data for maspin depleted DU145 cells; low expression of NF-kB p65 and 
maspin and high expression of IKKa. IKKa-/- cells, which were not sensitive to Rucaparib, 
expressed NF-kB p65 and maspin. (Expression data presented in Chapter three, section 3.3.5).  
4.3.11 NF-kB p65 enhances TSA resistance in MEF cells. 
MEF cell sensitivity to TSA was also investigated by SRB assay (Figure 4.20). Cell growth was 
inhibited by TSA concentrations >40nM in all MEF cells; in a dose dependant manner. TSA 
concentrations <40nM were not growth inhibitory to p65+/+ cells. p65-/- and IKKa-/- MEF cells 
were significantly more sensitive to TSA than p65+/+ cells (one-way ANOVA with Tukey’s 
multiple comparisons p<0.01). There was no significant difference between the sensitivity to TSA 
in MEF p65-/- and IKKa-/- cells (p>0.669, unpaired t-test).  
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Figure 4.20: Cytotoxicity to Trichostatin A in Mouse embryonic fibroblast cell lines by SRB assay.  
MEF cells were treated with Trichostatin A at various concentrations for 72 hours and cell number was 
determined. Data shown are the average of at least three independent experiments and error bars represent 
SEM. 
 
Mean TSA GI50 concentrations for MEF cells were calculated (Table 4.5). The concentration of 
TSA required to inhibit growth by 50% in MEF p65+/+ cells was 2.6-fold and 2.1-fold higher than 
the doses required for p65-/- and IKKa-/- cells, respectively.  
Table 4.5: MEF GI50 values following exposure to TSA for 72 hours. 
Cell line Mean GI50 (nM) ± SD 
MEF p65 +/+ 138 ± 16.05 
MEF p65 -/- 53 ± 4.3 
MEF IKKa -/- 65 ± 9.4 
 
Analysis of the data indicate that the absence of NF-kB p65 or IKKa leads to increased sensitivity 
to TSA. These findings do not correspond with the TSA sensitivity data for prostate cells. The 
data shows no significant difference in sensitivity to TSA in DU145 and PC3 cells; despite 
variance in NF-kB p65 and IKKa expression levels DU145 expressed low levels of NF-kB p65 
 156 
compared to PC3 cells and expression was inversely correlated to the expression levels of IKKa 
(Figure 3.9 and Table 4.3).    
4.4 Discussion 
The studies presented in this chapter evaluate the effects of Rucaparib and Trichostatin A, as 
single agents and in combination, in a panel of prostate and mouse embryonic fibroblast (MEF) 
cell lines of varied maspin and NF-kB expression.  
4.4.1 The effects of Rucaparib on prostate and MEF cell survival  
The cell viability of DU145 and PC3 cells exposed to low dose Rucaparib (3µM) was increased 
10% and 13% by WST-1 assay (Figure 4.2), respectively. This may be due to a biphasic dose 
response stimulation otherwise known as hormesis. The hormesis phenomenon has been observed 
in a range of biological systems and is well characterised in cancer therapeutics. It describes the 
drug action of low dose stimulation, arising due to homeostatic adaptation, followed by high dose 
inhibition (Bhakta-Guha and Efferth, 2015). A hormetic response following exposure to 
Rucaparib was cancer cell specific, indicating a PARP inhibitory effect on cancer cell metabolism.  
The WST-1 assay is a bio-reduction reaction dependent on the glycolytic production of NAD(P)H 
in viable cells, and therefore, the low dose stimulation observed in DU145 and PC3 cells could 
be attributable to enhanced mitochondrial metabolism following PARP inhibition. This 
suggestion is in line with a previously published study by Almeida et al. (2017), where PARP 
inhibition in colorectal and ovarian cancer cell lines resulted in an increase in NAD+ 
concentration. Similarly, Bhute and Palecek (2015) reported a reverse in NAD depletion in breast 
cancer cells following exposure to the PARP inhibitor Veliparib. Enhanced mitochondrial 
bioenergetics is considered a hallmark of cancer (Hanahan and Weinberg, 2011) and this could 
explain why a low dose stimulation was not observed in the normal prostate cells. The reduction 
in cell viability following exposure to higher concentrations of Rucaparib than 3µM is likely due 
to increased DNA damage, NAD+ depletion and consequently cellular stress and cytotoxicity.  
To investigate the biphasic response trend further, WST-1 data was compared to results obtained 
from cell counting, SRB and Resazurin assays. A biphasic dose response stimulation was not 
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observed by SRB and cell counting methods. These methods do not measure mitochondrial 
activity; they quantify live cell number and bind to protein components of the cell which are 
directly proportional to cell mass, respectively. The findings support that the low dose stimulation 
to Rucaparib identified by WST-1 is due to changes to mitochondrial metabolism. Resazurin, 
another measurement of metabolic activity, also presented a low dose stimulation to Rucaparib 
(8%) in DU145 cells, but not PC3 cells. The reason for variance between WST-1 and Resazurin 
findings in PC3 cells is unclear but are likely to be attributed to variances in cell health and cell 
cycle stage between experiments. This could be tested carrying out cell growth and viability tests 
between each experiment. Cell cycle could be assessed by measuring DNA content by flow 
cytometry. Overall, the chemical reduction of WST-1 and Resazurin assays is impacted by 
changes in intracellular metabolic activity rather than cytotoxicity, and because PARP can alter 
levels of NAD+, the effects of PARP inhibition in these assays is a result of changes in metabolic 
processes rather than cell death. Deregulated metabolism is an enabling characteristic of cancer 
development and warrants further investigation, however, was beyond the scope of this thesis. As 
the sensitivity to Rucaparib did not significantly differ between SRB and cell counting methods 
in prostate cells, the SRB method was selected for use in experiments with MEF cells and 
treatment combinations. The method has a stable endpoint, is fast and cost effective. Use of a 
single methodology is essential in pharmacological studies to ensure standardisation of response 
measurement (Haibe-Kains et al., 2013). 
Within the panel of cell lines studied, DU145 cells were 2 and 3.3-fold more sensitive to 
Rucaparib than PC3 and PNT1A cells, respectively (fold-change based on SRB data). Studies 
have demonstrated that PARP-1 is an essential mediator of NF-kB activation, which in turn is an 
essential mediator of resistance to DNA damaging agents (Veuger et al., 2009). Later studies from 
the same group highlighted the importance of NF-kB status in tumours; showing that inhibition 
of NF-kB signalling using PARP inhibitors can sensitise breast cancer cells to IR and 
chemotherapeutic agents (Hunter et al., 2012). Nakagawa et al. (2015) also supported the role of 
NF-kB signalling in PARP inhibitor sensitivity. They generated PARP-inhibitor resistant breast 
and ovarian cancer cell lines and measured upstream effectors and downstream products of NF-
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kB by polymerase chain reaction; to show upregulation of NF-kB signalling in PARP inhibitor 
resistant cells. The non-canonical NF-kB p65 subunit mediated sensitivity to PARP inhibition; 
knockdown of p65 was found to enhance PARP inhibitor sensitivity in PARP inhibitor-resistant 
cell lines. These studies support the data presented in Figure 3.9 that shows increased expression 
levels of NF-kB p65 protein in PC3 and PNT1A cells, compared to DU145 cells. However, 
DU145 cells were most sensitive to PARP inhibition and expressed reduced levels of the PARP-
1 protein. Investigation into DU145 cell PARP-1 activity is required; to elucidate that the 
increased sensitivity to Rucaparib is due to reduced NF-kB p65 signalling rather than reduced 
PARP activity. Cytotoxicity studies with MEF cells (Figure 4.19) revealed increased sensitivity 
to Rucaparib in p65-/- cells compared to MEF p65+/+ cells; further supporting the role of NF-kB 
in reducing PARP inhibitor sensitivity. MEF IKKa-/- cells were less sensitive to PARP inhibition. 
DU145 cells, which are most sensitive to Rucaparib, expressed increased levels of IKKa and 
reduced levels of NF-kB p65 protein compared to the other prostate cell lines which were less 
sensitive; strengthening a link between NF-kB and PARPi sensitivity.  
Prostate cell cytotoxicity data also highlights a potential role of maspin expression and PARPi 
sensitivity. The literature has explored a correlation between NF-kB and the expression of maspin, 
however, it is yet to investigate the role of maspin in relation to PARP inhibitor sensitivity. Luo 
et al. (2007) showed that prostate cell metastasis is regulated by the NF-kB subunit IKKa; which 
downregulates maspin and promotes a metastatic phenotype. Using transgenic mice models, they 
showed that inhibition of IKKa limited prostate cancer growth and progression; which correlated 
to increased expression of maspin. A more recent study examined cutaneous squamous cell 
carcinoma samples (+/- metastasis) by immunohistochemistry to measure the association of active 
IKKa and maspin with cancer behaviour. IKKa inversely correlated with maspin levels, and 
samples depleted in maspin were found exclusively in those derived from metastasis (Toll et al., 
2015). A series of studies carried out by Shukla et al, with the use of a natural compound apigenin, 
showed that increased levels of maspin were associated with reduced IKKa activity and nuclear 
expression of NFkB p65 (Shukla, 2008). Recently, they demonstrated that apigenin enhances 
maspin expression via p53 upregulation and downregulation of HDAC activity in prostate cancer 
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cells (Shukla, 2015). These findings support our data which shows low expression of maspin and 
increased expression of IKKa in DU145 cells, and high expression of maspin and low expression 
of IKKa in PC3 cells. MEF IKKa-/- cells expressed increased levels of maspin compared to MEF 
p65 +/+ and p65 -/- cells lines. As PARP is a known transcriptional co-activator of NF-kB (Hassa 
et al., 2001), inhibition of NF-kB by Rucaparib may enhance maspin expression. Our data showed 
that Rucaparib reduced the expression of IKKa in DU145 and PC3 cells (Figure 4.17 and Figure 
4.18) but there was no change to the expression of maspin at the 72-hour time point that was 
tested suggesting inhibition of maspin activity rather than protein levels.  
The enhanced sensitivity of DU145 cells to Rucaparib may also be due to genetic mutation; 
including mutated BRCA1. BRCA deficient and/or mutated cancers are exquisitely sensitive to 
PARP inhibition through the mechanism of synthetic lethality. PARP inhibition compromises 
SSB repair, and cells lacking functional HR mechanisms, such as BRCA, are subject to double 
strand breaks (DSB). Consequently, these cells are then damaged beyond repair (Farmer et al., 
2005). BRCA1 interacts with p65 leading to NF-kB activation, and NF-kB acts as a mediator of 
BRCA1-induced chemo-resistance. Therefore, the reduced sensitivity to Rucaparib seen in 
PNT1A and PC3 cell lines may be due to functional BRCA1 and high NF-kB p65 protein 
expression. The increased sensitivity to Rucaparib in DU145 cells could be in part due to 
dysfunctional BRCA1 which attributes to increased IKKa and therefore activation of NF-kB. 
Additionally, dysfunctional BRCA1 induces an HR deficient repair phenotype; a major cause of 
hypersensitivity to PARP inhibition. The cytotoxicity results presented in this chapter support 
previously published studies which demonstrate selective cytotoxicity to PARP inhibitors in 
BRCA mutated and deficient models; confirming the concept of synthetic lethality (Farmer et al., 
2005, Bryant et al., 2005).  
4.4.2 Rucaparib has increased effect on cell morphology and death in maspin depleted 
prostate cancer cells. 
Changes to prostate cell morphology following Rucaparib treatment were consistent with cell 
survival data from SRB assays. Changes to cell morphology representative of cell stress were 
greater in DU145 and PC3 cells, compared to PNT1A cells; demonstrating the efficacy of 
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Rucaparib in selectively targeting tumour cells. Assessment of nuclear morphology by DAPI 
assisted in the identification of cell death pathway. Apoptosis occurs in the vast majority of 
physiological cell deaths and is a common response to PARP inhibition in a variety of cancers 
(Shi et al., 2014). Features of apoptosis were apparent in all cell lines, particularly DU145 cells, 
which presented a high percentage of nuclear fragmentation and cell shrinkage. Interestingly, 
PNT1A and PC3 cells also presented signs of cell swelling in response to Rucaparib; suggesting 
that cell necrosis may also contribute to loss of cell viability in these cell lines. A potential reason 
for both apoptotic and necrotic features in these cells may be secondary necrosis; a process of cell 
elimination occurring when apoptotic cells are not cleared by scavengers (Silva, 2010). Further 
investigation is required to confirm the modes of cell death in these cells, whether it be apoptosis 
or necrosis, to enhance the understanding of molecular events taking place up to Rucaparib-
induced cell death.  
4.4.3 The effects of TSA on cell survival in prostate and MEF cells. 
HDAC inhibition has been reported to reduce the expression of proteins involved in HR DNA 
repair; resulting in impaired DSB repair and “BRCAness”. To this end, HDACi has emerged as a 
therapeutic strategy to pharmacologically manipulate HR repair for sensitisation to PARP 
inhibitors (Kachhap et al., 2010, Ha et al., 2014). Prior to combination studies with Rucaparib, 
the effects of the HDAC inhibitor, TSA, as a single agent were assessed.  
SRB and counting data confirmed that prostate cancer cells are significantly more sensitive to 
TSA than immortalised prostate cells; suggesting the possibility of a therapeutic window. 
However, there was no difference in sensitivity to TSA between DU145 and PC3 cell lines despite 
variances in the expression of maspin. Maspin is the only endogenous HDAC inhibitor that has 
been identified so far, and the biological effects of maspin are similar to those of pharmacologic 
HDAC inhibitors. Li et al. (2006) demonstrated that binding of maspin to HDAC1 did not block 
the action of the synthetic pharmacologic HDAC inhibitor M344. The group also reported 
increased maspin expression in both DU145 and PC3 cells following synthetic HDAC inhibition; 
demonstrating that the inhibitory effect of maspin on synthetic HDAC inhibition positively 
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feedbacks on maspin expression, and therefore contributes to tumour suppression. With this in 
mind, we would have expected TSA to have the greatest effect on PC3 cells.  
Assessment of cell viability by WST-1 assay revealed a 2.6-fold increase in DU145 cell sensitivity 
to TSA, compared to PC3 and PNT1A cells that were equally as sensitive. Walton et al. (2008) 
also assessed the effects of TSA on cell viability and metabolism in prostate cell lines. In line 
with our findings, they reported increased sensitivity to TSA treatment in DU145 cells. These 
findings indicate that TSA has a greater effect on DU145 cancer cell metabolism, despite no 
significant difference in cell cytotoxicity between PC3 cells. The reason for such effect is 
unknown. Higgins et al. (2009) investigated metabolic phenotypes in prostate cancer cell lines; 
including DU145 and PC3. They demonstrated a reduced reliance on oxidative phosphorylation 
in these cells, compared to less invasive LNCaP cells, due to mitochondrial dysfunction and 
therefore reduced mitochondrial enzyme activity. Despite this, the mRNA levels of mitochondrial 
enzymes were 5-fold higher in DU145 cells. This finding may explain the different effects on the 
cellular metabolism and viability of DU145 and PC3 cells exposed to TSA. The increased effect 
of TSA on DU145 cell metabolism may also be attributed to epigenetic status and expression of 
the maspin gene. Metabolic enzyme expression impacts the methylation and acetylation of DNA 
and histone proteins, driving vital biological outcomes such as cancer. Maspin specifically 
inhibits HDAC-1; a histone deacetylase commonly upregulated in malignancy. DNA methylation 
leads to recruitment of HDACs to promotor regions, leading to the repression of genes. Class 1 
HDAC inhibitors reverse promotor methylation and gene silencing (Sarkar et al., 2011). 
Therefore, a loss of HDAC inhibition, when maspin is downregulated, may increase DNA 
methylation and epigenetic gene silencing. In vitro models of human breast cancer have reported 
a loss of maspin expression, and this was often a result of aberrant methylation of the maspin 
promotor (Futscher et al., 2004). Inhibition of HDAC, by TSA, in maspin depleted DU145 cells 
may therefore override repressive histone modifications; leading to the upregulation of genes 
which may be associated with enhanced sensitivity to pharmacological HDAC inhibitors (Li et 
al., 2006). HDAC is endogenously inhibited by the presence of maspin in PNT1A and PC3 cells, 
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and these cells may therefore be metabolically less sensitive to pharmacological HDAC 
inhibition; compared to DU145 cells whereby HDAC is not endogenously inhibited.   
MEF p65+/+ cells were 2.6 and 2.1- fold less sensitive to TSA than MEF p65-/ and MEF IKKa-/- 
cells, respectively. These findings support the findings of Mayo et al. (2003), whereby NF-kB 
was identified as a mediator of HDACi resistance. They demonstrated that inhibition of NF-kB 
facilitated apoptosis in response to HDAC inhibition, concluding that the ineffectiveness of 
HDAC inhibitors to induce apoptosis may be attributed to the ability of tumour cells to respond 
to these treatments by up-regulating NF-kB. These results do not correspond with the prostate cell 
data, where there is no significant difference in TSA sensitivity between DU145 and PC3 cells at 
GI50; despite variations in the expression of NF-kB p65 and IKKa. Resistance to TSA in MEF 
p65+/+ cells could also be due to maspin deficiency. This link was not identified in the prostate 
cell lines, however, the MEF cells are isogenic and therefore we cannot rule it out. The expression 
of maspin in the MEF cells correlated to TSA sensitivity (Figure 3.13), with high maspin 
expressing IKKa-/- cells being most sensitive. Exact mechanisms contributing to variances in TSA 
sensitivity between MEF cells are unclear and warrant further investigation, but the data 
highlights an interesting difference in TSA sensitivity that is likely dependent on the presence of 
NF-kB p65. A combined molecular targeting that inhibits both NF-kB and HDAC, such as PARP 
and HDAC inhibitors, may provide a significant anti-cancer therapy.  
4.4.4 TSA- cell morphology and death 
Assessment of cell and nuclear morphology following TSA treatment support the findings from 
SRB cytotoxicity assays; whereby DU145 and PC3 are equally as sensitive to TSA. Our data 
reinforces the known selectivity of TSA to cancer cells, as the treated PNT1A cells are visibly 
resistant to morphological change. In line with the studies by Walton et al. (2008), TSA induced 
increased nuclear condensation, blebbing and fragmentation in the cell lines; suggesting that TSA 
is important in apoptotic signalling. PNT1A cells presented signs of apoptosis following treatment 
with higher concentrations of TSA but were significantly less sensitive to cell death than the other 
cell lines. It has been reported that various HDAC inhibitors, including TSA, arrest cell cycle 
progression leading to apoptosis. Cell cycle analysis was not carried out in the studies presented 
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in this thesis, however Choi et al. (2013) reported an accumulation of DU145 and PC3 cells in 
the sub-G1 phase of the cell cycle following treatment with the HDACi A248. Increased nuclear 
condensation and fragmentation was also observed, highlighting the importance of A248 in 
apoptotic signalling.  
Studies have also reported increased DNA damage signalling in cancerous cells following HDAC 
inhibition. Zhang et al. (2007) discovered that squamous carcinoma cells treated with TSA and 
IR exhibited delayed DNA repair compared to cells exposed to IR alone. They postulated that this 
response was due to suppression of genes and proteins associated with DNA repair such as 
BRCA1. Indeed, TSA was found to supress BRCA1 gene expression, therefore driving a HR 
phenotype and enhancing sensitivity to Rucaparib, implicating BRCA1 as a molecular target of 
TSA treatment. Of the prostate cell lines studied throughout this thesis, only DU145 cells are 
BRCA1 mutated. As there is no significant difference in TSA sensitivity between DU145 and 
PC3 cells, we cannot conclude that TSA contributes to apoptosis and DNA damage in these cell 
lines through suppression of BRCA1. These findings show that exposure to TSA alone is no more 
effective in maspin depleted cell lines. However, treatment may show promise in sensitising these 
cells to PARP inhibition by exacerbating DNA damage and death. The effects of TSA on DNA 
damage are explored in Chapter Six. 
4.4.5 Pharmacological inhibition of HDAC by TSA synergises prostate cancer cells to the 
PARP-1 inhibitor Rucaparib. 
A number of studies have shown that HDAC inhibitors synergise with PARP inhibitors in the 
treatment of cancers (Chao and Goodman, 2014, Marijon et al., 2018, Rasmussen et al., 2016) by 
preventing HR DNA repair and inducing “BRCAness”. However, the effect of these drugs in 
combination relative to NF-kB and maspin has not yet been explored. Studies by Hassa et al. 
(2005) suggested that PARP-1 interacts and is de-acetylated by HDAC-1. They showed that 
PARP-1 dependent activation of NF-kB is negatively regulated by HDACs 1-3; suggesting that 
acetylation of PARP-1 is vital for its role as a transcriptional coactivator. In support of these 
studies, our data revealed increased levels of HDAC-1, and consequently, reduced levels of 
PARP-1 and NF-kB in maspin depleted DU145 cells. The enhanced sensitivity to PARP inhibitors 
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in these cells may be further potentiated by HDAC inhibitors due to increased NF-kB signalling 
and DNA damage. Both drugs are reported to down-regulate BRCA1, and so we would expect 
co-treatment to have significantly greater effect on BRCA1 mutant DU145 cells. The findings 
presented in Figure 4.12 demonstrate that TSA enhances the effects of Rucaparib to inhibit cell 
growth; particularly in cancer cell lines. Unexpectedly, there was no difference in sensitivity to 
combination treatment, at respective GI50 concentrations, between DU145 and PC3 cells; 
suggesting that response to combined treatment is independent of maspin or BRCA1 status. 
However, it is important to note that the required Rucaparib GI50 concentration for DU145 cells 
is ~2-fold less than the concentration required for PC3 cells, and therefore we would expect 
DU145 cells to be significantly more sensitive to combination treatment if the GI50 concentration 
for PC3 cells was used. CalcuSyn software is a popular tool used to quantitatively measure the 
dose-effect relationship of drugs alone, and in combination, to determine drug synergy. Use of 
this software applies a non-subjective method to drug interaction and enables standardised 
interaction classifications (Bijnsdorp et al., 2011).  
In line with cytotoxicity data, co-treatment had an enhanced effect on cell and nuclear morphology 
in all cell lines, compared to treatments alone. Normal prostate cells were less sensitive to the 
combined effects of HDAC and PARP inhibition. DU145 and PC3 cells exposed to co-treatment 
exhibited increased cellular stress, increased nuclear condensation and fragmentation; 
representative of apoptosis. PC3 cells also presented cell swelling following co-treatment 
suggesting that a different mode of cell death is responsible for loss of cell viability and changes 
to morphology. As this response was also identified in cells exposed to Rucaparib alone, we can 
conclude that Rucaparib is responsible for the mechanism of cell death induced in these cells. 
Chao and Goodman (2014) reported non-apoptotic cell death in PC3 cells co-treated with the 
HDAC inhibitor SAHA and PARP inhibitor Olaparib; concluding that autophagy may be a 
potential mechanism of cell death. Further investigation into the mode of cell death in PC3 cells 
following treatments is required but is beyond the scope of this thesis.  
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4.4.6 Western blot analysis of Maspin, NF-kB and PARP-1 expression in prostate cell 
lines treated with Rucaparib, TSA as single agents and in combination.  
To investigate the potential mechanism involved in the sensitivity of prostate cancer cell lines to 
Rucaparib and TSA, alone and in combination, the expression levels of maspin, NF-kB and 
PARP-1 proteins were studied. Tables 4.6 and 4.7 summarise the changes to expression of these 
proteins in DU145 and PC3 cells exposed to Rucaparib and TSA, respectively. 
Table 4.6: The effects of Rucaparib on the expression levels of maspin, PARP-1, NF-kB p65 and 
IKKa proteins  in DU145 and PC3 cells.  
 Maspin PARP-1 NF-kB p65 IKKa 
DU145 no effect no effect  no effect reduced 
PC3 reduced reduced reduced reduced 
 
Table 4.7: The effects of TSA on the expression levels of maspin, PARP-1, NF-kB p65 and IKKa 
proteins  in DU145 and PC3 cells.   
 Maspin PARP-1 NF-kB p65 IKKa 
DU145 reduced no effect reduced reduced 
PC3 no effect no effect no effect reduced 
 
We expected to see a reduction in NF-kB, and an increase in maspin protein expression following 
treatments; however, this was not the case. Rucaparib had no effect on the expression of maspin 
in any of the prostate cell lines, indicating that inhibition of NF-kB with a PARP inhibitor does 
not enhance maspin. TSA had no effect on the expression of maspin in PC3 cells, however, a 
reduction in maspin expression was apparent in PNT1A and DU145 cells. Previous studies have 
reported an increase in maspin expression following TSA treatment (Abbas and Gupta, 2008) and 
therefore, further investigation is required to elucidate why our findings are different. A possible 
reason could be changes to DNA methylation following inhibition of HDAC; leading to the 
epigenetic silencing of genes that may affect the expression of downstream proteins. Interestingly, 
Rucaparib and TSA co-treatment further reduced the expression of maspin in all cell lines. TSA 
and Rucaparib single agents did not affect the expression of maspin in PC3 cells, therefore the 
reduction of maspin following co-treatment is an effect of the treatment combination. 
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IKKa protein levels were reduced following Rucaparib treatment in DU145 and PC3 cells, and 
expression levels were reduced further when combined with TSA. Treatment did not affect the 
expression of IKKa in PNT1A cells, demonstrating a cancer specific affect. Increased expression 
of IKKa has been implicated in prostate cancer progression via down-regulation of maspin. 
Goktuna et al. (2014) evidenced protection against tumour development in mice which were 
deficient in IKKa; highlighting the potential of IKKa as a therapeutic target in cancers of the 
colon. Luo et al. (2007) revealed that active IKKa repressed transcription of the maspin gene and 
correlated with metastatic progression. We did not find an inverse correlation between maspin 
and IKKa protein expression in our treatment studies and the reason for this is unknown. The 
expression studies were carried out with use of cell samples exposed to treatments for 72 hours, 
additional time-points may have revealed a change to maspin expression. Gene expression of NF-
kB and maspin, and activity of PARP and NF-kB were not assessed in our studies due to time 
constraints. These studies may provide further insight into the interplay between IKKa and 
maspin in cancer progression. A recent study by Mahato et al. (2011) investigated the role of 
IKKa in PC3 cell invasiveness; reporting upregulation of maspin in prostate cancer following 
IKKa silencing by siRNA. These findings are in line with the expression data obtained in our 
studies with MEF IKKa-/- cells; whereby maspin expression levels are higher compared to MEF 
cells which were not deficient for IKKa.  
The expression of NF-kB p65 was reduced following PARP inhibition in normal PNT1A cells 
but not in DU145 and PC3 cells. This may be attributable to the increased inflammatory signalling 
in tumour cells. Reduced levels of IKKa expression following PARP inhibition in these cell lines 
suggest that NF-kB may not be constitutively activated despite expression. However, the protein 
expression data is representative of total protein expression and further investigation into the 
cytoplasmic and nuclear expression of NF-kB subunits following PARP inhibition is warranted 
to elucidate NF-kB constitutive activation. Interestingly, TSA treatment reduced the protein 
expression levels of NF-kB p65 in PNT1A and DU145 cells, but not PC3 cells. Rucaparib and 
TSA co-treatment significantly reduced the expression levels of NF-kB p65 in PNT1A, DU145 
and PC3 cell lines. These findings demonstrate that the reduction of NF-kB p65 is dependent on 
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HDAC inhibition in PNT1A and DU145 cells. In PC3 cells reduced expression of NF-kB p65 is 
dependent on Rucaparib and TSA co-treatment.  
As PARP-1 is a known coactivator of NF-kB, the expression levels of PARP-1 following 
treatment were also investigated. Rucaparib and TSA as single agents had no effect on the 
expression levels of PARP-1, however expression was reduced following co-treatment in the 
cancerous cell lines. A possible explanation for the aforementioned is PARP trapping. In addition 
to the inhibition of PARP-1 catalytic activity, PARP inhibitors trap PARP at DNA breaks; 
preventing DNA SSB repair leading to the development of cytotoxic DSB’s and cell death. 
Various PARP inhibitors, including Rucaparib, have been reported to trap PARP in a number of 
cancer studies (Shen et al., 2015, Murai et al., 2014, Rouleau et al., 2010, Murai et al., 2012). 
Studies have also reported acetylation of PARP-1 following HDAC inhibition. For example, 
Robert et al. (2016) showed increased acetylation of PARP-1 in leukaemia cells exposed to TSA. 
They evidenced increased PARP-1 binding to DSB’s in chromatin, a mechanism similar to the 
PARP-1 trapping mechanism observed following PARP inhibition. The same group reported 
increased PARP trapping following combined HDAC and PARP inhibitor treatment. However, 
the ability of these drugs to trap PARP in chromatin is dependent on their cytotoxicity, and the 
reduced expression of PARP-1 following co-treatment in our cell lines correlates with cell 
cytotoxicity data. Combined HDAC and PARP inhibitor treatment has also been shown to 
decrease PARP-1 expression in other cancer studies, including the prostate (Rasmussen et al., 
2016, Yin et al., 2018). PARP-1 protein expression does not reflect the activity of PARP and 
therefore measurement of activity may provide further insight into the effects of PARP and 
HDAC inhibition.  
Overall, the protein expression data from treated cell samples show that maspin expression is not 
increased following combined PARP and HDAC inhibition. Co-treatment does reduce the 
expression of PARP-1 and NF-kB expression in DU145 and PC3 cell lines and therefore is an 
attractive therapeutic target.  
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4.5 Summary  
The studies presented in this chapter have shown that: 
• Rucaparib induces a low dose hormetic response that is specific to tumour cells. 
• SRB assay is the best technique to assess cell sensitivity to Rucaparib and TSA treatment. 
The technique provides a stable endpoint and correlates to data obtained from manual cell 
counts. 
• Maspin depleted cells are significantly more sensitive to Rucaparib treatment than maspin 
proficient cells.  
• Cells expressing reduced levels of PARP-1 and the NF-kB subunit p65 are most sensitive 
to Rucaparib; supporting the role for PARP-1 as a mediator of NF-kB activation which 
promotes resistance to DNA damaging agents.  
• NF-kB p65 knockout MEF cells are more sensitive to Rucaparib than NF-kB p65 
proficient MEF cells. 
• TSA enhances cell sensitivity to Rucaparib in DU145 and PC3 cells, underlining a 
promising strategy for tumour sensitisation. Response to co-treatment was not 
significantly different between DU145 and PC3 cells at GI50, suggesting that the 
differential expression of maspin does not affect sensitivity.  
• The expression of maspin is not affected by Rucaparib and TSA co-treatment in prostate 
cells. 
• PARP-1, IKKa and NF-kB p65 protein expression is reduced in DU145 and PC3 cells 
exposed to Rucaparib and TSA co-treatment. 
4.6 Future work 
Future work could be to assess PARP-1 activity in DU145 cells to confirm that an increased 
sensitivity to Rucaparib is due to reduced NF-kB signalling rather than reduced PARP-1 levels. 
It would also be useful to look at protein localisation by immunofluorescence in cells exposed to 
treatments as this would confirm whether Rucaparib and TSA, alone and in combination, affect 
NF-kB activity. Identification of a hormetic response by WST-1 assay in DU145 and PC3 cells 
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exposed to low doses of Rucaparib (section 4.3.1) highlighted a need for further investigation into 
the effects of Rucaparib on cancer cell metabolism and bioenergetics. Further investigation could 
include use of the Agilent Seahorse platform to directly measure live cell metabolic pathways in 
response to treatments. This system would enable identification of the metabolic pathway that the 
tumour cells are relying on and what effects Rucaparib are having on the pathway. To strengthen 
the nuclear and cellular morphology data assays could be carried out to confirm the mode of cell 
death that is induced following exposure to Rucaparib and TSA, alone and in combination. For 
example, the Caspase-Glo assay system from Promega measures the activity of caspase 3 and 7 
could be carried out to confirm cell death by apoptosis. Other commercial kits are also available 
to measure cell apoptosis and necrosis such as Apoptosis/necrosis assay kit from Abcam; this 
system simultaneously detects cell apoptosis, necrosis and healthy cells by flow cytometry or 
fluorescence microscopy.  
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Chapter Five  
Investigating the effects of PARP-1 and HDAC-1 inhibitors on cell 
migration in prostate cells with varied maspin expression. 
5.1 Introduction  
5.1.1 Cell migration 
Cell migration is the directed movement of cells and is fundamental to the development and 
maintenance of multicellular organisms. Dysregulated cell migration contributes to pathologies 
such as tumour development and metastasis (Trepat et al., 2012). Acquisition of invasive 
phenotypes such as a loss of cell-cell adhesion promotes the migration of tumours from their 
initial site of tumour growth to surrounding tissues and distant sites (Yilmaz and Christofori, 
2010).  
The main cause of death in cancer patients is organ failure due to uncontrolled tumour progression 
and metastasis. Metastatic tumour cells invade healthy tissues and distant organs, starving them 
of the nutrients and space required for normal function (Seyfried and Huysentruyt, 2013). 
Assessment of cell migration and the development of drugs which target migration are of 
paramount importance in cancer research. Inhibition of cell migration has the potential to limit 
cell metastasis; holding promise for a viable alternative means of therapy (Palmer et al., 2011). 
Various molecules play a role in the regulation of cell migration such as chemokines, cytokines, 
integrins and growth factors (Ilina and Friedl, 2009). Maspin is a known endogenous inhibitor of 
cell migration and is often downregulated in cancers (Maass et al. (2001), Ravenhill et al. (2010)). 
To this end, the development of treatments to induce re-expression of these molecules may limit 
cell migration and improve disease outcome.  
5.1.2 Assessment of cell migration in the presence and absence of Rucaparib and TSA. 
The traditional way to assess cell migration is by scratch assay. It is a simple, low cost technique 
that allows the observation of 2D cell migration in confluent cell cultures (Liang et al., 2007); 
however, the method is time consuming and relies on a large amount of cells. It is also difficult 
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to standardise this method and there are potential issues around effects of debris from damaged 
cells (Cormier et al., 2015). The xCELLigence cell analyser platform quantitively measures cell 
migration in real-time. It is a non-invasive assay requiring limited quantities of cell culture.  
This chapter ascertains the effects of Rucaparib and TSA treatment, alone and in combination, on 
the migration of prostate cell models using two different techniques. The xCELLigence real time 
cell analyser system was used in addition to a traditional scratch assay technique with time lapse 
microscopy.  
5.2 Chapter aims 
It is hypothesised that Rucaparib and TSA co-treatment will reduce cell migration in cancerous 
cell lines lacking maspin by reducing IKKa. It is expected that DU145 cells will have higher 
migration potential due to maspin depletion and increased IKKa. The aims of this chapter are 
detailed below:  
• To examine the effects of Rucaparib and TSA treatment, alone and in combination, on 
migration in PNT1A, DU145 and PC3 cells.  
• To investigate how the presence of maspin affects the migration of cells when exposed 
to Rucaparib and TSA treatments, alone and in combination.  
5.3 Results 
5.3.1 Real-time effects of Rucaparib and TSA treatment, alone and in combination, on 
prostate cell migration. 
The xCELLigence analyser measured prostate cancer cell migration exposed to treatments for 72 
hours. Briefly, cells were seeded into a specialised xCELLigence CIM-Plate as outlined in section 
2.2.9.1. Following an overnight incubation period, drugs were applied to the wells containing 
cells and cell impedance, representative of cell migration, was measured in real-time over a 72-
hour period. Cell impedance increased over the duration of the experiment in both cell lines. PC3 
cells were less migratory than DU145 cells at all time points in all treatment conditions (Figure 
5.1A and B). 
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DU145 cell migration was reduced by all treatment conditions, particularly cells exposed to 
Rucaparib as a single agent. There was no difference in DU145 cells exposed to TSA and co-
treatment at any time point (Figure 5.1A and C). The migration of PC3 cells was reduced in all 
treatment conditions. Rucaparib had the greatest effect on cell migration compared to TSA. PC3 
cell migration was further reduced following exposure to co-treatment (Figure 5.1B and D).  
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Figure 5.1: Real-time analysis of prostate cell migration in response to Rucaparib and TSA, alone 
and in combination, using the xCELLigence system.   
(A) DU145 and (B) PC3 prostate cell lines were exposed to Rucaparib and TSA, alone and in combination 
at their GI50 concentrations for 72 hours. The migration of (C) DU145 and (D) PC3 cells following 
exposure to treatments for 72 hours was compared against untreated controls.  Data is representative of a 
single experiment.  
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5.3.2 The effects of Rucaparib and TSA treatment, alone and in combination, on prostate 
cell migration by scratch assay 
Scratch assays were carried out in addition to xCELLigence experiments to enable visual 
assessment of cell migration over time. As outlined in section 2.2.8, cells were seeded into sterile 
tissue culture plates and incubated overnight to allow cell adherence. The following day a scratch 
was applied through the centre of each well containing cells and drugs were applied at their 
respective GI50 concentrations in 1% DMSO, alone and in combination. Cell migration was 
assessed for 72 hours, at 24-hour intervals, by microscopy. Image J densitometry was used to 
quantify and compare scratch closure between each treatment condition.  
PNT1A cell migration was not affected by treatment conditions in the first 24 hours of the assay. 
At 48 hours, cells migration was increased in response to Rucaparib and TSA as single agents, 
compared to control. At 72 hours, cell migration had increased in all treatment conditions but 
there was no difference in the migration of cells exposed to treatments compared to control, 
indicating that the drugs did not affect PNT1A cell migration at 72 hours (Figure 5.2A). Scratch 
wounds incubated for 72 hours were semi-quantified (Figure 5.2B); confirming that the difference 





Figure 5.2: Assessment of PNT1A cell migration by scratch wound healing assay in the absence or 
the presence of Rucaparib and TSA, alone and in combination.  
Cells were exposed to Rucaparib and TSA, alone and in combination at their GI50 concentrations. (A) 
Migration and wound closure were assessed against untreated controls at 24-hour intervals, for 72 hours. 
The presented images are representative of three independent experiments and solid blue lines indicate 
wound borders. Images were captured at a 10X magnification. Scale bar= 1000!m. (B) Percentage cell 
migration following 72hours drug treatment. Wound closure at 72 hours following treatment was quantified 
using ImageJ densitometry software. Untreated cells were used as a control. Bars represent the mean of 
three independent experiments ± SEM. 
 
DU145 cells gradually migrated over a 72-hour time period in all treatment conditions (Figure 
5.3A). Rucaparib did not affect cell migration at 48- or 72-hour time points. At 48 hours, TSA 
limited cell migration and this response was further enhanced with co-treatment. All treatments 
did not significantly affect cell migration at 72 hours (Figure 5.3B). 














Figure 5.3: Assessment of DU145 cell migration by scratch wound healing assay in the absence or the 
presence of Rucaparib and TSA, alone and in combination.  
Cells were exposed to Rucaparib and TSA, alone and in combination at their GI50 concentrations. (A) 
Migration and wound closure were assessed against untreated controls at 24-hour intervals, for 72 hours. 
The presented images are representative of three independent experiments and solid blue lines indicate 
wound borders. Images were captured at a 10X magnification. Scale bar= 1000!m. (B) Percentage cell 
migration following 72hours drug treatment. Wound closure at 72 hours following treatment was quantified 
using ImageJ densitometry software. Untreated cells were used as a control. Bars represent the mean of 
three independent experiments ± SEM. 
 
TSA and combination treatment were inhibitory to PC3 cell migration at 48 and 72 hours, 
compared to control, but Rucaparib was most inhibitory to cell migration at 48 and 72 hours 













5.4B) showed a 1.5,1.3 and 1.3 -fold reduction in cell migration following exposure to Rucaparib, 
TSA and co-treatment, respectively. The effect of Rucaparib on the inhibition of cell migration 
was significant (P<0.05). 
 
 
Figure 5.4: Assessment of PC3 cell migration by scratch wound healing assay in the absence or the 
presence of Rucaparib and TSA, alone and in combination.  
Cells were exposed to Rucaparib and TSA, alone and in combination at their GI50 concentrations. (A) 
Migration and wound closure were assessed against untreated controls at 24-hour intervals, for 72 hours. 
The presented images are representative of three independent experiments and solid blue lines indicate 
wound borders. Images were captured at a 10X magnification. Scale bar= 1000!m. (B) Percentage cell 
migration following 72hours drug treatment. Wound closure at 72 hours following treatment was quantified 
using ImageJ densitometry software. Untreated cells were used as a control. Bars represent the mean of 
three independent experiments ± SEM. 
 












Semi-quantified scratch migration data for each treatment condition was compared across each 
cell line to identify differences in treatment response. Data is presented in Figure 5.5 and results 
are expressed as percentage of untreated controls.  
After 72-hour treatment with Rucaparib, the migration of PC3 cells was significantly less than 
the migration of PNT1A and DU145 cells (P<0.05). Cell migration of both DU145 and PC3 cells 
was significantly less than the migration of PNT1A cells following TSA treatment. There was no 
significant difference in the effect of co-treatment on prostate cell migration. Collectively these 
data show that migration of PNT1A cells is unaffected by treatment, TSA affects DU145 and PC3 
cell migration whilst Rucaparib affects PC3 cell migration only.  
 
 
Figure 5.5: Comparison of prostate cell migration in response to Rucaparib and Trichostatin A 
treatment, alone and in combination.  
Cell migration after 72 hours was quantified using ImageJ densitometry software. Data is expressed as % 
cell migration against untreated controls. Results are representative of at least two independent experiments 
±SEM.  
 
5.3.3 The effects of maspin knockdown with siRNA on PC3 cell migration. 
Results presented in 5.3.1 and 5.3.2 support the role of maspin as an inhibitor of cell migration. 
To this end, the change in the migration of PC3 cells transfected with maspin siRNA sequences 
was investigated over a 96-hour period using xCELLigence technology. The results presented in 
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Figure 5.6 are from a single experiment but this preliminary data highlights an increase in PC3 
cell migration, over time, following knockdown of maspin. PC3 cells transfected with maspin 
siRNA sequence #1 were most migratory but increased cell migration was also apparent in cells 
transfected with maspin siRNA sequence #2.   
 
Figure 5.6: The effects of maspin siRNA on PC3 cell migration. 
The migration of PC3 cells in the presence or absence of maspin siRNA was measured by xCELLigence 
over a 92-hour period. 
 
5.4 Discussion 
Migration experiments were carried out to confirm differences in cell migration between cancer 
cell lines of varied maspin status, and to explore the effects of PARP and HDAC inhibition on the 
migration of these cell lines. Maspin depleted DU145 cells were significantly more migratory 
than PC3 cells in both xCELLigence and scratch experiments. DU145 cells should be less 
migratory as they have less metastatic potential than PC3 cells (Ravenna et al., 2014). The 
metastatic potential of DU145 cells does not correlate with cell migration and maspin expression 
levels.  
Normal prostate epithelial PNT1A cells were less migratory than DU145 cells but more migratory 
than PC3 cells. These findings correspond to maspin expression levels and support the role of 
maspin as an inhibitor of migration and invasion. Sheng et al. (1996) were the first to demonstrate 
the role of maspin as an inhibitor of cell invasion by blocking cell motility. They reported reduced 
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invasion and motility in breast and prostate cancer cells following treatment with recombinant 
maspin; concluding that the mechanism of action could be due to the protease inhibitory activity 
of maspin. A later study also demonstrated the inhibitory effect of maspin on vascular smooth 
muscle cell and cancer cell migration. However, they showed that the activity of maspin was 
independent of protease inhibition (Bass et al., 2002). The inhibitory effect of maspin on cell 
migration was later found to be due to binding of b1 integrins on the cell surface (Bass et al., 
2009).  
Increased cell migration in PC3 cells transfected with maspin siRNA confirm that maspin acts as 
a tumour suppressor by inhibiting cell migration; an enabling characteristic of tumour 
development. Cell migration was increased 23-fold and 8.5-fold following a 48-hour exposure to 
maspin #1 and #2 siRNA, respectively. At 92 hours migration was increased 5.6-fold and 3-fold 
in the presence of maspin #1 and #2 siRNA. Other studies have also reported a role for maspin as 
an inhibitor of cell migration in prostate cancers. For example, stable cell lines expressing maspin 
derived from a prostate tumour model showed decreased metastatic potential and increased 
adhesion to the extracellular matrix; a negative regulator of tumour migration and invasion 
(Abraham et al., 2003). More recent studies have demonstrated that maspin inhibits cell migration 
via its G-helix; which binds to β1 integrins on the cell surface (Ravenhill et al., 2010). The group 
also reported a 40% increase in PC3 cell migration following maspin silencing by siRNA; 
supporting a role for maspin in tumour progression.  
xCELLigence studies demonstrated reduced cell migration in both DU145 and PC3 cells 
following treatment with Rucaparib. At 72 hours, the effect was greatest in PC3 cells compared 
to untreated controls. The effects of Rucaparib on cell migration were not in line with growth 
inhibition studies whereby DU145 cells were most sensitive to Rucaparib. Although the effects 
of Rucaparib being greater in PC3 cells was unexpected, the cells lines tested were not isogenic 
and variances in the expression of various proteins may have impacted this. Scratch assay 
experiments also demonstrated reduced PC3 cell migration following exposure to Rucaparib for 
72 hours, however, Rucaparib had no significant effect on the migration of DU145 cells compared 
to untreated control. Rucaparib did not inhibit the migration of PNT1A cells at a GI50 drug 
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concentration. These data highlight a clear selective effect of Rucaparib in cancer cells in terms 
of cell migration. The protein expression data presented in Chapter Four, Figure 4.17 and Figure 
4.18 show that maspin protein expression is unaffected by Rucaparib in tumour cells, indicating 
that the effects of Rucaparib on cell migration occurs via a mechanism independent to maspin. A 
proposed mechanism by which Rucaparib could be reducing migration is through the modulation 
of β-catenin; a key regulator of cell migration (Yang et al., 2017). The PARP inhibitor PJ34 has 
been shown to inhibit β-catenin signalling and limit cell migration in cervical cancers (Mann et 
al., 2019).  
PARP-1 inhibition has been shown to limit cell migration through the modulation of other 
epithelial-mesenchymal transition (EMT) transcription factors such as E-cadherin and Vimentin. 
Endothelial and metastatic melanoma cells exposed to PARP inhibitors expressed increased levels 
of E-cadherin, a marker associated with reduced cell motility and invasion. PARP inhibition was 
found to reduce the expression of Vimentin, a marker that is over-expressed in tumours and is 
associated with malignant transformation (Rodriguez et al., 2013). As PARP-1 is a known co-
activator of NF-kB, it would not be unreasonable to suggest that the effects of PARP inhibition 
on cancer cell migration may be due to down-regulation of NF-kB, and in-turn reversal of EMT.  
Positive correlations between EMT transcription factors and NF-kB activation have been reported 
in several human cancers (Huber et al., 2004, Cheng et al., 2011, Taki et al., 2018). A prostate 
cancer study demonstrated that Transforming Growth Factor Beta (TGF-b) induced EMT was 
mediated by NF-kB signalling which promotes an invasive and metastatic phenotype. Chemical 
inhibition of NF-kB limited the invasive capability and expression of Vimentin in these cells, 
leading to reversal of EMT (Zhang et al., 2009). Breast cancer studies also reported decreased 
cell motility and EMT following inhibition of NF-kB (Pires et al., 2017). 
TSA treatment was inhibitory to DU145 and PC3 cell migration, but not to PNT1A cells; 
demonstrating a selective effect in tumour cells. This finding supports that normal cells are 
resistant to HDACi compared with tumour cells (Abbas and Gupta, 2008). xCELLigence studies 
revealed a greater effect of TSA on the inhibition of PC3 cell migration, compared to DU145 
cells. Results obtained from scratch assay showed a reduction in cell migration in DU145 and 
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PC3 cells exposed to TSA for 72 hours, compared to control, but these results were not 
statistically significant. The protein expression data presented in chapter four revealed a reduction 
in maspin expression following TSA treatment in PNT1A and DU145 cells but not in PC3 cells, 
supporting the role of HDAC inhibitors as inhibitors of migration in a mechanism dependent on 
maspin. Reduced PC3 cell migration in the presence of TSA may be additive to the inhibitory 
effects of maspin on HDAC. The reason for a reduction in maspin expression following TSA 
treatment in PNT1A cells is unknown but may explain why TSA fails to limit cell migration in 
these cells. Response to TSA is cell line and target specific and it could be postulated that reduced 
maspin expression in PNT1A cells exposed to TSA is a result of epigenetic modification and 
increased histone acetylation, leading to alterations in the expression of genes. Further exploration 
is required to elucidate mechanisms that contribute to the differential effects of HDAC inhibition 
on cell migration. 
There are contradictory reports on the effects of HDAC inhibition on cell migration, some which 
are in line with our findings and some which are not. Increased cell migration has been reported 
in a variety of tumours, such as those derived from the breast and lung, following treatment with 
HDAC inhibitors (Lin et al., 2012). Low and non-cytotoxic doses were used, allowing the 
conclusion that increased migration was a result of epigenetic activation of tumour-suppressive 
genes in HDACi treated cells, rather than the selection of cells that survived HDAC inhibitor 
toxicity. Combined treatment of HDAC inhibitors with other agents including protein kinase 
inhibitors supressed HDACi-activated tumour progressive proteins, cell migration and tumour 
growth. Elsewhere, the effects of HDAC inhibitors on prostate cancer cell migration and invasion 
were investigated. In support of our findings, inhibition of HDAC reduced cell migration and 
increased the expression of E-cadherin (Kim et al., 2011).  
Maspin has been associated with EMT markers such as E-cadherin. It has been shown that E-
cadherin was up-regulated, alongside enhanced cell-cell migration and adhesion, in maspin-
transfected MCF-7 breast cancer cells compared to controls (Ravenhill et al., 2010). This response 
was not reported in cells transfected with mutated maspin, suggesting that the G-helix of maspin 
was involved in the mechanisms in which E-cadherin expression was altered by maspin, and the 
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inhibitory actions of maspin on cell migration was dependent on a functional G-helix. To this end, 
the enhanced effects of PARP-1 and HDAC-1 inhibition on cell migration may reverse EMT via 
maspin and this may explain why response was 0.3-fold and 4.8-fold higher in PC3 cells 
expressing increased levels of maspin in scratch and xCELLigence experiments, respectively, 
compared to DU145 cells.  
Several studies also report the effects of HDAC inhibitors on the activity of NF-kB. For example, 
colon cancer cells exposed to the HDAC inhibitors Butyrate and TSA showed reduced proteasome 
activity and presented limited proteasome dependent degradation of IKBa and NF-kB activation 
(Place et al., 2005). Others have reported increased inflammatory signalling and activation of NF-
kB following HDAC inhibition. For example, the HDAC inhibitors MS-275 and suberoxylanilide 
hydroxamic acid (SAHA) were found to induce NF-kB activation via hyperacetylation of NF-kB 
p65 in the cell nucleus of leukaemia cells (Dai et al., 2005). Active NF-kB is a known driver of 
inflammatory signalling which promotes cancer cell migration, invasion and metastasis. Our data 
supports the studies of others which suggest that HDAC inhibition limits activation of NF-kB. 
Data also provides rationale for the potential role of TSA as an inhibitor of cancer cell migration 
via suppression of NF-kB activation. Protein expression data presented in Chapter 4 also supports 
this finding, highlighting reduced expression of IKKa, an activator of NF-kB, in cancer cell lines 
following TSA treatment. 
In view of these findings along with previous growth inhibition studies, the combined effects of 
HDAC and PARP-1 inhibitors on cancer cell migration were explored. The xCELLigence data 
highlighted a reduction in the migration of PC3 cells exposed to co-treatment, compared to single 
agents. The inhibition of DU145 cell migration was not enhanced by TSA and Rucaparib co-
treatment compared to either treatment alone, indicating that the effects of co-treatment on cell 
migration are cell type specific. Protein expression data of co-treated cell samples presented in 
Chapter four highlighted a decrease in the protein expression levels of maspin following co-
treatment in all cell lines, and a decrease in the expression of IKKa in PC3 cells. These findings 
suggest that Rucaparib and TSA co-treatment may inhibit NF-kB, but such response is cell type 
specific. The enhanced inhibitory effects of co-treatment on PC3 cell migration are independent 
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to the presence of maspin but may be due to reduced expression of IKKa. Scratch assay data 
revealed no significant effect on cell migration following co-treatment in any of the cell lines, 
compared to agents alone.   
Variation in results between methods are likely due to the different ways in which migration was 
measured between experiments. The xCELLigence method was reliant on directional cell 
impedance towards a chemotactic gradient to enable quantitative kinetic measurement of 
migration. This method requires regulated formation of lamellipodia, whereas assessment of cell 
migration by scratch assay is random (Petrie et al., 2009). The scratch data obtained from 
xCELLigence studies were from a single experiment due to the expense of materials and further 
experiments are required to confirm validity and reproducibility. Scratch assays are a cost 
effective and straightforward way to assess migration but are reliant on visual evaluation of cells 
and lack reproducibility. The method introduces injury to the cell, leading to cell debris and 
release of cellular contents into the wound area which may affect the migration process (Grada et 
al., 2017). The scratch protocol could be improved by using technology such as a wound maker™; 
a mechanical device designed to create homogenous wounds in cell monolayers.  
To add stringency to data, migration studies need to be repeated across a range of doses. Variance 
in GI50 drug concentrations between cell lines may have contributed to the migratory affects.    
5.5 Summary 
The studies presented in this chapter have shown that: 
• The inhibitory effects of Rucaparib on cell migration are specific to cancer cell lines, 
particularly PC3 cells which express increased levels of maspin and reduced levels of 
IKKa. 
• The inhibitory effects of TSA on cell migration were greater in PC3 cells when assessed 
by xCELLigence. Scratch assays showed reduced cell migration in both cancerous cell’s 
lines exposed to TSA suggesting that response was independent to the expression of 
maspin and NF-kB expression. 
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• The inhibitory effects of co-treatment on cell migration were greatest in PC3 cell lines 
despite a reduction in the expression of IKKa and maspin proteins. 
• The effects of treatments on cell migration are variable between techniques. 
5.6 Future work 
xCELLigence data is representative of a single experiment due to cost implications. To add 
stringency to the data further xCELLigence experiments could be carried out. Scratch assays 
could be developed to enhance the validity and reproducibility of data. One way to do this could 
be use of an automated system such as the IncuCyte cell migration kit and live-cell analysis 
system. The IncuCyte wound maker is a mechanical device that enables accurate assessment of 
cell migration/wound closure by creating consistent wounds in cell cultures without damaging the 
cells or the underlying plasticware. Cell migration experiments could be carried out in MEF NF-
kB p65 and IKKa knockout cells in the presence and absence of Rucaparib and TSA, to confirm 
an effect of NF-kB on cell migration. Future migration studies could also utilise prostate cells 
transfected with PARP-1 and IKKa siRNA to validate potential mechanisms.  
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Chapter Six 
Investigating the effects of PARP-1 and HDAC-1 inhibitors on DNA 
damage in prostate cell lines of varied maspin expression.  
6.1 Introduction 
DNA repair inhibitors such as PARP inhibitors increase the specificity and toxicity of traditional 
radio- and chemotherapeutic DNA damaging agents. As stand-alone agents, PARP inhibitors 
limit SSB repair in cancer cells, leading to an accumulation of genetically unstable DSBs (Curtin, 
2013). As tumours progress, they accumulate defects in DNA repair proteins which make them 
unable to repair DNA DSBs via the primary repair mechanism that is HR. These tumours are 
dependent on NHEJ, a backup mechanism which repairs DNA breaks in the absence of HR at the 
cost of genome stability. PARP inhibitors induce synthetic lethality in HR deficient tumours via 
targeting of the backup pathway on which these cells are dependent on (Nickoloff et al., 2017). 
Synthetic lethality arises when cancer cells are selectively targeted, leading to inactivation of two 
genes or pathways which is lethal and results in cell death (Nijman, 2011). The observation that 
PARP inhibitors can be used as inducers of synthetic lethality in HR repair deficient cells 
originated from two pivotal studies which reported that cells deficient in BRCA genes were 
exquisitely sensitive to single agent PARP inhibition (Bryant et al., 2005, Farmer et al., 2005). 
These findings were independently reported by the two laboratories using different BRCA 
deficient models and classes of PARP inhibitors; implying that the sensitivity of these cells was 
indeed due to PARP inhibition. PARP inhibition in HR-defective cells stimulates error-prone 
NHEJ (described in Chapter 1, section 1.3.2.1). Promotion of NHEJ results in chromosome 
instability and cell death; a promising target for PARP inhibitor cancer therapy by synthetic 
lethality (reviewed in Sunada et al. (2018)).   
HDAC inhibitors (HDACi) can induce cell death via accumulation of DNA damage, by down-
regulating and impairing the function of DNA repair proteins such as RAD51, BRCA, Ku70/Ku80 
and MRE11.These proteins are all implicated in the repair of DNA DSBs. RAD51 and BRCA 
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proteins are implicated in DNA DSB repair by HR, whereas Ku heterodimers and MRE11 are 
implicated in DNA repair by NHEJ, as discussed in Chapter 1, sections 1.3.2.1 and 1.3.2.2. 
HDAC inhibitors prevent accumulation of RAD51 and BRCA1 DNA repair proteins to the site 
of DNA damage by downregulating transcription factors and inducing acetylation of histones and 
nonhistone proteins, leading to limited DNA repair efficiency and increased DNA damage 
(reviewed in Newbold et al. (2016)). HDACis may also mimic synthetic lethality in tumour cells 
that do not harbour BRCA mutation; by pharmacologically inducing an HR deficient phenotype 
(BRCAness) and sensitising cells to the lethal effects of PARP inhibitors. To this end, a number 
of HDAC inhibitors have been shown to induce DNA damage in cancer cells and mimic a HR-
deficient phenotype. For example, the HDAC inhibitor Vorinostat has been shown to induce 
DSBs in normal and cancerous cell lines. Normal cells were able to repair the DSBs and cancerous 
prostate and lung adenocarcinoma cells were not. The cancerous cells also presented increased 
levels of phosphorylated H2AX (gH2AX), a known marker of DSBs, in the presence of Vorinostat 
(Lee et al., 2010). Reduced DNA repair and downregulation of the HR proteins BRCA1 and 
RAD51 has also been reported in breast cancer cells treated with the HDAC inhibitors Vorinostat 
and Panobinostat (Ha et al., 2014).  
These studies postulate the potential efficacy for combining the HDACi TSA with the PARPi 
Rucaparib to downregulate HR and enhance DNA damage by inducing synthetic lethality in 
tumours that are not BRCA deficient. Studies have demonstrated additive DNA damage and 
inhibition of DNA repair following combined PARP-1 and HDAC-1 inhibitor treatment. Prostate 
cancer cells exposed to the HDACi SAHA in combination with the PARPi Olaparib showed 
increased DNA damage which was observed by Immunofluorescence microscopy of gH2AX foci, 
a marker of DSBs. Co-treatment was also shown to downregulate HR-related protein expression 
(Chao and Goodman, 2014). Breast cancer studies have also demonstrated synergistic inhibition 
of breast cancer cell growth and DNA repair following combined PARP-1 and HDAC-1  inhibitor 
treatment; showing enhanced gH2AX foci and reduced expression of the HR repair protein 
RAD51, particularly in BRCA deficient cells (Marijon et al., 2018). The effects of combined 
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treatments on DNA damage relative to the expression of maspin or NF-kB have not yet been 
explored in tumour cells.  
There are several ways to assess DNA single and double strand breaks. The gold standard method 
for measuring DNA SSBs is single-cell gel electrophoresis under alkaline conditions, otherwise 
known as the alkaline comet assay (principle and method described in section 2.2.6.1). The test 
is simple, requires a small cell sample and enables analysis of data at the individual cell level 
(Speit and Hartmann, 2006). The technique is cost effective but relies on image analysis 
equipment and software to enable comet visualisation; which carries a cost implication. In the 
absence of analysis software, comet tails may be quantified manually but this process is labour 
intensive, and results may be subjective.  
Other techniques for the detection of SSBs include terminal deoxynucleotidyl transferase (TdT) 
dUTP nick-end labelling (TUNEL) assay and High-performance liquid chromatography (HPLC)-
electrospray mass spectrometry (MS). The TUNEL assay detects DNA breaks via the 
visualisation of DNA fragmentation. It relies on the ability of the enzyme TdT to incorporate 
nucleotide analogues, conjugated with a fluorochrome, onto the free 3’-OH of a DNA strand, 
enabling visualisation of nuclei containing the fragmented DNA. The assay is limited in its 
sensitivity and specificity as it relies on DNA damage and cell death via the apoptosis pathway 
and cannot differentiate between other modes of cell death. HPLC-MS involves separation of 
component compounds in a sample which are then fed into a MS to determine the mass of each 
ion. It is a sensitive method for the detection of DNA SSBs via identification and quantification 
of altered nucleobases. The technique requires skilled personnel and is expensive to set up and 
run (Figueroa-Gonzalez and Perez-Plasencia, 2017). 
The gH2AX assay (principle and method described in section 2.2.7.1) is a sensitive marker that 
correlates well with DSBs (Sharma et al., 2012). Identification of gH2AX foci by 
immunofluorescence microscopy is a powerful tool to examine the DNA damage produced in 
response to DNA damaging agents in tumour cells. H2AX molecules are rapidly phosphorylated 
to produce gH2AX molecules in response to DNA DSBs. These molecules surround the DSBs 
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and prompt recruitment and localisation of DNA damage response proteins such as MRE11 and 
BRCA1 (Podhorecka et al., 2010). The technique is the most sensitive assay to detect DNA 
damage as it enables acquisition of qualitative and quantitative data in a short timeframe 
(Ivashkevich et al., 2012).  
Other methods of DNA DSB detection include the neutral comet assay. Comet assays carried out 
in neutral pH conditions limit DNA unwinding but enable detection of DNA DSBs. Cells with 
increased frequency of DNA DSBs are more migratory to the anode under neutral assay 
conditions (Ostling and Johanson, 1984).   
This chapter investigates DNA damage in prostate cells following exposure to Rucaparib and 
TSA treatment, alone and in combination. The alkaline comet and gH2AX immunofluorescence 
techniques were utilised to detect single and double strand breaks, respectively. Expression of 
RAD51 protein, a marker of DSB repair by HR, was also investigated. 
6.2 Chapter aims 
It is hypothesised that Rucaparib and TSA co-treatment will enhance DNA damage in cancer cells 
via the mechanism of synthetic lethality.  
The aims of this chapter are:  
• To examine the effects of Rucaparib and TSA treatment, alone and in combination, on 
DNA SSBs in PNT1A, DU145 and PC3 cells.  
• To examine the effects of Rucaparib and TSA treatment, alone and in combination, on 
DNA DSBs in PNT1A, DU145 and PC3 cells.  
• To examine the DSB repair pathway utilised by PNT1A, DU145 and PC3 cells exposed 
to Rucaparib and TSA treatment, alone and in combination. 
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6.3 Results 
6.3.1 DNA single strand break formation in prostate cells treated with Rucaparib and 
TSA, alone and in combination. 
The alkaline comet assay, described in Chapter Two, section 2.2.6.1, was used to examine the 
formation of DNA single strand breaks (SSBs) in PNT1A, DU145 and PC3 cells treated with 
Rucaparib and TSA, alone and in combination. Briefly, cells treated with Rucaparib and TSA, 
alone and in combination, at their respective GI50 concentrations for 72 hours were embedded in 
agarose on a glass microscope slide, immersed in lysis solution and then exposed to an electric 
current to enable migration of negatively charged DNA fragments towards the anode. The 
migration of the broken DNA resembles a comet and the size of the comet tail represents the 
number of DNA SSBs. Comet tails were visualised by confocal microscopy and then 20 cells 
were manually scored and classified according to their tail distribution. Data was statistically 
analysed to identify significant difference in sensitivity between treatment groups using the two-
way ANOVA with multiple comparisons test.  
Results presented in Figure 6.1 highlight increased levels of DNA SSBs in PNT1A cells following 
Rucaparib and TSA treatment, alone and in combination, as demonstrated by fluorescent 
microscopy images of comet tails  (Figure 6.1A). Percentage tail distribution data (Figure 6.1B) 
revealed a 2.5-fold increase in class 2 comet tails following exposure to Rucaparib and TSA 
treatment, alone and in combination (p<0.0001), and a 2.8-fold increase in class 3 comet tails in 
cells exposed to Rucaparib. There was no significant difference in sensitivity between Rucaparib, 
TSA and co-treatment (two-way ANOVA with multiple comparisons), indicating that co-




Figure 6.1: Detection of single strand DNA breaks in PNT1A cells exposed to Rucaparib and TSA, 
alone and in combination.  
(A) Alkaline comet assay for the detection of single strand DNA breaks in PNT1A cells exposed to 
treatments at their GI50 concentrations for 72 hours. Images are representative of at least three independent 
experiments. Scale bar: 22μm. (B) Bar graph to summarise percentage comet classes for each treatment 
group. Cells were assessed visually and classified 0 (undamaged) to 4 (maximally damaged), according to 
the size and shape of the comet tail. There is a significant increase in class 2 comet tails following treatments 
in comparison with control (two-way ANOVA with Tukey’s multiple comparisons test, ****p<0.0001), 
however combination treatment is not significantly more effective than Rucaparib and TSA as single 
agents. 
 
The level of endogenous SSBs in DU145 cells were higher than PNT1A cells. Comet tail 
microscopy images presented in Figure 6.2A show increased DNA fragmentation, representative 
of DNA SSBs, in DU145 following Rucaparib and TSA treatment. Co-treatment increased DNA 
fragmentation in DU145 cells compared to Rucaparib and TSA alone, demonstrating that DU145 
cells have reduced capacity to repair SSBs in the presence of co-treatment. There was a 77% and 
31% increase in class 3 comet tail distribution in DU145 cells exposed to Rucaparib (p<0.0001) 
and TSA (p<0.05), respectively. Combination treatment enhanced SSBs in DU145 cells; 
demonstrated by a 44% increase in Class 4 comet tails (p<0.0001), as shown in Figure 6.2B.  





Figure 6.2: Detection of single strand DNA breaks in DU145 cells exposed to Rucaparib and TSA, 
alone and in combination.  
(A) Alkaline comet assay for the detection of single strand DNA breaks in DU145 cells exposed to 
treatments at their GI50 concentrations for 72 hours. Images are representative of at least three independent 
experiments. Scale bar: 22μm. (B) Bar graph to summarise percentage comet classes for each treatment 
group in DU145 cells. 50 cells were scored per treatment group and data is expressed as a percentage. 
Comet tail classification differs significantly between treatment groups (****p<0.0001). Cells treated with 
Rucaparib and TSA present higher levels of DNA breaks compared to control, however combination 
treatment has a significantly greater affect (two-way ANOVA with Tukey’s multiple comparison test, 
****p<0.0001). (B) Bar graph to summarise percentage comet classes for each treatment group in PC3 
cells. Comet tail classification differs significantly between treatment groups (****p<0.0001). 
 
Rucaparib and TSA also enhanced SSBs in PC3 cells (Figure 6.3). Class 2 comet tails were 3.3-
fold and 4.8-fold greater in cells exposed to Rucaparib and TSA, respectively. Class 3 comet tails 
were increased 3.8-fold and 2.5-fold following Rucaparib and TSA treatment, respectively. 
Combined treatment enhanced class 2 comet tails 1.5-fold and class 3 comet tails 5.6-fold, 
compared to untreated control cells (Figure 6.3B). Class 3 comet tails were increased 1.4-fold and 
2.2-fold following combination treatment, compared to Rucaparib and TSA, respectively; 
indicating that cells exposed to combination treatment are more sensitive to single strand DNA 
breaks.  





Figure 6.3: Detection of single strand DNA breaks in PC3 cells exposed to Rucaparib and TSA, alone 
and in combination.  
(A) Alkaline comet assay for the detection of single strand DNA breaks in PC3 cells exposed to treatments 
at their GI50 concentrations for 72 hours. Images are representative of at least three independent 
experiments. Scale bar: 22μm. (B) Bar graph to summarise percentage comet classes for each treatment 
group. 50 cells were scored per treatment group and data is expressed as a percentage. Comet tail 
classification differs significantly between treatment groups (****p<0.0001). 
 
 
Comet tail classifications representative of DNA SSBs in PNT1A, DU145 and PC3 cells exposed 
to co-treatment, for 72 hours, were compared to determine which cells were most susceptible to 
SSBs (Figure 6.4). Class three comet tails were increased 14 and 18-fold in DU145 (p<0.01) and 
PC3 (p<0.001) cells exposed to treatment, compared to PNT1A cells, respectively. Class four 
comet tails, indicative of increased DNA damage, were increased 49 and 19-fold in DU145 and 
PC3 cells, compared to PNT1A cells (p<0.01). These findings demonstrate increased DNA 
damage in DU145 and PC3 cells, as would be expected in tumour cells which are prone to genetic 
mutation and DNA damage. DU145 cells were significantly (p<0.01) more susceptible to DNA 










Figure 6.4: Comparison of single strand DNA breaks in prostate cells exposed to Rucaparib and TSA 
co-treatment. 
Bar graph to summarise percentage comet classes for prostate cells exposed to co-treatment. Data is 




6.3.2 DNA double strand break formation in prostate cells treated with Rucaparib and 
TSA, alone and in combination. 
To determine whether DNA double strand breaks (DSBs) accumulate following exposure to 
Rucaparib and TSA, DSBs were assessed using the gH2AX immunofluorescence assay, as 
described in Chapter Two, section 2.2.7.1. gH2AX foci were visualised by confocal microscopy 
and quantified after cells were treated with Rucaparib and TSA, alone and in combination, at their 
respective GI50 concentrations in 1% DMSO for 72 hours in culture medium. Untreated cells 
incubated in medium containing 1% DMSO were also quantified (negative control). Differences 
in sensitivity between treatment groups were statistically analysed using one-way ANOVA with 
multiple comparisons.  
Results show an accumulation of DNA DSBs in PNT1A (Figure 6.5), DU145 (Figure 6.6) and 
PC3 (Figure 6.7) cells following exposure to Rucaparib, compared to their respective controls. 
TSA as a single agent and in combination with Rucaparib did not significantly enhance gH2AX 
foci, compared to Rucaparib alone. DNA DSBs were increased in PNT1A cells and not increased 
in DU145 and PC3 cells exposed to TSA, compared to untreated control. The results demonstrate 
that cells were more susceptible to DNA damage when exposed to Rucaparib as a single agent.  
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PNT1A cells exposed to Rucaparib (28µM) for 72-hours presented 2.5-fold more DSBs 
(p<0.0001) than untreated control cells (Figure 6.5B) and this was apparent in the fluorescent 
microscopy images presented in Figure 6.5A which highlight increased expression of gH2AX foci 
within the cell nucleus (green dots). The levels of gH2AX foci present in PNT1A cells exposed 
to TSA (188nM) were increased compared untreated control but this was not significant. gH2AX 
foci were increased 2.1-fold in PNT1A cells exposed to Rucaparib and TSA in combination, 
compared to control. Rucaparib induced more DSBs in PNT1A cells as a single agent than in 
combination with TSA. This point is also visually apparent in the microscopy images presented 
in Figure 6.5.  
 
Figure 6.5: Detection of double strand DNA breaks by gH2AX immunofluorescence assay in PNT1A 
cells exposed to Rucaparib and TSA, alone and in combination.  
(A) Microscopy images to enable visual identification of gH2AX foci in PNT1A cells exposed to Rucaparib 
and TSA for 72 hours. Images are representative of three independent experiments. Scale bar: 12μm. (B) 
Bar graph to show mean fold change in gH2AX foci for each treatment group. gH2AX foci were quantified 
in the nucleus of 20 cells per treatment group.  (**p<0.01, ***p<0.001, ****p<0.0001).  
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DU145 cells exposed to Rucaparib (8µM) for 72-hours presented 2-fold more DSBs (Figure 
6.6B). than untreated control cells (p<0.01). This is apparent in the fluorescent microscopy images 
presented in Figure 6.6A which highlight increased expression of gH2AX foci within the nucleus 
of cells treated with Rucaparib, compared to control. As represented in Figure 6.6A there was a 
visible increase in gH2AX foci in cells treated with TSA (45nM), however, quantitative analysis 
revealed no significant difference in foci between untreated cells and those exposed to TSA 
(Figure 6.6B). Rucaparib and TSA in combination did not significantly increase gH2AX foci 
compared to Rucaparib as a single agent.  
 
Figure 6.6: Detection of double strand DNA breaks by gH2AX immunofluorescence assay in DU145 
cells exposed to Rucaparib and TSA, alone and in combination. 
(A) Microscopy images to enable visual identification of gH2AX foci in DU145 cells exposed to Rucaparib 
and TSA for 72 hours. Images are representative of three independent experiments. Scale bar: 11μm. (B) 
Bar graph to show mean fold change in gH2AX foci for each treatment group. gH2AX foci were quantified 
in the nucleus of 20 cells per treatment group.  (**p<0.01).  
 
The microscopy images presented in Figure 6.7 show that PC3 cells possess gH2AX foci 
representative of DNA DSBs prior to drug exposure (fluorescence green dots in the cell nuclei). 
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Treatment with Rucaparib (16µM) for 72-hours significantly enhanced the expression of gH2AX 
foci. Quantitative assessment confirmed this finding (Figure 6.7B), showing a significant 1.7-fold 
increase in DSBs (p<0.01). TSA treatment (49nM) did not increase the levels of double strand 
breaks in PC3 cells, compared to control. There was an increase in gH2AX foci following co-
treatment compared to untreated controls but this response was not significantly greater than 
Rucaparib as a single agent.  
 
Figure 6.7: Detection of double strand DNA breaks by gH2AX immunofluorescence assay in PC3 
cells exposed to Rucaparib and TSA, alone and in combination. 
(A) Microscopy images to enable visual identification of gH2AX foci in PC3 cells exposed to Rucaparib 
and TSA for 72 hours. Images are representative of three independent experiments. Scale bar: 11μm. (B) 
Bar graph to show mean fold change in gH2AX foci for each treatment group. gH2AX foci were quantified 
in the nucleus of 20 cells per treatment group.  (*P<0.05, **p<0.01).  
 
 
The graph presented in Figure 6.8A demonstrates that PNT1A cells were subject to increased 
levels of DNA DSBs following Rucaparib treatment at a dose inhibitory to cell growth by 50%, 
compared to DU145 and PC3 cells. PNT1A cells exposed to TSA expressed an increased number 
of gH2AX foci than PC3 cells but not DU145 cells, as shown in Figure 6.8B. There was no 
significant difference in the number of gH2AX foci between DU145 and PC3 cells following TSA 
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treatment. Data presented in Figure 6.8C show that PC3 cells are significantly less sensitive 
(p<0.01) to DNA DSBs following co-treatment compared to PNT1A and DU145 cells. DU145 
cells presented the highest mean increase in gH2AX foci, relative to control, following co-
treatment compared to PNT1A and PC3 cells.  
 
Figure 6.8: Mean fold-change in gH2AX foci: control following continuous exposure to Rucaparib 
and TSA, alone and in combination, for 72 hours.  
Mean gH2AX foci: control in PNT1A, DU145 and PC3 cells following exposure to (A) Rucaparib, (B) 




6.3.3 Western blot analysis of RAD51 protein expression as a marker of Homologous 
recombination in prostate cancer cells exposed to Rucaparib and TSA, alone and in 
combination.  
To determine whether DU145 and PC3 cells were able to repair Rucaparib and TSA-induced 
DNA DSBs by HR, the protein expression levels of RAD51 were investigated by Western 
blotting, as described in Chapter Two, section 2.2.4. The presence of RAD51 assists in the repair 
of DSB by HR. Briefly, cells were exposed to Rucaparib and TSA, alone and in combination, or 
no drug (negative control) at their respective GI50 concentrations in 1% DMSO for 72 hours in 
culture medium. Cells were harvested, lysates were prepared and loaded onto SDS-PAGE gels 
for protein separation; prior to electro-transfer, antibody probing and chemiluminescent detection.  
Results show increased expression of RAD51 protein in PNT1A cells subject to Rucaparib-
induced (28µM) DNA damage (Figure 6.9A). RAD51 protein expression levels were reduced in 
DU145 cells (Figure 6.9B) and unchanged in PC3 cells (Figure 6.9C) following exposure to 
Rucaparib at 8µM and 16µM GI50 concentrations, respectively. RAD51 expression levels were 
reduced in DU145 and PC3 cells but not in PNT1A cells following TSA treatment. Expression 
levels were further reduced in DU145 and PC3 cells exposed to Rucaparib and TSA in 
combination, relative to loading control, demonstrating increased DNA damage and reduced 
DNA repair by HR (Figure 6.9A-C).  
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Figure 6.9: RAD51 protein expression following exposure to Rucaparib, TSA and co-treatment. 
Western blot of whole cell extracts of (A) PNT1A, (B) DU145 and (C) PC3 cells following 72-hour 




6.4.1 The effects of Rucaparib and TSA on DNA SSB formation 
PNT1A, DU145 and PC3 cells exposed to Rucaparib presented increased levels of SSBs, 
compared to untreated controls. These findings are consistent with the known role of PARP-1 in 
the repair of SSB by BER (Durkacz et al., 1980). All cells were dosed at their respective GI50 
Rucaparib concentrations however levels of SSBs were higher in DU145 cells; 77% of the DU145 
comet tails examined following Rucaparib treatment were class 3, compared to 10% and 38% 
class 3 comet tails in PNT1A and PC3 cells, respectively. Further investigation is required to 
elucidate why Rucaparib induces more SSBs in DU145 cells than PNT1A and PC3 cells despite 
equal cell death. A possible reason for this finding in DU145 cells is maspin deficiency, and 
consequently reduced DNA repair capacity and evasion of apoptosis. It has been documented that 
maspin inhibits tumour progression and induces apoptosis (Berardi et al., 2013). Studies have also 

































control cells (Li et al., 2007). The results indicate that DU145 cells are more prone to DNA 
damage, as would be expected in a cell line harbouring a BRCA1 mutation (Yin et al., 2018). The 
data also postulates that less SSBs are needed to induce apoptosis in PNT1A and PC3 cells and 
this may be in part due to increased expression of maspin. Previous prostate cancer studies 
observed increased apoptosis in DU145 cells transfected with maspin; demonstrating a potential 
role for maspin in apoptosis (Li et al., 2007). A pro-apoptotic effect of maspin has also been 
reported in breast and squamous cell carcinoma cells (Liu et al., 2004, Zhu et al., 2017). Another 
contributing factor could be increased basal expression of IKKa in DU145 cells. Activation of 
NF-kB by stimuli such as radiation and chemotherapy has been shown to protect tumour cells 
from apoptosis; highlighting the potential of NF-kB inhibitors such as PARP inhibitors as 
adjuvant treatments to enhance the apoptotic response to traditional therapies (Baldwin, 2001).  
Single strand DNA breaks were increased in response to TSA exposure in PNT1A, DU145 and 
PC3 cell lines. The effects were greatest in DU145 and PC3 cells; whereby 31% and 25% of 
comet tails indicative of strand breaks were class three, respectively. 3% of comet tails were class 
three in PNT1A cells exposed to TSA, highlighting the selective efficacy of TSA as an inhibitor 
of DNA SSB repair in tumour cells. Class three comet tails were 10% higher in DU145 cells than 
PC3 following treatment. Despite a statistical insignificance the data suggests that the effect of 
TSA treatment on DNA SSBs may be regulated by maspin expression status. It has been reported 
that histone hyperacetylation induced by inhibition of HDAC alters the structure of chromatin, 
which may expose DNA to DNA-damaging agents such as cytotoxic agents or reactive oxygen 
species (ROS) (Lee et al., 2010). Various studies have also demonstrated the selectivity of HDAC 
inhibitors as inducers of ROS, DNA damage and apoptosis in various types of cancer cells (Rosato 
et al., 2003, Shankar and Srivastava, 2008, Song et al., 2018). Inhibition of HDAC-1 has been 
shown to hinder DNA repair and enhance tumour cell sensitivity to DNA damaging agents (As 
reviewed by Li and Zhu (2014)).  
Rucaparib and TSA co-treatment enhanced SSBs in DU145 and PC3 cells; 42% and 57% of comet 
tails were class 3 and 49% and 2% of comet tails were class four, respectively. Majority of comet 
tails were class 2 in PNT1A cells (77%). Co-treatment did not induce class 4 comet tails but 4% 
 202 
of comets assessed were class 3. These results highlight the selectivity of co-treatment to tumours 
cells. SSBs were increased 24.5-fold (based on class 4 comet tails) in DU145 cells exposed to co-
treatment compared to PC3 cells, demonstrating that DU145 cells are more prone to DNA damage 
and/or have a reduced DNA repair capacity. These results support the findings of others, who 
have shown that DU145 cells are defective in BRCA and are therefore more prone to DSBs due 
to ineffective DNA repair by HR (Yin et al., 2018). Maspin deficiency, and increased 
susceptibility to DNA damage and apoptosis, in DU145 cells, may also contribute to increased 
SSBs following co-treatment. Increased apoptosis and DNA damage has been reported in DU145 
cells exposed to the PARPi Olaparib and HDACi SAHA combination (Chao and Goodman, 
2014). These data demonstrate that PARP and HDAC inhibition is synthetically lethal in cells 
with mutated BRCA and reduced maspin expression.  
6.4.2 The effects of Rucaparib and TSA on DSB formation 
Results from gH2AX immunofluorescence experiments presented in section 6.3.2 show an 
increase in gH2AX foci following cell exposure to Rucaparib, at respective GI50 concentrations, 
compared to untreated controls. Rucaparib induced significantly more DSBs in PNT1A cells than 
DU145 and PC3 cells (p<0.05 and p<0.01, respectively). The results demonstrate that DNA DSBs 
accumulate in cells exposed to Rucaparib irrespective of their HR function and DNA repair 
capacity. Increased levels of DSBs in PNT1A cells exposed to Rucaparib, at respective GI50 
concentration, highlight the increased ability of normal cells to survive in the presence of DSB’s. 
Human fibroblast studies have also demonstrated an increased ability of normal cells to resolve 
drug induced DSBs compared to transformed cells (Chao and Goodman, 2014).  
gH2AX foci were increased in PNT1A cells exposed to TSA at GI50, compared to control, 
highlighting the ability of normal cells to repair DNA breaks. TSA exposure did not significantly 
increase gH2AX foci in the prostate cancer cell lines. Others have shown increased gH2AX foci 
following HDACi in normal and transformed cells, suggesting that the accumulation of HDACi-
induced DSBs is dependent on various genetic and cell specific mechanisms. The studies that 
have reported increased gH2AX following HDACi have used different inhibitors and cell lines. 
For example, normal human foreskin epithelial cells and transformed LNCaP and A549 cells 
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exposed to the HDACi Vorinostat presented increased gH2AX foci (Lee et al., 2010). 
Glioblastoma cells exposed to the HDACi SAHA also presented increased levels of gH2AX foci 
(Rasmussen et al., 2016).  
Rucaparib and TSA combination gH2AX foci data presented in Figure 6.5- Figure 6.7 show that  
co-treatment significantly increases (p<0.01) the accumulation of DSBs, compared to TSA 
treatment alone; but is less effective than Rucaparib as a single agent. Our findings are in contrast 
to the findings of others that have shown a significant increase in gH2AX foci formation following 
SAHA and Olaparib, and SAHA and Veliparib co-treatment, at their respective GI50 
concentrations, in Glioblastoma and prostate cell lines, respectively (Chao and Goodman, 2014, 
Rasmussen et al., 2016, Yin et al., 2018). 
DU145 cells exposed to co-treatment were more susceptible to DNA DSBs than PNT1A and PC3 
cells. gH2AX foci levels were lowest in PC3 cells exposed to co-treatment. These findings may 
be in part due to the reduced expression of maspin and reduced repair capacity in DU145 cells. 
These results support the findings of others, who have shown that DU145 cells are defective in 
BRCA and are therefore more prone to DSBs due to ineffective DNA repair by HR (Yin et al., 
2018). Maspin deficiency, and increased susceptibility to DNA damage and apoptosis, in DU145 
cells, may also contribute to increased DNA damage following co-treatment. Increased apoptosis 
and DNA damage has been reported in DU145 cells exposed to the PARPi Olaparib and HDACi 
SAHA combination (Chao and Goodman, 2014). These data demonstrate that PARP and HDAC 
inhibition is synthetically lethal in cells with mutated BRCA and reduced maspin expression.  
6.4.3 The effects of Rucaparib and TSA on the expression of RAD51 
To further explore the effects of PARP and HDAC inhibition on DNA damage the expression of 
RAD51, a HR DNA repair protein, was investigated. RAD51 protein expression levels, presented 
in Figure 6.9, show basal expression of RAD51 in all prostate cell lines. Expression levels were 
highest in PC3 cells and lowest in DU145 cells. RAD51 is a biomarker of HR function and 
reduced expression levels in DU145 cells indicates a reduced ability to repair DBSs by HR. This 
supports the DNA damage data presented in Figure 6.8 where levels of DNA DSBs are higher in 
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DU145 cells exposed to Rucaparib and TSA co-treatment than PC3 and PNT1A cells. BRCA1 
and BRCA2 mutations are associated with defective DNA repair by HR and have been reported 
in DU145 cells (Yin et al., 2018). To this end, RAD51 expression in these cells correlates with 
defective DNA repair by HR. Studies have demonstrated that reduced expression of RAD51 is 
associated with increased sensitivity to PARP inhibitors (McCabe et al., 2006, Liu et al., 2017, 
Cruz et al., 2018). These correspond to the data presented in 4.3.1 which show enhanced 
sensitivity to Rucaparib in BRCA mutant DU145 cells and decreased RAD51 expression in 
response to Rucaparib (Figure 6.9).  
Reduced expression of NF-kB p65 in DU145 cells (as shown in Figure 3.9) may contribute to 
defective DNA repair by HR, and consequently reduced RAD51 expression. Mouse embryonic 
fibroblasts (MEF) studies have reported increased genomic instability and compromised DNA 
repair in p65-/- MEFs compared to p65+/+ MEF cells. Sub-lethal irradiation of p65-/- cells and 
tissues was found to compromise DNA damage recovery. Similar results were also found in p65-
/- cells exposed to Doxorubicin, suggesting that inefficient DNA repair of cells deficient in p65 is 
not limited to irradiation (Wang et al., 2009a). NF-kB p65 has also been shown to affect HR and 
the repair of DNA breaks arising spontaneously, or in response to genotoxic stress. K562 
leukaemia cells exposed to the PARP inhibitor IQD were ~50% less responsive to treatment upon 
expression of p65 (Volcic et al., 2012). The studies support the protein expression data presented 
in Figure 3.9; whereby PARP and NF-kB p65 protein expression levels are lowest in DU145 cells. 
The results imply that ineffective DNA repair by HR and reduced expression of RAD51 in DU145 
cells may be in part due to reduced expression of PARP-1 and NF-kB p65. It has also been 
reported that histone deacetylases regulate tumorigenesis by repressing the expression of tumour 
suppressor genes and DDR genes such as BRCA1 (Li and Seto, 2016). Loss of maspin expression 
and therefore increased deacetylation of histones in DU145 cells may contribute to the differential 
expression of proteins identified in these cells. 
An increase in RAD51 protein expression following Rucaparib exposure in PNT1A cells suggests 
functional DNA repair by HR, and this may contribute to the reduced sensitivity to Rucaparib in 
these cell lines. The RAD51 expression data in Figure 6.9 corresponds to the Rucaparib sensitivity 
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data presented in 4.3.1, whereby PNT1A cells were less sensitive to Rucaparib than DU145 and 
PC3 cells. HR function has been correlated to RAD51 focus formation and sensitivity to 
Rucaparib in primary ovarian cancer cultures and cell lines. Cell were classified into two groups, 
HR deficient or proficient, based on their ability to form RAD51 foci in response to DNA damage; 
irrespective of BRCA status. Increased RAD51 foci following exposure to Rucaparib was 
observed, demonstrating that RAD51 is a potential biomarker for HR function and sensitivity to 
Rucaparib in tumour cells (Mukhopadhyay et al., 2010). 
DU145 cells exposed to Rucaparib presented reduced expression of RAD51, suggesting that 
PARP inhibitors are synthetically lethal to cells defective in HR. These findings are in support of 
other studies that demonstrate reduced expression of RAD51 and BRCA1 in nuclear and 
cytoplasmic DU145 cell extracts exposed to the PARP inhibitor Olaparib (Chao and Goodman, 
2014). The results suggest that the differential effects of Rucaparib on DU145 cells and expression 
of RAD51 is in part due to dysfunctional HR rather than maspin deficiency. HDAC-1 inhibition 
has been shown to downregulate RAD51 and reduce DNA repair by HR in melanoma cell lines 
(Krumm et al., 2016). Maspin depleted DU145 cells express increased levels of HDAC-1 
compared to PNT1A and PC3 cells and the expression levels of maspin remain the same following 
PARP inhibition (Figure 4.17). The expression of RAD51 was not affected by Rucaparib in PC3 
cells, demonstrating the specificity of increased RAD51 in HR defective tumours exposed to 
DNA damage.  
Exposure to the HDACi TSA did not affect the protein expression of RAD51 in PNT1A cells but 
expression was reduced in DU145 and PC3 cells. These findings are in line with other studies 
which have shown that HDAC inhibitors selectively hinder the expression of DNA DSB repair 
proteins in cancer cells but not in normal cells. The HDAC inhibitor PCI-24781 has been shown 
to hinder DNA DSB repair by HR; by reducing RAD51 expression levels and limiting function 
in colon cancer cell models. HCT116 colon-tumour-bearing mice exposed to oral doses of PCI-
24781 also presented decreased tumour expression of RAD51 (Adimoolam et al., 2007). A similar 
effect has been observed in prostate and lung cancer cells exposed to the HDACi Vorinostat. 
Vorinostat induced DNA DSBs in normal and cancer cells, but suppression of the DNA DSB 
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repair proteins RAD50 and MRE11 occurred only in cancer cells. Normal cells were able to repair 
the DNA breaks despite continued culture with Vorinostat, highlighting the selectivity of 
Vorinostat as a cytotoxic agent in cancer cells (Lee et al., 2010). Downregulation of DNA repair 
genes by HDAC inhibition has been shown to increase the sensitivity of PC cells to DNA 
damaging agents and radio-sensitisation of HDACis has been linked to decreased expression of 
the HR proteins BRCA1 and RAD51. An inability of these proteins to bind to DNA DSBs has 
also been reported (Kachhap et al., 2010).  
A further reduction in the expression of RAD51 in DU145 and PC3 cells exposed to Rucaparib 
and TSA in combination demonstrates that inhibition of PARP-1 and HDAC-1 is synthetically 
lethal to tumour cells and hinders HR DNA repair. These findings are consistent with other studies 
that have demonstrated reduced levels of RAD51 in cancer cells exposed to HDACi and PARPi 
co-treatment, and show that these effects are attributable to impaired DNA damage repair by HR 
and consequently enhanced DNA DSBs (Chao and Goodman, 2014, Rasmussen et al., 2016, Yin 
et al., 2018). Knockdown experiments also support the efficacy of combined PARP and HDAC 
inhibitor treatments in cancer cells; showing that loss of RAD51 enhances apoptosis in cells 
exposed to PARP and HDAC inhibitor co-treatment (Chao and Goodman, 2014). The results 
support a critical role of RAD51 in preventing DNA-damage induced cell death. 
6.5 Summary 
The in vitro studies presented in this chapter have shown that:  
• Rucaparib induces SSBs in PNT1A, DU145 and PC3 cells at their respective GI50 
concentrations. SSBs were increased in DU145 cells, followed by PC3 and PNT1A cells; 
showing that DU145 cells are more prone to DNA damage. This may be in part due to 
maspin deficiency as a result of increased expression of the NF-kB subunit IKKα.  
• TSA induces SSBs in PNT1A, DU145 and PC3 cells at their respective GI50 
concentrations. SSBs were greatest in DU145 and PC3 cells highlighting a selective effect 
of TSA as an inhibitor of SSB repair in tumour cells.  
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• Rucaparib and TSA co-treatment selectively enhances SSBs in tumour cells; particularly 
DU145 cells. The results support that DU145 cells are more prone to DNA damage and 
have a reduced DNA repair capacity.  
• Rucaparib induces significant levels of DSBs to PNT1A cells, at their respective GI50 
concentration, demonstrating an increased ability for normal cells to survive in the 
presence of DSBs. 
• Rucaparib, as a single agent, is more effective at inducing DNA DSBs than co-treatment. 
Co-treatment does induce more DNA DSBs in DU145 cells despite a 50% cell survival 
in all cell lines, but not more than Rucaparib alone. This differential affect may be in part 
due to maspin, IKKα and BRCA deficiency which hinders the ability of DU145 cells to 
repair DNA breaks by HR.  
• Low expression of RAD51 in DU145 cells correlates with increased sensitivity to 
Rucaparib. Reduced RAD51 expression in DU145 cells exposed to Rucaparib 
demonstrates that Rucaparib is synthetically lethal to DU145 cells which are 
dysfunctional for DNA repair by HR. 
• RAD51 expression is reduced in DU145 and PC3 cells exposed to TSA but not PNT1A 
cells. TSA selectively hinders DSB repair by HR in tumour cells. 
• RAD51 expression is further reduced in DU145 and PC3 cells exposed to Rucaparib and 
TSA co-treatment, demonstrating that co-treatment inhibits DNA repair and is 
synthetically lethal to tumour cells.  
6.6 Future work 
The data presented supports the existing reports that the BRCA mutant, maspin depleted, DU145 
cell line is more susceptible to DNA damage and has a reduced DNA repair capacity. Future work 
could include assessing the effects of Rucaparib and TSA on DNA damage and repair in a wide 
range of tumour cell lines deficient for maspin and proficient for IKKα. Rucaparib and TSA 
induced DNA damage in isogeneic paired prostate cancer cell lines that are either proficient or 
deficient for maspin, PARP-1 and IKKα could also be investigated. This would provide a 
significant amount of insight into the crosstalk between maspin and the NF-kB pathways. 
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RAD51 expression data has provided fundamental insight into the effects of Rucaparib and TSA 
on DNA repair by HR. The studies carried out in this chapter investigated total RAD51 protein 
expression levels in cell samples but did not assess the accumulation of RAD51 nuclear foci in 
response to treatments. Assessment of RAD51 foci by immunofluorescence could be carried out 
in future studies to aid identification of HR functional status within cells. The effects of Rucaparib 
and TSA on DNA damage were investigated after 72-hour exposure to treatments. Future studies 
could also look at kinetics of DNA repair by following the effects of treatment over time and after 
removal of treatments. Reduced gH2AX foci in response to drug removal would indicate an 
increased ability for cells to repair DNA DSBs in the absence of treatment.  
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Chapter Seven  
Investigating the effects of Maspin and PARP-1 siRNA on prostate cell 
sensitivity to Rucaparib and TSA.  
7.1 Introduction 
This chapter investigates the effects of maspin and PARP-1 on prostate cell sensitivity to 
Rucaparib and TSA. Small interfering RNA (siRNA) were utilised to explore the roles of maspin 
and PARP-1 in cell survival following exposure to Rucaparib and TSA treatments.  
7.1.1 Cell transfection 
Transfection is the process of deliberately introducing genetic material into mammalian cells to 
enable the study of gene function (Thermo Fisher Scientific). Gene transfection can be achieved 
by various techniques such as viral, physical and chemical mediated gene delivery. 
Viral transfection utilises the ability of a virus to introduce foreign DNA into mammalian cells. 
Commonly used viruses include retrovirus, lentivirus and adenovirus (Huang et al., 2011). The 
virus integrates into the host genome, is expressed and replicated within the host, passing the 
foreign DNA into subsequent generations of daughter cells. Viral transfection is highly efficient 
but can only deliver small pieces of DNA into cells, is labour intensive and may cause an 
inflammatory reaction or mutation due to random insertion into the host genome (Reviewed in 
Kim and Eberwine (2010) and Nayerossadat et al. (2012)). 
Physical transfection methods include electroporation, sonoporation, microinjection and 
ultrasound. These methods are able to directly penetrate DNA into cells by electric impulse, fine 
needle puncture, or high-pressure gas, respectively. Physical transfection methods are effective 
for single or multiple targets at an intended location, however gene transportation to the nucleus 
is difficult due to restricted access in passing through the membrane and consequently low 
transfection efficiency (reviewed in Kaestner et al. (2015)). Physical methods are labour intensive, 
cause damage to the cell and require use of expensive equipment. 
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Chemical transfection methods are the most frequently used in mammalian cells and include 
cationic and neutral lipids such as Lipofectamine, FuGene 6 and HiPerFect. The principle of 
chemical transfection is similar to viral, whereby positively charged chemicals make complexes 
with negatively charged nucleic acids. These positively charged complexes are attracted to the 
negatively charged cell membrane and pass through it; to enable translocation to the cell nucleus 
(reviewed in Jin et al. (2014a)). Chemical transfection methods are advantageous to viral methods 
as they are less toxic, do not cause mutation and there is no size limitation on the DNA delivered 
to the cells. Efficiency of chemical transfection is dependent on cell membrane conditions and 
nucleic acid/chemical ratio (Ramamoorth and Narvekar, 2015).  
7.1.1.1 siRNA  
Small interfering RNA (siRNA) are double stranded RNA molecules which regulate gene 
expression. They exploit the RNA pathway by targeting complementary mRNA for degradation 
to induce gene silencing (Dana et al., 2017).  
Delivery of siRNA into mammalian cells to induce gene silencing is achieved using the chemical 
transfection methods discussed in section 7.1.1. Successful silencing of a specific gene following 
siRNA transfection can be determined by assessment of protein expression levels, after a suitable 
incubation time. siRNA gene silencing is a commonly used technique to validate gene function 
and provides opportunity for the development of innovative therapies to treat diseases such as 
cancer. The potential of siRNA-based therapy has been increasingly recognised as an effective 
treatment for cancer, with the aim of blocking multiple disease-causing genes (reviewed in 
Mahmoodi Chalbatani et al. (2019)). Silencing of cancer-associated genes by siRNA has been 
shown to have antiproliferative and apoptotic effects in a range of cancer cells in vitro. For 
example, Melanoma cells subject to siRNA mediated knockdown of ribonucleotide reductase, a 
rate-limiting enzyme primarily expressed in proliferating cells such as cancer cells, presented 
reduced cell proliferation and increased cell cycle arrest (Zuckerman et al., 2011). Inhibition of 
cell proliferation and increased apoptosis has also been reported in colorectal and breast cancer 
cells subject to siRNA-mediated knockdown of STAT6; a transcription factor associated with 
cancer cell proliferation, increased malignancy and poor prognosis (Salguero-Aranda et al., 
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2019). siRNAs have also shown promise in sensitising tumour cells to chemotherapy by silencing 
genes which are associated with drug resistance during chemotherapy (reviewed in Guo et al. 
(2013)). A barrier that must be overcome to ascertain effective widespread use of siRNA in the 
clinic is the potential for off target effects which may result in unpredictable cellular consequences 
and immune stimulation (reviewed in Singh et al. (2018)). To overcome this, drug delivery 
systems such as nanoparticles are being developed for the safe and effective delivery of siRNA 
therapies into tumour cells. Various siRNA therapies are currently undergoing clinical trials and 
one siRNA therapeutic, ONPATTRO™ (patisiran), has been FDA approved for commercial use 
(Hu et al., 2019). ONPATTRO™ is a lipid nanoparticle-based siRNA used to treat nerve damage 
caused by hereditary transthyretin amyloidosis (Akinc et al., 2019). The clinical approval of 
ONPATTRO paves the way for the development of universal siRNA therapeutics. There are still 
challenges to overcome due to the complexity of the microenvironment in the human body (Zhang 
et al., 2018).  
The siRNA studies presented in this chapter were carried out to provide mechanism to the effects 
of Maspin and PARP-1 in cell survival following exposure to Rucaparib and TSA treatments. The 
siRNA sequences used to silence maspin and PARP-1 are presented in Chapter Two, Table 2.6. 
Throughout the studies presented in thesis, PNT1A, DU145 and PC3 cells have been used as 
prostate models and have shown some interesting patterns between NF-kB, PARP-1 and maspin. 
However, ultimately, these cells are not isogenic and therefore patterns cannot be directly 
compared. Utilisation of siRNA in these cells to knock down PARP-1 and maspin proteins aims 
to provide a mechanism to the patterns previously observed in earlier chapters. 
7.2 Chapter aims 
The aims of this chapter are detailed below:  
• Further investigate the expression of maspin and/or PARP-1 on the sensitivity to PARP-
1 and HDAC-1 inhibitors. This was achieved through the selective knockdown of maspin 
or PARP-1 
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• Investigate the effects of Rucaparib and TSA, alone and in combination, in the presence 
of maspin siRNA on cell survival in PNT1A cells. 
• Investigate the effects of Rucaparib and TSA, alone and in combination, in the presence 
of maspin siRNA on PARP-1 expression in PC3 cells. 
• Investigate the effects of Rucaparib and TSA, alone and in combination, in the presence 
of PARP-1 siRNA on cell survival in DU145 and PC3 cells. 
7.3 Results 
7.3.1 Knockdown of maspin with siRNA in PNT1A and PC3 cells 
Variation in siRNA sequences and a time course of target knockdown was investigated to 
determine optimal conditions for the silencing of maspin in PNT1A and PC3 cells. Cells were 
seeded and incubated overnight to enable cell adherence prior to lipid transfection (method 
described in Chapter Two, section 2.2.10) with 10nM of siRNA oligos targeting maspin or a non-
specific control (-ve). Maspin expression levels were determined by Western blotting 24, 48 and 
72-hours following siRNA transfection.  
The data presented in Figure 7.1 and Figure 7.2 show knockdown of maspin using single siRNA 
sequences in PNT1A and PC3 cells, respectively. Percentage knockdown was determined against 
negative control siRNA as 100% at each timepoint. Maspin expression in negative control siRNA 
cell samples did not significantly differ to cells alone (data not shown). 
Knockdown of maspin with maspin siRNA sequence #1 was not achieved in PNT1A cells at 24 
and 48-hour timepoints (Figure 7.1). At 72 hours maspin expression was reduced by 62% in 
PNT1A cells transfected with maspin siRNA sequence #1. Maspin siRNA sequence #2 did not 
effectively knockdown maspin at any timepoint; at 72 hours maspin expression was reduced by 




Figure 7.1: Time course of siRNA knockdown of Maspin in PNT1A cells. 
(A) Western blot of whole cell extracts of PNT1A cells at 24, 48 and 72 hours after transfection with non-
specific siRNA (-ve), or maspin single siRNA sequences (#1 and #2) at 10nM final concentrations. (B) 




Maspin expression was reduced in PC3 cells exposed to maspin siRNA sequences at 48 and 72 
hours (Figure 7.2). At 48 hours, maspin expression was reduced by 93% and 91% in the presence 
of maspin siRNA #1 and #2, respectively. At 72 hours maspin expression was reduced by 69% 





Figure 7.2: Time course of siRNA knockdown of Maspin in PC3 cells. 
(A) Western blot of whole cell extracts of PC3 cells at 24, 48 and 72 hours after transfection with non-
specific siRNA (-ve), or maspin single siRNA sequences (#1 and #2) at 10nM final concentrations. (B) 
Percentage knockdown of maspin in PC3 cells vs -ve control. 
 
 
7.3.2 The effects of maspin on PNT1A cell sensitivity to Rucaparib and TSA. 
Following identification of optimum maspin siRNA sequence and exposure timepoints for maspin 
knockdown, PNT1A cells transfected with maspin siRNA #1 were exposed to Rucaparib and/or 
TSA to investigate the effects of maspin knockdown on cell sensitivity to treatments, by SRB 
assay (Figure 7.3-Figure 7.5). Cancer cells harbour a number of genetic defects and therefore the 
PNT1A cell line (proficient for maspin, NF-kB and PARP-1) was selected to look at the effects 
of maspin knockdown in a non-cancerous cell line. Maspin protein expression levels were not 
investigated following exposure to drug treatments for 72 hours, therefore it cannot be confirmed 
whether maspin remains knocked down for the duration of the experiment. 
Results presented in Figure 7.3 show a 21% reduction in PNT1A cell survival following maspin 
siRNA #1 transfection and Rucaparib treatment, compared to unsilenced cells exposed to 
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Rucaparib treatment alone at GI50 (27uM). Maspin siRNA #2 and Rucaparib treatment reduced 
cell survival by 10% compared to Rucaparib alone. Negative control siRNA increased cell 
survival by 17% in the presence of Rucaparib, compared to Rucaparib alone. There was no 
significant difference between maspin siRNA #1 combined with Rucaparib and Rucaparib alone; 
there was a significant difference (p<0.05) in cell survival in cells exposed to maspin siRNA #1 
combined with Rucaparib compared to negative control siRNA. Cells were exposed to siRNA 
sequences and Rucaparib for 72 hours and results were obtained by SRB assay.  
 
 
Figure 7.3: siRNA knockdown of maspin enhances PNT1A cell sensitivity to Rucaparib.  
Percentage survival of PNT1A cells relative to control following exposure to 10nM maspin siRNA and 
GI50 Rucaparib for 72 hours. Cell sensitivity was assessed using the SRB assay and differences between 
treatment conditions were statistically analysed in Graphpad PRISM (one-way ANOVA, * p<0.05).  
 
Results presented in Figure 7.4 show a 39% reduction in PNT1A cell survival following maspin 
siRNA #1 transfection and TSA treatment, compared to unsilenced cells exposed to TSA 
treatment alone at GI50 (188nM). Negative control siRNA increased cell survival by 11% in the 
presence of TSA, compared to TSA alone. Maspin siRNA #2 and TSA treatment reduced cell 
survival by 16% compared to TSA alone. There was no significant difference between maspin 
siRNA #1 combined with TSA and TSA alone; there was a significant difference (p<0.05) in cell 




Figure 7.4: siRNA knockdown of maspin enhances PNT1A sensitivity to TSA. 
Percentage survival of PNT1A cells relative to control following exposure to 10nM maspin siRNA and 
GI50 TSA for 72 hours. Cell sensitivity was assessed using the SRB assay and differences between treatment 
conditions were statistically analysed in Graphpad PRISM (one-way ANOVA, *p<0.05).  
  
 
Maspin knockdown enhanced PNT1A cell sensitivity to Rucaparib and TSA co-treatment, as 
shown in Figure 7.5. Cell survival was reduced by 39% and 19% in the presence of siRNA #1 
and #2, respectively. Sensitivity to co-treatment was most significant in PNT1A cells transfected 
with maspin siRNA sequence #1 (p<0.05, one-way ANOVA). There was no significant difference 
between maspin siRNA #1 combined with co-treatment and co-treatment alone. There was a 
significant difference (p<0.05) in cell survival in cells exposed to maspin siRNA #1 combined 
with co-treatment compared to negative control siRNA. 
 
Figure 7.5: siRNA knockdown of maspin enhances PNT1A sensitivity to Rucaparib and TSA co-
treatment.  
Percentage survival of PNT1A cells relative to control following exposure to 10nM maspin siRNA and 
GI50 Rucaparib and TSA co-treatment for 72 hours. Cell sensitivity was assessed using the SRB assay and 
differences between treatment conditions were statistically analysed in Graphpad PRISM (one-way 




The data presented in Figure 7.3-Figure 7.5 show that PNT1A cell survival is reduced in the 
presence of maspin #1 siRNA and co-treatment, compared to maspin #1 siRNA and Rucaparib 
alone. However, cell survival in the presence of maspin siRNA #1 and co-treatment is no greater 
than maspin #1 siRNA and TSA alone. Co-treatment is not additive. 
7.3.3 The effects of Maspin knockdown on PARP-1 protein expression following exposure 
to Rucaparib and TSA, alone and in combination.  
 
Maspin expressing PC3 cells were selected for use to explore the effects of maspin on PARP-1 
protein expression, following exposure to Rucaparib and TSA, alone and in combination. PC3 
cells express the highest levels of PARP-1 (expression data presented in Chapter Three, Figure 
3.8 and Figure 3.9) and are therefore a suitable model to investigate the effects of maspin on 
PARP-1 protein expression. DU145 cells express low levels of maspin and PARP-1 compared to 
PC3 cells. The expression of PARP-1 following maspin knockdown in PC3 cells will allow us to 
establish whether maspin deficiency in DU145 cells contributes to reduced expression of PARP-
1. 
PC3 cells were exposed to -ve or maspin siRNA sequences in the presence of Rucaparib and TSA, 
alone and in combination (Figure 7.6). PARP-1 protein levels were assessed by Western blotting 
using the method outlined in Chapter Two, 2.2.4. Briefly, PC3 cells were transfected with maspin 
siRNA for 48hours (as described in Chapter two, section 2.2.10) to achieve optimum knockdown 
and then dosed with Rucaparib and/or TSA at their respective GI50 concentrations for 72-hours. 
Expression data presented in Figure 7.6 shows reduced expression of PARP-1 in PC3 cells 
transfected with maspin #1 siRNA, compared to negative control. PARP-1 expression was not 
reduced in PC3 cells transfected with maspin #2 siRNA. Earlier maspin siRNA studies have also 
shown reduced efficacy of this maspin siRNA sequence and the expression data is from a single 
experiment without loading control. PARP-1 expression levels in PC3 cells exposed to maspin 
#1 and #2 siRNA were reduced following exposure to Rucaparib and TSA, alone and in 
combination. These results are preliminary, repeat experiments and use of loading control are 
necessary to ensure reproducibility and validity of findings.  
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Figure 7.6: The effect of maspin on the protein expresssion of PARP-1 in PC3 cells exposed to 
Rucaparib and TSA, alone and in combination. 
Western blot of whole PC3 cell extracts transfected with non-specific siRNA (-ve), or maspin single siRNA 
sequences (#1 and #2) at 10nM final concentration for 48 hours and then exposed to Rucaparib and TSA, 
alone and in combination, for a further 72-hours. Results are representative of a single experiment.  
 
 
7.3.4 Knockdown of PARP-1 with siRNA in DU145 and PC3 cells  
DU145 and PC3 cells were transfected with PARP-1 siRNA (method detailed in Chapter Two, 
2.2.10) and protein expression levels were assessed by Western blotting (Chapter Two, 2.2.4) 24, 
48 and 72-hours following transfection to determine the optimum timepoint required to achieve 
PARP-1 knockdown. Cells were seeded and incubated overnight to enable cell adherence prior to 
lipid transfection with 10nM of siRNA oligos targeting PARP-1 or non-specific control (-ve) 
(siRNA sequences presented in Table 2.6). Figure 7.7 shows successful knockdown of PARP-1 
in DU145 and PC3 cells following PARP-1 siRNA transfection for 48 and 72 hours. PARP-1 
























Figure 7.7: Time course of siRNA knockdown of PARP in DU145 and PC3 cells. 
Western blot of whole cell extracts of DU145 and PC34 cells at 24, 48 and 72 hours after transfection with 
non-specific siRNA (-ve) or PARP-1 at 50nM final concentrations. 
 
DU145 and PC3 cells were transfected with PARP-1 siRNA for 48 hours and exposed to 
Rucaparib and/or TSA for 72 hours to investigate the effects of PARP-1 on cell sensitivity to 
treatments (Figure 7.8-Figure 7.13).  
DU145 cell sensitivity to Rucaparib was reduced 8% in the presence of PARP-1 siRNA, 
compared to cells exposed to Rucaparib alone. Survival was reduced by 6% in cells exposed to 
Rucaparib and -ve siRNA, compared to Rucaparib alone; as shown in Figure 7.8.  Cell survival 
















Figure 7.8: The effects of PARP-1 knockdown on DU145 cell sensitivity to Rucaparib. 
Percentage survival of DU145 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and 16µM Rucaparib for 72 hours. Cell sensitivity was assessed using the SRB assay and differences 
between treatment conditions were statistically analysed in GraphPad PRISM (one-way ANOVA).  
 
 
The data presented in Figure 7.9 show a significant 12% reduction in cell survival in DU145 cells 
exposed to TSA treatment and PARP-1 siRNA, compared to cells exposed to TSA alone. Cells 
transfected with control siRNA were 8% more sensitive to TSA treatment than cells exposed to 
TSA alone, but less than cells subject to PARP-1 silencing. This was also significant. 
 
Figure 7.9: The effects of PARP-1 knockdown on DU145 cell sensitivity to TSA. 
Percentage survival of DU145 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and 45nM TSA for 72 hours. Cell sensitivity was assessed using the SRB assay and differences 




PARP-1 knockdown significantly enhanced DU145 cell sensitivity to Rucaparib and TSA co-
treatment (Figure 7.10). Survival was reduced by 31% when cells were transfected with PARP-1 
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siRNA and exposed to co-treatment, compared to cells which were exposed to co-treatment alone. 
Cell survival of co-treated DU145 cells transfected with PARP-1 siRNA was 22% less than co-
treated DU145 cells transfected with control siRNA. These results indicate that PARP-1 plays a 
role in cell sensitivity to Rucaparib and TSA co-treatment in DU145 cells. 
 
Figure 7.10: siRNA knockdown of PARP-1 enhances DU145 cell sensitivity to Rucaparib and TSA 
co-treatment. 
Percentage survival of DU145 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and Rucaparib and TSA co-treatment for 72 hours. Cell sensitivity was assessed using the SRB assay 
and differences between treatment conditions were statistically analysed in GraphPad PRISM (one-way 




PARP-1 siRNA and exposure to Rucaparib reduced PC3 cell survival by 16% compared to cells 
exposed to Rucaparib alone (Figure 7.11). Survival was reduced by 19% compared to control 




Figure 7.11: The effects of PARP-1 knockdown on PC3 cell sensitivity to Rucaparib. 
Percentage survival of PC3 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and 16µM Rucaparib for 72 hours. Cell sensitivity was assessed using the SRB assay and differences 





PARP-1 silencing significantly increased PC3 cell sensitivity to TSA treatment by 20%, 
compared to cells exposed to TSA, as shown in Figure 7.12. Control siRNA combined with TSA 
reduced PC3 cell survival by 3% compared to cells exposed to TSA alone. There was a 17% 
reduction in survival in PARP-1 silenced cells +TSA, compared to negative control. 
 
 
Figure 7.12: The effects of PARP-1 knockdown on PC3 sensitivity to TSA.  
Percentage survival of PC3 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and 49nM TSA for 72 hours. Cell sensitivity was assessed using the SRB assay and differences 





PARP-1 knockdown significantly enhanced PC3 cell sensitivity to Rucaparib and TSA co-
treatment (Figure 7.13). Cell survival was 38% less when transfected with PARP-1 siRNA and 
exposed to co-treatment, compared to cells which were exposed to co-treatment alone. Cell 
survival in co-treated PC3 cells transfected with PARP-1 siRNA was significantly less (p<0.05) 
than co-treated PC3 cells transfected with control siRNA (22% reduction). 
 
Figure 7.13: siRNA knockdown of PARP-1 enhances PC3 sensitivity to Rucaparib and TSA co-
treatment.  
Percentage survival of PC3 cells relative to control following exposure to 50nM PARP-1 siRNA for 48 
hours and Rucaparib and TSA co-treatment for 72 hours. Cell sensitivity was assessed using the SRB assay 
and differences between treatment conditions were statistically analysed in Graphpad PRISM (one-way 
ANOVA, *p<0.05, **p<0.01).  
 
 
The results presented in Figure 7.10 and Figure 7.13 demonstrate that PARP-1 silencing enhances 
cell sensitivity to Rucaparib and TSA co-treatment in DU145 and PC3 cells. Cell survival of 
DU145 and PC3 cells following PARP-1 silencing and exposure to co-treatment was compared 
and statistically analysed using an independent t-test. Data presented in Figure 7.14 shows no 
significant difference in cell survival between DU145 (69% survival) and PC3 (62% survival) 




Figure 7.14: DU145 and PC3 cell survival following PARP-1 gene silencing and exposure to 
Rucaparib and TSA co-treatment. Basal PARP-1 status does not effect sensitivity to co-treatment. 
 
7.4 Discussion 
In this chapter, maspin and PARP-1 siRNA knockdown experiments were carried out to explore 
the role of maspin and PARP-1 expression on prostate cell behaviour and sensitivity to Rucaparib 
and TSA. PNT1A and PC3 cells were utilised to investigate the knock down of maspin and PARP-
1 as these cells endogenously express these proteins. Based on previous optimisation studies, final 
concentrations of 10nM maspin (Louise Brown, unpublished results) and 50nM PARP-1 siRNA 
(Jill Hunter, unpublished results) were used. 
7.4.1 The effects of maspin silencing on prostate cell sensitivity to Rucaparib and TSA.  
The results presented in Figure 7.1 and Figure 7.2 show the optimum siRNA incubation times to 
achieve maspin knockdown in PNT1A and PC3 cells, respectively. A longer incubation time 
(72hours) was required to achieve successful maspin knockdown in PNT1A cells compared to 
PC3 cells (48hours). siRNA-induced gene knockdown efficiency and duration is dependent on a 
number of factors such as cell type, target mRNA turnover rate and cell location (Hong et al., 
2014). These factors may explain the differences in knockdown between PNT1A and PC3 cells. 
There was no variance in proliferation rates between these cells (Table 3.4). PC3 cells express 
increased levels of maspin protein (Figure 3.9), therefore, maspin silencing is not likely due to 
the amount of basal maspin expression as the data shows silencing of maspin earlier (48hours) in 
PC3 cells, compared to PNT1A cells (72 hours). A potential reason for increased knockdown 
efficiency in PC3 cells may be maspin protein localisation in the cell. In mammalian cells 
intracellular proteins are targeted for proteasome degradation as part of cell regulation, such as 
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cell cycle and regulation of transcription factors (reviewed in Ciechanover (2005)). The data 
presented in Chapter Three, section 3.3.5, show that maspin is located in the cytoplasm and 
nucleus of PC3 cells but only the cytoplasm of PNT1A. Cytoplasmic localisation of maspin in 
PC3 cells may make maspin more readily targeted for degradation.  
The PNT1A cell line model was utilised in the studies to provide mechanism on the effects of 
maspin on cell survival, in the presence of Rucaparib and TSA as single agents and in 
combination; to support patterns observed in earlier chapters where maspin depleted cell lines 
were shown to be more sensitive to Rucaparib. PNT1A cells are a “normal” wild type cell line 
proficient for maspin and could be considered the best prostate cell model to provide preliminary 
proof of principle data in our hands. siRNA-induced maspin silencing in PNT1A cells enhanced 
cell sensitivity to Rucaparib and TSA treatment, alone and in combination, demonstrating that 
maspin expression impacts cell sensitivity to PARP and HDAC inhibitors.  
PNT1A cells were ~1.5-fold more sensitive to Rucaparib with maspin knockdown than maspin 
proficient cells exposed to cells exposed to control siRNA + Rucaparib. Maspin siRNA did not 
achieve 100% silencing and the effects on cell sensitivity would likely have been greater had it 
been achieved. The results are in line with our initial growth inhibition studies carried out in 
Chapter Four, section 4.3.1; whereby maspin depleted DU145 cells were 3.3 and 2-fold more 
sensitive to Rucaparib than PNT1A and PC3 cells, respectively. The results suggest that there is 
a selective sensitivity to Rucaparib in cells with less maspin; supporting a role for maspin as a 
predictor of sensitivity to PARP inhibitors. This may be in part due to enhanced expression of 
IKKa; a driver of inflammation and carcinogenesis. Studies have demonstrated that active IKKa 
is coupled with metastatic potential through the attenuation of maspin. It has been shown that 
mutation preventing IKKa activation slows down PC growth and inhibits metastasis in human PC 
cells and a transgenic adenocarcinoma of the mouse prostate (TRAMP) model, and this was 
correlated to increased expression of maspin. Furthermore, siRNA-mediated knockdown of 
maspin increased the metastatic potential of IKKaAA/AA TRAMP cells (cells with an inactive allele 
of IKKa) to that of wild-type TRAMP cells (Luo et al., 2007). Immunohistological analysis of 
metastatic and non-metastatic cutaneous squamous cell carcinoma samples also reported an 
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inverse correlation between active IKKa and maspin. Samples negative for maspin were found 
exclusively in the metastatic group (Toll et al., 2015).  
The protein expression data presented in Chapter Four, Figure 4.17, shows reduced expression of 
IKKa in maspin depleted DU145 cells exposed to Rucaparib; supporting a role for Rucaparib as 
an inhibitor of NF-kB in maspin deficient tumours. These results go hand in hand with data from 
previous studies which have demonstrated that potentiation of IR-induced cytotoxicity by PARP 
inhibition occurs only when NF-kB is present, suggesting that PARP-1 mediates its effects 
through NF-kB (Veuger et al., 2009, Hunter et al., 2012). The IKKa-/- MEF survival data in 
Chapter Four support the requirement for NF-kB to sensitise cells to PARP inhibitors; A GI50 
could not be achieved in IKKa-/- cells exposed to Rucaparib at increasing doses up to 50µM. These 
cells were shown to be proficient in the expression of maspin (Figure 3.13); supporting the 
prostate cell sensitivity data in Chapter Four where maspin proficient PNT1A and PC3 cells 
express reduced levels of IKKa. siRNA investigations have also demonstrated an inverse 
correlation between IKKa and maspin; reporting a significant upregulation of maspin in PC3 cells 
treated with IKKa siRNA for 48 hours (Mahato et al., 2011). PARP knockdown by PARP-1 
siRNA has also evidenced reduced protein expression of IKKa in breast cancer models (Wielgos 
et al., 2018). These data support our findings and highlight the requirement of NF-kB for PARP 
signalling (Hassa et al., 2001). 
HDAC-1 is highly expressed in some prostate cancers and its activity is considered a popular 
mechanism for the repression of various genes in cancer, such as tumour suppressor genes and 
genes which are implicated in cell cycle control and apoptosis (reviewed in Halkidou et al. 
(2004)). A link between increased HDAC-1 and a malignant phenotype has been reported, due to 
its role in modulating gene transcription and contribution to DNA damage signalling and repair 
on multiple levels (Weichert et al., 2008a, Weichert et al., 2008c). HDAC-1 targets various genes 
associated with the DNA damage response to mediate DNA repair, such as ATM, ATR, p53 and 
Ku70 (reviewed in Robert and Rassool (2012)). HDAC-1 prepares the chromatin surrounding 
DNA DSBs for activation of the DNA damage response pathway and assists in the sealing of 
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DSBs via NHEJ or HR (reviewed in Roos and Krumm (2016)). For example, HDAC1 proteins 
localise at the site of a DSB and promote binding of Ku70 for NHEJ. PARP-1 and Ku proteins 
compete for DNA repair (Wang et al., 2006). In the presence of reduced maspin and consequently 
increased HDAC-1, it could be postulated that there is a reduced ability for PARP-1 to access the 
DNA breaks and initiate repair. 
It may be suggested that increased expression of HDAC-1 due to maspin silencing may contribute 
to increased PARP inhibitor sensitivity in cells which normally are HDAC-1 depleted and express 
increased levels of PARP-1. This effect may occur via the transcriptional repression of genes 
involved in DNA repair, such as PARP-1 and RAD51. Protein expression studies in this thesis 
have supported this theory, showing reduced expression of PARP-1 and RAD51 in maspin 
depleted DU145 cells, compared to maspin proficient cells (Figure 3.9 and Figure 6.9, 
respectively). Maspin silencing has also been shown to reduce the expression of PARP-1 in PC3 
cells (Figure 7.6). HDAC-1 expression was not assessed but it is likely that it was upregulated in 
the absence of maspin. This is in line with protein expression data in Chapter Three and Chapter 
Four where DU145 cells, which express reduced levels of PARP-1, are most sensitive to 
Rucaparib. Maspin proficient PNT1A and PC3 cells, which express reduced levels of HDAC-1, 
exhibit reduced sensitivity to Rucaparib (data presented in Chapter Four). These cells also express 
increased levels of RAD51, indicating an ability to repair DSBs. To this end, we can postulate 
that silencing of maspin in PNT1A and PC3 cells will increase target for HDAC-1 inhibition 
which will in turn enhance cell sensitivity to TSA.  
PNT1A cells were ~1.8-fold more sensitive to TSA following maspin knockdown with siRNA 
compared to those cells exposed to control siRNA + TSA; supporting that the loss of maspin is a 
tumorigenic event. Indeed, other studies have reported increased HDAC activity following 
maspin silencing by siRNA in PC3 cells (Li et al., 2006). More recently the same group suggested 
that down-regulation of maspin may increase pathological DNA methylation and epigenetic gene 
silencing in normal cells; contributing to a tumorigenic phenotype (Li et al., 2011). This may 
explain the increased sensitivity to TSA treatment in maspin silenced PNT1A cells. There was no 
significant difference in the cell sensitivity to TSA in maspin deficient and proficient DU145 and 
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PC3 cells in the studies presented in Chapter Four; indicating that the effect of TSA on cells is 
cell type dependant or independent to maspin expression status. Although the data suggests that 
the effects of TSA is independent to maspin expression status in these cells, given that the cells 
aren’t isogeneic and we don’t know the complement of other complexes in which HDAC-1 may 
act, therefore, differences between these cell lines may not be as great as when using siRNA. The 
effects of TSA in the presence of maspin siRNA was not tested in DU145 and PC3 cell lines. The 
increased sensitivity to TSA in response to maspin knockdown in PNT1A cells may be due to 
increased HDAC activity, and therefore more target, and consequently changes to the acetylation 
state of transcription factors and other proteins in the cell, as previously discussed. PNT1A cells 
present increased DNA DSBs in the presence of chemical HDAC inhibition by TSA at GI50 (Table 
4.3); demonstrating an ability for “normal” dells to withstand, and repair, DNA breaks induced 
by HDAC inhibition. This goes hand in hand with the RAD51 expression data presented in 
Chapter Six, Figure 6.9, where RAD51 expression, a marker for HR-mediated DNA repair, was 
not reduced in the presence of TSA, in PNT1A cells.  
PNT1A cell sensitivity to Rucaparib and TSA co-treatment was enhanced ~1.6-fold in the 
presence of maspin siRNA compared to siRNA control cells exposed to co-treatment; 
demonstrating that maspin indeed affects cell sensitivity to treatments. Co-treatment was more 
effective than Rucaparib alone, but no more effective than TSA alone, in the presence of maspin 
siRNA, implying a rescue effect by Rucaparib. This does not fit with the sensitivity data in 
Chapter Four whereby co-treatment was additive in maspin depleted DU145 cells. However, there 
could be a range of things going on that may contribute to this finding such as the pleotropic 
effects of HDAC-1 inhibitors at the cellular level. Nevertheless, the data highlights that maspin 
affects cell response to treatments and provides a proof of principle for targeting tumours which 
are deficient for maspin.  
7.4.2 The effects of maspin knockdown on PARP-1 protein expression in PC3 cells 
exposed to Rucaparib and TSA.   
PC3 cells were utilised to investigate the effects of maspin knockdown on PARP-1 protein 
expression following PARP and HDAC inhibition. These cells express the highest levels of 
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PARP-1 and were selected for use to provide a proof of principle association between maspin and 
PARP-1 in a cancer model. The results presented in Figure 7.6 show reduced expression of PARP-
1 in the presence of maspin siRNA; highlighting a correlation between maspin and PARP-1 
protein expression. These findings are in line with the expression data presented in Chapter three 
section 3.3.5; whereby PARP-1 protein expression levels were low in maspin depleted DU145 
cells and high in maspin proficient PC3 cells. Therefore, reduced expression of PARP-1 in 
response to maspin silencing in PC3 cells may be a potential mechanism to drive tumorigenesis 
via NFkB.  
The expression of PARP-1 protein was further reduced in maspin silenced PC3 cells exposed to 
Rucaparib. These results demonstrate a correlation between maspin and PARP-1 expression 
levels. PARPi’s, such as Rucaparib primarily inhibit PARP-1 enzyme activity rather than 
expression. A previous study explored the role of PARP-1 activity and expression in a range of 
human cancer cell lines; reporting no significant positive correlation between PARP-1 expression 
and PARP-1 activity (Zaremba et al., 2009). This is in line with the protein expression data for 
PARP-1 presented in Chapter Four, Figure 4.18 whereby the expression of PARP-1 protein was 
unchanged following inhibition of PARP activity by Rucaparib.  
PARP-1 inhibition and increased histone deacetylase activity in response to maspin silencing may 
contribute to the reduction in PARP-1 protein expression shown in Figure 7.6. Histone 
modifications have been widely recognised in the control of gene expression and disease 
regulation (Chen et al., 2015). Increased HDAC activity influences biological processes that 
contribute to carcinogenesis such as cell proliferation and inflammation. HDAC activity has also 
been implicated in the modification of ADP ribosylation; a process implicated with PARP 
(Bassett and Barnett, 2014).  
PARP-1 protein expression was reduced in maspin silenced PC3 cells treated with TSA, 
compared to maspin silenced PC3 cells without treatment. This result was unexpected as the data 
presented in Chapter Four, Figure 4.17, showed that PARP protein expression levels were not 
changed by exposure to TSA in maspin depleted DU145 cells. To this end, the findings suggest 
that the mechanism by which TSA inhibits HDAC-1 activity and epigenetically regulates PARP-
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1 is independent to the inhibitory effects of HDAC-1 by maspin. It can be postulated that maspin, 
an endogenous inhibitor of HDAC-1, may regulate HDAC in a more specific and selective 
manner, dependent on cellular and molecular contents, compared to pharmacological HDAC 
inhibitors which can enhance the deacetylation of a large number of genes in an unspecific manner 
(reviewed in Kaplun et al. (2012)). This may explain why we see a reduction in the expression of 
PARP-1 following exposure to TSA in maspin silenced PC3 cells, compared to PC3 cells which 
expression maspin.  
PARP-1 protein expression was reduced in maspin silenced PC3 cells exposed to Rucaparib and 
TSA co-treatment, but the effects were not greater than maspin silenced PC3 cells exposed to 
either Rucaparib or TSA as single agents. These data do not correlate to the DU145 data in 
Chapter Four, where DU145 cells (depleted in maspin) express reduced levels of PARP-1 protein 
in the presence of co-treatment, compared to either treatment alone (Figure 4.17). The varied 
effects of co-treatment on the expression of PARP-1 in maspin depleted/silenced cells could be 
due to the fact that these PC3 and DU145 are not isogeneic and therefore differential off target 
effects of the drugs in combination may lead to changes in epigenetic regulation between cell 
lines. Furthermore, in PC3 cells, we have shown successful knockdown of maspin at 48 hours 
(Figure 7.2), although 100% knockdown was achieved and we can’t confirm that maspin remains 
silenced for the duration of drug exposure (a further 72 hours from knockdown). This could also 
be attributable to the differential findings between maspin depleted DU145 cells and maspin 
silenced PC3 cells exposed to co-treatment. Nevertheless, the expression of PARP-1 protein is 
reduced in maspin silenced PC3 cells, compared to maspin expressing cells; with and without 
exposure to Rucaparib and TSA as single agents, and in combination.  
7.4.3 The effects of PARP-1 silencing on prostate cell sensitivity to Rucaparib and TSA.  
The results presented in Figure 7.7 show an optimum siRNA incubation time of 48 hours to 
achieve PARP-1 knockdown in DU145 and PC3 cells, respectively.  
PARP-1 was silenced in DU145 and PC3 cells to investigate the theory of PARP-1 “trapping”. 
The theory proposed that PARP inhibition is more cytotoxic than PARP-1 loss/inactivation due 
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to the trapping of PARP-1 at DNA breaks (Murai et al., 2012). Our data aimed to elucidate 
whether PARP-1 silencing had a similar affect.  
PARP-1 silencing had no significant effect on DU145 or PC3 cell sensitivity to Rucaparib (Figure 
7.8 and Figure 7.11); suggesting that increased sensitivity to Rucaparib in DU145 cells (Chapter 
four) may not be an effect of low PARP-1 protein expression. A potential reason for a lack of 
significant alteration to Rucaparib sensitivity with PARP-1 silencing could be that 100% PARP-
1 knockdown was not achieved and residual PARP activity may be present from PARP-1 and 
PARP-2; the closest paralog of PARP-1 (Luo and Kraus, 2012b). Another explanation for an 
insignificant sensitivity to Rucaparib is that we cannot be sure how long PARP-1 knockdown is 
lasting. Optimum knockdown was ascertained at 48 hours and was still occurring at 72 hours; but 
given that inhibitors were present for a further 72 hours following optimum knockdown, we 
cannot be sure that silencing is occurring for the duration of the experiment. As we were unable 
to achieve complete PARP-1 silencing or a loss of effect to Rucaparib we were unable to 
determine whether PARP-1 trapping occurs in the presence of PARP-1 silencing. The results 
conclude that the sensitivity to Rucaparib in DU145 cells (Chapter Four) is likely related to the 
differential expression of IKKa and maspin as opposed to PARP-1.  
The data presented in Figure 7.9 show a 12% reduction in DU145 cell survival in the presence of 
TSA treatment and PARP-1 siRNA, compared to cells exposed to TSA alone. Cells transfected 
with control siRNA were 8% more sensitive to TSA treatment than cells exposed to TSA alone, 
but less sensitive than cells subject to PARP-1 silencing with TSA. Despite a 4% increase in 
sensitivity to TSA in DU145 cells exposed to PARP siRNA compared to control siRNA the 
effects were insignificant; highlighting that PARP-1 silencing had no effect on DU145 cell 
sensitivity to chemical HDAC inhibitors. 
PC3 cells transfected with PARP-1 siRNA were significantly more sensitive to TSA than cells 
exposed to control siRNA + TSA. The mechanism responsible for enhanced PC3 cell sensitivity 
to TSA following PARP-1 silencing in these cells is unknown. It could be postulated that the 
effects are independent to PARP-1 and maspin expression. If these proteins were implicated, we 
would have expected TSA sensitivity to be variable in DU145 and PC3 cells, that express different 
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levels of PARP-1 and maspin proteins. Differential sensitivity to TSA was not found in these cells 
(growth inhibition data presented in Chapter Four, Table 4.3). We are unable to draw firm 
conclusions from the data as the cells lines that are not isogenic and express different proteins, 
thus additional complexities may be at play, however the siRNA data does add strength to the 
hypothesis that inhibition or knockdown of PARP-1 and HDAC-1 in combination has potential 
for cancer therapy. 
Interestingly, PARP-1 silenced DU145 and PC3 cells were significantly more sensitive (p<0.05, 
p<0.01, respectively) to Rucaparib and TSA co-treatment than cells control siRNA cells + 
combination and cells which express PARP-1 exposed to combination alone. PARP-1 expression 
and regulation is a complex process involving various different mechanisms (Krishnakumar and 
Kraus, 2010). The effects of PARP-1 silencing and inhibition have been investigated in other 
studies that have used synchronised isogeneic HeLa cells proficient or deficient for PARP-1. 
PARP-1 inhibition and silencing were shown to have differential effects on DNA SSB repair and 
radio sensitivity. SSB repair was reduced 10-fold in PARP-1 proficient cells compared to PARP-
1 silenced cells exposed to PARP inhibition. PARP-1 silenced cells were 2.5-fold more sensitive 
to IR compared to PARP-1 proficient cells (Godon et al., 2008). PARP-1 siRNA prevents PARP-
1 recognition and binding to DNA breaks to initiate NHEJ. This may allow other molecules to 
bind to the exposed DNA breaks, leading to the regulation and modification of other signalling 
pathways. Inhibition of residual PARP-1 enzymatic activity by Rucaparib limits PARP-1 
enzymatic binding to the site of DNA breaks and binding of Rucaparib to DNA breaks prevents 
the binding of other molecules. This may explain why PARP-1 deficient cells are increasingly 
sensitive to Rucaparib and TSA co-treatment.  
There was no significant difference in cell survival between DU145 and PC3 cells subject to 
PARP-1 silencing and co-treatment. These results are in line with the survival data in Chapter 
Four where there was no difference in cell sensitivity to co-treatment, at respective GI50 
concentrations, between DU145 and PC3 cells. This reiterates that the effects of co-treatment in 
relation to PARP-1 expression may be independent to maspin status. The results in this chapter 
help to demonstrate the complex interplay between maspin, PARP-1 and drug actions and raises 
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questions about the role of NF-kB in these responses. It can be postulated that PARP-1 inhibition 
and depletion limits DNA repair via NHEJ and consequently cells rely on HR for DNA repair. 
HDAC inhibitors limit HR, and therefore the drug combination is synthetically lethal to tumour 
cells. 
7.5 Summary 
The studies presented in this chapter have shown that: 
• Maspin siRNA sensitises PNT1A cells to Rucaparib; demonstrating a selective sensitivity 
to PARP inhibitors in cell expressing reduced maspin. This may be in part mediated by 
increased levels of IKKa.  
• TSA was not additive to cell sensitivity to Rucaparib in the presence of maspin siRNA. 
• Maspin siRNA reduces the expression of PARP-1 in PC3 cells. A possible mechanism 
for this is increased levels of HDAC-1 due to maspin knockdown, and consequently 
deacetylation of PARP-1. 
• Rucaparib and TSA treatments, alone and in combination, further reduce the expression 
of PARP-1 in the presence of maspin siRNA, but effects are greatest in cells exposed to 
Rucaparib and TSA as single agents.  
• PARP siRNA does not affect sensitivity to Rucaparib in DU145 and PC3 cells, supporting 
that increased sensitivity to Rucaparib in DU145 cells is related to depleted levels of 
maspin rather than PARP-1. 
• PARP siRNA does not enhance DU145 cell sensitivity to TSA but does PC3 cells. These 
effects may be due to interreference with other molecular mechanisms within the cell 
lines. 
• PARP siRNA significantly enhances DU145 and PC3 cell sensitivity to Rucaparib and 
TSA co-treatment. This may be due to synthetic lethality; whereby PARP-1 depletion and 
inhibition hinders DNA repair by NHEJ and inhibition of HDAC-1 by TSA limits repair 
via the HR backup pathway.  
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7.6 Future work 
Future work could investigate the effects of maspin siRNA on PC3 cell sensitivity to treatments, 
to compare against the findings obtained in PNT1A cells. The effects of maspin siRNA on cell 
sensitivity to treatments could also be explored in isogenic cell lines proficient and deficient for 
IKKa to add strength to the known links between maspin and IKKa, and differential sensitivity 
to treatments. The effects of maspin siRNA on IKKa and HDAC-1 expression were not explored 
due to time constraints. Studies utilising IKKa siRNA to look at the expression of maspin and 
PARP-1 proteins would strengthen the existing data and confirm or refute a mechanism between 
maspin, IKKa and PARP-1. The effects of PARP-1 silencing on sensitivity to treatments, alone 
and in combination, could also be explored in isogenic cells proficient and deficient for PARP-1.  
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Chapter Eight  
Summary and future directions  
The increase in cancer incidence is evidenced by recent statistics suggesting that 1:2 people in the 
UK will develop the disease during their life. The most common forms of cancer in males and 
females are those of the prostate and mammary gland respectively, making research into these 
conditions of great importance. Of particular interest are new therapeutic targets and combinations 
potentially allowing specific focus on aggressive, metastatic cancers which are associated with a 
poor prognosis.  
PARP inhibitors were originally developed for their ability to potentiate existing 
chemotherapeutics or radiotherapy. PARP inhibitors have been investigated and often found to 
be effective in a range of clinical settings, in combination with chemotherapies or as maintenance 
therapies in recurring tumours including those derived from the breast, ovaries, colon and prostate 
(reviewed in Mirza et al. (2018)). Studies have also investigated the efficacy of PARP inhibitors 
for the treatment of non-oncological diseases such as stroke, myocardial infarction, chronic heart 
failure and neurodegenerative diseases. Use of PARP inhibitors for myocardial infarction is the 
only non-oncological indication to result in clinical study (reviewed in Curtin and Szabo (2013)). 
In 2005 with the realisation that BRCA defective tumours are exquisitely sensitive to stand alone 
PARP inhibitor therapy, the landscape changed such that, in oncology, the focal point of research 
for the last 15 years has been cancers which are defective in BRCA1/2 and DNA repair by 
homologous recombination (HR). More recently, and with the advent of a growing body of 
evidence and mechanisms of PARP inhibitor resistance (Noordermeer and van Attikum, 2019), 
PARP inhibitors in combination with other therapeutics has once again become a focus. 
Repurposing of PARP inhibitors is a vastly growing area and further research is needed to 
elucidate other novel ways of using these drugs (and other repair inhibitors) to provide 
personalised cancer therapy. Further successful clinical application of PARP inhibitors requires 
the identification of predictive markers for tumours likely to be susceptible. Described in this 
thesis are the stand-alone effects of the PARP inhibitor Rucaparib and then in combination with 
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the HDAC inhibitor TSA. This work did not investigate the potentiation of cancer therapeutics 
such as ionising radiation (IR).  
Rucaparib was selected for use in the studies presented in this thesis. There are currently four 
PARP inhibitors approved by the FDA for anticancer therapy: Olaparib, Rucaparib, Niraparib and 
Talazoparib. Olaparib was the first PARPi to enter clinical practise for ovarian tumours and it has 
been extensively used in research studies. For example, in November 2018, 48% of ovarian cancer 
trials used Olaparib, compared to 7.3% of trials with Rucaparib (reviewed in Yi et al. (2019)). All 
approved PARPis have shown comparable inhibition of PARP-1, however, Rucaparib inhibits 
PARP-1, PARP-2 and PARP-3. PARP-3 has been reported to trigger the activity of PARP-1 in 
the absence of DNA. Additional inhibition of PARP-1 may potentiate Rucaparib’s effects 
(reviewed in LaFargue et al. (2019)). Rucaparib is currently being researched in a range of 
advanced solid tumour types, independent of BRCA status, such as prostate and urethral cancers 
(Wilson et al., 2017, Garje et al., 2020). 
It has recently been reported that the phenotypic and therapeutic relevance of BRCA1/2 mutations 
is poorly defined in most cancer types (Jonsson et al., 2019). BRCA1/2 mutation is not an agnostic 
marker for PARPi response and more biomarkers are required (reviewed in (Curtin et al., 2019). 
Maspin is required for epithelial specific gene expression. The expression level of Maspin in 
normal epithelial cells is much higher than that in malignant cells. It has pleiotropic effects; 
maspin has a large number of intracellular partners and has been shown to regulate cellular 
response to oxidative stress and increase tumour cell sensitivity to drug-induced apoptosis. 
Maspin also acts as a suppressor of metastasis in different types of cancer including prostate. In 
breast, colon, thyroid, lung, oral squamous, and prostate cancer, increased maspin expression 
predicts a better prognosis (reviewed in Berardi et al. (2013) and outlined in Table 1.4 and Table 
1.5). Maspin interacts and endogenously inhibits HDAC-1 (Kaplun et al., 2012) and chemical 
inhibition of HDAC has been found to prevent activation of NF-kB (Place et al., 2005). Studies 
with PC cells and clinical specimens have demonstrated re-expression of maspin following 
inhibition of HDAC-1 (Abbas and Gupta, 2008). This antagonistic expression pattern may be in 
part due to reduced IKKα.  
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The HDAC inhibitor TSA was selected for use in the studies presented in this thesis. It is 
commonly selected for use in laboratory investigations due to its high potency and toxicity. It is 
a cheap and effective HDAC inhibitor for use in preliminary experiments and was readily 
available within our laboratory. It exhibits the same biological effect as SAHA (Vorinostat), an 
analogue of TSA that has been approved for use in cutaneous T-cell lymphoma by the FDA 
(reviewed in Eckschlager et al. (2017)). 
Previous work in our group has shown that PARP inhibitors mediate their effects via NF-kB 
(Veuger et al., 2009, Hunter et al., 2012). An important paper in Nature suggested that a reason 
men get prostate cancer is because of the loss of maspin expression via a pathway downstream of 
NF-kB (Luo et al., 2007).  
The primary aim of the work presented in this thesis was to investigate the effects of PARP-1 and 
HDAC-1 inhibitors (alone and in combination) on cell behaviours in cell lines expressing varied 
levels of the tumour suppressor maspin. A relationship between maspin and NF-kB was explored 
in relation to cell sensitivity to these treatments. To achieve this aim, at the outset of this work, a 
role for PARP-1 inhibitors in maspin deficient tumours was investigated. 
The initial cell models intended for use in the studies carried out in this thesis were breast 
tumour MCF-7 cells. These cells are stably transfected with the pcDNA 3.2 vector containing 
maspin and mutant maspin to produce the stable cell lines MCF-7 empty vector (MCF-7 CTR), 
MCF-7 maspin (MCF-7 MTR) and MCF E224A (MCF-7 244) as described in (Ravenhill et al., 
2010). During preliminary characterisation and optimisation studies, these cells presented 
inconsistent growth patterns and become frequently contaminated. Upon further investigation 
by Western blotting, the maspin transfected cell samples were found to lack expression of 
maspin; indicating that the plasmid had been lost. The transfected cells were obtained from an 
external source and it was not possible to generate new stably transfected cell lines. For this 
reason, these cell models were not suitable for use and were not taken forward in the 
experiments presented in this thesis.  
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The FDA has approved PARP inhibitors for treatment of metastatic breast, ovarian and 
related cancers. During this PhD project, in late 2018, the FDA granted “breakthrough therapy” 
status for the use of Rucaparib in BRCA1/BRCA2-mutated metastatic castrate-resistant prostate 
cancer (mCRPC); based on initial data from the TRITON-2 phase 2 clinical trial (Adashek et al., 
2019). According to the drug manufacturer AstraZeneca, the FDA have also granted 
“breakthrough therapy” status for the use of Olaparib in patients with mCRPC (AstraZeneca, 
2020). Thus, the data presented in this thesis utilised prostate cancer cell lines PC3 and DU145 
proficient or depleted for Maspin, respectively. An immortalised prostate cell line, PNT1A was 
also used. Mouse embryonic fibroblasts (MEF) proficient and deficient for NFkB p65 and IKKα 
were also utilised to compare maspin protein expression levels and to investigate sensitivity to 
treatments. All cell lines were characterised in Chapter Three. Importantly, data presented in 
Chapter Three verified the characteristics of the cell models used throughout this thesis to ensure 
that cells were of the correct genotype and phenotype for subsequent studies. DU145 cells were 
selected for use as published data suggested that DU145 are entirely deficient of Maspin 
(Ravenhill et al., 2010). However, in our hands, DU145 cells express maspin albeit negligible 
levels at much lower levels than PC3 or PNT1A cells (maspin expression was 7.4 and 6-fold 
higher in PC3 and PNT1A cells compared to DU145 cells, respectively); therefore, these cells are 
referred to as maspin depleted cells throughout this thesis. Others have also reported increased 
expression of maspin in PC3 cells compared to DU145 cells (McKenzie et al., 2008). The effect 
of PARP and HDAC inhibitors on various biological endpoints such as cell survival, migration 
and DNA strand break formation were investigated in Chapters Four, Five and Six, respectively. 
In Chapter Seven mechanistic studies were carried out with use of siRNA to explore the roles of 
maspin and PARP-1 in cell survival following treatment with Rucaparib and TSA, alone and in 
combination.  
A number of key conclusions were drawn from each section of this thesis, the most pertinent and 
novel being that; 
• Maspin deficiency sensitises prostate tumours to the stand-alone effects of PARP 
inhibitors. 
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• PARP inhibitor stand-alone effects are at least in part mediated via down regulation of 
IKKα 
• Maspin expression may represent a novel predicative biomarker for PARP inhibitor 
sensitivity in prostate cancers. 
• Combination of PARP-1 and HDAC inhibitors represents a promising therapeutic 
strategy for prostate cancer irrespective of BRCA status.   
 
The key data underpinning these findings are summarised below. Two proposed models (Figure 
8.1 shows both the stand-alone effects of Rucaparib in maspin depleted tumours (left side) and 
the many facets of PARP-1 action and potential effects of combination therapy (right side). Figure 
8.2 shows a proposed mechanism of PARP trapping in response to combination therapy of 
Rucaparib and TSA) have been generated to summarise the findings and hypothesis generate by 




Figure 8.1: Hypothetical model for the stand-alone effects of Rucaparib and the many facets of 
PARP-1 action. 
The left side of the model proposes the stand-alone effects of Rucaparib. In the presence of high IKKα, 
and consequently depleted maspin, Rucaparib targets IKKα and reduces it, independently of NF-kB. IKKα 
inhibition by Rucaparib limits cell survival, migration and induces DNA breaks leading to apoptosis. These 
effects are mediated through the downregulation of proposed targets implicated in cell migration (β-catenin) 
and DNA damage and repair (ATM and RIF1); in response to inhibition of IKKα. Depleted maspin 
therefore acts as a biomarker for tumours high in IKKα which may be targeted by PARP inhibition for 
cancer therapy. Flat ends of lines represent inhibition and arrows represent excitatory effects. The right 
side of the model proposes that maspin inhibits HDAC-1 which limits stimulation of DNA-PKcs, 
deacetylation of Ku70 and sequestering of bax. Maspin also inhibits phosphorylation of Akt which reduces 
DNA-PKcs activity and DNA repair by NHEJ. Inhibition of HDAC-1 also causes hyperacetylation of 
HSP90, leading to its inhibition. Proteins that interact with HSP90 including BRCA cannot do so and are 
degraded. Rucaparib blocks/inhibits Ku70/DNA-PKcs and blocks NHEJ. It may also activate bax, leading 
to increased apoptosis. HDAC inhibition blocks DNA-PKcs and induces “BRCAness” and consequently a 
HR repair defect. Combined inhibition of Rucaparib and TSA inhibits DNA repair via both NHEJ and HR, 
resulting in synthetic lethality. Excess DNA damage resulting from combined treatment may also activate 
APAF1, a pro-apoptotic protein required for apoptosis. This proposed mechanism of action is depicted with 
red and green lines. Red lines with flat ends represent inhibition and red lines with arrows represent the 
downstream effects which are limited in the presence of maspin and therefore inhibition of HDAC-1. If 




Figure 8.2: Hypothetical model for the combined effects of Rucaparib and TSA in the context of 
PARP trapping. 
DSBs pose a major threat to genomic integrity. They arise as a result of exposure to DNA damaging agents 
such as IR and chemotherapy, ROS or when replication forks encounter DNA lesions. PARP inhibitors also 
limit the repair single strand DNA lesions and contribute to the accumulation of DSBs.In the presence of a 
HDACi, PARP-1 is acetylated and activated to activate and recruit DNA-PKcs for DNA repair by NHEJ. 
Inhibiting HDAC-1 causes acetylation of Ku70 leading to its inactivation and release of pro-apoptotic factor 
bax. The balance between DNA repair and cell death is dependent on the amount of DNA damage, damage 
tolerance or regulation of signalling pathways involved in DNA repair. Combined HDAC and PARP 
inhibition decreases NHEJ and increases apoptosis by trapping PARP-1 at the site of the DNA break which 
in turn, blocks access to DNA-PKcs. HDACi’s also hinder DNA repair via HR and induce a “BRCAness 
phenotype”. Thus, in the presence of combined treatment, NHEJ is hindered, BRCA is degraded and cells 
are unable to rely on DNA repair via HR. Consequently, cells are subject to cell death.   
 
The data presented in this thesis has contributed to a manuscript published in Molecular Cell 
Research in 2017 (Jenkinson et al., 2017). A further two manuscripts are under preparation; 
• Repurposing of PARP inhibitors for maspin deficient tumours 
• Co-targeting of HDAC and PARP for prostate cancer therapy 
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8.1 The stand-alone effects of the PARP inhibitor Rucaparib in prostate 
cells of varying maspin expression 
Previous research has demonstrated that radio-resistance is mediated by NF-kB activity since 
PARP inhibitors could only radio-sensitise NF-kB proficient but not deficient tumour cell lines 
(Veuger et al., 2009, Hunter et al., 2012). Veuger et al, demonstrated that only p65+/+ MEFs and 
not p65-/- MEFs were sensitised to IR by a very low non-toxic dose of 0.4uM PARP inhibitor. In 
the studies presented here, we explored the stand-alone effects of the PARP inhibitor Rucaparib 
at much higher doses of 0-50uM in the context of lowered or absent maspin with a view to provide 
insight into the potential interplay between PARP-1, maspin and NF-kB. 
NF-kB plays a key role in the regulation of immune response and is activated by canonical and 
non-canonical pathways; both of which are tightly regulated by an IKK complex comprised of 
IKKα, IKKβ and NEMO, as described in Chapter One. 
Cell survival following exposure to Rucaparib, as measured by SRB assay and cell counting, 
correlated positively with maspin status, with the calculated GI50 in PTN1A, PC3 and DU145 
cells being 28µM, 16µM and 8µM, respectively. These survival data correlate with 
epifluorescence data in Chapter Four; indicating enhanced apoptosis in all cell lines exposed to 
Rucaparib with higher nuclear fragmentation and cell shrinkage in the DU145 cells. Maspin 
knockdown reduced levels of PARP-1 in PC3 cells (data presented in Figure 7.6) which is 
interesting as DU145 cells also have lower PARP expression than PC3 cells. One proposed 
mechanism is that reduced maspin will lead to elevated HDAC-1 levels, deacetylation of PARP-
1 by HDAC-1 has been shown to affect PARP-1 at the transcriptional level through deacetylation 
of the promoter (Rajamohan et al., 2009). Therefore, it might be argued that it is this reduction in 
PARP-1 expression, and therefore activity, that leads to an increase in sensitivity to Rucaparib 
following maspin siRNA and thus may also account for the differential sensitivity to Rucaparib 
between DU145 and PC3 cells. PARP activity was not directly measured in the studies described 
here and this should certainly be carried out in future. However, data in Chapter Seven show that 
knockdown of PARP-1 in DU145 and PC3 cells did not significantly affect sensitivity to 
Rucaparib and it is therefore unlikely that enhanced sensitivity to Rucaparib is due to lower 
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PARP-1 levels. Many studies have attempted to correlate PARP-1 expression with sensitivity to 
PARP inhibitors and they give varied data and are context dependent. The vast majority conclude 
that higher PARP-1 activity correlates with increased sensitivity with many citing low PARP 
levels as a resistance mechanism. For example, a recent cervical cancer study reported a strong 
correlation between PARP activity and sensitivity to Olaparib (Bianchi et al., 2019). Moreover, 
addition of maspin siRNA #1 sensitised PTN1A cells to Rucaparib, enhancing sensitivity by ~1.5- 
fold, compared to control siRNA + Rucaparib. Interestingly, reduced cell survival following 
Rucaparib exposure was seen in p65-/- MEFs while no GI50 could be obtained in IKKα-/-MEFs. 
This led us to consider the possibility that stand-alone PARP inhibition can mediate effects via 
other subunits of NF-kB. It was hypothesised that IKKα activity could negatively regulate maspin 
expression particularly as p65-/- MEFs express more IKKα than p65+/+ MEFs. In support of these 
findings; the IKKα knockout MEF cells expressed increased levels of maspin and DU145 cells 
depleted for maspin expressed the highest amount of IKKα. These findings are in line with other 
studies that have demonstrated downregulation of maspin by IKKα; characterised by increased 
IKKα expression in the absence of maspin (Mahato et al., 2011, Alameda et al., 2011). The results 
from Chapter Three therefore confirmed an inverse correlation between maspin expression and 
IKKα. It has been shown that IKKα can interact with the promoter of the maspin gene which 
resulting in gene silencing. IKKα mediated inhibition of maspin expression has been proposed to 
commit prostate cancer to a metastatic fate (Luo et al., 2007). In line with this, our data using 
siRNA for maspin in PC3 cells (Chapter Five) showed increased cell migration as measured by 
xCELLigence, albeit this was a single experiment. Strikingly, knockdown of maspin (siRNA #1) 
enhanced PC3 cell migration by 23-fold at 48 hours. IKKα could therefore be targeted for prostate 
cancer therapy (reviewed in Gamble et al. (2012)), however, at the time of writing this thesis, 
IKK inhibitors are yet to be used therapeutically in the clinic. IKKα is an NF-kB activator and 
affects NF-kB in both of its two pathways (described in Chapter One) as well as having NF-kB 
independent roles. In the canonical pathway IKKα forms an IKK complex with IKKβ and NEMO 
to mediate the phosphorylation of IKBα and in turn activate NF-kB. In the non-canonical pathway 
IKKα exerts its effects by liberating the RelB complex to enable NF-kB activation.   
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Several lines of evidence have indicated that IKKα functions as an oncogenic molecule and 
promoter of cancer progression and metastasis in a range of tumour types. Of specific relevance 
to the studies described here, the amount of nuclear IKKα in human prostate cell lines correlates 
with metastatic progression and studies have shown that a mutation preventing IKKα activation 
slows down prostate cancer growth and inhibits metastagenesis (Luo et al., 2007). Others have 
demonstrated that blocking IKKα expression in DU145 and PC3 cells using synthetic siRNAs 
inhibited prostate cancer cell invasiveness, migration, growth and attachment (Mahato et al., 
2011). Interestingly, a nuclear function of IKKα has been implicated in tumour progression with 
nuclear IKKα promoting pancreatic cancer through inhibition of maspin expression (discussed in 
Alameda et al. (2011)). Cell localisation studies carried out in Chapter Three revealed that IKKα 
was both nuclear and cytoplasmic in all prostate cells, however, expression was predominantly 
cytoplasmic in the PTN1A and PC3 cells. Intriguingly, there was increased nuclear expression of 
IKKα, indicative of activation, in DU145 cells.  
Maspin depleted DU145 cells expressed reduced levels of the NF-kB subunit p65 but increased 
levels of IKKα while PC3 cells expressed increased levels of NFkB p65 and reduced levels of 
IKKα. The results in Chapter Three therefore highlighted a correlation between maspin and NF-
kB p65 and an inverse correlation between these proteins and IKKα. It may be that IKKα regulates 
the level of p65. For example, Lawrence et al. (2005) demonstrated accelerated removal of 
p65/p50 NF-kB subunits from proinflammatory gene promoters by IKKα which limited the 
activation of NF-kB. siRNA for PARP-1 has been shown by others to lower levels of IKKα 
(Wielgos et al., 2018). This was not investigated in the studies presented in this thesis. Although 
the effect of siRNA for PARP-1 on IKKα has been previously investigated, at the time of writing 
this thesis, no studies have been conducted on the effect of a PARP inhibitor on IKKα protein 
levels and correlated this with maspin status. Given there was a correlation between maspin levels 
and Rucaparib sensitivity, we investigated the effect of Rucaparib on IKKα protein expression 
levels. Protein expression data in Chaper Four demonstrated that Rucaparib was able to decrease 
the levels of IKKα in both PC3 and DU145 cells. Strikingly the level of IKKα was unchanged in 
the normal PTN1A cells that were least sensitive to Rucaparib. These results indicate that 
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activation of IKKα  may be reduced in the presence of a PARP inhibitor, supporting the role of 
PARP-1 as a co-activator of NF-kB. The expression of maspin and NF-kB p65 in DU145 and 
PC3 cells exposed to Rucaparib for 72 hours was unchanged; indicating that sensitisation to 
Rucaparib may occur by altering the expression of IKKα and not p65. PARP inhibitor resistant 
cell lines have been shown to be re-sensitised by an IKKα inhibitor BAY 11-7082 (Nakagawa et 
al., 2015).  
Others have also suggested that PARP inhibitors may mediate their effects via IKKα. Her2 
overexpressed tumours are hypersensitive to PARP-1 inhibition independently of any defect in 
HR DNA repair (Wielgos et al., 2018). An earlier study by Merkhofer et al. (2010) reported that 
Her2 overexpression activates the canonical NF-kB signalling pathway via the IKKα, catalytic 
subunit of the IKK complex, without the stimulation of an inflammatory stimuli such as TNFα. 
Thus, the sensitivity of Her2 overexpressing tumours to PARP inhibitors may in part be due to 
inhibition of IKKα activation of the canonical NF-kB pathway. Although this is in line with our 
previous studies suggesting that potentiation of IR by a PARP inhibitor is mediated via NF-kB 
p65, as described above (Veuger et al., 2009), expression data presented in this thesis suggest that 
the effect of stand-alone treatment with Rucaparib on IKKα is independent of the canonical 
pathway. The RelB protein expression data in Chapter Three suggests that the effects of Rucaparib 
on IKKα are also independent to the non-canonical NF-kB signalling pathway. RelB protein 
expression levels were lowest in DU145 cells and highest in PC3 cells. Expression was confined 
to both the cytoplasm and nucleus of PNT1A and DU145 cells but confined only to the nucleus 
in PC3 cells. If the effects of Rucaparib were via the non-canonical NF-kB signalling pathway, 
we would have expected PC3 cells, expressing high active levels of RelB, to be more sensitive to 
Rucaparib. In our hands, DU145 cells, expressing lower levels of RelB, were most sensitive. 
Although IKKα is part of a signalosome complex with IKKβ and NEMO, it is considered to have 
roles independent of NF-kB activation. IKKα has been shown to exhibit pro-tumorigenic effects 
in its own right (Mahato et al., 2011, Colomer et al., 2018). Thus, our data suggest that the effects 
of Rucaparib on the survival and migration of prostate cancer cells are at least partly via the 
depletion of IKKα. These effects are likely to be mediated via substrates independent of its role 
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in NF-kB signalling. Figure 8.1 outlines some of the proposed targets, although these were not 
investigated directly. Proposed IKKα targets include, maspin, Wnt/ β-catenin, ATM and RIF1. 
Although other targets are possible, and some may yet to be identified. 
Knockdown of IKKα is known to inhibit migration in prostate cell lines and the xCELLigence 
data presented in Chapter Five show that Rucaparib reduces migration in both DU145 (42%) and 
PC3 cells (58%), in real-time, at 72-hours. However, the scratch assay data evidenced that 
Rucaparib did not limit DU145 migration, but reduced PC3 cell migration by ~32%, at 72-hours. 
DU145 cell migration data in response to Rucaparib is variable between the methods but it is clear 
that Rucaparib is most inhibitory to PC3 cell migration. It is possible that reduced IKKα following 
Rucaparib treatment is mediating an upregulation of maspin, leading to reduced cell migration. 
Indeed, others have shown that knockdown of IKKα sensitises cells to death and increases maspin 
expression (Mahato et al., 2011). However, as described above, the protein expression data from 
cell samples exposed to treatments (Figure 4.16-Figure 4.18) refutes the hypothesis that inhibition 
of IKKα by Rucaparib would enhance maspin expression as maspin expression was not affected 
by 72-hour exposure to Rucaparib. This is not unsurprising since our data shows that knockdown 
of maspin sensitises PTN1A cells to Rucaparib and therefore an alternative mechanism is more 
likely. For example, IKKα may be mediating its effects on migration via the Wnt/β-catenin 
signalling pathway which is known to be involved in migration and invasion. Agarwal (2006) 
showed that reduction of Wnt-induced β-catenin-dependent activity via RNAi targeting IKKα led 
to significantly reduced migratory ability. 
A recent study demonstrated that IKKα is important for the DNA damage response, specifically 
ATM activation and that this is independent of NF-kB activation (Colomer et al., 2019). They 
showed that IKKα and ATM can interact, and abolishing IKKα attenuates ATM activation leading 
to a reduction in the phosphorylation of key DDR factors and consequently compromised DNA 
repair. There is a multitude of evidence for PARP-1 in ATM activation; reduced activation of 
ATM in the absence of PARP-1 and PARP-1 deficient cells exhibit ATM activity that is defective 
and reduced in HR repair. The effect of PARP inhibitors on ATM activation is proposed to 
demonstrate a “duality of response” in terms of ATM activation and this is context dependent 
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(Bryant and Helleday, 2006). Thus, reduced IKKα following Rucaparib exposure could be leading 
to reduced ATM activity and unrepaired DSBs. Rap1 interacting factor (RIF1) is also involved in 
DNA damage response signalling and maintaining genomic integrity (Kumar and Cheok, 2014). 
It acts downstream of ATM facilitating NHEJ. Its recruitment is compromised when IKKα is 
abolished.  
Before considering the DNA strand break data from Chapter four, it is important to consider that 
the prostate cells used in this thesis were not isogenic and therefore increased sensitivity to 
Rucaparib in the DU145 cells may be in part due to other mechanisms such as dysfunctional 
BRCA. Human tumours defective in BRCA are unable to repair DNA DSBs via the error free HR 
repair pathway. Many studies have shown that PARP inhibitors are exquisitely toxic to these cells 
although the mechanistic basis remains to be fully elucidated. Evidence suggests that DU145 cells 
are BRCA defective (Yin et al., 2018). RAD51, a marker of HR function, was investigated in 
Chapter Six to confirm HR dysfunction in DU145 cells and to further explore the effects of 
inhibitors on HR repair. Protein expression data revealed lower basal RAD51 expression in 
DU145 cells and expression of RAD51 was further reduced in DU145 cells exposed to Rucaparib; 
confirming dysfunctional DNA repair via HR. These findings support previous reports that have 
evidenced the role of RAD51 as a biomarker for HR repair and sensitivity to PARP inhibitors 
(Cruz et al., 2018). 
Heightened sensitivity to PARP inhibition has been observed in cells with other HR defects 
including PTEN deficiency. Like BRCA defects, PTEN deficiency is purported to be synthetically 
lethal with PARP inhibition (Mendes-Pereira et al., 2009). The PC3 cells are known to be null for 
PTEN although we did not independently test for this (Vlietstra et al., 1998, Byun et al., 2003) 
The impact of PTEN loss is controversial (reviewed in Michels et al. (2014)). Some studies have 
reported increased sensitivity to PARP inhibitors in the absence of PTEN, likely due to 
downregulation of RAD51 and consequently impaired HR; whereas others have failed to observe 
a correlation between PTEN status and RAD51 expression, PARP inhibitor sensitivity and the 
expression of genes associated with synthetic lethality. In our hands the latter was true; the data 
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in Figure 6.9 showed high basal expression of RAD51 in PC3 cells and expression was not 
reduced in the presence of Rucaparib. 
As both PC3 and DU145 cells are both HR defective (due to BRCA mutation and PTEN 
deficiency, respectively) it is unlikely that this defect solely accounts for the enhanced sensitivity 
to Rucaparib seen in the DU145 cells. Also reduced expression of IKKα, in the presence of 
Rucaparib, occurred in both DU145 and PC3 cells; an event that is therefore independent of BRCA 
or PTEN status. The mechanism by which PARP inhibitors sensitise cells are likely to be 
overlapping rather than a single mechanism in a given cell at a given time. The data presented in 
this thesis suggests that the different sensitivities to Rucaparib between PC3 and DU145 cells is 
at least in part also a consequence of maspin expression. Whether it is maspin itself (for example 
via altered NHEJ) or maspin as a biomarker for high IKKα levels has yet to be determined.  
The basal levels of DSBs were lowest in DU145 cells and highest in PTN1A cells which is 
contrary to what would be expected given the reported BRCA defect in DU145 cells which would 
be expected to contribute to a reduced DNA repair capacity. However, a BRCA defect would not 
account for the increased basal SSBs seen in the DU145 cells compared to the other cell lines. It 
can be postulated that the lower basal DSBs in the DU145 cells are a consequence of altered levels 
of maspin. Low maspin has been shown to lead to increased phosphorylation of AKT (Nam and 
Park, 2010) which in turn leads to increased activity of DNA-PKcs and an enhancement of NHEJ 
(reviewed in (Liu et al., 2014). PARP-1 also stimulates DNA-PKcs in the presence of NAD+ to 
facilitate DSB repair via NHEJ. Such reaction is blocked by PARP depletion or inhibition leading 
to a shift in repair, possibly by HR (Mitchell et al., 2009).  
Thus, lower basal levels of DSBs in the background of HR defect is likely a consequence of NHEJ 
repair of these breaks which is not induced in maspin proficient PNT1A cells.  
The high basal SSBs in DU145 cells are also likely to be a consequence of downregulated maspin. 
Endogenous maspin correlates with GST activity and therefore maspin depleted cells will exhibit 
elevated levels of ROS and DNA strand breaks as a consequence (Li et al., 2006). Indeed, 
knockdown of maspin in PC3 cells has been shown to increase intracellular ROS. ROS levels 
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were not measured in the work described in this thesis, but this should be factored into future 
work. These basal SSBs will activate PARP-1 and an inhibitor of PARP will prevent their repair 
through multiple mechanisms (as proposed in Figure 8.2); reduced IKKα, decreased BER and 
inhibition of DNA-PKcs and NHEJ. Therefore, to further elucidate the mechanisms underlying 
increased sensitivity to Rucaparib in maspin depleted cell lines, the effect of Rucaparib on the 
level of SSB and DSBs was investigated to enable comparison with cytotoxicity data in Chapter 
Four. Data presented in this thesis did not investigate break induction or measure the kinetics of 
repair but looked at levels of breaks following 72-hours and therefore their persistence. The 
studies described in Chapter Six demonstrated that PARP-1 inhibition by Rucaparib increased 
both SSB and DSBs in all prostate cell lines. More class 3 comets were seen in response to 
Rucaparib in DU145 cells compared to the other cell lines despite equal cell cytotoxicity (GI50). 
The ability to recover and survive following DNA damage is postulated to correlate with repair 
capacity. Here, the data indicate that the number of breaks do not correlate directly with survival; 
indicating that in maspin depleted cells, a higher barrier of entry to cell death possibly exists. 
Indeed, maspin deficient cells are known to be resistant to apoptosis. To this end, a yeast 2-hybrid 
screen showed that maspin is an endogenous inhibitor of HDAC-1 (Li et al., 2006). Li et al. also 
confirmed a maspin/HDAC1 interaction in human prostate tissue and cell lines; siRNA of maspin 
in PC3 cells increased HDAC activity. This was not confirmed in the studies described here but 
should certainly be explored in future studies. 
Low maspin and higher HDAC levels will increase deacetylation of Ku70 which in turn 
complexes with bax (Figure 8.1) This sequesters the complex and has been shown to be a 
mechanism by which ku can lead to radio-resistance (Lee et al., 2012). Rucaparib induced 
significant DSBs in PNT1A cells compared to DU145 and PC3 cells, despite 50% cell survival 
in all cells. These findings support the findings of others whereby normal cells have an increased 
ability to survive and resolve drug induced DSBs, compared to transformed cells. Taken together 
the data also highlights the need to exercise caution when attempting to correlate levels of breaks 
with survival. The outcomes seem to also be irrespective of p53 status. This is not unexpected 
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given the recent report of both p53 dependent and independent mechanisms of cell death caused 
by PARP inhibition (Nguyen et al., 2011)  
Overall, the results summarised here show that Rucaparib can sensitise all prostate cells regardless 
of their HR status. Similarly, Luo et al. (2007) showed that reduction of PARP-1 by siRNA could 
reduce the growth and invasion capacity of prostate cancer cell lines regardless of the BRCA1/2 
mutation. Maspin correlates with response to stand alone treatment with Rucaparib. These results 
support the potential of maspin status as a biomarker of response for cancer therapy with PARP 
inhibitors in prostate cancer.  
8.2 Sensitivity assay selection and the hormetic response 
Cell viability and growth assays were carried out to identify a standardised method for measuring 
drug response. The data presented in Chapter Four identified the SRB assay as a primary screen 
for novel compounds against cell lines. This assay is inexpensive and was the only method where 
results correlated to data obtained from manual cell counts.  
Discrepancies in drug sensitivity were found in WST-1 and Resazurin assays compared to manual 
cell counts. For example, the Rucaparib GI50 for DU145 cells was 37µM and 39µM in WST-1 
and Resazurin assays, compared to 9µM in manual cell counts, respectively. A need for 
standardisation in pharmacological assays among researchers has been identified following the 
identification of inconsistencies between two large-scale studies on the sensitivity of hundreds of 
cell lines to various drugs (Haibe-Kains et al., 2013).  
An interesting finding from the Rucaparib sensitivity studies in Chapter Four was a low dose 
hormetic response in DU145 and PC3 tumour cells, but not “normal” PNT1A cells. Increased cell 
proliferation in response to low dose Rucaparib (3µM) only occurred in Tetrazolium and 
Resazurin salt assays. These results are based on cell metabolism in culture, whereas SRB assay 
results are based on protein content that is directly proportional to cell mass. A hormetic response 
arises when homeostatic adaptations to low toxic doses of drug leads to increases cell proliferation 
as an adaptation to stress as a means to override the cytotoxic effects of the drug. This is overcome 
at higher doses of compound. This response is characterised in cancers (Calabrese, 2005) and 
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such defence mechanism is often a result of altered mitochondrial bioenergetics (reviewed in 
Porporato et al. (2018)). Further exploration into the effects of Rucaparib on mitochondrial 
bioenergetics were beyond the scope of this thesis but is warranted to confirm a “Warburg effect”; 
the metabolic switch from aerobic glycolysis to oxidative phosphorylation in tumour cells 
(Vander Heiden et al., 2009). PARP-1 has been implicated in the regulation of bioenergetic 
metabolism. PARP-1 activation has been shown to downregulate mitochondrial respiration and 
oxidative metabolism; leading to the onset of disease (reviewed in Bai and Canto (2012)). To this 
end, PARP inhibitors may serve as therapies, beyond BRCA mutations, to alter deregulated 
cellular bioenergetics; a hallmark of cancer and disease. This could be explored by measuring the 
specific activity of mitochondrial complexes using a Mitochondrial ToxGlo or Seahorse XF 
assay, to confirm a metabolic switch in response to treatment. 
8.3 The stand-alone effects of the HDAC inhibitor TSA in prostate cells of 
varying maspin expression 
Numerous studies have shown disordered expression of HDACs in human tumours. Higher 
expression of HDAC can predict poor patient prognosis independent of other variables such as 
tumour type. HDACs have pleiotropic effects on cellular processes which may explain their role 
in tumour development and resistance to therapy (discussed in Chapter One). The most widely 
studied effects of HDACs are angiogenesis, cell cycle, apoptosis and DNA repair (reviewed in Li 
and Zhu (2014).  
As eluded to in the preceding discussion, maspin is an endogenous HDAC-1 inhibitor and it is 
speculated that maspins effect on cell behaviour is in part conducted through HDAC1 inhibition. 
The class I HDACs contribute to DNA damage signalling on multiple levels; HDAC1 and 2 have 
a central role in preparing the chromatin surrounding the DSB for the activation of the DDR and 
sealing of the DSB by NHEJ or HR (reviewed in Roos and Krumm (2016)). Results in Chapter 
Six showed reduced expression of RAD51 in tumour cells exposed to TSA, providing evidence 
that HDAC inhibitors such as TSA hinder DSB repair by HR in tumour cells. Others have also 
reported a reduction in RAD51 expression following treatment with the HDACi Valproic acid 
(Kachhap et al., 2010). High HDAC1 levels in maspin depleted cells will also promote the DNA 
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damage response through selective stimulation of NHEJ via deacetylation of Ku70, for example. 
Ku70 then serves as a scaffold for other factors involved in repair. Conversely, inhibition of 
HDAC via maspin might be expected to specifically upregulate genes that promote cell cycle 
arrest and down regulate genes involved tumour survival including those involved in the DNA 
damage response (Figure 8.1). Our data briefly discussed above and further below, support this.   
The work described in this thesis looked at the level of HDAC-1 in the prostate cell lines and 
correlated this with maspin expression and sensitivity to the HDAC inhibitor TSA; a potent and 
specific inhibitor of class 1 and 2 HDACs. In Chapter three, the data showed that PC3 cells have 
lower HDAC-1 protein expression than maspin depleted DU145 cells, providing further evidence 
that maspin suppresses HDAC1 expression. Previous studies have shown that the pan HDAC 
inhibitor SAHA, an analog of TSA, can selectively sensitise prostate cancer cells as measured by 
survival. Moreover, they demonstrate differences in sensitivity amongst DU145 and PC3 cells 
(Chao and Goodman, 2014). In line with this, studies in Chapter Four highlighted increased 
sensitivity to TSA in DU145 and PC3 cells versus PTN1A cells, demonstrating a tumour specific 
effect. The selective effect in tumour versus normal cells is proposed to be a consequence of 
HDAC overexpression in tumours which we propose could result –in part- from reduced maspin. 
To this end, the data in Chapter Seven showed that Maspin knockdown in PTN1A cells increased 
sensitivity to TSA 1.8-fold. Thus, we would expect to see greater sensitivity to an HDAC inhibitor 
in maspin deficient tumours with high HDAC expression. Our finding is limited as HDAC-1 
levels were not measured following maspin knockdown and we cannot conclude definitively that 
this increased sensitivity is mediated via increased HDAC-1 expression. Moreover, the finding 
that there was no significant difference between DU145 and PC3 cell sensitivity (measured by 
SRB and counting) following exposure to TSA for 72 hours suggests that there may be an 
alternative mechanism driving sensitivity to HDAC inhibitors or that we cannot simply correlate 
maspin or HDAC-1 levels with sensitivity. To this end, the literature presents opposing findings 
to maspin expression and sensitivity to HDAC inhibitors. Li et al. (2006) demonstrate that the 
HDAC inhibitor M344 was more effective in maspin low cell lines. This was not the case in our 
studies. 
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To add further uncertainty, the effect of HDAC inhibitors on the expression of maspin is also 
variable. The majority of data in the literature suggests that maspin is increased in response to 
HDAC inhibition (Abbas and Gupta, 2008, Liao et al., 2014) while others show no effect 
(Horswill et al., 2008) and perhaps unexpectedly -in our hands- TSA treatment reduced maspin 
expression in PNT1A and DU145 cells but not PC3 cells. The effects of HDAC inhibition may 
be inhibitor and cell-type specific. 
Increased maspin would be expected to reduce cell migration and despite our data suggesting that 
TSA reduces maspin expression, cell migration data presented in Chapter Five demonstrated 
reduced cell migration in DU145 and PC3 cells but not PTN1A cells exposed to a GI50 of TSA. 
This data is in line with the growth inhibition studies presented in Chapter Four although the 
effect of treatment with TSA on cell migration was greater in PC3 cells. The latter finding may 
be a consequence of higher HDAC activity in these cells. These data demonstrate a tumour 
specific affect and that, at least in our hands, the mechanism of reduced migration may be 
independent of maspin in DU145 cells. 
Sensitivity to HDAC inhibitors may depend on other mechanisms that differ between normal and 
cells. Normal cells have a greater capacity to repair and survive DNA damage. They exhibit 
greater genomic stability and have a greater complement of functioning repair pathways. The 
selectivity of HDACi in tumour cells could be a result of HDACi causing DNA damage that only 
normal cells are able repair. The gH2AX foci data in Chapter Six supports this, showing that TSA, 
at GI50 concentration, induces more DSBs in PNT1A cells compared to DU145 and PC3 cells, 
despite the survival in all cell lines. As described above, both DU145 and PC3 cells are likely HR 
defective due to BRCA mutation and loss of PTEN, respectively. Thus, sensitivity to HDAC 
inhibitors in our cell lines and the lack of difference between DU145 and PC3 cells may relate to 
HR deficiency. Without HR repair capacity, NHEJ will be relied upon which TSA is likely to 
block based on the mechanism previously described (Figure 8.1). In line with this, Wiegmans et 
al. (2015) showed that BRCA competent cell lines displayed reduced sensitivity to all HDACi 
tested compared to BRCA mutant cell lines. Several HDAC inhibitors repress expression of HR 
proteins including Rad51. HDAC inhibitors have also been shown to increase the proapoptotic 
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protein Bax, leading to a reduced threshold for the induction of apoptosis (Singh et al., 2005). In 
support of this, epifluorescence data in Chapter Four showed that HDAC inhibition by TSA, at 
GI50, increased nuclear condensation and fragmentation in all cell lines, compared to untreated 
cells. Nuclear condensation was increased 2.4, 1.3 and 3.2-fold and nuclear fragmentation 5.2, 
3.4 and 1.8-fold in PNT1A, DU145 and PC3 cells, respectively. These data indicate that TSA was 
apoptotic in all cell lines at GI50. 
Data in Chapter five demonstrated that TSA increased SSBs in all cells especially DU145 and 
PC3 cells but the level of DSBs was not altered which was unexpected. HDAC inhibitors are 
known to increase the levels of intracellular ROS which will mediate induction of DNA strand 
breaks; although ROS were not specifically measured in the studies described here. Moreover, 
inhibition of repair pathways by TSA will lead to reduced/slowed repair of breaks. The alkaline 
comet assay does not necessarily only measure single strand breaks but can also measure 
incomplete excision repair sites and double strand breaks (Pu et al., 2015). The time point 
investigated of 72 hours looks only at persistent breaks and so does not give a full picture of strand 
break induction and resolution in our models, However, as outlined above, DSBs were not 
significantly increased in DU145 and PC3 cells exposed to TSA but were increased in PNT1A 
cells. If we take the right side of model 1 presented in Figure 8.1, it could be that ku70 is 
acetylated, rescuing DNA repair and limiting apoptosis in response to HDAC inhibition in tumour 
cells. However, PARP-1 is activated which will in turn recruit and upregulate DNA-PKcs and 
consequently DNA repair via NHEJ. Therefore, at 72 hours, no more DNA breaks are identified 
as they have been resolved prior to this timepoint.  
Overall, the work presented in this thesis and published literature agree that there is a selective 
toxicity for HDAC inhibitors towards tumour cells over normal cells. HDAC inhibitors are able 
to induce cell death in tumour cells and in our hands – prostate cancer cell lines.  However, it is 
clear that there is no consistent marker by which sensitivity can be predicted in tumour cells. 
Evidence presented in this thesis is contradictory and together with the literature, shows that 
sensitivity depends very much on the HDAC inhibitor employed, the methods of end point 
assessment and the cell line or model used. Toxicity amongst tumour cells is unlikely to result 
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from the same mechanism in each case and is instead cell line and context dependent. Moreover, 
HDAC inhibitors have a global impact on the acetylation status of many genes and overlapping 
mechanisms are more likely than an exclusive mode of action. This makes employing HDAC 
inhibitors as a targeted therapy for cancer difficult to implement. Indeed, the use of an HDAC 
inhibitor as stand-alone therapy has been disappointing in clinical trials with little clinical benefit 
for solid tumours including prostate cancer (reviewed in Kaushik et al. (2015)). Instead, 
combinations of HDAC inhibitors with other small molecules may enable a specific mechanism 
of action to be harnessed and potentiated (Thurn et al., 2011). Indeed, this is a growing area of 
research and one such area is the combination with PARP inhibitors.  
The enhanced sensitivity of maspin depleted tumours to Rucaparib and endogenous inhibition of 
HDAC-1 by maspin, led to the novel idea of combining Rucaparib with the HDAC-1 inhibitor, 
TSA, with a view to further enhance cell sensitivity to either treatment alone; particularly cells 
deficient for maspin that express increased levels of HDAC-1. At the outset of the work described 
here, only a handful of studies had investigated combination of PARP and HDAC inhibitors for 
cancer therapy (Zhang et al., 2012, Jasek et al., 2014, Chao and Goodman, 2014, Min et al., 2015). 
At the time of writing this, numerous studies have sought to investigate the combination of 
HDACi and PARPi for cancer therapy (Rasmussen et al., 2016, Marijon et al., 2018, Yin et al., 
2018). Nevertheless, not all studies are consistent with one another and there are many contentions 
that are not openly acknowledged by each of the papers.  
The studies described in this thesis extend these studies and confirm the work of others who show 
that HDAC-1 and PARP-1 inhibitors in combination decrease cell survival compared to 
treatments alone. Nevertheless, the pleiotropic effects of maspin and HDAC-1 mean that cell line 
models are not elegant enough to decipher exact mechanisms of these molecules and therefore 
specific gene knockdown studies are required. In some instances, the effects of HDAC-1 and 
PARP-1 inhibitor combined treatments differ from others and overall show that the effects will 
be cell and drug type dependent. 
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8.4 The combined effects of the PARP inhibitor Rucaparib and the HDAC 
inhibitor TSA in prostate cells of varying maspin expression 
Combinations of PARP inhibitors with other molecules has been based on 3 key biological 
interactions:  
1) Increasing levels of DNA damage to ultimately tip the cell over the threshold level for survival 
across to death via apoptosis. 
 2) Increased “PARP trapping”. PARP inhibitors increase cell kill via two mechanisms; inhibition 
of PARylation which increases the binding of PARP to DNA by prevention of automodification 
and release and by reducing base excision repair. “Trapped” PARP-DNA complexes are more 
cytotoxic than unrepaired single-strand breaks since they simultaneously prevent access to the 
break by other repair factors. Such ‘tethering’ was originally proposed by (Veuger et al., 2003, 
Veuger et al., 2004) and has since been demonstrated by others (Murai et al., 2012, Robert et al., 
2016, Hopkins et al., 2019). HDACis have been shown to differentially acetylate not just ku70/80 
but also PARP-1 leading to PARP trapping (Robert et al., 2016); a theory initially proposed by 
(Veuger et al., 2003). 
3) Simulating an HR defect in proficient tumours. The efficacy of PARP inhibitors in tumours 
deficient in HR repair such as those with BRCA mutations has led to the development of strategies 
to pharmacologically mimic HR deficiency in tumours for sensitisation to PARP-1 inhibitors. 
HDAC inhibitors have emerged as a class of therapeutic agents which mimic HR deficiency and 
sensitise cells to DNA repair inhibitors by impairing the repair of DNA DSBs, leading to cell 
death (Chao and Goodman, 2014). 
HDAC inhibitors have been shown to induce a “BRCAness” phenotype in tumour cells (Ha et al., 
2014) and are therefore an attractive treatment to synergise with PARP inhibitors and induce 
synthetic lethality. HSP90 stabilises many tumour suppressors. Hyperacetylation of HSP90 leads 
to its inhibition and proteins that interact with HSP90 including BRCA cannot do so thus leading 
to their degradation (Kim et al., 2017).The loss of HR capacity thus requires a reliance on NHEJ 
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pathway which as demonstrated here (Figure 8.2) is upregulated by PARP and therefore 
susceptible to inhibition by a PARP inhibitor.   
It is clear that there are multiple mechanisms by which we might see enhanced effects on survival 
endpoints in cancer cells exposed to a combination of a PARP inhibitor and an HDAC inhibitor. 
These mechanisms are unlikely to be mutually exclusive. 
Studies have supported the rationale to combine HDAC inhibitors with PARP inhibitors, 
irrespective of BRCA expression, for cancer therapeutics. They have not explored the effects of 
co-treatment in the context maspin. HDAC-inhibitor mediated depletion of HR has been shown 
to sensitise breast cancer cells to the PARP inhibitor Veliparib irrespective of BRCA status (Ha 
et al., 2014), highlighting the potential of PARP-1 and HDAC-1 inhibitor co-treatment in tumours. 
Briefly, the data in Chapter Four demonstrated a 1.5-fold increase in sensitivity to Rucaparib, at 
GI50, in both DU145 and PC3 cells co-treated with TSA at GI50, compared to PNT1A cells. 
Survival was reduced by 64%, 49% and 42% in PNT1A cells exposed to Rucaparib, TSA and 
combination, respectively. Survival was reduced by 39%, 20% and 70% in DU145 cells, and 51%, 
28% and 74% in PC3 cells exposed to Rucaparib, TSA and combination, respectively. The 
epifluorescence data in Chapter Four highlighted an increased effect of co-treatment on the 
nuclear morphology of all cells, particularly DU145 and PC3 cells which presented increased 
nuclear fragmentation, membrane blebbing and apoptotic bodies compared to cells exposed to 
Rucaparib and TSA as single agents. Co-treatment did not have an increased effect on the nuclear 
morphology of PNT1A cells exposed to co-treatment, compared to Rucaparib and TSA as single 
agents. These data support an important tumour specific sensitivity to co-treatment and this is in 
line with other studies (Chao and Goodman, 2014, Yin et al., 2018). At their GI50 concentrations, 
survival following co-treatment was not significantly different between DU145 and PC3 cells, 
indicating that sensitivity to co-treatment may be independent of maspin status. Although, GI50 
concentration for Rucaparib was 2-fold higher in PC3 cells. Maspin siRNA and combination 
treatment were no more effective than maspin siRNA and TSA and Rucaparib alone, in PNT1A 
cells. This finding was not comparable to the survival data in Chapter Four whereby maspin 
depleted DU145 cells were most sensitive to combined treatment, compared to treatments alone. 
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However, the data do demonstrate increased sensitivity to combined treatment in the presence of 
maspin siRNA, suggesting that maspin may play a role in sensitivity to co-treatment. 
Combined Rucaparib and TSA treatment selectively enhanced SSBs in tumour cells; particularly 
DU145 cells. Reduced expression of maspin in DU145 cells exposed to co-treatment (Chapter 
Four) also supports a potential role of maspin in cell death susceptibility. Overall the SSB studies 
in Chapter Six have shown that DU145 cells are more prone to SSB DNA damage and these 
findings are in line with the growth inhibition data presented in Chapter Four. Moreover, when 
the inhibitors were used in combination at GI50 concentrations, DU145 cells were more 
susceptible to DSBs than PNT1A and PC3 cells. DSB levels were lowest in PC3 cells. Others 
have shown a significant increase in DSBs in DU145 cells exposed to the PARPi Olaparib and 
HDACi SAHA in combination, at 48-hours, compared to Olaparib and SAHA alone. This effect 
was not observed in RWPE-1 epithelial cells, demonstrating that the effects of combined 
treatment on DSBs was selective to tumour cells and not epithelial cells (Chao and Goodman, 
2014). This finding has also been reported in a more recent prostate study that utilised the PARPi 
Veliparib in combination with HDACi SAHA (Yin et al., 2018). In previous studies, Veuger et 
al. (2004) looked at whether a PARPi increases breaks or is directly inhibiting NHEJ via a 
decrease in DNA-PK activity and were able to show that it is the latter.  
The proposed model presented in Figure 8.2 shows that in the presence of an HDAC inhibitor, 
PARP will be acetylated and activated which in turn will lead to reciprocal activation of DNA-
PKcs and recruitment to promote NHEJ. Conversely, an HDAC inhibitor will also acetylate Ku70 
leading to its inactivation and release of bax. Thus, there is a simultaneous stimulation of repair 
and apoptosis and the cell may be tipped towards one or the other depending on the amount of 
damage or regulation of each signalling pathway. Moreover, inhibiting IKKα by Rucaparib will 
lead to breaks that require HDAC mediated up regulation of repair which will be simultaneously 
inhibited by TSA. That being said, there is no significant difference between DU145 and PC3 cell 
survival in the presence of combined Rucaparib and TSA at GI50 concentrations, despite variances 
in DSBs. Levels of DSBs do not correlate to cell survival and it is postulated that different 
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mechanisms are happening in each cell line and the drugs may be inducing various off target 
effects which are cell type specific.  
Individual enzyme activity and specific forms of repair were not measured in this study, however, 
previous studies within the group (Veuger et al. (2004)) have shown that in the presence of 
adequate substrate (the absence of inhibitors), PARP1 and DNA-PK co-operate at the sites of 
DNA damage and regulate the activity of one another. In the presence of an inhibitor, the 
activation of one by the other will be prevented and the inhibited enzyme will ‘block’ the access 
of the other. PARP was also shown to have preferential binding to blunt ended breaks and will 
therefore bind first at the site of a break. ‘Trapping’ of PARP at the site of a break will impede 
NHEJ. The combined use of a PARP inhibitor and an HDAC inhibitor will lead to increased 
apoptosis as NHEJ will be blocked via PARP trapping and acetylation of ku70 with concomitant 
release of Bax. Indeed, Robert et al. (2016) show that TSA can decrease NHEJ by acetylation and 
by PARP trapping. Excess damage resulting from the combined action of the inhibitors may also 
activate APAF1, a pro-apoptotic protein required for apoptosis that is part of the apoptosome 
complex. APAF1 is upregulated in a Ku dependent manner (reviewed in De Zio et al. (2013)). 
The balance of breaks and complement of active repair pathways will thus decide the cell fate. 
Thus, we hypothesised that inhibited PARP will be more deleterious than loss of PARP and 
therefore lead to excessive DNA damage such that the balance will be tilted in favour of apoptosis 
(Figure 8.2).  
To demonstrate this, an elegant set of data described in this thesis enabled us to compare PARP-
1 siRNA + TSA to Rucaparib + TSA on cell survival. In all prostate cancer cell lines, Rucaparib 
+TSA was more deleterious than PARP1 siRNA and TSA (29% versus 88% and 27% versus 80% 
survival in DU145 and PC3 cells, respectively). Taken together, these data point towards PARP 
trapping as a predominant mechanism of cell death. However, we must acknowledge the caveat 
that PARP-1 siRNA did not induce a complete knockdown of PARP-1 and it was not confirmed 
that knockdown lasted as far out as the timepoints of the studies. Thus, there may be some 
upregulation of NHEJ as a consequence of residual/return of PARP activity. This study should 
therefore be repeated in PARP+/+ and PARP-/- MEFs.  
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Some of the studies investigating PARP-1 and HDAC inhibitors have demonstrated synergy 
between the compounds (Chao and Goodman, 2014, Rasmussen et al., 2016, Yin et al., 2018, 
Marijon et al., 2018). We do not see synergy with Rucaparib and TSA. The combination of TSA 
and Rucaparib can be equated to the use of DNA-PK and PARP inhibitors in combination since 
our models suggest that both a PARP inhibitor and an HDAC inhibitor will act in a large part via 
reduction of NHEJ. DNA-PK and PARP inhibitors have at least additive effects (Veuger et al 
2003). TSA combined with Rucaparib was more effective at preventing the clearance of DSBs 
than Rucaparib alone in DU145 cells but not more effective in PNT1A and PC3 cells; this may 
be due to overlap in pathways.  
A characteristic feature of malignancies, including prostate cancer, is the ability of cancer cells to 
invade surrounding tissues and migrate into distant tissues. The data presented here built on those 
of others by also looking at the effects of the inhibitors in combination on migration. 
xCELLigence cell migration data presented in Chapter Five showed reduced cell migration PC3 
cells exposed to Rucaparib and TSA in combination, compared to DU145 cells. Scratch assay 
data showed no significant reduction in cell migration in PNT1A, DU145 and PC3 cells exposed 
to combination treatment, compared to Rucaparib and TSA as single agents. Despite variation in 
results between methods the data indicates that the effects of co-treatment on cell migration are 
cell type specific. PC3 cells are less migratory throughout treatment conditions and this correlates 
with the role of maspin. However, PC3 cells subject to co-treatment were found to express 
reduced levels of maspin (Figure 4.18). Maspin plays a role in limiting cell migration, therefore, 
increased cell migration would have been expected in response to a reduction in maspin. Reduced 
maspin expression and migration in PC3 cells exposed to co-treatment highlights maspins 
pleotropic effects. It also suggests that the effects of co-treatment on cell migration may be 
independent to maspin expression.  
Reports have demonstrated that HDAC enzymes are important for HR mediated DNA repair and 
assembly of RAD51 foci, showing decreased RAD51 and HR-mediated DNA repair in the 
presence of HDAC inhibitors (Adimoolam et al., 2007). To this end, combination of a HDAC 
inhibitor with a PARP inhibitor was predicted to be selectively toxic; particularly in BRCA mutant 
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DU145 cells which are deficient for HR DNA repair. A further reduction of RAD51 in tumour 
cells exposed to combined treatment, as shown in Figure 6.9, demonstrates the selectivity of these 
agents to inhibit DNA repair and induce synthetic lethality.  
In summary, TSA sensitises tumour cells to Rucaparib irrespective of maspin expression status. 
This sensitisation is in line with other studies that have demonstrated reduced cell viability in 
prostate tumours exposed to PARP-1 and HDAC-1 inhibitors combined, compared to agents 
alone (Chao and Goodman, 2014, Yin et al., 2018). Maspin expression did not correlate with 
sensitivity to combined treatments at GI50, albeit the concentration of Rucaparib required to 
achieve GI50 in PC3 cells was 2-fold greater than that required for DU145 cells. Maspin siRNA + 
combined treatment increased PNT1A cell sensitivity, compared to cells exposed to combined 
treatment alone. Although the PNT1A cells are “normal” prostate cells, this preliminary finding 
indicates that maspin can affect cell response to combined treatment and provides a proof of 
principle for targeting tumours which are deficient for maspin. Nevertheless, our data shows 
increased sensitivity to co-treatment in tumour cells of varied maspin expression and this is likely 
a result of PARP trapping and a reduced capacity for DNA repair by NHEJ and HR, and 
consequently synthetic lethality.  
8.5 General conclusions  
At the outset of this body of work, the aim was to investigate a possible link between maspin, 
PARP1 and NF-kB with a view to repurposing PARP inhibitors in a subset of tumours or 
identifying a biomarker of predicted sensitivity.  
As work progressed, the realisation that maspin is an endogenous HDAC1 inhibitor driving varied 
levels of HDAC1 in tumour cells coupled with the concept that HDACs are often overexpressed 
in tumours and are a poor predictor of prognosis meant the work was expanded to include the 
HDAC1/2 inhibitor, TSA. Whilst Rucaparib and TSA used alone were able to sensitise all cell 
lines tested, only Rucaparib sensitivity correlated with maspin expression. No differential effects 
of TSA between tumour cells of varied maspin expression were observed in the studies presented 
in this thesis. Ultimately, amongst a growing background of similar studies, we tested the 
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combination of a PARP inhibitor (Rucaparib) and an HDAC inhibitor (TSA). Two working 
models (Figure 8.1 and Figure 8.2) have been proposed and which warrant further investigation. 
The models proposed fit our findings and extends those already in the literature.  
Although there are many studies in the literature aimed at investigating individual aspects of the 
model(s) put forward here and most support the key findings described in this thesis -none have 
attempted to piece the interrelated roles of PARP, NF-kB and maspin together as we have here. 
The results add to the controversy surrounding maspins differential tumour suppressive effects in 
tumours. The data in this thesis also highlighted a potential mechanism between NF-kB, maspin 
and HDAC-1; a mechanism for potential for therapeutic exploitation (Figure 8.1). An inverse 
correlation was demonstrated between maspin and IKKa as well as p65. However, tumour 
metastasis is a complex and progressive process, so it is unlikely that the inverse correlation 
between these proteins are the sole regulators of tumourigenesis. 
We have provided several lines of evidence that a PARP inhibitor stand-alone effects can be via 
IKKa particularly in maspin deficient tumour cells.  
The pleiotropic actions (eg HDACs are transcription factors, repair factors signal transducing 
molecules) of each of these proteins along with their differing and altering expression levels in 
each cell line in response to drug exposure has meant that drawing up an effective model that 
encompasses all events/pathways/mechanism is not possible. Moreover, the literature presents no 
consensus on the relationship between HDAC1 or PARP expression levels and sensitivity to the 
compounds. It is therefore unlikely that the events/pathways/mechanisms are the same for every 
scenario but rather will be dependent on tissue and cell type. This was further confounded by the 
fact that DU145 cells are BRCA defective and PC3 cells are PTEN null  
In summary our intriguing and novel results point to a broader utility of PARP inhibitors in the 
treatment of prostate cancer beyond hereditary BRCA1-and BRCA2-deficient tumours. The 
series of investigations presented in this thesis add some insight into the interaction of maspin and 
NF-kB proteins and how this can affect sensitivity to PARP-1 and HDAC-1 inhibitors, however, 
they have not elucidated a specific mechanism between these molecules. The use of siRNA 
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strengthened the findings by demonstrating increased sensitivity to Rucaparib in the absence of 
maspin. PARP silencing had no effect on cell sensitivity to Rucaparib in tumour cells, further 
supporting that sensitivity to PARP inhibition may be mediated by maspin. Our data shows 
increased sensitivity to co-treatment in tumour cells of varied maspin expression and this is likely 
a result of PARP trapping and a reduced capacity for DNA repair by NHEJ and HR, and 
consequently synthetic lethality. 
There is scope for these molecules to be utilised as biomarkers to predict therapeutic response and 
our evidence proposes that maspin depletion which indicates high IKKα may be one such marker 
for PARP-1 inhibition.  
Our results also demonstrate the efficacy of combined Rucaparib and TSA treatment in tumours, 
irrespective of maspin expression status. The data points to a proposed mechanism whereby 
combined Rucaparib and TSA increase PARP-1 trapping at DNA breaks, leading to the 
downregulation of key DNA repair pathways and consequently synthetic lethality.  
The studies highlight the importance of utilising different cell models to eliminate cell-type 
specific effects and to limit generalisations that are not applicable to a broader context. The studies 
have also highlighted the importance of utilising proficient and deficient cell lines and siRNA to 
explore mechanistic interactions between molecules in cell models, and to provide a proof of 
principle for future scoping.  
8.6 Future	work	
This has been a huge endeavour and many questions remain. However, all the work taken together 
in this thesis demonstrate one very important point – cell line models are not sufficient to enable 
conclusive models to be designed even with the addition of siRNA.  
Future work relevant to specific areas of study have been described in each chapter, however, 
summarising the investigations as a whole has highlighted other potential avenues for future 
investigation.  
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Western blots for protein expression in response to treatments are a snapshot in time and are not 
kinetic. Assessment of protein expression at multiple time points throughout treatment exposure 
will extend and consolidate this work. Western blotting should also be carried out to look at the 
expression levels of HDAC-1 and IKKa in response to maspin siRNA. Isogenic cell lines 
proficient and deficient for maspin could also be utilised and phosphorylated IKKa for activation 
relative to maspin could be measured. These studies would strengthen our findings and confirm 
the link between IKKa and maspin. 
It is important to assess the specific DNA repair pathways in each of the cell lines and measure 
the changes in those repair pathways following treatment with each of the inhibitors. Both 
induction and kinetics of repair need to be carried out. This will help to elucidate the mechanisms 
underlying HDAC and PARP inhibition and the role of these inhibitors in altering the response 
to DNA damage. 
With regards to drug treatments, GI50 doses were used in the studies presented throughout this 
thesis. It would be useful to calculate a combination index (CI). CI is a model that accounts for 
the entire shape of the growth inhibition curve and determines whether drug combination is 
synergistic. The effects of PARP inhibition in combination with an ATM inhibitor could also be 
assessed. We propose that IKKα targets ATM for DNA repair. It would be interesting to see 
whether PARP-1 inhibitors synergise with ATM inhibitors to limit IKKα and compromise DNA 
repair for cancer therapy.  
The extent to which acetylation of PARP-1 induced by TSA contributes to PARP trapping and 
decreased NHEJ activity could be investigated using HDAC inhibitors and cell lines stably 
























The sensitivity of breast cancer (MCF-7) cells to Rucaparib was assessed by SRB assay at 72 
hours. Cells transfected with maspin (MTR) or mutated maspin (244) were less sensitive to 
Rucaparib than MCF-7 control (CTR) cells (Figure A3). Rucaparib concentrations of 26μM, 
24μM and 9μM were required to achieve GI50 in MCF MTR, 244 and CTR cells, respectively. 
These results support the survival data presented in Chapter Four of this thesis whereby maspin 
depleted prostate cancer (DU145) cells were most sensitive to Rucaparib. 
 
Figure A 3: Breast cancer cell growth inhibition by Rucaparib. 
MCF-7 cells previously transfected with empty vector pcDNA3.2 (MCF-7 CTR), pcDNA3.2 maspin 
(MCF-7 MTR) and pcDNA3.2 mutant maspin (MCF-7 244) were treated with Rucaparib at various 
concentrations for 72 hours to investigate the effects of maspin on cell sensitivity to Rucaparib. Results 
were obtained by SRB assay and data shown is representative of three independent experiments and 





Jenkinson, S.E., Brown, L.J., Ombor, J., Milburn, J.A., Smulders-Srinivasan, T., Veuger, S., 
Edwards, D.R. and Bass, R., 2017. Identification of novel peptide motifs in the serpin maspin that 
affect vascular smooth muscle cell function. Biochimica et Biophysica Acta (BBA)-Molecular 
Cell Research, 1864(2), pp.336-344. 
Contribution to publication 
To investigate the effect of the novel maspin peptides S4B and S5B on breast and prostate cancer 
cell proliferation by WST-1 assay (method outlined in Chapter Two, section 2.2.3.1). The 
peptides were designed from the structural moieties of maspin; S4B and S5B were derived from 
strand 4 and 5 of maspin beta sheet B, respectively. The peptides did not affect tumour cell 
proliferation, supporting that the effects of S4B and S5B on cell proliferation are specific to 
vascular smooth muscle cells.  
 
Supplementary Figure: S4B and S5B do not affect the proliferation of breast or prostate cancer cell 
lines. The effect of peptides on cancer cell lines MDA-MB-231 (breast), PC3 (prostate) and DU145 
(prostate) was determined by WST-1 assay after 48-hour incubations in 10μM of S4B (open bars), S5B 
(closed bars) or S4/5B control (hatched bars). No significant changes were observed in proliferation 
compared to the control peptide. All data are combined from three separate experiments. Data presented as 
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